<SEC-DOCUMENT>0000939767-19-000157.txt : 20190731
<SEC-HEADER>0000939767-19-000157.hdr.sgml : 20190731
<ACCEPTANCE-DATETIME>20190731161253
ACCESSION NUMBER:		0000939767-19-000157
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20190628
FILED AS OF DATE:		20190731
DATE AS OF CHANGE:		20190731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		19988874

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel2019063010-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:c3e096d5b7674d8ea9c9ad6502f841aa,x:57b9b8388e8d4ca69210e115e9ac6f51-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:exel="http://www.exelixis.com/20190628" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:AmendmentFlag" id="Fact-0D034E00754B5551E714E231C4923916-wk-Fact-0D034E00754B5551E714E231C4923916" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-8FD2A8238FDB5582F401E231C48CA1C0-wk-Fact-8FD2A8238FDB5582F401E231C48CA1C0">--01-03</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-46BF84598624C055E38BE231C48FD581-wk-Fact-46BF84598624C055E38BE231C48FD581">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-BC89D796E328D0A32C04E231C48527F8-wk-Fact-BC89D796E328D0A32C04E231C48527F8">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-0DCFCE6100C9FBBA6FB7E231C48E01BB-wk-Fact-0DCFCE6100C9FBBA6FB7E231C48E01BB">0000939767</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-A7C65FF32F498C224398E231C45760DA-wk-Fact-A7C65FF32F498C224398E231C45760DA">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-A0D53BE6F0146D146596E231C457CDBF-wk-Fact-A0D53BE6F0146D146596E231C457CDBF">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5">299876080</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-E74606558B0226F4AFDDE231C4640017-wk-Fact-E74606558B0226F4AFDDE231C4640017">302784854</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41">299876080</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:CommonStockSharesOutstanding" id="Fact-8128CED27A255CDEB63FE231C461B23E-wk-Fact-8128CED27A255CDEB63FE231C461B23E">302784854</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q2DEC30-JUN29" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-16F345F01953046CEB3CE231C4403A6E-wk-Fact-16F345F01953046CEB3CE231C4403A6E">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q2Q2QTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-87A31F1D23D0488FC515E231C4407F7C-wk-Fact-87A31F1D23D0488FC515E231C4407F7C">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-E8B0510F4D0B5AA6B9B1E231C4413E86-wk-Fact-E8B0510F4D0B5AA6B9B1E231C4413E86">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-F637FF5F0338C5167E91E231C43F594D-wk-Fact-F637FF5F0338C5167E91E231C43F594D">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q2DEC30-JUN29" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-6699277FFC24D0563079E231C4963835-wk-Fact-6699277FFC24D0563079E231C4963835">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q2Q2QTD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-098AC4BE22032B1988DDE231C4960EC1-wk-Fact-098AC4BE22032B1988DDE231C4960EC1">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-44EED50ABC0AC834268BE231C4959404-wk-Fact-44EED50ABC0AC834268BE231C4959404">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-986BDEF24DF3E5799619E324999D2515-wk-Fact-986BDEF24DF3E5799619E324999D2515">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q2DEC30-JUN29" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-D768C70B83D205279A74E231C4961806-wk-Fact-D768C70B83D205279A74E231C4961806">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q2Q2QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-EB64BE5F80A483824186E2B93A288753-wk-Fact-EB64BE5F80A483824186E2B93A288753">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-C6C6BB38F7C3594F179DE2B93A1D1474-wk-Fact-C6C6BB38F7C3594F179DE2B93A1D1474">413000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-AF501F44226AD4A5FF12E231C496FD27-wk-Fact-AF501F44226AD4A5FF12E231C496FD27">807000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="D2018Q2Q2QTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-4F15E06F59A17AD80B10E231C43E9C27-wk-Fact-4F15E06F59A17AD80B10E231C43E9C27">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2QTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-59CDABF2D6C45F5BC819E231C43E7D70-wk-Fact-59CDABF2D6C45F5BC819E231C43E7D70">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q2YTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-D2233C827CA25D35882DE231C43F6CB9-wk-Fact-D2233C827CA25D35882DE231C43F6CB9">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-885864F0CD5615F96590E231C457FD01-wk-Fact-885864F0CD5615F96590E231C457FD01">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-50B4079A052058F49951E231C45B0EF0-wk-Fact-50B4079A052058F49951E231C45B0EF0">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q2" name="us-gaap:PreferredStockSharesIssued" id="Fact-CD11292302CC0DE24BCFE231C45704C3-wk-Fact-CD11292302CC0DE24BCFE231C45704C3">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="exel-20190628.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul22">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Fiscal">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-29</xbrli:startDate>
			<xbrli:endDate>2019-04-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-28</xbrli:startDate>
			<xbrli:endDate>2019-04-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Jun01-Jun28_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-31</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-30</xbrli:startDate>
			<xbrli:endDate>2019-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>exel:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA" toRefs="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766 d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57 d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627" toRefs="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938" toRefs="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB" toRefs="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345" toRefs="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0" toRefs="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937 d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544" toRefs="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s7F569E9CF9F155E4BCA4AA25EC52D94C"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><span style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:298px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:149px;"></td><td style="width:149px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:right;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e413-wk-Fact-398EB30CEBBCE2086764E26437E38B1B" name="dei:DocumentType" contextRef="FD2019Q2YTD">10-Q</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d277971135e428-wk-Fact-34B88F625E626678BDC6E2CB04B17691" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">For the quarterly period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d277971135e439-wk-Fact-6CA696FB4A4013567AEDE231C46C9CE9" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q2YTD" format="ixt:datemonthdayyearen">June 28, 2019</ix:nonNumeric></span></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">or</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d277971135e459-wk-Fact-35E23755D6A40AFD0A6CE2CADB55EC15" name="dei:DocumentTransitionReport" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d277971135e469-wk-Fact-5E8EABDB74C4B186C34EE27386ACBE7A" name="dei:EntityFileNumber" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;">000-30235</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo2017aa08.jpg" alt="exellogo2017aa08.jpg" style="height:64px;width:192px;"></img></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e491-wk-Fact-A9129BE9D9E7DA6506A3E26F973BEEE2" name="dei:EntityRegistrantName" contextRef="FD2019Q2YTD">EXELIXIS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e512-wk-Fact-4F88CBF82DAFBB5AB1A8E26FBD320DA6" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q2YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e517-wk-Fact-DCECF88F926BC07F364BE27017A72D60" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q2YTD">04-3257395</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d277971135e532-wk-Fact-A6882D5FFC0AB3A2EECDE27046A8AC9D" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">1851 Harbor Bay Parkway</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d277971135e538-wk-Fact-41EB1EE40FC9B81EC15FE2706A7A668B" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">Alameda,</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d277971135e543-wk-Fact-30D4ED56CA292C28FF3FE2708C3EEFB9" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">CA</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d277971135e548-wk-Fact-38D8F2DD691797D14ABCE270A88797A1" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">94502</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d277971135e556-wk-Fact-CB24FD6EBCF8F499B083E270E5E3F3D7" name="dei:CityAreaCode" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d277971135e561-wk-Fact-62910D1AA01D3AEAFF29E270CA5415CA" name="dei:LocalPhoneNumber" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">837-7000</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.62698412698413%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e602-wk-Fact-BEA9363D9D793DA776F0E2719D52883D" name="dei:Security12bTitle" contextRef="FD2019Q2YTD">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e607-wk-Fact-DCD38F0964B2B3F3764BE2717F35E7CB" name="dei:TradingSymbol" contextRef="FD2019Q2YTD">EXEL</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d277971135e612-wk-Fact-85746CB4810C9EE253D6E271BF19F008" name="dei:SecurityExchangeName" contextRef="FD2019Q2YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d277971135e617-wk-Fact-135B08DBBBAB16770ED0E271FA2A2F0C" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d277971135e631-wk-Fact-765BC42F0F3AED559B97E2721F71414E" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q2YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:26%;"></td><td style="width:4%;"></td><td style="width:20%;"></td><td style="width:27%;"></td><td style="width:3%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d277971135e662-wk-Fact-080FFAFE526CC4609762E27254A2B04A" name="dei:EntityFilerCategory" contextRef="FD2019Q2YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d277971135e713-wk-Fact-1AA19B36CFA1117B9E90E272724E39D6" name="dei:EntitySmallBusiness" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d277971135e729-wk-Fact-9F9D66854DB4A0B706A8E2728DF6BFAF" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="font-family:Wingdings;font-size:10pt;">&#168;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d277971135e760-wk-Fact-355191110BC2963509BF273548FD2E44" name="dei:EntityShellCompany" contextRef="FD2019Q2YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277971135e776-wk-Fact-426FBA4DA7FE8E51AE0AE231C46B624C" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q3Jul22" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">302,906,238</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> shares of the registrant&#8217;s common stock outstanding. </span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s7616097BE26A5B9C836D3082DAB99E51"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s4DD00DA08BBA5F608F39140FA91401F8"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF86B524DA8DB5BB7B0EA09CDBB7319E2"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sF86B524DA8DB5BB7B0EA09CDBB7319E2">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s58A5F5A75C4B59C69137514D327A2306"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s58A5F5A75C4B59C69137514D327A2306">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s539EEE3CFDC35BC78EF31892E580C700"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s539EEE3CFDC35BC78EF31892E580C700">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6647F4249AF75A829AC5E7AC1DBFFBE6"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s6647F4249AF75A829AC5E7AC1DBFFBE6">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s07ED532AEF1D555CBAFEBB9EEFFA57DD"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s07ED532AEF1D555CBAFEBB9EEFFA57DD">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s35DE942E11495D9588E9E5435CD9E40A"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s35DE942E11495D9588E9E5435CD9E40A">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC8C2D16D15D751DA9C1C949F929F2062"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC8C2D16D15D751DA9C1C949F929F2062">9</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s47B6D56B23FA554BAF560B6C05936779"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s47B6D56B23FA554BAF560B6C05936779">25</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFD34F67AA8AA5B868FA8A72E182F8733"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFD34F67AA8AA5B868FA8A72E182F8733">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC9B1FAA46D94557C812802C87485F846"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sC9B1FAA46D94557C812802C87485F846">37</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s4B0CB353AD64500FBC6985507E32EC3F"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA8AA4464D7735C9C87C95CF68133060F"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sA8AA4464D7735C9C87C95CF68133060F">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s45BB62DCA4245CE8B65498C0C7183295"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s45BB62DCA4245CE8B65498C0C7183295">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0CB6C2B2D44D52E39069F70696A4C016"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s0CB6C2B2D44D52E39069F70696A4C016">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5B655C5E68CA58529EDAF616B08796F4"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5B655C5E68CA58529EDAF616B08796F4">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2B3DDBF0606E5E19B05180196F96F800"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s2B3DDBF0606E5E19B05180196F96F800">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFF23C2722EE35F79B19B6CB3BEC69356"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sFF23C2722EE35F79B19B6CB3BEC69356">60</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEED4CFD7DBBA520D80B4536F9FCBC0F2"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEED4CFD7DBBA520D80B4536F9FCBC0F2">60</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s3A00878D13E954F9A06A17D2F9920D49"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4DD00DA08BBA5F608F39140FA91401F8"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</span></div><div><a id="sF86B524DA8DB5BB7B0EA09CDBB7319E2"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> Item 1. Financial Statements</span></div><div><a id="s58A5F5A75C4B59C69137514D327A2306"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2018*</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e551-wk-Fact-93396699141361E328C7E231C47489B6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">369,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e585-wk-Fact-3327E69FD30B91F4B321E231C46C66ED" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">452,328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF" name="us-gaap:ShortTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e624-wk-Fact-8DA38EB09C159648B9D1E231C49EB65C" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e663-wk-Fact-C24AFDB65FBBA1E39222E231C461AEEE" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e702-wk-Fact-CACC8D14CC82B815D59EE231C44C667A" name="us-gaap:InventoryNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e741-wk-Fact-6CC1DCF54B3059CD5FA6E231C450D210" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e780-wk-Fact-778AD48461D708D3D932E231C498360A" name="us-gaap:AssetsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">957,247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e819-wk-Fact-8C777A59195473D6E06FE231C46CA92E" name="us-gaap:LongTermInvestments" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">337,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544" name="us-gaap:LongTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e859-wk-Fact-11BD26FD71BDB949C36BE231C48D8C87" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e898-wk-Fact-BDAF3FADB3E4FBED7CE7E231C46AAA2F" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e937-wk-Fact-705EF9248DFCDC918917E231C44F2EE4" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e976-wk-Fact-46C13E9EDA3F333CED1BE231C4886BA2" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">210,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1015-wk-Fact-42AFF11119B5CB16AD27E231C49C574C" name="us-gaap:Goodwill" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1054-wk-Fact-5036163CDFFA8EFF5DFDE231C463895F" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1098-wk-Fact-6077AC819FD698C01D1EE231C4844313" name="us-gaap:Assets" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,643,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1219-wk-Fact-1A820338DDC1752F2114E231C495D103" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1253-wk-Fact-49B1085ECF14489B887AE231C46D019C" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1293-wk-Fact-2B2A8F02938D53C0B481E231C4762B81" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1332-wk-Fact-44E2432780D7D1399FECE231C487D2AB" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1371-wk-Fact-1E8C7DD47B52722CC48BE231C48FFBC3" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1410-wk-Fact-D0A13340B1628806C194E231C4861769" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1449-wk-Fact-8CAE734F92DD2B2556A3E231C47692A9" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1488-wk-Fact-0BDDD6183D8E6D0D014EE231C49F2513" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1527-wk-Fact-574AC09395D318FBDAAAE231C48A7B4B" name="exel:OperatingAndFinanceLeasesLiabilityLongTerm" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,543</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3" name="exel:OperatingAndFinanceLeasesLiabilityLongTerm" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1566-wk-Fact-229DE50DEF12B74C475CE231C49D47E0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1605-wk-Fact-0A31F19CA2F4C93C4B96E231C490D5E6" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1644-wk-Fact-D051332CC3AF195BE4EEE231C48ABEB4" name="us-gaap:Liabilities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1683-wk-Fact-BE17891463096ECA70CAE231C48EFF8E" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q2" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1764-wk-Fact-99C747DE653ECBA011D9E231C48DE0B8" name="us-gaap:PreferredStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 302,784,854 and 299,876,080 at June 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1803-wk-Fact-09EE11327AB9D847DD8FE231C49A60B7" name="us-gaap:CommonStockValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1842-wk-Fact-03FBB525858D962BBAE1E231C4771979" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1881-wk-Fact-28A6EC3FFF9380B99748E231C4904BEC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277973521e1921-wk-Fact-AB056D7FB3C3EA5574FDE231C488FA2F" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1962-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e2006-wk-Fact-7E5C2FF395C84D46289BE231C46C6CF7" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,643,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s539EEE3CFDC35BC78EF31892E580C700"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e680-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e699-wk-Fact-4F7C2030B0B97CB91993E231C43E6734" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e718-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e738-wk-Fact-50091E677B09B1D05D0EE231C4388469" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e753-wk-Fact-86F42DC59D3F418CDD1BE231C4B67703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e772-wk-Fact-D3E4E43AD79C4893D9B1E231C454E6C0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e791-wk-Fact-83181898E532FF40688FE231C4796437" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e811-wk-Fact-DCC8DAB3437F1E74BCECE231C44105D8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e831-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e850-wk-Fact-24161066F0F7476E837BE231C4A56D73" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e869-wk-Fact-31347911C2A9E3B534C9E231C4637FEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e889-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">399,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e991-wk-Fact-FA17F23C378A02BDF47DE231C4B6597A" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1010-wk-Fact-37B03D2EFF3598084DA3E231C4376B55" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1029-wk-Fact-4C7AC6BD22E111D8B6B6E231C44F6DD8" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1049-wk-Fact-E2F1FF0D48BFC4265812E231C4A7FF99" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1069-wk-Fact-0F7FC73FE5888E182DF8E231C482BE40" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81,932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1088-wk-Fact-929A07F13F4828CCAFA4E231C4724573" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">42,488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1107-wk-Fact-642C0E3ABB8EEE7A9E3AE231C43D7BC9" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1127-wk-Fact-84CA7C08F545565774C4E231C4A86AA0" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1147-wk-Fact-E7C38F1AF89F04E3C26BE231C4B9711C" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1166-wk-Fact-90740CCFCC87D9728FABE231C4323734" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,853</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1185-wk-Fact-480334831CFEF97916BDE231C44C0FBA" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1205-wk-Fact-D9A234E40EFCB19B623FE231C44D7CBB" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1225-wk-Fact-AF450CEF291F922CE164E231C4912810" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">148,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1244-wk-Fact-62D96B9EF59F2ACF6469E231C4AEF15A" name="us-gaap:OperatingExpenses" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1263-wk-Fact-C0F84FB18B188601B349E231C4B38EFB" name="us-gaap:OperatingExpenses" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">279,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1283-wk-Fact-A0B4B1420F639FA4F6E4E231C4A722DC" name="us-gaap:OperatingExpenses" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">197,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1304-wk-Fact-D284AF06FC8CE4404CADE231C4784088" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1323-wk-Fact-697279857112B21C89D8E231C4781914" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">85,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1342-wk-Fact-765DA0857B10289DFBA2E231C43BFF24" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">176,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1362-wk-Fact-F556A5C6045B3F820347E231C4346ADC" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202,077</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expense), net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1464-wk-Fact-8AF25846D0BE23E50DD9E231C49EC8DB" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1483-wk-Fact-37AE4285E79B0D09FA37E231C4B0A4EF" name="us-gaap:InterestIncomeOther" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,697</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1502-wk-Fact-47AF38BA57F3E4F7D76CE231C446D660" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1522-wk-Fact-32026EAF2654618FBFA7E231C4AA85E6" name="us-gaap:InterestIncomeOther" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1542-wk-Fact-1B9F842616813BE404F6E231C4464C24" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277975668e1561-wk-Fact-D7EFA64AE8C69619FF77E231C4A0B066" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1581-wk-Fact-1D82234933E95547F29BE231C4B49F70" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1601-wk-Fact-A660457319FD4C6D6C70E231C4A64868" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1621-wk-Fact-C253682F306DA0C1B6D5E231C446E66B" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,778</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1640-wk-Fact-9218DE217749DD55E252E231C4A107C9" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1659-wk-Fact-316024DC6F3D42BF5D23E231C4A8D1A7" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1679-wk-Fact-8D785BCEDAAF9C55A53DE231C4413AFB" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1699-wk-Fact-81B70EDAF84EC843EE64E231C49F8D85" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,767</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1718-wk-Fact-19F42E7DD991783B7EF2E231C4B467FF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1737-wk-Fact-0BC5155CFF2C4B5FFE26E231C46F55AF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">190,438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1757-wk-Fact-BF54AC4A24B420DE88B4E231C43A073B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">206,766</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277975668e1777-wk-Fact-EBD8030D420964FD023FE231C4B8333F" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277975668e1797-wk-Fact-02379BCDEC313F7AAD11E231C47F6E60" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277975668e1817-wk-Fact-943A5A8B43BBD83CEFC9E231C4419503" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277975668e1838-wk-Fact-5DAFBEF242A84CB7BC15E231C48FD013" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1864-wk-Fact-ACA33AEAAB4725288007E231C442BE5F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1883-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1902-wk-Fact-B80960B704D8361B606AE231C4A09B4D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1922-wk-Fact-2A814F972C0BD074AFC1E231C43F3652" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1942-wk-Fact-4B26B5AB9595C15EACD3E231C452EDCE" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1961-wk-Fact-F3A995FE72E51F9D3971E231C4A986C0" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q2Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e1980-wk-Fact-9F4C610798472730DF9CE231C47B1AEF" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2000-wk-Fact-BB84C7A53A3F37741239E231C44DA175" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q2DEC30-JUN29" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2020-wk-Fact-0299983057549E97DDBEE231C4A8C4BF" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2039-wk-Fact-D29BE3A6B68F7E6F3193E231C43E6608" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q2Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2058-wk-Fact-E3AFB87B37B6205B4E96E231C4A21E71" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2078-wk-Fact-43D96EC8BE7C5483B2A2E231C43B448B" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q2DEC30-JUN29" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, basic </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2093-wk-Fact-4044463EA64232983585E231C4379D71" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2112-wk-Fact-266587292C7A6833D40AE231C433B369" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q2Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2131-wk-Fact-57892A0C65D150C9B129E231C48EA534" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2151-wk-Fact-29A95E9E14C8CF8203C4E231C4A9A235" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q2DEC30-JUN29" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">296,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2172-wk-Fact-939D5E643961456211DFE231C4B20A6E" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2191-wk-Fact-9C5B62466C75220A7FA3E231C47AF2DA" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q2Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2210-wk-Fact-461891499FE2723E9818E231C44E4D54" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277975668e2230-wk-Fact-20D4CCDAE0A8ED18948DE231C435BB67" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q2DEC30-JUN29" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">313,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">      </span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><a id="s6647F4249AF75A829AC5E7AC1DBFFBE6"></a></div><div style="line-height:120%;padding-top:20px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e598-wk-Fact-ACA33AEAAB4725288007E231C442BE5F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e617-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e636-wk-Fact-B80960B704D8361B606AE231C4A09B4D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e656-wk-Fact-2A814F972C0BD074AFC1E231C43F3652" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $413, $0, $807 and $0, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e834-wk-Fact-6B31F55CF62600F10450E231C434000D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e853-wk-Fact-6857FCD418F62C6E01F2E231C4358FCF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e872-wk-Fact-554E5ABB145FD1448009E231C437C9A8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277976473e892-wk-Fact-D004AC02AA989303FEDCE231C436FD6D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e918-wk-Fact-E625688885FF57CAFAA9E231C43924D6" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e937-wk-Fact-11629364F13040E1431CE231C435C482" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e956-wk-Fact-663B83BF5218ACFEAF1EE231C438DE33" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277976473e976-wk-Fact-7264C9C7F206CFB5971BE231C43895FD" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s07ED532AEF1D555CBAFEBB9EEFFA57DD"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e791-wk-Fact-F3B983C5C1A25D1ECEEEE231C4904A07" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">301,519,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e810-wk-Fact-7AF2929F30C016B06491E231C491D0AE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e829-wk-Fact-E7B4BCE1947B92A4B01FE231C4945906" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,188,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e849-wk-Fact-4E6FCCF4358D4436CEEFE231C492956D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e868-wk-Fact-2E9D2A5307E4E92271FCE231C494395B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">804,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e888-wk-Fact-C7A1EE9B14540F7650F0E231C494C375" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,385,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e976-wk-Fact-6BD0AE1DF3219A74E456E231C490B30B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e995-wk-Fact-ACA33AEAAB4725288007E231C442BE5F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1069-wk-Fact-B6E5C3B1D371BA10DB83F32770963C59" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1107-wk-Fact-6B31F55CF62600F10450E231C434000D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1128-wk-Fact-D90EC0F075A821DC0754F326F205BD46" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,264,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1142-wk-Fact-9D775E464783BAFF2D8DF326F3F66601" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1161-wk-Fact-25F71F39A4DCFBCC5FFEF326F5776E10" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1219-wk-Fact-09EDBD39DC0CD79E3A3AE231C4953780" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1273-wk-Fact-48A41889233A74AFFC56F327B02E4784" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1331-wk-Fact-5D9FE01A5EC4CA0D0529E231C4932444" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1352-wk-Fact-E7A9EDAC33C3F65F8FFBE231C466BFEE" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">302,784,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1371-wk-Fact-33C29D0FCDF8E0798424E231C46AB67C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1390-wk-Fact-2887D1C3E6BD2FB4DCC6E231C46C621D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1410-wk-Fact-15AEEEEC559C38EEBF24E231C469DE66" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e1429-wk-Fact-3807618F1E469F0ED00EE231C467FFBB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1449-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at March 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1851-wk-Fact-74A94E301A0FE65B0D79E231C440902D" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">296,694,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1870-wk-Fact-8E2D32825FEA7C4EA271E231C43C8AD5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1889-wk-Fact-7226943225C2D520C251E231C43E7A73" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,125,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e1909-wk-Fact-B1904F7234B8652D19B4E231C43D69C3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e1929-wk-Fact-0EF77CD21878039E0CD2E231C43CC865" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,454,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e1949-wk-Fact-7F28215F6A433B128B21E231C43ED973" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q1Fiscal" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">670,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2037-wk-Fact-05C351918F4FE711EAFCE231C43CB9AC" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2056-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2130-wk-Fact-460E22C69790E6CAE1D7E231C43DA1AC" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2168-wk-Fact-6857FCD418F62C6E01F2E231C4358FCF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2189-wk-Fact-CE23BD25434BF854E97EE231C43FDA11" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,197,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2203-wk-Fact-2206B40278B4B0F07D5EE231C43B6F99" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2222-wk-Fact-574C37EC0FCAF3645D2CE231C43D3203" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2280-wk-Fact-0B771E0F00CD5C9681D4E231C43D55F1" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2334-wk-Fact-3CD2E5C485BF942DB3DDE231C43A9D92" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2392-wk-Fact-CA21072E27374D29635BE231C43B7746" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2413-wk-Fact-163DA00AE5F8891A9784E231C43C27F0" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">297,892,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2432-wk-Fact-11C5E8318656A97FA1AAE231C43C5DFF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2451-wk-Fact-BDE5D5F6AFF2D4BC5923E231C43B030B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,142,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e2471-wk-Fact-95D61F1C2C7777C036F3E231C43F792D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e2491-wk-Fact-12915F52C678D491FF49E231C43BFF0A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,367,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2511-wk-Fact-1B5B2840456185E2435BE231C43FFA3C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">775,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2932-wk-Fact-5D510C9190F560BB9E72E231C4648933" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">299,876,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2951-wk-Fact-B84CF36E533822EBA362E231C46917F0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e2970-wk-Fact-C86F8C2ADBB11C369156E231C466F485" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e2990-wk-Fact-109BF504E684107F77A3E231C467DB06" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e3010-wk-Fact-5DEE42FA41BCED0CC284E231C46E1EAC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3118-wk-Fact-10C5D7C54928A22C3A3D44C6DCB7984B" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3137-wk-Fact-B80960B704D8361B606AE231C4A09B4D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3211-wk-Fact-CF8D8ED4D32F89CDDDCFE231C46B14EF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3249-wk-Fact-554E5ABB145FD1448009E231C437C9A8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3270-wk-Fact-2BEAD5113ECB62111B83E231C46A40C0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,908,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3284-wk-Fact-160D2E22BB66EF802357E231C46883F4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3303-wk-Fact-DEC9CD8E55AF3B353776E231C46A2C96" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3361-wk-Fact-154C2A6989C3919E50B0E231C46BCD30" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,846</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3415-wk-Fact-CCF7825C73341D9E98B5E231C46752D5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3473-wk-Fact-6C6C8F78BC3080605666E231C4690374" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3494-wk-Fact-E7A9EDAC33C3F65F8FFBE231C466BFEE" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">302,784,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3513-wk-Fact-33C29D0FCDF8E0798424E231C46AB67C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3532-wk-Fact-2887D1C3E6BD2FB4DCC6E231C46C621D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3552-wk-Fact-15AEEEEC559C38EEBF24E231C469DE66" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e3571-wk-Fact-3807618F1E469F0ED00EE231C467FFBB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3591-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e3993-wk-Fact-210A650B8A0D880966E2E231C4A8619D" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">296,209,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4012-wk-Fact-37533C211990CB39BF7DE231C4A6ED1F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4031-wk-Fact-5B38E61FF36E3E8228A8E231C4A9C8F8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,114,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4051-wk-Fact-4C4D341067612DEDC7B8E231C4ABC82E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4071-wk-Fact-BF916A2AEA5FF32F0F9DE231C4AA75C7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,829,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4091-wk-Fact-46CC1A4A94C716FA8A19E231C4A72828" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">284,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Accounting Standards Update (ASU) No. 2014-09, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4181-wk-Fact-BFB15673FC46D8384DB3E231C4A49EEA" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4200-wk-Fact-EDFB2604DDAC9F1B878CE231C4A6A3A6" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No.&#160;2016-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4295-wk-Fact-A32CBEA42C527B378E40E231C4A775E7" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4314-wk-Fact-890674B2F854679BBAD5E231C4A91E1F" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4407-wk-Fact-88862EDA205945E922C7E231C4A88787" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4426-wk-Fact-2A814F972C0BD074AFC1E231C43F3652" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4500-wk-Fact-1E147BD21BA55C5F6712E231C4A42F5D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4539-wk-Fact-D004AC02AA989303FEDCE231C436FD6D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4561-wk-Fact-05F608BDB96805DD2C17E231C4A03F73" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,682,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4575-wk-Fact-7DAF788DCA9CDB4C85E5E231C4A28B4B" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4594-wk-Fact-441A5C844FB4FB4CDD88E231C4A39DCE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4652-wk-Fact-4C121D584FCE4CBB447DE231C4A5BC89" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4706-wk-Fact-E91DA41BAC14AE1105ECE231C4A17146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4764-wk-Fact-10C3D8C1CB89CD34B5B3E231C4A33B50" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4785-wk-Fact-163DA00AE5F8891A9784E231C43C27F0" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">297,892,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4804-wk-Fact-11C5E8318656A97FA1AAE231C43C5DFF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4823-wk-Fact-BDE5D5F6AFF2D4BC5923E231C43B030B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,142,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4843-wk-Fact-95D61F1C2C7777C036F3E231C43F792D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277983881e4863-wk-Fact-12915F52C678D491FF49E231C43BFF0A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,367,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277983881e4883-wk-Fact-1B5B2840456185E2435BE231C43FFA3C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">775,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="s35DE942E11495D9588E9E5435CD9E40A"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e509-wk-Fact-B80960B704D8361B606AE231C4A09B4D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e528-wk-Fact-2A814F972C0BD074AFC1E231C43F3652" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e584-wk-Fact-7CB2C2D7F968FD8E109FE231C4A75E34" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e603-wk-Fact-0884BEE04DD7A69BD1C6E231C4AC2FC1" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e623-wk-Fact-18E83557C0118F31C1FEE231C4A27767" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e642-wk-Fact-70A685DDB71C0082419AE231C4B72C05" name="us-gaap:ShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">401(k) matching contributions made in common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e662-wk-Fact-633D5C14BEAC3D13F2C3E231C4B57842" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e681-wk-Fact-DCFE99E7BB6524BF2307E231C4AD4D25" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization and other changes in right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e701-wk-Fact-312AA8B0517866327ECBE231C4AA595B" name="exel:RightOfUseAssetAmortization" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,071</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e721-wk-Fact-256B1512DB76549A5AC5E231C4B4CE11" name="exel:RightOfUseAssetAmortization" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e741-wk-Fact-4755F1F7F8C9D54B232E273928A2F282" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">33,067</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e760-wk-Fact-9F0A8381C46FBC8A53172739287E92DC" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gain on other equity investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e780-wk-Fact-EE3E90207A2B88C3C404E231C4B071B1" name="us-gaap:GainLossOnSaleOfOtherInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e800-wk-Fact-08C2D4BF68CFE89482F1E231C4B62756" name="us-gaap:GainLossOnSaleOfOtherInvestments" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accretion of investments, net and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e821-wk-Fact-7B1AEBAE3B879B04655DE231C4AE063F" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e841-wk-Fact-589C80C04B7237DC32E1E231C4B530C4" name="us-gaap:OtherNoncashIncomeExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e904-wk-Fact-2347F96A2F014A45E329E231C4B95B0B" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e923-wk-Fact-A21E21DA02B71E975B42E231C49FCD36" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e944-wk-Fact-4C10F54CA9E97A2A3CC4E231C4A03892" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e963-wk-Fact-433685ACD2EED001BD4DE231C4AD4E16" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e984-wk-Fact-FB20047B16F6B8D9E377E231C4AEB82C" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1004-wk-Fact-C327B73E9B2262DEBED0E231C4A441EB" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of unbilled collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1025-wk-Fact-FB1B3EC438F6D19CF68DE231C4A86103" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1045-wk-Fact-33F9527823CACEC322CEE231C4A9337D" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1065-wk-Fact-057AFAEFAFC25115B2C2E231C4B767A3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1084-wk-Fact-D2A5EED5808AD57190DCE231C4B1BAD9" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1105-wk-Fact-C3579A5A99C3213D17F6E231C4B817F8" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1125-wk-Fact-118224085444D1EBB33CE231C4B2596A" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1145-wk-Fact-A9FA94405957D48A1F19E231C4A8C966" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1164-wk-Fact-4FEA6EC7703804ABF5B1E231C4ABFEF9" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1185-wk-Fact-9A3C92DC53493F7B5AFFE231C49F0920" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1205-wk-Fact-D2AA4937DDCA9767449FE231C49F9F4C" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1225-wk-Fact-71F11C90ED1A1779CC4EE231C4A65302" name="exel:IncreaseDecreaseInAccruedClinicalLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1244-wk-Fact-8AF2A8E6BB93F5AD10EAE231C4B0F872" name="exel:IncreaseDecreaseInAccruedClinicalLiabilities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1265-wk-Fact-1F1D910A00725FB46008E231C4A197DC" name="exel:IncreaseDecreaseInRebatesAndFeesPayable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1284-wk-Fact-61A345BCDDD8CB42042DE231C49ED7F6" name="exel:IncreaseDecreaseInRebatesAndFeesPayable" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1305-wk-Fact-8D1ABCFB8EBF3D104CA1E231C4A20BE4" name="exel:IncreaseDecreaseInAccruedCollaborationLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1324-wk-Fact-4C8E1ADD2324A10F58A3E231C49F2B79" name="exel:IncreaseDecreaseInAccruedCollaborationLiability" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current and long-term deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1345-wk-Fact-4D593EBB8FE20E68B3A2E231C4B8A5D6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1364-wk-Fact-5DA16EF022D28807C8C9E231C4B6E555" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1384-wk-Fact-FE18FAA570CC197A664EE231C4B71787" name="exel:IncreaseDecreaseInLeaseLiabilityNoncurrent" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,777</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1403-wk-Fact-76205CE7C254997E5ED0E231C4B825AA" name="exel:IncreaseDecreaseInLeaseLiabilityNoncurrent" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current and long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1424-wk-Fact-0D1D54862DB310C19576E231C4AC01A8" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1443-wk-Fact-A1D48FE024D39C19DCEDE231C4AEFC11" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1463-wk-Fact-8495DF829ACDDAA26C69E231C4AAD93D" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">293,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1482-wk-Fact-C58F6C6BBB6C3D442ABEE231C4A41FB8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">146,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1543-wk-Fact-8F128C773B6FF38A19D5E231C4A739D4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1563-wk-Fact-C5621A5ED3C4FB863C11E231C4A1DBA0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1584-wk-Fact-F11D5AFA7614BB5E6918E231C4B392BE" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1604-wk-Fact-2C90A2CCA735CAF37266E231C4AD35C8" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">227,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1625-wk-Fact-BE16FB26E0D3B83751A9E231C4B26EFC" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1644-wk-Fact-33CECCA5F64577A6E988E231C4AB756E" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sale of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1664-wk-Fact-26FEC1F4E6C811796563E231C4A057B3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1683-wk-Fact-183153D80E16F90BF15FE231C4AC0BEB" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from other equity investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1703-wk-Fact-345DD6A6BA03BB2627C5E231C4A77E28" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1722-wk-Fact-3277AE841AF036448EC9E231C4AFE810" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1743-wk-Fact-B2CECABF4D79470EA1CBE231C4B307D8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">250,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1763-wk-Fact-AA0296B6682D8D6F73D0E231C4B34474" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">91,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1825-wk-Fact-2E9940DC23BA261FD0D5E231C4AADC02" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1844-wk-Fact-1F8E83D096279AF005E4E231C4A55F60" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1864-wk-Fact-B70E49139DBAE3F99A32E231C4B91DBD" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1883-wk-Fact-A98897774B377CE096A5E231C4B0F9C9" name="us-gaap:ProceedsFromStockPlans" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1903-wk-Fact-52DC709C0B33084F4FB7E231C4A0C1F0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1923-wk-Fact-190156C5E3A104511259E231C4A6D4D5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Principal payments on financing lease obligation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d277978785e1944-wk-Fact-4ADD9FB58639B5D82F70E231C4B896F6" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1964-wk-Fact-361CD9EA5DDB448A819CE231C4AC63D1" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e1984-wk-Fact-4435E0F4144D07B6A59DE231C4B4BD38" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2003-wk-Fact-2CCB477483FCA3AF4468E231C4A3040D" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2023-wk-Fact-99A3DB597B425E5ED165E231C4AF4586" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2042-wk-Fact-C130F013C33EE62CE406E231C4AA5013" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,697</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2062-wk-Fact-0EE8CC5629FA14CBB5A7E231C4A3D199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2081-wk-Fact-1FA1A8CFE095CE90F68DE231C4A3FC97" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2106-wk-Fact-89C66780BE1D0B94DA83E231C4B3ADCA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d277978785e2125-wk-Fact-38A5D9EB56083282C921E231C4B09545" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosure:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred to acquire Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277978785e2338-wk-Fact-ED7C76A22F1DEDCCB875E231C45332F5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277978785e2357-wk-Fact-87F2A4D6A6AC4D447F8EE231C451FC9F" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant inventive payment and an amendment to our existing lease for office and research space. Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC8C2D16D15D751DA9C1C949F929F2062"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div><a id="s10B48DBCF580588E88011F2F8F550972"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-0-wk-Fact-B40D02783970E25BD79EE231C45A37FF" continuedAt="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-1" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-1" continuedAt="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277984132e432-wk-Fact-ECC7FDC9114379A2D148E231C45B48D2" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q2YTD" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277984132e436-wk-Fact-8417ECBA9F86C21A77F0E6F5CA906316" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277984132e440-wk-Fact-CA475057AEBCA9E4BA3BE6F70010800B" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-F4F925D23E2A17F79DEBE231C4C8053B-0-wk-Fact-BC05B6DD23644205AAA4E231C45C34EA" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-873E457FF91028A0E2C3E231C4C7AF2B-0-wk-Fact-4956EE39E184EEACC1CFE231C45BE26C" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FiscalPeriod" id="TextSelection-8B1C180CF24CD9C4794AE231C4C89168-0-wk-Fact-D7F5DF70644324E18313E231C45D1600" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019, March 30, 2018, June 29, 2018 and March 29, 2019, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2019, March 31, 2019, June 30, 2018 and March 31, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-6EE5D812E9B97499764AE231C4C8E324-0-wk-Fact-4A95CCD08A617F441B92E231C45C7534" continuedAt="TextSelection-6EE5D812E9B97499764AE231C4C8E324-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277984132e534-wk-Fact-BEF847B642D471CAC1FDE231C45D00EA" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q2YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-2" continuedAt="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-6EE5D812E9B97499764AE231C4C8E324-1">All of our long-lived assets are located in the U.S.</ix:continuation> See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:UseOfEstimates" id="TextSelection-90B334C10DDE114C6B4CE231C4C7D639-0-wk-Fact-51E295E63D67DA50FFC1E231C45A15F8" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-D6CB69FBB2301D8599CDE231C4C83760-0-wk-Fact-112FCD2BF5A661C9CB43E231C46C5EC8" continuedAt="TextSelection-D6CB69FBB2301D8599CDE231C4C83760-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Accounting Standards Codification (ASC) Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-D6CB69FBB2301D8599CDE231C4C83760-1"><ix:continuation id="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Condensed Consolidated Financial Statements. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div><a id="s356001AF71B55342AACFFC1E173D842C"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-9575069913D0C501269CE231C4C8A4D1-0-wk-Fact-1BAA8938F148571831EAE231C4A378DF" continuedAt="TextSelection-9575069913D0C501269CE231C4C8A4D1-1" escape="true">REVENUES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-87901CC17B3BDBAD5ACFE231C4C96D35-0-wk-Fact-58DB03B1076D4AB68486E231C4A13D37" continuedAt="TextSelection-87901CC17B3BDBAD5ACFE231C4C96D35-1" escape="true"><ix:continuation id="TextSelection-9575069913D0C501269CE231C4C8A4D1-1" continuedAt="TextSelection-9575069913D0C501269CE231C4C8A4D1-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e683-wk-Fact-BB3F3684AF445C5F1510E231C4462578" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e702-wk-Fact-F032A66A1A622A210A7BE231C4470696" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">172,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e721-wk-Fact-16CE19CBAD55007F003EE231C44139D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">464,168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e741-wk-Fact-9BAB84E51F02E6074CB6E231C444B91A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e756-wk-Fact-C927A66B1B3FA056B953E231C444FF50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,743</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e776-wk-Fact-4F03AA2DEC862BD9A48DE231C443D924" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,810</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e796-wk-Fact-331CA3BC969912104F00E231C44447B7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,912</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e817-wk-Fact-6A1D3F2650F969822848E231C446ED16" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,974</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e838-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e857-wk-Fact-4F7C2030B0B97CB91993E231C43E6734" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e876-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e896-wk-Fact-50091E677B09B1D05D0EE231C4388469" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1000-wk-Fact-C0861B81A0D95FFEB585E231C444DF96" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1019-wk-Fact-94378C10C74323D9A7B1E231C4437FD3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1038-wk-Fact-1D5276EFE4EAC3CFDF8BE231C445D875" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1058-wk-Fact-5E0693FFD4B16123A31AE231C4400623" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1080-wk-Fact-3D0A5BFEE7001E6DC7FCE231C441DA46" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,898</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1099-wk-Fact-A22C595D4A3B113A65F0E231C4413F95" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1118-wk-Fact-8AD478EC4CAD0F8759DBE231C440BF52" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1138-wk-Fact-3AD02ECA678E73C02F5FE231C445DD1F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e1160-wk-Fact-A9EF62295D1B68B89B08E231C446B80A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1180-wk-Fact-E41DDF6616AD80EB393AE231C4436F57" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e1199-wk-Fact-E63EBAE27FCD89818DA8E231C4477BD2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1220-wk-Fact-3F98F5A86B7FAB66F9CDE231C44470A8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1240-wk-Fact-86F42DC59D3F418CDD1BE231C4B67703" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1259-wk-Fact-D3E4E43AD79C4893D9B1E231C454E6C0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1278-wk-Fact-83181898E532FF40688FE231C4796437" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1298-wk-Fact-DCC8DAB3437F1E74BCECE231C44105D8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1324-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1343-wk-Fact-24161066F0F7476E837BE231C4A56D73" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1362-wk-Fact-31347911C2A9E3B534C9E231C4637FEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1382-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">399,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span><ix:nonFraction id="d277989623e1412-wk-Fact-86FEAADED3B607A95BA5E231C4A32505" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><ix:continuation id="TextSelection-0D880880E2DE33B68E7FE231C4C953B1-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9575069913D0C501269CE231C4C8A4D1-2" continuedAt="TextSelection-9575069913D0C501269CE231C4C8A4D1-3"><ix:continuation id="TextSelection-87901CC17B3BDBAD5ACFE231C4C96D35-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1648-wk-Fact-B015F4CE2F307092586EE231C4747F2D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">189,015</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1667-wk-Fact-D4FBD20DE1AC5A1CFF19E231C47620B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1686-wk-Fact-1B6366209B2C01DCC623E231C4763237" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">364,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1706-wk-Fact-302F767BA3EE0E87E009E231C4734C31" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">270,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1721-wk-Fact-21813CEBD623B02C465AE231C4777593" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1740-wk-Fact-2B355D0DF4302A93C00EE231C4712EB8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1759-wk-Fact-3B62F2C54CD57A8B23F1E231C47331DD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1779-wk-Fact-310AE8EEEE98CC333C43E231C472F841" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1804-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1823-wk-Fact-4F7C2030B0B97CB91993E231C43E6734" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1842-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e1862-wk-Fact-50091E677B09B1D05D0EE231C4388469" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">280,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2125-wk-Fact-D117BFD29DC8FEBEB879E231C47CD6EE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2139-wk-Fact-950748D06EFFA9D02EEDE231C4776BF4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2159-wk-Fact-83FB7BE9C60D718B59F4E231C47B0D85" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2174-wk-Fact-5D9449DC22E163947DC3E231C4757748" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2190-wk-Fact-D72BC4062AB6DE954683E231C478EA18" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2209-wk-Fact-D14CD3D79403C74E2040E231C47D9978" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2224-wk-Fact-B27D77DDA808A2C38A96E231C477B844" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2244-wk-Fact-4669F98DEAEE39EC1E18E231C47CDD5C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2260-wk-Fact-1D7A7EEB1259365EA3CDE231C47964CB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2279-wk-Fact-4718AD87A433F69D056CE231C4823C85" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2294-wk-Fact-DC0BC572957FFF6EBC41E231C47A6025" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2314-wk-Fact-4B6E8B659D0E7BA065C8E231C4771417" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2330-wk-Fact-DED6C70B4A79CB4BE06FE231C47BF31B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2349-wk-Fact-22D247C94FE42C759C6FE231C48503B6" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2364-wk-Fact-1D76F2D7DF400F188A86E231C4767EE0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2384-wk-Fact-CE1C370B5732E2806ABCE231C481F331" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2400-wk-Fact-44104B4E05ED3389D7B5E231C47AE5D8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2419-wk-Fact-A1F29EFD36EC0900C03FE231C474E6FA" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2434-wk-Fact-2766E417FC8AAA012FA5E231C47E6A20" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2454-wk-Fact-09A50D3785726B6AB2EDE231C48120E5" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2470-wk-Fact-8F453D113FED12620742E231C47B651E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2489-wk-Fact-58B4719F465FC543C6E8E231C480ED82" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2504-wk-Fact-280A0EE092476EDB5D0FE231C47658F8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2524-wk-Fact-DCE2C7EF5C7CAD48B8E1E231C4759153" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2540-wk-Fact-0F49709A38697D37BB33E231C47D01CA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2559-wk-Fact-339D4D02C8D05C13C205E231C4788F17" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2574-wk-Fact-B5994DBE78E624A04922E231C47D8DF3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2593-wk-Fact-F367C8F43B50B69CF86FE231C47F1620" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2614-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2628-wk-Fact-61AD1F294A5A300FC94FE3359C6ED5BA" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2648-wk-Fact-24161066F0F7476E837BE231C4A56D73" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2663-wk-Fact-54284BF458040B9B70E1E3359C8437B0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2921-wk-Fact-88F21E3E26F19F9A03E9E231C482308E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">69,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2935-wk-Fact-396ACE837010D244A9CCE231C477DC97" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2955-wk-Fact-0B4DA2569BF5210C4F6EE231C48482B6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2970-wk-Fact-16ADD12153867EF466EDE231C480D978" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e2986-wk-Fact-47CF20DA221E94151B0CE231C4811F6E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56,595</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3005-wk-Fact-21A8F8CB7D1ED11BFDF4E231C47D8D0E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3020-wk-Fact-73750D21313D8A7FD72DE231C47E1B1D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3040-wk-Fact-7A0EA1AD7D19CB77B72DE231C482A58B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3056-wk-Fact-039F2A64EC2C10612C6CE231C4847D28" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3075-wk-Fact-28FCD53CCD5881363054E231C47F37D7" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3090-wk-Fact-4112E0B10DF0FDB2BB22E231C4856DB1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3110-wk-Fact-B18612EEC7F5324D225AE231C47AA8D4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3126-wk-Fact-2C5D2D4F854AF945163BE231C4804E81" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3145-wk-Fact-BFB5366D6278041F83E5E231C484A8B7" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3160-wk-Fact-A9D184F4942C848B8D59E231C479C7E0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3180-wk-Fact-9A5C6371E6031468D11AE231C47AF7B4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3196-wk-Fact-F54BFDC980D5BF0F1055E231C47C590F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3215-wk-Fact-FCB02BEB9D68E26C893BE231C47CAC5E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3230-wk-Fact-5F75F6508ACEC9A3399CE231C47931D5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3250-wk-Fact-50841154615FBBE75C6AE231C47E2BDF" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3266-wk-Fact-2B4C7C20340050B93346E231C4798A49" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3285-wk-Fact-01BB6F26F2020D33DEF2E231C482FB29" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3300-wk-Fact-5640CFB40461EEA8B339E231C4842C7C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,622</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3320-wk-Fact-CB524CBE94EEF1992562E231C47FFA4B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3336-wk-Fact-6792640A1121EED4CF6CE231C47CD6E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3355-wk-Fact-EA1E56DF5BBA5A0D535EE231C47B288F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3370-wk-Fact-69436EAADF65C283F15FE231C4818E80" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3390-wk-Fact-1CD676CA77FA5D8D65DCE231C48074A3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3411-wk-Fact-31347911C2A9E3B534C9E231C4637FEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3425-wk-Fact-D04FAB80235563ABDE76E231C479ECD0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3445-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">399,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3460-wk-Fact-E13E55FFC4A7F834CD5FE231C47C072F" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3673-wk-Fact-35F36E66CF0D32964AE2E231C4846A29" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">196,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3692-wk-Fact-703C6EC79C6E8A83DE7BE231C4865EE1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">150,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3711-wk-Fact-CED8F937ADCF8805DB5DE231C481A282" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378,473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3731-wk-Fact-D820511486075A722FD7E231C47F8E4F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3746-wk-Fact-A3B43BC5D2B03835563BE231C4805E25" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3765-wk-Fact-22DA57CC6DFB841D0AE9E231C481E7F0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3784-wk-Fact-B069417F60DE284B3364E231C4833196" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3804-wk-Fact-307FB6D66985F828E47EE231C481AA4D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3824-wk-Fact-6552DFDFD9CC8C3E32F4E231C485B1DD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3843-wk-Fact-406160131F10E4357CE6E231C4817931" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3862-wk-Fact-4A720B4BFE2FBAE8B398E231C47F5AAA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3882-wk-Fact-399D1E1AF393F1A4A28FE231C480FBE2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3907-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">240,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3926-wk-Fact-24161066F0F7476E837BE231C4A56D73" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3945-wk-Fact-31347911C2A9E3B534C9E231C4637FEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">455,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e3965-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">399,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><ix:continuation id="TextSelection-E756B2A2CAA2A59D467BE231C4C9D4C8-0" continuedAt="TextSelection-0D880880E2DE33B68E7FE231C4C953B1-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-9575069913D0C501269CE231C4C8A4D1-3"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="TextSelection-F25F426A0670F25170EBE231C4C9B329-0-wk-Fact-BA702A9DBF4CA0B3E02CE231C4A24CD6" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4117-wk-Fact-7AEBC825E95DE0655563E231C4641AA9" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4136-wk-Fact-7FE8E294C8389EF1FAA2E231C46150C2" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4155-wk-Fact-A329B4C24CD91985412DE231C467768F" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4175-wk-Fact-3D191EA67C7879CDB0A7E231C4674CB8" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4272-wk-Fact-C6236B350E4BA3840495E231C45F44F5" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4291-wk-Fact-216EAF89268918E89908E231C46562A0" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4310-wk-Fact-AD3AB550ED5E4EAAE525E231C460BE25" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,681</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4330-wk-Fact-4356F5FEBBF9C9D62903E231C465CE1E" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91,238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4350-wk-Fact-E236EE14B67B3004949FE231C462C330" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4370-wk-Fact-02A785D5C81A58E373D5E231C46005B1" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4390-wk-Fact-20F1CC2CAD58ABA4AB24E231C46172E2" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4411-wk-Fact-9E3ADE1FEBD38EE39E0FE231C463391D" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4432-wk-Fact-6DAD4C2DFFED0186D3E3E231C467732E" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4452-wk-Fact-B6B6CEE2C931AFB616C9E231C46835EF" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4472-wk-Fact-55F2223A29057A73D095E231C46429FC" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4493-wk-Fact-BE6984B99817636EA971E231C462AD6C" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4519-wk-Fact-645EFC9DE5926A7491DFE231C463BFEE" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4538-wk-Fact-03718AF21872E6FBBC41E231C466B169" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4557-wk-Fact-7A07293D9F0CBCA010BEE231C4667562" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4577-wk-Fact-D00B7B72D5D7D9F866CAE231C4684168" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-54DB65108F633F2840FCE231C4C85AF2-0-wk-Fact-BC9447AF098DDE737A7DE231C4A4C365" continuedAt="TextSelection-54DB65108F633F2840FCE231C4C85AF2-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-54DB65108F633F2840FCE231C4C85AF2-1" continuedAt="TextSelection-E756B2A2CAA2A59D467BE231C4C9D4C8-0">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.</ix:continuation> <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-24944439722AF98D3256E231C4C97ACC-0-wk-Fact-7136E5A2ADAD7328B431E231C4A34EA6" continuedAt="TextSelection-24944439722AF98D3256E231C4C97ACC-1" escape="true">Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-24944439722AF98D3256E231C4C97ACC-1" continuedAt="TextSelection-24944439722AF98D3256E231C4C97ACC-2"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4810-wk-Fact-F4E012750659216D6F36E231C497E1D9" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4829-wk-Fact-F69BB2C8117D0C44D7A7E231C49C1BDA" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4848-wk-Fact-D1F954611E49C807BFD9E231C499D22D" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4868-wk-Fact-DE122CBD38CBDDC50F9CE231C49AF7DC" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4883-wk-Fact-D80E58F5941A852445B7E231C497D782" name="exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e4902-wk-Fact-98DD90A3C9943EEA3E98E231C4972966" name="exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e4961-wk-Fact-B432973169983474B162E231C49BCBB2" name="us-gaap:ContractWithCustomerAssetReclassifiedToReceivable" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5078-wk-Fact-113AA4F492D17A9BD3CEE231C49B605F" name="exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5098-wk-Fact-F966E403D8DE77B7D974E231C498996E" name="exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e5156-wk-Fact-738329FF6306B4AA75E3E231C49991C1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e5199-wk-Fact-196CC2331B3327BFC3A3E231C499DBF5" name="exel:ContractWithCustomerAssetCurrentOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e5219-wk-Fact-42AE4BCF00D5FF14AD57E231C497A44F" name="exel:ContractWithCustomerAssetNoncurrentOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5239-wk-Fact-1CAB3171D614D1F02C12E231C49AA3AC" name="exel:ContractWithCustomerLiabilityCurrentOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277989623e5259-wk-Fact-8AEB2BDA355F24762417E231C49AA849" name="exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5285-wk-Fact-2B10E90F4701572B56C0E231C4986D46" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5304-wk-Fact-0D95C6D7BFF19828D276E231C497F81E" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5323-wk-Fact-D0A13340B1628806C194E231C4861769" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277989623e5343-wk-Fact-229DE50DEF12B74C475CE231C49D47E0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-24944439722AF98D3256E231C4C97ACC-2" continuedAt="TextSelection-24944439722AF98D3256E231C4C97ACC-3"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-24944439722AF98D3256E231C4C97ACC-3"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277989623e5378-wk-Fact-BCB3C5834D3F231A5689E231C4A4F8F4" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">36.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277989623e5382-wk-Fact-6143F9A7CE9B262EA2AD274349A40E7B" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">61.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277989623e5386-wk-Fact-F9E5793A3C1A0A5F0B26274373A40E8D" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277989623e5391-wk-Fact-D9F8F70BAB01637BE558E231C4A5815F" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</span></div></div><hr style="page-break-after:always"></hr><div><a id="s529A11253A4C52C087328376B5FE7278"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-0-wk-Fact-099FEDDC5B5629787C94E231C4B6DACD" continuedAt="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-1" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-1" continuedAt="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. <ix:continuation id="TextSelection-6A312E17CA4B827D1870E231C4CAD00C-0" continuedAt="TextSelection-6A312E17CA4B827D1870E231C4CAD00C-1">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-6A312E17CA4B827D1870E231C4CAD00C-1" continuedAt="TextSelection-A39C4D254FE04AD14ED6E231C4CA8188-0"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e643-wk-Fact-1A88CC7AF6DC5D95A713E231C454F9EE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e662-wk-Fact-BB674E2970767E389705E231C4532148" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e681-wk-Fact-531F2C0C9B39C594BF46E231C453E443" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e701-wk-Fact-831EF5E3B803D1C77E26E231C45369F7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e718-wk-Fact-C3F7BE21593F56206F90E231C4B3C8BE" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e726-wk-Fact-F08A770DB2DCE20F3C7BE231C4B74419" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e730-wk-Fact-5E1972C2611F9D180302E231C4B2010A" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in the Current portion of deferred revenue and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e735-wk-Fact-F4BDA5807FE65B0096A4E231C4B102EC" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e755-wk-Fact-66B92E6DBD76F3E215552EACD154F287" name="exel:CollaborativeArrangementAnnualReimbursementLimit" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, first-line RCC and second-line HCC by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e763-wk-Fact-3480C8E053911811DA21E231C4B60265" name="exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e767-wk-Fact-A50BD5E00653121AC409E231C4B169A1" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including an increase from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e771-wk-Fact-8465742988CC5467ECC1E231C4B7FE78" name="exel:CollaborationAgreementMilestonePaymentsEarned" contextRef="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e776-wk-Fact-22645B6969C954591600E231C4B30668" name="exel:CollaborationAgreementMilestonePaymentsEarned" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (MHLW)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#8217;s total potential commercial milestones by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e784-wk-Fact-690B40F989C1693EEEE5E231C4B5DF97" name="exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e788-wk-Fact-9B86E2CF72E10958E41BE231C4B434E4" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-2" continuedAt="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-3"><ix:continuation id="TextSelection-3A0E41E9BA689C6F40BEE231C4CAE379-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e999-wk-Fact-C747874DFD98BAF6A788E231C456A3EA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1018-wk-Fact-9F85AF43A7B48A80A1F7E231C4565ABD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1037-wk-Fact-333CEAEE5D6DD21D5C12E231C4567E89" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1057-wk-Fact-DA34AB0F74679B5F5B82E231C4554C7A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1074-wk-Fact-8CC11815B0CC1248E6A6E231C4B889E1" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1088-wk-Fact-081E08A4CCD8A362F8AD2EADFA692F0D" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. <ix:continuation id="TextSelection-86B0E447B986BE976286E231C4C9868F-0" continuedAt="TextSelection-86B0E447B986BE976286E231C4C9868F-1">Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-86B0E447B986BE976286E231C4C9868F-1" continuedAt="TextSelection-3A0E41E9BA689C6F40BEE231C4CAE379-0"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1310-wk-Fact-0AA25D72FCEBA4F029AEE231C49C7BAE" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1329-wk-Fact-3421BE323DF468DB2471E231C49B893C" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1348-wk-Fact-9722E09BE0045C3AA74EE231C499F58F" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1368-wk-Fact-95DA52DFA503C4041901E231C49A1A72" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1388-wk-Fact-0EC7431636F1C783BDC127525A3C6CAD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1407-wk-Fact-F6380618914F424831FFE231C49C883C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1426-wk-Fact-31D5EA177B1D875E2811E231C4990094" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,813</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1446-wk-Fact-6E0187E31047D2B20829E231C4993FBD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the launch,&#160;we&#160;received a&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1473-wk-Fact-056DBCEDFB043F06B1F42ED8F7E3386B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q2Jun01-Jun28_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;milestone payment from Daiichi Sankyo in June 2019. We are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277991397e1479-wk-Fact-33613171D04D5FDF62E42ED0294C8E06" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><ix:continuation id="TextSelection-A39C4D254FE04AD14ED6E231C4CA8188-0" continuedAt="TextSelection-86B0E447B986BE976286E231C4C9868F-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1688-wk-Fact-5E6B182861EA889A8ED92752ABC08CA1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1707-wk-Fact-D7EEA4DE798749BB26E32752AE335343" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1726-wk-Fact-D234831B908731F8F704F32EE1593E85" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e1746-wk-Fact-D7A9C06F4456442392E9F32EE1467880" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">antibody-drug conjugate</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1766-wk-Fact-2E37B4D04AFCA13ED98B2EE65BA296FC" name="exel:CollaborationAgreementsUpfrontPayments" contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1774-wk-Fact-32FCFF1BECA85D57FD752F01089D104B" name="exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the preclinical development funding commitment. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the accompanying Condensed Consolidated Statements of Income.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we exercise the option, we</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would be required make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1794-wk-Fact-05D8B79CBA0FACD00FD72EF6ECD503ED" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1798-wk-Fact-B430E7C65785AF5809AA2EEF061A6350" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277991397e1802-wk-Fact-6A04EE4804E34312E8532EEF05FBB83C" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">262.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277991397e1812-wk-Fact-86FEAADED3B607A95BA5E231C4A32505" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-1517E0343D8A60C7F082E231C4CA82E2-0-wk-Fact-F1FF0D1C7692038E9401E231C4B2D0F8" continuedAt="TextSelection-1517E0343D8A60C7F082E231C4CA82E2-1" escape="true">Such royalties accruing to GSK were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1517E0343D8A60C7F082E231C4CA82E2-1" continuedAt="TextSelection-6A312E17CA4B827D1870E231C4CAD00C-0"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e2019-wk-Fact-B4A17CF6C987F1A48370F330AE9B3DF0" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e2038-wk-Fact-EAAF1E1E7E8723681973F330AE92AEA8" name="us-gaap:RoyaltyExpense" contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e2057-wk-Fact-5EF1252E9B5EFAA86DCDF330AE8C040B" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277991397e2077-wk-Fact-AC87DC1216A36DE9A52BF330AE88281C" name="us-gaap:RoyaltyExpense" contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s69AE9200BBAE5A888BD6E148350F713E"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. <ix:nonNumeric contextRef="FD2019Q2YTD" name="exel:CashCashEquivalentsAndInvestmentsTextBlock" id="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-0-wk-Fact-97C6C6A253AB5B407FD2E231C44A9641" continuedAt="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-1" escape="true">CASH AND INVESTMENTS </ix:nonNumeric></span></div><ix:continuation id="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-1" continuedAt="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-7FC8C77291367FD67D87E231C4CA3CD1-0-wk-Fact-4AFBBA5E49FEACC14FBBE231C448A228" escape="true"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-878B317CB1A4EB1FB79CE231C4CBA20A-0-wk-Fact-B6B2428D86F15F0D3CAEE231C4321A61" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e531-wk-Fact-93396699141361E328C7E231C47489B6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">369,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e569-wk-Fact-5DD0B6131A23A5F2B474E341854249EC" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">248,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e589-wk-Fact-973E360317E74E5D2298E231C45FDF7E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">183,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e604-wk-Fact-134AE5685C003C0F4FF6E231C45DB785" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e642-wk-Fact-CCE739A2751E0ECED40FE231C459C584" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e662-wk-Fact-4398D6AD1407D04A5F12E231C45B3F68" name="us-gaap:RestrictedCashCurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e682-wk-Fact-11BD26FD71BDB949C36BE231C48D8C87" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e720-wk-Fact-9D7CCCFDD5B3200F0DC244AD5DF418FE" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e740-wk-Fact-4D15D742437BC8EC8AD3E231C45E08E7" name="us-gaap:RestrictedCashNoncurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e765-wk-Fact-89C66780BE1D0B94DA83E231C4B3ADCA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e784-wk-Fact-0EE8CC5629FA14CBB5A7E231C4A3D199" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e803-wk-Fact-38A5D9EB56083282C921E231C4B09545" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e823-wk-Fact-1FA1A8CFE095CE90F68DE231C4A3FC97" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-2" continuedAt="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-3"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-784F93B75A16EA0B775DE231C4CBB85D-0-wk-Fact-4FFA9BDE71685CCCD9A8E231C44AAFE0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1148-wk-Fact-D9C48B4924B1AB2A673AE231C43425FD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1167-wk-Fact-117EB7B9223FF451F795E231C4383031" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1186-wk-Fact-C029A7C99051712220B3E231C449E1C2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1206-wk-Fact-CB5837AB8FA4DEA7CAA3E231C437CF31" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1221-wk-Fact-BC57072FAFA2435D0CCBE231C43428C4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">406,238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1240-wk-Fact-7814E4131E367D9075C8E231C44BC811" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1259-wk-Fact-8F25ECD991D6964A3188E231C4364A19" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1279-wk-Fact-B880C2E9A91F61A58ACCE231C439A09B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">406,238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1299-wk-Fact-1CF9E933DA299C13C0EDE231C44A8918" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">559,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1318-wk-Fact-8367B973C8B498498FFCE231C4492861" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e1337-wk-Fact-C101F2957AFA878715D5E231C44BA26D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1358-wk-Fact-2462EE6DAC9FDB22C840E231C43978AE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">562,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1378-wk-Fact-1DC82FC977FA62BD7120E231C4334EF7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1397-wk-Fact-D05967463B615A72CFB2E231C437EDCA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1416-wk-Fact-0068C33615B4F9822BCCE231C4326E66" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1436-wk-Fact-6C950D42F5E63AD96E98E231C433F57A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1456-wk-Fact-8941229AFE9612451712E231C4362E36" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,132,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1475-wk-Fact-57637833082E132907BBE231C44BC47C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e1494-wk-Fact-034CE73C8E56523A879BE231C44906D9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1515-wk-Fact-2B58AC1634D39FDE8E9AE231C43AA299" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,135,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1535-wk-Fact-1CFF43F3E0DC9F878971E231C4334670" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1554-wk-Fact-0544650E1157D8A006B4E231C437B6D9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1573-wk-Fact-E163BEF72D26798C4022E231C43573FE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1593-wk-Fact-B533B0E51A1C394B0EABE231C433660A" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1613-wk-Fact-F056DF24C38295109F88E231C44A2486" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1632-wk-Fact-EA21576A79C2E6A6C865E231C44BE8B5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1651-wk-Fact-EFCC8696160B851472A2E231C4388BC0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1671-wk-Fact-AFF7DEC4A3C4CCBFE3D5E231C435E70E" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1696-wk-Fact-FD7F0A41BD3898645A9BE231C4358271" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,157,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1715-wk-Fact-57637833082E132907BBE231C44BC47C" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e1734-wk-Fact-034CE73C8E56523A879BE231C44906D9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e1755-wk-Fact-236D729C994B50E7FBCEE231C4378046" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,161,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2061-wk-Fact-303D69D2AA3E42F6C863E231C47EE562" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2080-wk-Fact-9AB781898E05A8C67098E231C47D28F0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2099-wk-Fact-C32488F7ABCC16B71B21E231C483A006" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2119-wk-Fact-CD3B5C3B10BA188150DAE231C485ACDA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2134-wk-Fact-65D4E216FBD137762BF1E231C485DCD6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2153-wk-Fact-02BB322DB4B7506DAC94E231C47ECE14" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e2172-wk-Fact-A69AD4B080703095A9EEE231C487D744" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2193-wk-Fact-BA10D4EE06E8C658B6DFE231C4889D91" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2213-wk-Fact-2E24144B1A6CD69043FAE231C487819B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2232-wk-Fact-76D3A6AEE4F503860490E231C4792325" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e2251-wk-Fact-4A3726D9E0C11E05D26FE231C47B1957" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2272-wk-Fact-F7192DB4AC761A1CB8E6E231C488B95B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2292-wk-Fact-ED2F58A55ABEFC184A52E231C4874329" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2311-wk-Fact-28555D06026BA406D01BE231C4875721" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e2330-wk-Fact-7D1C803429E17928F360E231C47B7505" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2351-wk-Fact-97A7063282AE06C0D536E231C4788A7D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2371-wk-Fact-0A142BA40894D3EA395AE231C4873701" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2390-wk-Fact-11D96E0E938933BE1687E231C47CBE09" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e2409-wk-Fact-D73F9845EC969D187C27E231C4879DFF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2430-wk-Fact-A087C9E3ACF4CC180813E231C43A8A0A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2450-wk-Fact-43436FB2AB0D50C049ADE231C487F780" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2469-wk-Fact-96E230AD2FAD569AF610E231C4860645" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2488-wk-Fact-0E322AEC2F0FB758FCB0E231C47C69FD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2508-wk-Fact-EABB322C4275D74B56ECE231C47EFC3D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2528-wk-Fact-64077D42E3729B6DAA77E231C47A3BB5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2547-wk-Fact-AB56FA9DE74770B35C4AE231C487153A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2566-wk-Fact-1EE6E64752E6B3FCA7CDE231C478F6BF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2586-wk-Fact-A0BE34E589B28309345FE231C4893076" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2611-wk-Fact-6D780552FB3ED54E4646E231C48980E9" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">852,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2630-wk-Fact-11D96E0E938933BE1687E231C47CBE09" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e2649-wk-Fact-D73F9845EC969D187C27E231C4879DFF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e2670-wk-Fact-F503D333C4C07251B853E231C48937E4" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">851,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="TextSelection-87C7FAE300BC4F31E0D6E231C4CA4311-0-wk-Fact-FD9F95260D6295BB3E8EE231C4490918" continuedAt="TextSelection-87C7FAE300BC4F31E0D6E231C4CA4311-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3120-wk-Fact-70F856DD8883CD40F468E231C4B00959" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3139-wk-Fact-AC971774632C0847BC35E231C4AEDEA8" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3159-wk-Fact-1E6B7227F49810D850E4E231C4AF712A" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3179-wk-Fact-9E44E7509A4657D25283E231C4B1CF12" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3199-wk-Fact-35ACA5A1FEAB69C0EB61E231C4AEAFF8" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3219-wk-Fact-A6B43A08E7B4B3ADFB69E231C4B122F3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3240-wk-Fact-9E21DE6EF4972E3288E4E231C4AEBB41" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3259-wk-Fact-FCD479864035C31E9593E231C4AB0E2E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3279-wk-Fact-80ED2C3B74D25182C0FEE231C4B18B1D" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3299-wk-Fact-040C5601A192E764B088E231C4ABDEEB" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3319-wk-Fact-1A3376D0B6F1C7664BCAE231C4AD98E6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3339-wk-Fact-4C749623FD9FBC647DF4E231C4AA8A42" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-3"><ix:continuation id="TextSelection-87C7FAE300BC4F31E0D6E231C4CA4311-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3760-wk-Fact-1C36707CBAB6B7341400E231C45BDA06" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3779-wk-Fact-357AA8B17D7D0A4AE7F2E231C45E9B55" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3799-wk-Fact-E15BA8442F5CC8A1FF4DE231C46122A0" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3819-wk-Fact-A0AA51A6087BEA1A8DEAE231C45B3C00" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3839-wk-Fact-008C49C27E9D0165C03DE231C4586909" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3859-wk-Fact-A1F0579208619D06A5F0E231C4603793" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3875-wk-Fact-11AECDDC32AA5183FB5BE231C4592870" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3894-wk-Fact-7D88FC31388F881F47C2E231C45EAE8E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3914-wk-Fact-944B1D459B1EA77B439AE231C45F578D" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3934-wk-Fact-B07EB165477344568DBAE231C461C787" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3954-wk-Fact-DEF897441BF4E9524549E231C45F4B1E" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e3973-wk-Fact-D1492182DD70D20655EAE231C4616404" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e3995-wk-Fact-1119EC40AEE1CB2F941BE231C45EE594" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e4014-wk-Fact-9288ABA2934B4189F0A6E231C4623448" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4034-wk-Fact-3753CFA08E3A57373195E231C45A2DA7" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4054-wk-Fact-7C56793421933A30992FE231C45BD33C" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4073-wk-Fact-69C6154371085BCA9209E231C46022ED" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e4092-wk-Fact-352F1F1CF33446172BB9E231C46017D4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4119-wk-Fact-6B4BCEEE64C87FE8511EE231C45C0425" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e4138-wk-Fact-7662B94A9B953BF09306E231C45C4AA2" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4158-wk-Fact-FC72BE3DD418B26CABB9E231C4608EAC" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e4178-wk-Fact-F12299F25EC6A899BAF0E231C45DE73A" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4198-wk-Fact-8C5983C2FB3FEFC61EC0E231C45A5E0B" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277995911e4218-wk-Fact-BC0EC3A0880C83C68A85E231C45E8142" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277995911e4233-wk-Fact-EC9018E6CCF8FD50CD71E231C44A6631" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2019Q2" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">42</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277995911e4237-wk-Fact-F6D45A2F96EBDA8E9F82E231C448BA3F" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2018Q4" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">199</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277995911e4262-wk-Fact-5BBB5694A53AC024DEA4E231C44083CB" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-263BC9010CCC49BF8283E231C4CBC43E-0-wk-Fact-25AED417852870F3B9C7E231C4491FB1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4376-wk-Fact-10813411E74ED0F287CAE231C43A19D9" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">809,607</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4395-wk-Fact-60EB8B5F3BAB46E80BCCE231C43A7002" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">674,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4410-wk-Fact-62992509DAA73C163405E231C43A5DAF" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">326,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4429-wk-Fact-4B178FE4AD65DDD05FB8E231C43A2F6D" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4454-wk-Fact-2B58AC1634D39FDE8E9AE231C43AA299" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,135,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277995911e4473-wk-Fact-A087C9E3ACF4CC180813E231C43A8A0A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the most recent date for which they reported ownership data, their beneficial ownership was more than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277995911e4493-wk-Fact-9DF9C91D30B7C106CD20E231C44B5AB0" name="exel:OwnershipInterestByMinorityShareholder" contextRef="FI2018Q4" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and investments managed by BlackRock was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277995911e4507-wk-Fact-5E8C015B16191AD8C961E231C449C5DC" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">421.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277995911e4512-wk-Fact-074F17778E76307D4C4CE231C433645A" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">298.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277995911e4516-wk-Fact-FBE59881D9D2FE3C13EFE231C432A315" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" contextRef="FI2019Q2" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277995911e4520-wk-Fact-19FDE63016ADA876D6F6E231C43202C6" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> invested in the BlackRock Liquidity Money Market Fund. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277995911e4526-wk-Fact-D6AB157C99EF319A76C6E231C44AB857" name="exel:RelatedPartyTransactionsAdvisoryFeesIncurred" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in fees for BlackRock advisory services performed during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation><div><a id="s97B15E61BEB053D390B25D2438DCD7C5"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-0-wk-Fact-DCA448A7C0E9A6CC876FE231C44A3280" continuedAt="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-91AC9DCA57B9F9F42A19E231C4CB31D4-0-wk-Fact-283F75870D397E2A296EE231C4911BAB" escape="true"><ix:continuation id="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-1" continuedAt="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e487-wk-Fact-8C75851FE71B04E79B44E231C457E34B" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e506-wk-Fact-12C7BD771E93FE7FEEF8E231C4558E4E" name="us-gaap:InventoryRawMaterials" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e521-wk-Fact-F6A970B84DDDBEF7EBC9E231C4585014" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e540-wk-Fact-C17ABAB904592C6D5A0BE231C456CF81" name="us-gaap:InventoryWorkInProcess" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e560-wk-Fact-E0892DCE1551B21EE894E231C4576EE4" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e579-wk-Fact-F134151AF8A962C27B3EE231C4580321" name="us-gaap:InventoryFinishedGoods" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e604-wk-Fact-1EE216D5D4B7E09BF2F5E231C4559BF1" name="us-gaap:InventoryGross" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e623-wk-Fact-CA0443CA65E6511AEAFAE231C459773C" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e725-wk-Fact-3CB44351BF4417904778E231C457387A" name="us-gaap:InventoryGross" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e744-wk-Fact-76F1F14D8B50B16A126BE231C4581E2B" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e759-wk-Fact-3FD6035FFD8040631C67E231C459D143" name="us-gaap:InventoryGross" contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e778-wk-Fact-A3E09F95634407DB126EE231C4565BD9" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e803-wk-Fact-1EE216D5D4B7E09BF2F5E231C4559BF1" name="us-gaap:InventoryGross" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277996608e822-wk-Fact-CA0443CA65E6511AEAFAE231C459773C" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277996608e836-wk-Fact-3D61EC933CE5AE9C5490E231C4457048" name="us-gaap:InventoryWriteDown" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277996608e840-wk-Fact-6DC60CC23CC71642E48DE231C43D676C" name="us-gaap:InventoryWriteDown" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, also a portion of our work in process.</span></div></ix:continuation><div><a id="s419B0490693550919FA2CD978B6AA5B6"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-0-wk-Fact-A3F84486C4E0626739E3E231C4901542" continuedAt="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-1" escape="true">PROPERTY AND EQUIPMENT </ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-D5CC73BD109BA90A6BD3E231C4CC3296-0-wk-Fact-8F4C7734F431444E9B68E231C48F921E" escape="true"><ix:continuation id="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-1" continuedAt="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e474-wk-Fact-A1E0E0D4CAF85E8DF750E231C448EFDD" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e493-wk-Fact-36821607730EB879C09CE231C489E0E1" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e508-wk-Fact-FEA7491BA66443BC63F5E231C48AF712" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e527-wk-Fact-4E67A768BE1578D4D43DE231C448A49C" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e547-wk-Fact-0A91621C19999EEC99A4E231C4490F37" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e566-wk-Fact-1BD6006712553038A4EAE231C48961A4" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e586-wk-Fact-DBCCD29FD159E8A56F1BE231C44BFB96" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e605-wk-Fact-E2ED95E3F654C2328C26E231C47407CF" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e625-wk-Fact-3DEB8B5EDA5D6CE3824AE231C47464B6" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e644-wk-Fact-7E706F6BBD5E87A29654E231C48A8250" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e664-wk-Fact-183A98C0C7686EC49038E231C4760EA3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e683-wk-Fact-212486D8A46E379A8997E231C44C1495" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277997082e703-wk-Fact-19354D91B2B4A3CB10F1E231C448F30B" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d277997082e723-wk-Fact-2A4AA32A6F3DD1397D5FE231C44DF290" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e749-wk-Fact-BDAF3FADB3E4FBED7CE7E231C46AAA2F" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-2" continuedAt="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-3"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277997082e783-wk-Fact-88772D325A59ABEAF1ACE231C49035CC" name="us-gaap:Depreciation" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d277997082e787-wk-Fact-8FDC3C0404006B1A6524E231C4937A0C" name="us-gaap:Depreciation" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-3">, respectively.</ix:continuation> </span></div><div><a id="s80D57E09170458A683562880FA01D7D4"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-0-wk-Fact-3095418B05EB840A8469E231C445D25B" continuedAt="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-1" continuedAt="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-2"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-4F3139F794243CCAC862E231C4CCE61F-0-wk-Fact-EB6B80A617E6EA5DE947E231C444C976" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e612-wk-Fact-87D20BE314E4D7AC7EA3E231C49DAE18" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e631-wk-Fact-9A000BE88A0D3FF54528E231C49B2130" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e650-wk-Fact-5CAC4178B10A55D2C586E231C49BEA15" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e670-wk-Fact-4EE68556CE126ADD2D14E231C49A5D9D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e685-wk-Fact-89D624E0DD999605952EE231C49D79BE" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e704-wk-Fact-1CBACE4A593E724B8C26E231C49DFDC1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e723-wk-Fact-4E03CE475BBA3DF993BCE231C49BE87F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e743-wk-Fact-50C8A51BCC6FEE27139FE231C49B6550" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e768-wk-Fact-2BB3A5468F52B4A910AAE231C49C4408" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e787-wk-Fact-D93FCF4A7237CCEB7E67E231C49CB3D9" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e806-wk-Fact-772C7871B0C1807FE366E231C49A4744" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e826-wk-Fact-93947E35FBD2B63D0E1AE231C49CFED7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278000074e851-wk-Fact-A46B7427B3BD1C007F56E231C4452CB3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,044,367</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="TextSelection-B6F7A0885F8AB877F193E231C4CC5901-0-wk-Fact-2CC81F6D3A65D742AAAEE231C4474D13" continuedAt="TextSelection-B6F7A0885F8AB877F193E231C4CC5901-1" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B6F7A0885F8AB877F193E231C4CC5901-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1066-wk-Fact-E20B5D4FE30CCE2E6AAAE231C4A2694D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1085-wk-Fact-21620E5FE5F797F8A689E231C4AE297D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1104-wk-Fact-286E264F9CFF542D35F5E231C4AE24C5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1124-wk-Fact-8A88322AB5116561D61AE231C4AF4C65" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1144-wk-Fact-7D58E44BD9C48ED68702E231C4A174B6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1163-wk-Fact-41A512D3C257FCF6F41FE231C4AF67DE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1182-wk-Fact-F7A698FE3AAD9ECAA314E231C4AE8C6C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1202-wk-Fact-F03E2009AEC694F83CBCE231C4A92845" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-2" continuedAt="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-C1B073AF8BC55492FC21E231C4CC0252-0-wk-Fact-52C5C7BCB80F6E6E130BE231C447140F" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:48%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1440-wk-Fact-6B611F7AAB3C67E67100E231C44E925E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1455-wk-Fact-F354622E0F0E3C724631E231C4528FCE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1470-wk-Fact-A86441104AC3A91E3ECDE231C47014CF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1485-wk-Fact-D78521D257C4739929B2E231C44E100B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1502-wk-Fact-19D17CA665687EFD3E98E231C44F1228" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1517-wk-Fact-AAA2513F46AE2D5DD314E231C44ED449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1532-wk-Fact-AB630C28EE875B2B11A1E231C451C5B0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1547-wk-Fact-425542F444F8E7789D31E231C46D60F9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1564-wk-Fact-0F349268BF2CD4AE9D88E231C451C8CE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1579-wk-Fact-0E2B706D13C8E4DEEB33E231C44EDE9A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1594-wk-Fact-25CA6BC5612170F33038E231C454DFE3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1609-wk-Fact-EA6237C37F16FCAFBB62E231C44D0164" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1626-wk-Fact-70F0B21289091F1FEF6DE231C44FEF91" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1640-wk-Fact-1A411A9550315C3AEB13E231C44E08AA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.5</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1654-wk-Fact-13F509AAF389AB75533EE231C44F7EC4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.5</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1668-wk-Fact-4AA5A3D152F85FA9F7A4E231C46E5A3F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1746-wk-Fact-42301D3DED169A716BDDE231C44F23FC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1761-wk-Fact-5D921E51AA3E811084D7E231C451C9A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1776-wk-Fact-FE707F219CAAC80815C3E231C44FAB59" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1791-wk-Fact-4A054F419F32C3CF7811E231C46BE4E9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1808-wk-Fact-C4693B72090D48503B46E231C45028B1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1823-wk-Fact-51641F4EC5958B351720E231C4724C8E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1838-wk-Fact-0CF6BCD9E83905578DE3E231C4556A00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1853-wk-Fact-13E09F8A97B243DAE36EE231C46EB5B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1870-wk-Fact-D24F4EEC4B42BB04BE71E231C4717563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1885-wk-Fact-096F4831D1F6BEAA37C8E231C46D2505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1900-wk-Fact-9F41665F7DDECBCF8250E231C44E47EC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e1915-wk-Fact-0B2CEEC6D5F3319A5DB4E231C458C139" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1933-wk-Fact-BAF310754A23D8245117E231C456111F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1947-wk-Fact-8ADC82790CB3305F50E5E231C44CF094" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1961-wk-Fact-E5D7E98C33DFE0260CABE231C46F0327" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e1975-wk-Fact-51623801595F537A3C19E231C4730901" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-45F6716A24E1F5F207B4E231C4CC535C-0-wk-Fact-D6CF94EA11E5B7170BDFE231C44CA963" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2143-wk-Fact-E39939E363B7326D35CEE231C49888E5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,674,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2162-wk-Fact-059CD1191330DE3F63ADE231C498839C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2208-wk-Fact-F04C4525EF6E7B9D2C5EE231C4907D5F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">801,166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2227-wk-Fact-AA60E2718BCD1EE482CEE231C454ED2D" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278000074e2273-wk-Fact-76749F4BB7FFE8ECD0BFE231C498DE70" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,147,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2293-wk-Fact-85696090A4541A58E07AE231C44C5169" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278000074e2339-wk-Fact-898289C8B5A5455AB72CE231C453C5D8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">88,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2359-wk-Fact-A0E5CA8BE0BAC376D373E231C493B30B" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278000074e2405-wk-Fact-C1DD69BB09A33C37129CE231C450A3C0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2019Q2YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">29,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2425-wk-Fact-655702E1C8932A5AAE0FE231C4969369" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2471-wk-Fact-2B79E8CC5AAA03C7EB0FE231C45565BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">21,210,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2490-wk-Fact-9BA9979C1814B08F0F65E231C494B0D6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q2" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e2504-wk-Fact-EE6358B80706502DE8ABE231C4942984" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q2YTD" format="ixt-sec:duryear">3.5</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2520-wk-Fact-87149AA680CBAE73D554E231C453AF8C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2535-wk-Fact-80E48F3002FC5D28CB61E231C452D23F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,670,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2554-wk-Fact-5058D0319128ADCF6443E231C451B00C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q2" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e2568-wk-Fact-8897C6A797E38A368BA6E231C455FDC9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q2YTD" format="ixt-sec:duryear">2.8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2584-wk-Fact-F5A5044B60C2634948E4E231C450D766" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">237,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d278000074e2609-wk-Fact-A5818D7C749F644090E8E231C4438DB9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonNumeric id="d278000074e2613-wk-Fact-AE54A404DEAE7E7F7141E231C447F3E4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">2.4</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-8B91FF3D83F1F965913BE231C4CC2A52-0-wk-Fact-B473D284144F7326BB8CE231C4414FDB" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2766-wk-Fact-B02F64CF7515DB342607E231C489BDDC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,857,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2785-wk-Fact-3DA1A1FE47DE059028B6E231C48C7AAB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2831-wk-Fact-7BD077FEB57179677EB9E231C488C0C9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">272,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2850-wk-Fact-6EB2331E512B0344BB3DE231C48B4C68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">21.72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278000074e2896-wk-Fact-0938AFB8A46508D204DCE231C48A1758" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">366,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2916-wk-Fact-BFC9D6DAE129076BABA5E231C489BA24" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">10.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278000074e2962-wk-Fact-D79952FC2B351E5AB1C4E231C48B366F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">180,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e2982-wk-Fact-55507C4FC752829EE531E231C488308A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e3028-wk-Fact-8131A9C7B986BCFA2FD4E231C48B9551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,583,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e3047-wk-Fact-8A9F319968F9F0ACF398E231C48AFEDC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d278000074e3061-wk-Fact-7F7441EDB50B869C8980E231C48AA4DA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.7</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278000074e3077-wk-Fact-8813CD00F10855094F02E231C48BEE4E" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2018, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278000074e3096-wk-Fact-3C3D016B5B2916C2B060E231C443BADB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">693,131</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable. During the quarter ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had achieved one of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278000074e3119-wk-Fact-12D9AC29F74A9354A01A2ECA679FA044" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">114,843</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the PSUs and determined that it was probable that we would achieve the second of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278000074e3131-wk-Fact-E2B129D1FE42629C57DC2ECC20615850" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">172,272</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional PSUs. We expect those PSUs to vest over various dates through May 2021 and have recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278000074e3135-wk-Fact-E8D2B4B85BE89EAC9071E231C443926F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those PSUs during the three months ended June 30, 2019; the remaining unrecognized compensation expense for those PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278000074e3140-wk-Fact-67E92021BB320E0D9012E36C5DE05DD2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of June 30, 2019. The total unrecognized compensation expense for the remaining PSUs for which we have not yet determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278000074e3148-wk-Fact-57AE0412ACC337BA16F0F34C97BB1FAE" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q2_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278000074e3159-wk-Fact-27D864CFE60733EAB13AE231C4476C54" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d278000074e3163-wk-Fact-ED22E795FCBF3186D847E231C446FC8E" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.6</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation><div><a id="s7161153631FF5627A41DDEB13A9A3E72"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-0-wk-Fact-E08BD04138491CCB2DEDE231C471BFA9" continuedAt="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-1" continuedAt="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277997145e404-wk-Fact-77CA44FB88D23B47FF7AE231C47233B0" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.8</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277997145e408-wk-Fact-53921B965D454C3D8491E231C475396E" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q2YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.7</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277997145e422-wk-Fact-49E55CCA1AC79D6EB074E231C47280C5" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q2Q2QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d277997145e427-wk-Fact-291EE21BBF87F95BA839E231C476A5BB" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q2DEC30-JUN29" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-2" continuedAt="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-3"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-3"> differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.</ix:continuation> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="s941D65EE90F956FD962FC64E87FFFD98"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-3F8F969F9FFE07B4B466E231C4CDA3F6-0-wk-Fact-BE2B2832CC5A947581CEE231C4B052F4" continuedAt="TextSelection-3F8F969F9FFE07B4B466E231C4CDA3F6-1" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3F8F969F9FFE07B4B466E231C4CDA3F6-1"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-9DD104F1C5667DC189DFE231C4CD34DB-0-wk-Fact-A9A90091A8B2E752A615E231C4B467EA" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e693-wk-Fact-ACA33AEAAB4725288007E231C442BE5F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e712-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e731-wk-Fact-B80960B704D8361B606AE231C4A09B4D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,817</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e751-wk-Fact-2A814F972C0BD074AFC1E231C43F3652" name="us-gaap:NetIncomeLoss" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e848-wk-Fact-4044463EA64232983585E231C4379D71" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">302,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e867-wk-Fact-266587292C7A6833D40AE231C433B369" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q2Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e886-wk-Fact-57892A0C65D150C9B129E231C48EA534" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e906-wk-Fact-29A95E9E14C8CF8203C4E231C4A9A235" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q2DEC30-JUN29" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">296,874</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e926-wk-Fact-B5324BE960F58B8B7342E231C49DB0E1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e945-wk-Fact-80117E5448CE95D0775AE231C4AAD3A1" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2018Q2Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">14,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e964-wk-Fact-2DC97B0D90E6106E362DE231C4B97B22" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">13,421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e984-wk-Fact-CD79A30A1804918C0230E231C45896E2" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2018Q2DEC30-JUN29" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">16,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1004-wk-Fact-939D5E643961456211DFE231C4B20A6E" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1023-wk-Fact-9C5B62466C75220A7FA3E231C47AF2DA" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q2Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1042-wk-Fact-461891499FE2723E9818E231C44E4D54" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">314,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1062-wk-Fact-20D4CCDAE0A8ED18948DE231C435BB67" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q2DEC30-JUN29" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">313,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1169-wk-Fact-4B26B5AB9595C15EACD3E231C452EDCE" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1188-wk-Fact-F3A995FE72E51F9D3971E231C4A986C0" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q2Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1207-wk-Fact-9F4C610798472730DF9CE231C47B1AEF" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1227-wk-Fact-BB84C7A53A3F37741239E231C44DA175" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q2DEC30-JUN29" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1247-wk-Fact-0299983057549E97DDBEE231C4A8C4BF" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1266-wk-Fact-D29BE3A6B68F7E6F3193E231C43E6608" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q2Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1285-wk-Fact-E3AFB87B37B6205B4E96E231C4A21E71" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1305-wk-Fact-43D96EC8BE7C5483B2A2E231C43B448B" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q2DEC30-JUN29" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-E92E60A82323CE137D28E231C4CDBE01-0-wk-Fact-95341AD2CEB6E8FEA5E1E231C49E5652" continuedAt="TextSelection-E92E60A82323CE137D28E231C4CDBE01-1" escape="true">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="TextSelection-E92E60A82323CE137D28E231C4CDBE01-1" continuedAt="TextSelection-E92E60A82323CE137D28E231C4CDBE01-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></ix:continuation></div><ix:continuation id="TextSelection-E92E60A82323CE137D28E231C4CDBE01-2"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:48%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1488-wk-Fact-6BD1930805CF21AE3E4EE231C49FF758" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1502-wk-Fact-CDAAE68C6F68356DE648E231C4B59544" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1516-wk-Fact-8B3AC51D933ED92BCD98E231C4A1F15D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278001369e1530-wk-Fact-86159D2B7C15B05B40B0E231C49EA032" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s63EF180CD0085784A4302677A1D0D8FF"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-0-wk-Fact-F648FB816879BF255B60E231C433A6FF" continuedAt="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-AA979453EFC3A55C4D5FE231C4CDE588-0-wk-Fact-7E72811EA780245AC2F4E231C49ED8D0" continuedAt="TextSelection-AA979453EFC3A55C4D5FE231C4CDE588-1" escape="true"><ix:continuation id="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-1" continuedAt="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e562-wk-Fact-F3E6B2671A09164C511CE231C48CB878" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e581-wk-Fact-E2B513E7CD39754084C6E231C4932D23" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e600-wk-Fact-7E6A8A2C18384EBAC909E231C4923BA5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e616-wk-Fact-AD38B22DED4E87185DFEE231C48FF556" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e635-wk-Fact-CE49CA60F80FC86FCA2DE231C48E73BA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">406,238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e654-wk-Fact-5A3D8478A4A7589839B2E231C48E0FD1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">406,238</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e675-wk-Fact-4CBB7F015392519EB256E231C494731C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e694-wk-Fact-400FD381B9FC3986508CE231C4954722" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">562,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e713-wk-Fact-3911F2513ABA80A369F8E231C49289B8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">562,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e734-wk-Fact-46E31914309FD524C21FE231C48D6E51" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e753-wk-Fact-E0540A5D72BFAF06211DE231C48C5068" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e772-wk-Fact-B3CF3328E63852ACBC60E231C493316E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">112,254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e793-wk-Fact-EA2CA2A643016AE1468EE231C48F8916" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e812-wk-Fact-9270E7C9885AF8FA6BA0E231C49668ED" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,081,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e831-wk-Fact-B9B6F1ACECA61AA97799E231C48DE323" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,135,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e852-wk-Fact-702B26A9FEF55BF03899E231C499C6BC" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e871-wk-Fact-3648EC8F6F4C77FD09FEE231C48FB869" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e890-wk-Fact-C3C80941E463CCB997F1E231C4951BB1" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e916-wk-Fact-0BDAE211E0B951EE8E4CE231C4933D73" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e935-wk-Fact-13246CE59A7C072CD560E231C48B7BF3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,104,234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e954-wk-Fact-652C0DEC91ED1E6908FBE231C495BF5A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,158,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1118-wk-Fact-D2201E726634895F1F6CE231C4B61A03" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1137-wk-Fact-85A9C8BA3D5E5B373824E231C48DB126" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1156-wk-Fact-F0372C860B57F3578F9CE231C4B94C60" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1172-wk-Fact-ADFB4B5DF888A2B6F803E231C4513C37" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1191-wk-Fact-3B39D55A911530F52220E231C4B71AB4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1210-wk-Fact-BDF3DDFE05B323F65D46E231C48BFE65" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1231-wk-Fact-488FB4AFC4D268F9DC33E231C444215C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1250-wk-Fact-A8A932B6280EFAEF27D3E231C44BDE76" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1269-wk-Fact-95A2F4063E549A8560B5E231C44334C5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1290-wk-Fact-F271472F4B06B09828B9E231C45A843E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1309-wk-Fact-45FEF055A91D7194A21AE231C471A2A5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1328-wk-Fact-BDBA4EB85B5073516577E231C496E994" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1349-wk-Fact-19FA1C4997BFFB353C7FE231C4702A01" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1368-wk-Fact-AD49B31D5A577701748AE231C48E7B2E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1387-wk-Fact-B1367375A7F792003619E231C4475631" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1408-wk-Fact-8F4B96C81172BD400EC6E231C4ABA716" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1427-wk-Fact-4BE5AD9CF55A71E04C7FE231C459EFF9" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1446-wk-Fact-F4A7BA2F3212257B97E1E231C48F5588" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1472-wk-Fact-568AE4C3D259478E717BE231C451240A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1491-wk-Fact-7ACBCAA185E7F1DE802FE231C49D9FDF" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">796,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278002751e1510-wk-Fact-6E68585F85EDC72E006AE231C4791CB1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">844,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-AA979453EFC3A55C4D5FE231C4CDE588-1"></ix:continuation>We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Leases&#8221; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.</span></div></ix:continuation><div><a id="s406957BC083A55BE82FF4048A9404328"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeFinanceLeasesTextBlock" id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-0-wk-Fact-02B9439DB7B16D3D1107E231C439D1F1" continuedAt="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-1" escape="true"><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-0-wk-Fact-DB109E31502A8719C23FE231C4391487" continuedAt="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-1" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-1" continuedAt="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-2"><ix:continuation id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-1" continuedAt="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278004142e397-wk-Fact-5DC9AEEA9A07C4490FFEE231C43453D1" name="us-gaap:AreaOfRealEstateProperty" contextRef="FI2019Q2_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">169,606</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e401-wk-Fact-CDD30ADAB00D6A2A35F3E231C43DC9FD" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" contextRef="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term; none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it probable that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Lease Amendment) provides, among other things, for the (i) expansion of the Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278004142e415-wk-Fact-CD8A364924FC92895541E231C4436675" name="exel:OperatingLeaseAdditionalAreaOfRealEstateProperty" contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">37,544</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278004142e419-wk-Fact-DC46296FF8736FF224EAE231C43AFF0E" name="exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty" contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">2,703</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e423-wk-Fact-32DABE0B5AE4A9110508E231C43F8046" name="exel:TenantLeaseImprovementsAllowance" contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. We surrendered the 1751 Space in April 2019, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have taken possession of a portion of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for that portion of the Lease. We expect to take possession of the remaining portion of the 1601 Expansion Space in September 2019, and therefore we have not yet recorded a right-of-use asset or lease liability for that portion of the Lease as of June 30, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The monthly base rent for the Premises, other than the 1601 Expansion Space, is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e434-wk-Fact-F1A2EC823973921105DCE231C43AFEE5" name="exel:LesseeOperatingLeaseMonthlyBasePayment" contextRef="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">224,505</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through January 31, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e438-wk-Fact-319A6AB07CA48BF0D218E231C435C211" name="exel:LesseeOperatingLeaseMonthlyBasePayment" contextRef="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">283,933</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. The monthly base rent for the 1601 Expansion Space, which is expected to start on December 1, 2019, will be </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e442-wk-Fact-C57AD3FC534E6C2E4F18E231C44246D2" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" contextRef="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">71,334</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through November 30, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e446-wk-Fact-5CDD74222ADDB9D5B2C6E231C43DEFE4" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" contextRef="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">90,481</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. In addition, we are required to pay the landlord for certain operating expenses and taxes they incur related to the Premises.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-2" continuedAt="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-3"><ix:continuation id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-2" continuedAt="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-3"><ix:nonNumeric contextRef="FD2019Q2YTD" name="exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" id="TextSelection-4D9D8AFBB2744FBC0502E231C4CD5D75-0-wk-Fact-643D6FADE16C2EBA59D1E231C436438A" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e567-wk-Fact-8224D61949D6C093189EE231C4739210" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e586-wk-Fact-6B40B4C634B2DF75D298E231C4583195" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e601-wk-Fact-BFCA4D9AC30573B19F1CE231C47EA833" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e620-wk-Fact-D4EFE4CAEAE1F1CD3EC2E231C4806798" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e640-wk-Fact-3B9936765580E95A3C4EE231C4543D9C" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e659-wk-Fact-F4634EC9C4F4DFB39799E231C47B0C61" name="us-gaap:OperatingLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e720-wk-Fact-86E97F7E5773094FFF3DE231C4446B9B" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e739-wk-Fact-234CD7B4F7FE0E272AD1E231C448991F" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e759-wk-Fact-B28933A27669ACB51C33E231C452FCFA" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e778-wk-Fact-894A80FBAE97721D5267E231C455B960" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e798-wk-Fact-FF63F61130332B0E6D6EE231C4734EE3" name="us-gaap:FinanceLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e817-wk-Fact-B5F22FC6AF13405D3806E231C454D86F" name="us-gaap:FinanceLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e842-wk-Fact-0ECB644B5B059D968842E231C4520305" name="exel:OperatingAndFinanceLeasesLiabilityTotal" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e861-wk-Fact-872FBD6EA210CE59D532E231C4598EA5" name="exel:OperatingAndFinanceLeasesLiabilityTotal" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-BE7FF3DA9D3DC9F9E6DFE231C4CEAEF3-0-wk-Fact-1A92C6E440337F6EF74CE231C43CFB77" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1078-wk-Fact-567B44C971ABC830AABEE231C47B2E8A" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1097-wk-Fact-2C4DD00353384F238C48E231C47012BA" name="us-gaap:OperatingLeaseCost" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1116-wk-Fact-FDB927D866413F60D73AE231C47D593D" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1136-wk-Fact-DC18A9B7B0449B54130CE231C46F0823" name="us-gaap:OperatingLeaseCost" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1151-wk-Fact-5B3CEE4541B38AE433B8E231C4581EBC" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1170-wk-Fact-66255C91EC10D94EAE7FE231C473BD93" name="us-gaap:VariableLeaseCost" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1189-wk-Fact-55224565E4BAEEB7A509E231C4768740" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1209-wk-Fact-87A670B4F0925F95E8D5E231C4713DCC" name="us-gaap:VariableLeaseCost" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1234-wk-Fact-92C2C37998870E7F19DEE231C4733A1B" name="us-gaap:LeaseCost" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1253-wk-Fact-267E1FB2A155B0D3424AE231C47825F8" name="us-gaap:LeaseCost" contextRef="D2018Q2Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1272-wk-Fact-9E168965F1AC620DF24AE231C4737CBB" name="us-gaap:LeaseCost" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1292-wk-Fact-59B1F001036D64AA0C8DE231C46DE477" name="us-gaap:LeaseCost" contextRef="D2018Q2DEC30-JUN29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278004142e1313-wk-Fact-9529A278CDD82CA6A446E231C4437185" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q2YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-93953BA1E7086323F5D4E231C4CD3CC2-0-wk-Fact-F56B0446EA3F9F5A2D89E231C435CBB8" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1352-wk-Fact-74791CBFC0499BE8EC2AE231C4326D00" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1388-wk-Fact-1F9AE19632072FFE1872E231C4B40E6D" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1408-wk-Fact-07E5A0EBC5275224AA9AE231C4A0E44D" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1428-wk-Fact-76041EC4CF66477E6B82E231C49F6B7C" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1448-wk-Fact-36609FDF53F89EA5EA63E231C49D740D" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1468-wk-Fact-C6F25F63D2F00D719FC3E231C49D1F74" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1488-wk-Fact-31A27982A2B01E94E742E231C49E443F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278004142e1529-wk-Fact-7E5125DA9E0AB4F09D48E231C4319ED7" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d278004142e1552-wk-Fact-4D904521D749D717216D305631F4893E" name="exel:TenantLeaseImprovementsAllowance" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d278004142e1579-wk-Fact-3B9936765580E95A3C4EE231C4543D9C" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-3" continuedAt="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-4"><ix:continuation id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-3" continuedAt="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-4"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278004142e1603-wk-Fact-B572FA54367D3AD5AE22E231C43AE24D" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q2" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d278004142e1611-wk-Fact-6CC22C432B61839E419AE231C442A991" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q2" format="ixt-sec:duryear">8.6</ix:nonNumeric> years</span></span></ix:continuation></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-4"><ix:continuation id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-4">.</ix:continuation></ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</span></div></div><hr style="page-break-after:always"></hr><div><a id="s9ad5115a348c4f0ab7b37e15e26f3f69"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. <ix:nonNumeric contextRef="FD2019Q2YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-1ADA7858E5636F57D68BE231C4CE350A-0-wk-Fact-1266D559C77DA1C606F5E231C4563B5B" continuedAt="TextSelection-1ADA7858E5636F57D68BE231C4CE350A-1" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1ADA7858E5636F57D68BE231C4CE350A-1"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an exclusive option and license agreement with Aurigene, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">biotechnology company based in India focused on oncology and inflammatory disorders, to in-license up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278002834e404-wk-Fact-A5C3740BDDB4DC6B14ED3EAA69C37E50" name="exel:CollaborationAgreementNumberOfPrograms" contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> oncology programs from Aurigene. Under the terms of the agreement, we will make an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e408-wk-Fact-775E3BB39A4A218312362F02F596608B" name="exel:CollaborationAgreementsUpfrontPayments" contextRef="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license three preexisting programs. In addition, Exelixis and Aurigene will initiate three Aurigene-led drug discovery programs on mutually agreed upon targets for additional upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e412-wk-Fact-C752F71E98C9996E6DEE2F070171C856" name="exel:CollaborationAgreementAdditionalUpfrontPayments" contextRef="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program. We will also contribute research funding of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e416-wk-Fact-67FE91A6EA92DC30BDC4306661CB6F2A" name="exel:CollaborationAgreementResearchAndDevelopmentObligation" contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Aurigene for discovery and preclinical development work on all </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d278002834e421-wk-Fact-A5C3740BDDB4DC6B14ED3EAA69C37E50" name="exel:CollaborationAgreementNumberOfPrograms" contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs. For each option we decide to exercise, we would be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e425-wk-Fact-1F5A8D84A579981FA0BA305A2496E7DA" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e429-wk-Fact-C704C75B17339A71D88E2F02D4B988EC" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e435-wk-Fact-2584906A73751124AD302F0B98E0969C" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d278002834e439-wk-Fact-9D7D9C9C309C284C06802F0BFCB64756" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div></ix:continuation><div><a id="s47B6D56B23FA554BAF560B6C05936779"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> filed with the Securities and Exchange Commission (SEC) on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX was first approved by the U.S. Food and Drug Administration (FDA) for previously treated patients with advanced RCC in April 2016, and then in December 2017, the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib. This most recent approval was based on results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, which demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo. We remain highly focused on optimizing the execution of the commercial launch in HCC in the U.S. through our commercial and medical affairs organizations and established distribution network.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Both partners also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans, recently receiving regulatory approval from the European Commission (EC) for CABOMETYX as a treatment for HCC in adults who have previously been treated with sorafenib. Takeda has also made significant progress on bridging studies in both RCC and HCC and achieved an important regulatory milestone in April 2019 with its application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for approval to manufacture and sell CABOMETYX as a treatment for unresectable and metastatic RCC in Japan</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our partners for rest of world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising&#160;over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s late-stage development program. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two VEGF receptor-targeted therapies. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with immune checkpoint inhibitors (ICIs) to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. The most advanced of these combination studies include CheckMate 9ER, a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated advanced or metastatic RCC, for which enrollment was completed in April 2019, and CheckMate 040, a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC. Both trials are in collaboration with Bristol-Myers Squibb Company (BMS). Additionally in May 2019, as part of our clinical collaboration with BMS, we initiated COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, and plan to further evaluate the combination of cabozantinib and nivolumab, with or without ipilimumab, in various other tumor types. In an effort to diversify our exploration of combinations with ICIs, we also initiated COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with the Roche Group&#8217;s (Roche&#8217;s) ICI, atezolizumab, versus sorafenib in previously untreated advanced HCC, and COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion phase, which is ongoing. Findings from the dose-escalation stage of COSMIC-021 demonstrated that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. The expansion phase of COSMIC-021 now comprises twenty tumor expansion cohorts evaluating the combination of cabozantinib and atezolizumab, including multiple therapeutic settings of RCC, urothelial carcinoma (UC), and non-small cell lung cancer (NSCLC) and single therapeutic settings of HCC, castration-resistant prostate cancer (CRPC), triple-negative breast cancer, epithelial ovarian cancer, endometrial cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, DTC and head and neck cancer of squamous cell histology, and is currently enrolling. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on initial encouraging results from the ongoing expansion cohorts in patients with CRPC and in chemotherapy and ICI</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">pretreated NSCLC, we have recently expanded the original 30-patient cohorts for each of these disease states to allow enrollment of an additional 50 patients for a total of 80 patients each. Additionally, four new cohorts, consisting of two expansion and two exploratory cohorts, are being added to COSMIC-021: two new expansion cohorts will evaluate the combination of cabozantinib and atezolizumab in patients with metastatic CRPC who have received prior enzalutamide or abiraterone therapy, with or without prior docetaxel therapy; and two new exploratory cohorts will evaluate single-agent cabozantinib and single-agent atezolizumab in patients with metastatic CRPC, with the purpose of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">determining the individual contribution of each therapy. With this recent protocol amendment, COSMIC-021 now encompasses a total of 24 expansion cohorts, including the three exploratory cohorts that will evaluate cabozantinib as a single-agent therapy in NSCLC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> UC and CRPC, and the fourth exploratory cohort that will evaluate atezolizumab in CRPC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depending on the results from COSMIC-021, we may evaluate the combination of cabozantinib and atezolizumab in various late-stage clinical trials, including in NSCLC and CRPC. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical and commercial potential of cabozantinib, we also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we reinitiated internal drug discovery efforts in 2017 with the goal of identifying new product candidates to advance into clinical trials. Notably, these efforts are led by some of the same experienced scientists responsible for the discovery of cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization by regulatory authorities. Using our expertise in medicinal chemistry, tumor biology and pharmacology, we are advancing drug candidates toward and through preclinical development. Furthest along in these internal drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that is currently in a phase 1 clinical trial in patients with advanced solid malignancies.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. In furtherance of this strategy, we have entered into multiple collaboration and license agreements, including with:&#160;StemSynergy, Inc., which is focused on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; Invenra, Inc., which is focused on the discovery and development of multispecific antibodies for the treatment of cancer; Iconic Therapeutics, Inc. (Iconic), which is focused on the advancement of a next-generation antibody-drug conjugate (ADC) program targeting tissue factor in solid tumors; and most recently, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene Discovery Technologies Limited (Aurigene), which is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the discovery and development of novel therapies for cancer</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To further enhance our early-stage pipeline, we expect to enter into additional, external collaborative relationships around assets and technologies that complement our internal drug discovery and development efforts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Second Quarter 2019 Business Updates and Financial Highlights</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the second quarter of 2019, we continued to execute on our business objectives, generating significant revenue from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2019, Takeda applied to the Japanese MHLW for approval to manufacture and sell CABOMETYX as a treatment for unresectable and metastatic RCC in Japan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, CheckMate 9ER, the phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab versus sunitinib in patients with previously untreated advanced or metastatic RCC completed enrollment. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we announced the initiation of COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, which will be conducted in collaboration with BMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we announced that Daiichi Sankyo launched MINNEBRO as a treatment for patients with hypertension in Japan. As a result of the launch,&#160;we&#160;received a&#160;$20.0 million&#160;milestone payment from Daiichi Sankyo in June 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we announced an exclusive option and license agreement with Iconic to advance an innovative next-generation ADC program for cancer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2019, at the American Society of Clinical Oncology Annual Meeting, clinical data from cabozantinib and cobimetinib were the subject of nine and two presentations, respectively.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2019, Genentech informed us that IMspire170, Genentech&#8217;s phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab in patients with previously untreated BRAF V600 wild-type advanced melanoma, did not meet its primary endpoint. Genentech is continuing to pursue the cobimetinib development program with IMspire150, a phase 3 pivotal trial evaluating the combination of cobimetinib with atezolizumab and vemurafenib in patients with previously untreated BRAF V600 mutant melanoma, as well as </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a series of early-stage clinical trials investigating the combination of cobimetinib and atezolizumab in multiple tumor settings.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, to expand patient enrollment in certain existing CRPC and NSCLC cohorts and to add new expansion and exploratory cohorts in CRPC (for an aggregate of twenty expansion cohorts and four exploratory cohorts).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an exclusive option and license agreement with Aurigene, a biotechnology company </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">based in India </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on oncology</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and inflammatory disorders</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, to in-license up to six oncology programs from Aurigene. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Financial Highlights</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for the second quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$193.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$145.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for the second quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$240.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$186.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for the second quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$81.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$42.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for the second quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$58.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$51.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the second quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$20.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for the second quarter of 2019 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$79.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.26</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.25</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, diluted, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$87.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.29</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.28</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share diluted, for the second quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1,161.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$851.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will continue to face challenges and risks that may impact our ability to execute on our 2019 business objectives. In particular, for the foreseeable future, we expect our ability to maintain or increase unrestricted cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and potentially for other indications for which cabozantinib is in late-stage clinical trials, if warranted by the data generated from such trials. The commercial success of CABOMETYX in its approved indications is subject to a variety of factors, most importantly, the drug&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other competitive treatments available or in development for these conditions. CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Achievement of our 2019 business objectives will also depend on the success of our development and commercialization strategies to navigate increased competition, including that from, but not limited to, ICIs, as well as the use of combination therapy to treat cancer. Our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with internal drug discovery operations. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal Year Convention</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020 and ended December 28, 2018, are indicated as being as of and for the periods ended June 30, 2019 and June 30, 2018, and the years ending December&#160;31, 2019 and ended December&#160;31, 2018, respectively.</span></div><div><a id="s282E90035010555394EB7DDD5FFB88BE"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">46,600</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">82,506</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(31</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">240,275</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">186,108</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">455,762</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">399,827</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gross product revenues, Discounts and allowances, and Net product revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">240,418</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">172,646</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">464,168</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">332,082</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(46,743</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(26,810</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">74</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(90,912</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(51,974</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">75</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">189,015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">141,121</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">34</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">364,905</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">270,055</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,660</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,715</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,351</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,053</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(17</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,675</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,836</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">373,256</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">280,108</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in product revenues for CABOMETYX for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to a 28% and 27% increase, respectively, in the number of units of CABOMETYX sold </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and, to a lesser extent,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increases in the average selling price of the product. The increases in CABOMETYX sales volumes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the continued growth of CABOMETYX in advanced RCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following FDA approvals in April 2016 of CABOMETYX for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy and in December 2017 for previously untreated patients with advanced RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as the U.S. launch of CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib, following FDA approval in January 2019. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in product revenues for COMETRIQ for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to a 7% and 22% decline, respectively, the number of units of COMETRIQ sold. COMETRIQ sales volume has continued to decrease since the launch of CABOMETYX in April 2016.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases in discounts and allowances for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily the result of the overall increases in product sales volume and increases in the volume and dollar amount of chargebacks associated with Public Health Service and Veterans Affairs hospitals. We expect our discounts and allowances as a percentage of gross product revenues to increase during 2019 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as compared to 2018 as our business evolves, as the number of patients participating in government programs increases, and as the discounts and rebates paid to government payers increase</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">36,393</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">31,908</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">60,902</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100,938</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(40</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,898</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,805</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">22,826</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16,904</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(691</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,559</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(1,222</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,877</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">46,600</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40,272</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">82,506</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">119,719</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(31</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen, Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda, which were partially offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues were $20.4 million and $30.5 million, respectively, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to $25.8 million and $92.3 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Milestone revenues for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included recognition of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.0 million milestone from Daiichi Sankyo for the launch of MINNEBRO tablets as a treatment for patients with hypertension in Japan. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included $9.5 million in revenues recognized in connection with a $16.0 million milestone from Takeda for the submission in April 2019 of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese MHLW</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. See &#8220;Note 2. Collaboration Agreements - Takeda&#8221; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for information regarding the April 2019 amendment to our January 2017 collaboration agreement with Takeda, which increased the amount of this milestone from $10.0 million to $16.0 million. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the three and six months ended June&#160;30, 2018 included recognition of a $25.0 million commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&#8217;s achievement of $100.0 million in net sales cumulatively over four consecutive quarters. Milestone revenues for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included recognition of $46.0 million in revenue of a $50.0 million milestone from Ipsen for the approval of cabozantinib for the first-line treatment of adults with intermediate- or poor-risk advanced RCC by the EC, of which $45.8 million was recognized in the first quarter of 2018 and the remaining $0.2 million was recognized in the second quarter of 2018. Milestone revenues for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included recognition of a $20.0 million milestone upon Daiichi Sankyo&#8217;s submission to the Japanese MHLW of a regulatory application for esaxerenone as a treatment for patients with hypertension. Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">R</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan were $14.9 million and $28.9 million </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $5.4 million and $9.7 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product in the fourth quarter of 2016</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increased demand of CABOMETYX</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which is currently approved and commercially available in 44 and 32 countries </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">outside of the U.S.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We were entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial $</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales; this amount was reached in the second quarter of 2018. As of June 30, 2018 and going forward, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales (with separate tiers for Canada); these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD$30.0 million of annual net sales and a tiered royalty thereafter </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers for Canada will also reset each calendar year. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we also began to earn royalties on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sale of MINNEBRO by Daiichi Sankyo in Japan.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">connection with our collaboration arrangements with Ipsen and Takeda were $10.2 million and $20.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $5.1 million and $10.8 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases were primarily the result of reimbursements from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen and Takeda for their share of the increase in spending on the CheckMate 9ER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> study.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech were $2.7</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> million and $5.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $4.2 million and $7.0 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Sales of COTELLIC in the U.S. have declined following </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Genentech&#8217;s decision to scale back the personal promotion of COTELLIC commencing in January 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration revenues were reduced by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.8 million and $15.1 million, respectively, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the net sales by Ipsen of any product incorporating cabozantinib as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">compared to $5.6 million and $10.8 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,539</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,997</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">26</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,040</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11,636</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increases in Cost of goods sold for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily the result of the increases in product sales volume described above. We do not expect our gross margin to change significantly during the remainder of 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">81,932</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">42,488</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">93</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,221</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">80,245</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">81</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs, stock-based compensation, consulting and outside services and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in clinical trial costs, license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs, personnel expenses, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">stock-based compensation and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparator drug purchases</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$16.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$33.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in clinical trial costs were primarily due to costs associated with the expanding clinical trial program for cabozantinib that now includes four phase 3 pivotal studies (CheckMate 9ER, COSMIC-311, COSMIC-312 and COSMIC-313), as well as the multi-cohort phase 1b study (COSMIC-021). License and other collaboration costs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of the collaboration and license agreement we entered into with&#160;Iconic in May 2019. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$9.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the allocation of general corporate costs increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">support our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">expanded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery and development efforts</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to the increases in headcount, as well as the expense recognition for restricted stock units attributable to research and development that were granted in September 2018 that will vest upon the achievement of specific performance targets (the PSUs).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened Research and development expenses on a project-by-project basis.&#160;We group our Research and development expenses into three categories: Development, Drug discovery and Other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Research and development expenses by category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28,369</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,045</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">56,556</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23,240</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,526</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11,208</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29,113</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21,867</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,089</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,081</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,801</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,935</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,945</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,069</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,332</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">51,919</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">30,279</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">100,539</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">57,465</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License and other collaboration costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14,975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,341</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,481</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,341</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other drug discovery</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,440</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,949</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,974</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,939</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total drug discovery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21,415</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,290</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28,455</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,280</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,598</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,919</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16,227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,500</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">81,932</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">42,488</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">145,221</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">80,245</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of Research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, preliminary data from and final results of clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we expect our near-term research and development expenses to primarily </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. Notable studies of this program include: CheckMate 9ER and CheckMate&#160;040, each in collaboration with BMS; company-sponsored COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; company-sponsored COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and company-sponsored COSMIC-311. In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we are conducting internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. As a result, we expect our Research and development expenses to increase for 2019 as compared to 2018 as we continue to expand the cabozantinib development program and our product pipeline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses were as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">58,815</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">51,853</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">118,953</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">105,869</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation and marketing costs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Selling, general and administrative expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in stock-based compensation, consulting and outside services, personnel expenses and the expense for the Branded Prescription Drug Fee; those increases were </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partially offset by a decrease in corporate giving. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to support the company&#8217;s commercial and research and development organizations as well as the expense recognition for the PSUs. Consulting and outside services increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases in marketing activities in support of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the CABOMETYX </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">launch in HCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and continued support of the product in an increasingly competitive RCC market</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount. The expense for the Branded Prescription Drug Fee, which is also included in Selling, general and administrative expenses, increased $1.0 million and $2.4 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Corporate giving, consisting predominantly of donations to independent patient support foundations, decreased $2.0 million and $4.8 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our Selling, general and administrative expenses to increase modestly for 2019 as compared to 2018 to support our overall organizational growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other income (expense), net, was as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,975</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,697</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">159</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,062</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,592</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">184</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">803</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(72</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">828</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">97</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">754</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,778</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,625</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">196</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">13,890</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,689</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">196</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Interest income for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were the result of both an increase in our investment balances and an increase in the yield earned on those investments.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provision for Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q2 2019 v. Q2 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,725</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">901</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,200</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35,621</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,415</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">943</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rates were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20.8%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18.7%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.0%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.7%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of the remaining valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div><div><a id="sBD67A11BA7575775859C46C329A918AD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1,161.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements, Accounting and Financial Results,&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.&#160;Our assumptions may prove to be wrong or other factors may adversely affect our sources of cash and, as a result, we may not </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">have the cash resources to fund our operations as currently planned, which would have a material adverse effect on our business. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Furthermore, even if we believe we have sufficient funds for our current and future operating plans</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">293,321</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">146,273</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash used in investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(250,586</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(91,800</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,279</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,224</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our operating activities provided cash of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$293.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$146.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of for the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as share-based compensation charges, 401(k) matching contributions made in common stock, deferred income taxes and depreciation and amortization; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the increase in cash provided by operating activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was $96.0 million in milestone payments received from Ipsen, Takeda and Daiichi Sankyo, including $60.0 million in payments for milestones that had previously been recognized and were included in Trade receivables, net as of December 31, 2018, and an increase in cash received on sales of our products, reflected in a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$93.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in Net product revenues. Those increases were partially offset by an </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$81.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> increase in operating expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our investing activities used cash of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$250.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$91.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily due to investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$518.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Property and equipment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$258.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was primarily due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$227.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Property and equipment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$139.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$12.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div><a id="s01E42406EE605D05AF650252582F2E66"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Except as follows, there were no material changes outside of the ordinary course of business in our contractual obligations from those as of December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2019, we entered into an amendment to the existing Lease Agreement (the Lease) relating to our corporate headquarters located at 1851, 1801, 1751 and 1601 Harbor Bay Parkway, Alameda, California. See &#8220;Note 11. Leases&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about the amendment to the Lease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we entered into an exclusive option and license agreement with Iconic. See &#8220;Note 3. Collaborations&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about the option and license agreement with Iconic, including a description our preclinical development funding commitment and potential future milestone payments we may be required to make to Iconic.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div><a id="s86DD3DDBFFC85DA5BC0AAC5BA2322988"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock option valuation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been no significant changes in our critical accounting policies and estimates during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div><a id="sFD34F67AA8AA5B868FA8A72E182F8733"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our market risks at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our exposure to market risk for changes in interest rates relates to our investment portfolio. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an increase in the interest rates of one percentage point would have had a net adverse change in the fair value of interest rate sensitive assets of $6.9 million as compared to $3.4 million as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our exposure to market risk for changes in currency exchange rates relates to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">royalty revenues and sales-based milestones we receive from our collaboration agreements are a percentage of the net sales made by those partners from sales made in countries outside the U.S. and are denominated in currencies in which the product is sold, which is predominantly the Euro. For the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, an average 10% strengthening of the U.S. dollar relative to the currencies in which these products are sold would have resulted in revenues being reduced by approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and $3.8 million, respectively. </span></div><div><a id="sC9B1FAA46D94557C812802C87485F846"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Controls and Procedures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the effectiveness of controls.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in internal control over financial reporting. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4B0CB353AD64500FBC6985507E32EC3F"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</span></div><div><a id="sA8AA4464D7735C9C87C95CF68133060F"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are not a party to any material legal proceedings. We may from time to time become a party or subject to various legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div><a id="s45BB62DCA4245CE8B65498C0C7183295"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report and our other reports filed with the SEC, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase unrestricted cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and potentially for other indications for which cabozantinib is in late-stage clinical trials, if warranted by the data generated from such trials. The commercial success of CABOMETYX in its approved indications is subject to a variety of factors, most importantly, the drug&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or in development for these conditions.&#160;If revenue from CABOMETYX decreases or remains flat, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations. Furthermore, as a consequence of our collaboration agreements with Ipsen and Takeda, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaborators dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaborators depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, foreign sales of CABOMETYX by our collaborators could be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions or barriers and changes in tariffs, including as a result of the pending withdrawal of the United Kingdom (UK) from the European Union (EU) (commonly referred to as &#8220;Brexit&#8221;) and the uncertainty surrounding the date and the terms of the withdrawal, escalating global trade and political tensions, or otherwise. If our collaborators are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX has been approved for the treatment of advanced RCC and previously treated HCC in the U.S., the EU and other territories. With these approvals, our ability to grow our company remains contingent upon, among other things, further success in the clinical development, regulatory approval and market acceptance of cabozantinib, the active pharmaceutical ingredient in CABOMETYX, in potential additional indications. We cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval. Even if we and our partners receive the required regulatory approvals to market cabozantinib for any additional indications or in additional territories, we and our partners may not be able to effectively commercialize CABOMETYX in these additional indications or territories. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to increase revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, we may not be able to grow product revenues. The degree of market acceptance of CABOMETYX will depend upon a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of CABOMETYX in comparison to competing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the safety of CABOMETYX, including the existence of serious side effects of CABOMETYX and their severity in comparison to those of competing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#8217;s relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">potential unexpected results connected with analysis of data from future or ongoing clinical trials of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of CABOMETYX label expansions for additional indications, if any, relative to competitive treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the price of CABOMETYX relative to competitive therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">price increases taken by us and the impact on the net sales price of CABOMETYX as a result of any new laws, regulations or other government initiatives affecting pharmaceutical pricing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, market access and product distribution support;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to obtain and maintain coverage and reimbursement for CABOMETYX from commercial and government payers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to CABOMETYX.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in the event that any of these or other factors cause market acceptance of CABOMETYX to decrease, this could negatively impact our revenues, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are competitive, highly diversified and are characterized by rapid technological change, particularly in the area of novel oncology therapies. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage. Further, our competitors may be more effective at using their technologies to develop commercial products. As a result, our competitors may be able to more easily develop products that would render our products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates that we are not aware of at an earlier stage of development that may compete with our marketed products and product candidates. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing research activities similar to ours. Delays in the development of cabozantinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, the specific indications for which CABOMETYX is approved are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of ICIs. While we have adapted our cabozantinib development strategy to address the fact that the approach to treating cancer with ICIs in combination with other therapeutic agents has become highly prevalent in indications for which our products are approved, we cannot ensure that our clinical trials will show efficacy in comparison to competing products or product combinations. Moreover, the complexities of such a development strategy have required and may continue to require collaboration with some of our competitors. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also may face competition from manufacturers of generic versions of our marketed products, and both Congress and the FDA are seeking to promote generic competition, including through proposals focused on drug patenting, importation and provision of drug to generic applicants for testing. Such generic competition often results in very significant decreases in the overall sales or prices at which branded products can be sold.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and product distribution capabilities for our products or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and pre-commercial-stage oncology-focused biotechnology companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, we may be unable to maximize the commercial potential of CABOMETYX and COMETRIQ in their approved indications. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly judge the requisite size and experience of our current commercialization teams or the level of distribution necessary to market and sell CABOMETYX successfully in multiple indications. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize our products will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers for storage and distribution of our commercial supplies of both CABOMETYX and COMETRIQ in the U.S. Furthermore, we rely on our collaboration partners for ongoing and further commercialization and distribution of CABOMETYX and COMETRIQ in their respective territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs) with the effect of introducing earlier patient access to CABOMETYX and COMETRIQ.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third-party services related to the distribution of CABOMETYX and COMETRIQ on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and press manufacturers for discounts and rebates. Payers may also limit reimbursement for newly approved products and indications.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct or inaccurate reporting, the laws that may affect our ability to operate include, without limitation:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute (AKS), which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Among other things, this statute prohibits persons and entities </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests, value-added services to customers, and providing anything at less than its fair market value;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Open Payments program of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (PPACA), which was created under the Physician Payments Sunshine Act and its implementing regulations and requires certain manufacturers </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities, as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">well as state and local laws requiring the registration of pharmaceutical sales representatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals) and its foreign equivalents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state pharmaceutical price and price reporting laws and regulations that require us to provide notice of price increases and/or file complex ancillary reports concerning prices and pricing and discount practices. Laws and regulations in this area, and associated compliance obligations, may increase general and administrative costs, </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cause volatility in our revenues due to speculative buying practices by purchasers, or diminish our revenues as a result of the imposition of caps on pricing and price increases</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, govern certain marketing practices, including off-label promotion. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. These individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, we may face uncertainties as a result of executive, legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. The decision has been appealed to the U.S. Court of Appeals for the Fifth Circuit, and the Trump administration filed its brief in support of the decision of the Texas District Court judge on May 1, 2019. While the Texas District Court Judge, as well as the Trump Administration and the Centers for Medicare and Medicaid Services, have stated that the ruling will have no immediate effect pending the appeal, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the PPACA will impact the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not have a material adverse impact on our business financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business. The Trump Administration has also indicated an intention to regulate prescription drug pricing, and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are pending federal and state Congressional proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited buy-in options that would be available to individuals above a certain age. Federal legislation has also been proposed that would authorize states to permit individuals to &#8220;buy in&#8221; to their state Medicaid programs. At the state level, several states are considering legislation that would allow individuals to &#8220;buy in&#8221; to the state&#8217;s Medicaid program or that would otherwise establish a &#8220;public health option,&#8221; and the State of Washington recently enacted such legislation (S.B. 5526, effective July 28, 2019), but it has yet to be implemented. If enacted, the pending proposals could have a significant impact on the healthcare industry. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At this stage, we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business. However, such proposals, if enacted, could have the potential to impact access to and sales of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which reauthorized the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which applicants for such products </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">partially pay for the FDA&#8217;s pre-market review of their product candidates and pay other specified fees, including yearly program fees in the case of most New Drug Application (NDA)-approved prescription drugs. The legislation includes, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting, importation, and provision of drug to generic applicants for testing. While we cannot currently predict the specific outcome or impact on our business of such regulatory actions or legislation, they do have the potential to facilitate the development and future approval of generic versions of our products or otherwise limit or reduce the term for our market exclusivity, which could result in very significant decreases in the overall sales or prices of our marketed products and materially harm our business and financial condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the overall trend towards managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. Insurers also continue to pursue means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. These policy actions could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for, and patient access to, pharmaceutical products has come under increasing attention and scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation designed to, among other things: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reduce the prices of drugs and make them more accessible and affordable for patients; reform the structure and financing of public health insurance pharmaceutical benefits, most importantly, Medicare and Medicaid; facilitate value-based arrangements between manufacturers and payers; bring more transparency to drug pricing rationale and methodologies; and expedite the development and approval of generic drugs and biosimilars. Also, the Trump Administration&#8217;s budget proposal for fiscal year 2020 contains drug pricing and price control measures that could be enacted during the 2020 appropriations process. It is entirely unclear what, if any, legislative, regulatory and/or administrative measures that impact pharmaceuticals will eventually be implemented; however, both Congress, on a bipartisan basis, and the Trump Administration have indicated that they will continue to seek reforms in this area. We cannot know the final form of any such reforms or how they could affect our business</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with its evaluation of proposals concerning the pricing of, and access to, pharmaceutical products, many companies in our industry have received governmental requests for documents and information relating to drug pricing and patient support programs. Requests take various forms, including through a Congressional inquiry (e.g., from the U.S. Senate Finance Committee) or a subpoena from the U.S. Department of Justice. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects. It is possible that these inquiries could result in: negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products; and/or reduced reimbursement of our approved products, including by federal health care programs such as Medicare and Medicaid as well as state health care programs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing, including the National Medicaid Pooling Initiative. With respect to drug pricing transparency, for example, in October 2017, Jerry Brown, the Governor of California at the time, signed SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">threshold to certain purchasers and related reports to the government. SB-17 is currently subject to challenge, but in the meantime, manufacturers must comply with its requirements. It is possible that laws such as SB-17 will encourage federal and state healthcare programs to reduce the amount of reimbursements they provide for prescription drugs, and any reduction in reimbursement from these government healthcare programs may result in a similar reduction in payments from private payers. We also believe that pricing transparency requirements, such as the requirement for us, in certain circumstances, to provide lengthy notices of price increases to purchasers, may influence customer ordering patterns for CABOMETYX and COMETRIQ, and that this, in turn, may increase the volatility of our revenues as a reflection of changes in inventory volumes. Therefore, the implementation of these cost</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in some foreign countries, particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to twelve months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner, Ipsen, may be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of scrutiny. In recent years, some pharmaceutical manufacturers were named in class action lawsuits challenging the legality of their patient assistance programs and support of independent charitable patient support foundations under a variety of federal and state laws. Our patient assistance program and support of independent charitable foundations could become the target of similar litigation. Though not affecting CABOMETYX, at least one insurer also has directed its network pharmacies to no longer accept manufacturer co-payment coupons for certain specialty drugs the insurer identified. In addition, certain state and federal enforcement authorities and members of Congress have initiated inquiries about co-pay assistance programs. Some state legislatures have also been considering proposals that would restrict or ban co-pay coupons.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there has been regulatory review, Congressional interest and enhanced government scrutiny of donations by pharmaceutical companies to patient assistance programs operated by charitable foundations. The HHS Office of Inspector General has established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor&#8217;s product. If we are deemed not to have complied with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Further, numerous organizations, including pharmaceutical manufacturers, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support, and certain of these organizations have entered into, or have otherwise agreed to, significant civil settlements with applicable enforcement authorities. Additionally, in March 2019, the Senate Finance Committee launched an inquiry into alleged ties between pharmaceutical manufacturers and patient assistance charitable foundations. It is possible that future legislation may propose establishing requirements that affect pharmaceutical manufacturers and such charitable organizations. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to laws and government regulations relating to privacy and data protection that have required us to modify certain of our policies and procedures with respect to the collection and processing of personal data, and future laws and regulations may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to maintain compliance with these regulations could jeopardize certain business transactions and create additional liabilities for us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection in the U.S. continues to evolve, and there has been an increasing focus on privacy and data protection, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws governing the collection, use and disclosure of personal information. For example, in June 2018, Jerry Brown, the Governor of California at the time, signed into law the California Consumer Privacy Act of 2018 (CCPA),&#160;subsequently amended in September 2018, which goes into operation on January 1, 2020 and will give California residents expanded privacy rights and protections and will provide for civil penalties for violations and statutory damages under a private right of action for data breaches. There are similar legislative proposals being advanced in other states, and Congress is also considering federal privacy legislation. In addition, most healthcare providers who are expected to prescribe our products, and from whom we obtain patient health information, are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage a HIPAA-covered entity (or its business associate) to use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR), which became enforceable on May 25, 2018, regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the United States. Switzerland is updating the Swiss Data Protection Act, and updates to data protection laws in other countries may occur in due course. In connection with these new laws, in particular the CCPA and GDPR, we have modified or are reviewing certain of our policies and procedures with respect to the collection and processing of personal data. We will continue to review all future privacy and other regulations implemented pursuant to the CCPA, GDPR and other applicable laws to assess whether additional procedural safeguards are warranted, which may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to provide adequate privacy or data security protections or maintain compliance with these laws and regulations could jeopardize certain domestic and cross-border business transactions and create additional liabilities for us, including the imposition of sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an Abbreviated New Drug Application (ANDA) for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail under &#8220;Item 1. Business-Government Regulation-The Hatch-Waxman Act&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on February 22, 2019. In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our drugs prior to the expiry of one or more listed patents for the drug, we may end up engaging in litigation with the potential generic competitor to protect our patent rights, which would require us to incur significant expense and result in distraction for our management team, and could also have an adverse impact on our stock price. Moreover, if any such ANDAs or 505(b)(2) NDAs were to be approved, and if our listed patents covering cabozantinib were held to be invalid (or if any such competing generic versions of cabozantinib were found not to infringe our patents), we would have generic competitors in the market, and the resulting generic competition would negatively affect our business, financial condition and results of operations. In particular, generic cabozantinib products would be significantly less costly than ours to bring to market. Thus, regardless of the regulatory approval pathway, the introduction of a generic version of any of our marketed products could result in significant decreases in the overall sales or prices of these marketed products and materially harm our business and financial condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new potential product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval in a particular indication. Moreover, the results of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">preliminary studies do not necessarily predict clinical or commercial success, and later stage clinical trials may fail to confirm the results observed in earlier stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of cabozantinib in new indications</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or of our other product candidates, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or a tolerable safety profile;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects that we had expected to be promising;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lower-than-anticipated patient registration or enrollment in our clinical testing, resulting in the delay or cancellation of clinical testing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaborators to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials of cabozantinib or another product candidate, or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of the clinical testing of cabozantinib or our other product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our clinical and commercial collaboration partners to fund a significant portion of the clinical development of cabozantinib and our product candidates. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for the financial obligations associated with the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">characteristics of the product candidate under investigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of patients who ultimately participate in the clinical trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the length of time required to enroll suitable patient subjects.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or supplemental New Drug Application (sNDA) can be submitted to the FDA, or a marketing authorization application to the European Medicines Agency or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA and decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC, previously treated HCC and MTC, or approves one of our other product candidates, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC in November 2012, we are subject to a post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet ultimately fail to yield product candidates for clinical development for a number of reasons. For example, potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">develop suitable product candidates through internal discovery efforts or if we are unable to successfully obtain rights to suitable product candidates, our business and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor evolving social media communication guidelines and comply with applicable laws and regulations, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a materially adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements, Accounting and Financial Results</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to maintain or increase profitability.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$154.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$690.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the year ended December 31, 2018, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; other collaboration revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We expect to continue to spend significant additional amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug development expertise, which efforts could involve substantial costs. To offset these costs, we will need to generate substantial revenues. If these costs exceed our expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1,161.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$851.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of December 31, 2018. Our business operations grew substantially during 2018 the first six months of 2019. In order to maintain business growth, we plan to continue to execute on our U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib and our other product candidates, internal discovery activities and the execution of strategic transactions. Our ability to achieve these business objectives will depend on many factors including but not limited to: </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to control costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing internal drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including any disruptions resulting from government shutdowns, the uncertainty surrounding the date and the terms of the pending Brexit, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets.&#160;Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160; Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Condensed Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements from the Financial Accounting Standards Board (FASB) and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and, as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The 2017 comprehensive tax reform bill could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2018 and June 30, 2019, or are expected to be recorded in future periods. Additionally, further guidance may be forthcoming from the FASB and SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts, possibly with retroactive effect. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of earnings and applicable tax rates in the various places that we operate, the accounting for stock options and share based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws such as the passage of the Tax Cuts and Jobs Act, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2018, we had federal and state net operating loss carryforwards of approximately $1.1&#160;billion. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2031 for federal income tax purposes and 2028 for California state income tax purposes. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2018, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The transition away from the London Interbank Offered Rate (LIBOR) could affect the value of certain short-term investments, as well as our ability to seek additional debt financing.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Actions by governmental entities may impact certain financial instruments in which we have invested or may invest in the future. For example, some of these financial instruments may rely in some fashion upon LIBOR, which is an average interest rate, determined by the ICE Benchmark Administration, that banks charge one another for the use of short-term money. The UK's Financial Conduct Authority, which regulates LIBOR, has announced plans to phase out the use of LIBOR by the end of 2021. While only a small percentage of our short-term investments include financial instruments subject to LIBOR, and while we do not currently have any outstanding debt that is subject to LIBOR, there remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, and any potential effects of the transition away from LIBOR on certain instruments in to which we may enter in the future are not known. The transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that currently rely on LIBOR. The transition may also result in reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes.&#160; Any such effects of the transition away from LIBOR, as well as other unforeseen effects, result in expenses, difficulties, complications or delays in connection with future financing efforts, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The UK&#8217;s pending withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Brexit has created significant uncertainty concerning the terms of the UK withdrawal from the EU and the future relationship between the UK and the EU. On April 11, 2019, the European Council agreed at its Special Meeting to extend the UK&#8217;s departure date to October 31, 2019. It is possible the UK could withdraw from the EU prior to October 31, 2019 pursuant to agreed terms for a transition period; however, both the EU and the UK are preparing for a &#8220;no deal&#8221; scenario in which the UK will leave the EU as a &#8220;third country&#8221; without the benefit of any transition arrangements. In addition, the resignation of Theresa May and election of Boris Johnson as UK Prime Minister has further increased this uncertainty, since the UK&#8217;s future position on Brexit will depend significantly upon the policies and political decisions of the incoming administration under the new premiership, and Prime Minister Johnson has emphasized a commitment to complete the UK&#8217;s departure by October 31, 2019, with or without any transition agreements in place. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The &#8220;no deal&#8221; scenario has been recognized by the policy makers in the UK and the EU as likely to cause significant market and economic disruption. The effects of Brexit will depend on whether the UK retains access to EU markets either during a transitional period or more permanently. Brexit could disrupt the single internal market principle, which ensures the free movement of goods, services and people between the UK and the EU, undermine bilateral cooperation in key policy areas and significantly disturb trade relationships between the UK and the EU. In addition, Brexit&#160;could lead to legal uncertainty and potentially divergent national laws and regulations as the UK determines which EU laws to replace, amend or adopt.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the UK from the EU would have, and how such withdrawal would affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU. Any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that result from Brexit may have an adverse impact on this part of our supply chain. Trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaborator Ipsen to market our products in Europe. Furthermore, the announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations, and the pending withdrawal of the UK from the EU may also adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subject us to a number of risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo and BMS for the development and ultimate commercialization of certain compounds generated from our research and development efforts. Our dependence on our relationships with collaborators for the development and commercialization of compounds subjects us to, a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborators may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, deliver product that fails to meet appropriate quality and regulatory standards and results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes that may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for COTELLIC, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators may experience financial difficulties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; lack of success in their efforts to obtain regulatory approvals in a timely manner, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with the terms of our collaboration agreements and related ancillary agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">related to Good Manufacturing Practice, Good Clinical Practice, Good Distribution Practice and Good Pharmacovigilance Practice;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators could independently move forward with competing drug candidates, developed either independently or in collaboration with others, including our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to enter into additional collaboration arrangements with third parties in an area or field of exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of, development of our drug candidates.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations and our product development efforts could be delayed, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our internal drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations continue to expand through our clinical development and commercial progress, we are appropriately expanding our supply chain by entering into new agreements with additional third-party contract </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">manufacturers and suppliers. This will continue for the foreseeable future for all of our product candidates, as well as our current and future commercial products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to ensure compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and have a material adverse impact on our business, financial condition and results of operations. Through our third-party contract manufacturers and data service providers, we have implemented product serialization designed to comply with the Drug Supply Chain Security Act (DSCSA), pursuant to which, subject to limited exemptions, all prescription pharmaceutical products manufactured and distributed in the U.S. were required to be serialized as of November 27, 2018. If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our collaborators&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientific advisors and collaborators may be subject to restriction and change.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These advisors and collaborators are not our employees and may have other commitments or pursue other opportunities that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as advisors and collaborators or otherwise limit our access to these experts, or that the advisors themselves may now be more reluctant to work with industry partners. In any of these circumstances, we may lose work performed by these advisors and collaborators or be unable to engage them in the first place, and our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Information Technology, Data Privacy and Intellectual Property</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber-attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cyber-security efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous companies have been subject to a wide variety of security incidents, cyber-attacks (including through use of ransomware) and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack, and such threats can also vary in motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our contract manufacturing organizations, contract research organizations or vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others. Any such event that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cyber-security systems at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter partes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, should any third parties receive FDA approval of an ANDA for a generic version of cabozantinib or an 505(b)(2) NDA with respect to cabozantinib, and if our patents covering cabozantinib were held to be invalid (or if such competing generic versions of cabozantinib were found to not infringe our patents), then they could introduce generic versions of cabozantinib or other such 505(b)(2) products before our patents expire, and the resulting generic competition would negatively affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to develop or commercialize certain product candidates, which could severely harm our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, facilities, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, operational and financial systems, procedures and controls and must expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, in the second quarter of 2018, we moved our corporate headquarters from South San Francisco, California to Alameda, California. This relocation may make it more difficult to retain certain employees, and any resulting loss of talent and need to recruit and train new employees could be disruptive to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, a disaster could cause significant delays in our programs and make it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability or otherwise have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">contamination or discharge, or any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, any hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as a result of multiple factors, including pricing information required to be disclosed by us pursuant to drug pricing transparency laws</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements, including COTELLIC and MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in the amount of deductions from gross sales, including changes to the discount percentage of rebates and chargebacks mandated by the government programs in which we participate, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and chargebacks and changes in patient demographics;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third-party vendor relationships;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221; section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in the fourth quarter of 2018, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against deferred tax assets was released. Therefore, beginning in 2019, we record income tax expense at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an estimated tax rate that will likely approximate statutory tax rates, adjusted for discrete tax items, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">which has resulted in a significant reduction in our net income and net income per share. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the possibility of such fluctuations in our revenues and expenses, we believe that quarter-over-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements related to our or our collaborators&#8217; clinical trials or delays in those clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaborators&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products or clinical trial data by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications seeking a path to U.S. approval of generic versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and any failure to achieve the operating results projected by securities analysts</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel or board members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the extent to which coverage and reimbursement is available for both CABOMETYX and COMETRIQ from government and health administration authorities, private health insurers, managed care programs and other third-party payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the uncertainty of the date and the terms of the pending Brexit and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including possible repeal and/or replacement of or adverse judicial rulings against all or portions of PPACA or increases or changes in tariffs and other trade restrictions stemming from Trump administration and foreign government policies, or future U.S. federal government shutdowns, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><a id="s0CB6C2B2D44D52E39069F70696A4C016"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s5B655C5E68CA58529EDAF616B08796F4"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s2B3DDBF0606E5E19B05180196F96F800"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="sFF23C2722EE35F79B19B6CB3BEC69356"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="sEED4CFD7DBBA520D80B4536F9FCBC0F2"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/25/2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit32amendedandrestate.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">S-1,</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as amended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">333-96335</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4/7/2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000090/exel20190401exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Third Amendment dated April 1, 2019, to Lease Agreement dated May 2, 2017, between Ascentris 105, LLC and Exelixis Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4/5/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190630exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated May 17, 2019, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190630exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Second Amendment dated May 17, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190630exhibit311.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190630exhibit312.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32.1&#8225;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190630exhibit321.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8225;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3A00878D13E954F9A06A17D2F9920D49"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s7616097BE26A5B9C836D3082DAB99E51"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">E</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">I</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">NC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief&#160;Financial&#160;Officer </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>exel20190630exhibit102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE9BBE67A22470887F097400EC81939C1"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECOND AMENDMENT TO SUPPLY AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECOND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE SUPPLY AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of 17 May, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda CA 94502, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Ipsen Pharma SAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, a French corporation having an address at 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Licensee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Licensee may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Collaboration and License Agreement dated February 29, 2016, as amended by Amendment No. 1 dated effective December 20, 2016, Amendment No. 2 dated effective September 14, 2017, and Amendment No. 3 dated effective October 26, 2017 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), pursuant to which the Parties have been collaborating on the development and commercialization of cabozantinib; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Licensee are parties to that certain Supply Agreement dated February 29, 2016, as amended by that certain Side Letter between the Parties dated August 26, 2016, Amendment No. 1 dated effective October 26, 2017, and a second Side Letter dated effective December 7, 2017, subsequently extended on April 6, 2018 (together, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Supply Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), pursuant to which Exelixis has been manufacturing and supplying cabozantinib to Licensee for development and commercial use under the License Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Amendment to amend the Supply Agreement to reflect updates to the supply process, in particular to outline the ongoing process for launch supply in new territories and supersede the Side Letter, and make certain other changes, all on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;AMENDMENTS TO DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;A new definition of &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reworked Product</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall be added and shall read: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reworked Product</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean Finished Product that has been shipped to the Licensee, which the Licensee subsequently requires a modification to the packaging of such Finished Product; and the Licensee sends this Finished Product to the nominated Exelixis Third Party subcontractor for repacking of the primary pack into a new carton with an updated patient information leaflet (PIL).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;The definition of &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacture</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Manufacture</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means all activities related to the manufacturing of the Compound, Products and Reworked Product, in final labeled, packaged form for commercial use, including in-process and finished product testing, release of product or any component or ingredient hereof, quality assurance activities related to manufacturing and release of product, ongoing stability tests and regulatory activities related to any of the foregoing. &#8220;Manufacturing&#8221; has a correlative meaning.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;PRODUCT SUPPLY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The first sentence of  Section 2.2(a) is hereby deleted in its entirety and replaced with the following:  </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;(a)&#160;&#160;&#160;&#160; Rolling Forecast.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;On or prior to the [ * ] of each Calendar Quarter during the Term of this Supply Agreement, Licensee shall provide Exelixis a rolling forecast of the quantity of Finished Products, and Reworked Products, to be used for commercialization that Licensee plans to order during the [ * ] period commencing the following Calendar Quarter, itemizing the applicable quantity for each form of the Product (i.e., dosage strength and packaging configuration) (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Order Forecast&#8221;)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. The rolling forecast will provide the required Finished Goods quantities. Additionally, the forecast will include primary-packaged tablet (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Britestock&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) quantities that are necessary to fulfill the required Finished Goods deliveries.  An example of the Order Forecast schedule is attached at Exhibit A Parts 2 and 3.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.2(b) is hereby deleted and replaced in its entirety with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(b) &#160;&#160;&#160;&#160;Binding Commitment.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;The [ * ] of each Order Forecast shall constitute a binding commitment on Licensee to purchase and Exelixis to supply [ * ] of the order commitment set out therein of the Finished Product. Reworked Product is specifically excluded from any binding commitment, other than purchase order placement for Reworked Product per section 2.3(a)(v). . The [ * ] of the Order Forecast shall be a binding commitment on Licensee to purchase [ * ] of the order commitment for [ * ] the Finished Product. For clarity, the following [ * ] of the Order Forecast are indicative only and shall not be binding on the Licensee. The Licensee shall place such orders in accordance with Section 2.3 (a).&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.3(a) is deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(a)&#160;&#160;&#160;&#160;Purchase Orders. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">For the Term of this Supply Agreement, Licensee shall submit to Exelixis binding purchase orders (each, a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purchase Order</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) for all Product, including without limitation Finished Product and Reworked Product, to be delivered as further described in Section 2.3(a)(i-iii) below. An example of the Purchase Order scheduling sequence is attached at Exhibit A Part 1. Exelixis shall accept or reject each Purchase Order in writing within [ * ] after its receipt of such Purchase Order; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">provided, however</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that Exelixis shall accept such Purchase Order, if the quantities of Product are equal to those set forth to be delivered for such Calendar Quarter in the Order Forecast. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i) &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Finished Goods. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">On or before the [ * ] of the Calendar Quarter, Licensee shall submit to Exelixis a binding Purchase Order for Finished Product to be delivered during the [ * ] after the Purchase Order is submitted. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii) &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Unallocated Britestock.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;In each Calendar Quarter, it is expected that there will be a known quantity of Britestock remaining after all Finished Goods in fulfillment of the applicable Purchase Order have been packaged (such britestock, &#8220;Unallocated Britestock&#8221;). On or before the [ * ] of the Calendar Quarter and [ * ] per Calendar Quarter and unless otherwised agreed between the parties, Licensee may submit to Exelixis a Purchase Order to convert the Unallocated Britestock to Finished Goods respecting a [ * ] delivery lead time for receipt of the Finished Goods. Exelixis will use commercially reasonable efforts to reduce delivery lead time. In order to support the accelerated new market launches for Cabometyx in EU and RoW, Licensee and Exelixis agree that Exelixis will in good faith target to release within [ * ] from Licensee&#8217;s written request for utilization in a new market (EU or RoW). This lead time is dependent upon Licensee&#8217;s ability to provide required information to Exelixis (eg. label information/artwork; product requirements such as serialization information).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii) &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excess-Yield Britestock.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;All Britestock produced in a given batch that is in excess of Finished Goods plus Unallocated Britestock, if any, shall be defined as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excess-Yield Britestock</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;. On or before the [ * ] of any month and [ * ] per Calendar Quarter and unless otherwised agreed between the parties, Licensee may submit to Exelixis a Purchase Order to completely convert all Excess-Yield Britestock to Finished Goods respecting a [ * ] lead time for receipt of Finished Goods. Exelixis will use commercially reasonable efforts to reduce delivery lead time. In support of this </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis will confirm to Ipsen the quantity of Excess Yield Britestock on or before the [ * ] of such month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv) &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Unused Britestock.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis will promptly notify Licensee in the event that there is any unused Britestock. Any Britestock remaining after [ * ] from manufacturing date  will be destroyed unless Licensee provides prior written notice to Exelixis of its intent to utilize such unused Britestock by including such unused Britestock in a Purchase Order in accordance with any of the ordering processes outlined above. Licensee will use commercially reasonable efforts to utilize Britestock within [ * ]. If destroyed, Exelixis will invoice Licensee for the cost of the Britestock, as well as the actual costs incurred by Exelixis for the destruction.             </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v) &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reworked Product.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;From time to time, labelling updates may require that Finished Product be returned by Licensee, in its sole discretion, for repackaging by Exelixis. Licensee may submit to Exelixis on or before the [ * ] of any Calendar Month, but no more than [ * ] per Calendar Quarter, a Purchase Order for such Reworked Product, respecting a [ * ] lead time from receipt of such Purchase Order. Exelixis will use commercially reasonable efforts to reduce delivery lead time. It is acknowledged that the Purchase Order SKU quantities may be reduced by Licensee by up to [ * ], but in any event orders, whether original or revised, for Reworked Product shall never  be [ * ].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.3(c) is deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Delivery and Shipping Terms. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Purchase Orders submitted for quantities of Product that are in accordance with Section 2.3(a) and/or Section 2.3(b) as applicable will be binding on both Parties after acceptance in writing by Exelixis; provided, however, that should Exelixis neither reject a Purchase Order nor provide written confirmation of acceptance within [ * ] of receipt, Exelixis shall be deemed to have accepted the Purchase Order effectively. The Purchase Order will specify a single delivery date for such order to be delivered.  Exelixis shall deliver all Finished Product [ * ].  For Purchase Orders placed for commercialization in Canada; Exelixis shall deliver [ * ], as notified by Licensee.  Licensee shall deliver all Reworked Product to [ * ]. Exelixis shall deliver all Reworked Product from [ * ].  Exelixis shall be responsible for obtaining all licenses or other authorizations for the exportation of such shipments and shall supply Licensee with the documentation required for filing or claiming credit or deduction for any applicable taxes and/or duties.  Licensee shall be responsible for obtaining all freight, handling, insurance, and shipping expenses for such shipments, and shall be the importer of record and responsible for all duties and taxes for such shipments, and shall be responsible for obtaining all distribution licenses for the Products.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 2.4(g) of the Supply Agreement is deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(g)&#160;&#160;&#160;&#160;Inventory Management; Safety Stock.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Each Party shall manage its inventory in a manner that maximizes the remaining shelf life of its inventory.  Licensee shall carry a reasonable quantity of inventory of the Finished Product for its own use and the use of its partners, and Exelixis shall carry a reasonable quantity of raw materials, including API, which may be used in the event of an interruption to the supply chain.  The quantity of such safety stock shall be reviewed and discussed at the [ * ] S&amp;OP meeting and agreed upon by the Parties [ * ].  The Parties shall replace and replenish the safety stock continuously on a first to expire, first out basis.  Each Party shall be responsible for the cost of maintaining its own safety stock.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">A new Section 2.4(h) shall be added and shall read</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">:</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.4(h)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Reworked Product Yield. Exelixis shall in good faith target to ensure that at least [ * ] of Reworked Product units sent by Licensee, are returned to Licensee; excluding any sample quantities required to support quality release.  The parties acknowledge that this yield percent will be dependent upon whether product received from Licensee being undamaged and without defect. &#8221;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.7&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clause 2.5(d) &#8220;Damage after Delivery&#8221; shall be deleted in its entirety and replaced with the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.5(d)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Damage after Delivery. Licensee shall bear the risk of damage to the Product after delivery to Licensee pursuant to Section 2.3(c). If the Product is damaged after delivery to Licensee pursuant to Section 2.3(c) and Licensee intends to order replacement Product, Licensee shall promptly notify Exelixis of the damage and any orders for replacement Product, and Exelixis may at it sole discretion but in good faith, accept or reject all or a portion of the order for the replacement Product. If the Product is damaged after delivery to the Third Party, Exelixis shall promptly notify Licensee of such damage and provide Licensee with replacement Reworked Product free of charge as soon as possible but in no event later than [ * ] from the original agreed delivery date.  For clarity, such Reworked Product replacement is Licensee&#8217;s only remedy for any such damage at the Third-Party repackaging vendor, and the Parties explicitly agree that no other compensation will be available from Exelixis or such Third-Party repackaging vendor for such damage.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;FINANCIALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Clause 3.1 shall be amended to add a new clause 3.1(d) and shall read:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1(d)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Reworked Product. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The service charge for the Reworked Product (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Service Charge</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) will be [ * ]. The cost of Exelixis Third Party subcontractor performing the rework activities shall be agreed in advance of Purchase Order placement with Licensee.&#8221;  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly modified herein, all terms and conditions set forth in the Supply Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Supply Agreement as modified by this Amendment, and together with the License Agreement, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.3&#160;&#160;&#160;&#160;Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.4&#160;&#160;&#160;&#160;Counterparts; Electronic or Facsimile Signatures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;{SIGNATURE PAGE FOLLOWS}</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><a name="s098753B4EDE90375F26A400EC8664A19"></a></div><div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto have caused this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;By: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  President and Chief Executive Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IPSEN PHARMA S.A.S</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Ronan Stephens</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Ronan Stephens</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:   SVP Supply Chain</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB8F57C862811B59596C6400EC8849332"></a></div><div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:135%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;text-decoration:underline;">EXHIBIT A, Part 1</font></div><div style="line-height:135%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:135%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;text-decoration:underline;">Forecast and Purchase Orders</font></div><div style="line-height:135%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">EXHIBIT A: Part 2: Rolling Order Forecast (Example Only)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">EXHIBIT A: Part 3: Rework Order Forecast (Example Only)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>exel20190630exhibit103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0DFF92B68187BC8B1DF6400F8B062448"></a></div><div><div style="line-height:120%;text-align:left;font-size:13pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font><font style="font-family:inherit;font-size:13pt;">&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:624px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECOND AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECOND</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is entered into as of May 7, 2019 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) by and between Exelixis, Inc., a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and Takeda Pharmaceutical Company Limited, a Japanese corporation with principal offices located at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, JAPAN (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Collaborator</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Exelixis and Collaborator may be referred to herein individually as a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Party</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; or collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#2e2e2e;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;Exelixis and Collaborator are parties to the Collaboration and License Agreement dated January 30, 2017, as amended on March 22, 2018 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">License Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), under which the Parties have been collaborating on the development and commercialization of cabozantinib in Japan; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Parties desire to enter into this Amendment to modify certain reimbursement obligations and certain milestone payments payable under the License Agreement on the terms and conditions set forth below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;REGULATORY ACTIVITIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Section 5.5(c) of the License Agreement is hereby deleted in its entirety and replaced with the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(c)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PV Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As between the Parties, Exelixis shall be responsible for the cost and expense incurred by Exelixis for establishing and maintaining such global safety database and the preparation of periodic aggregate safety reports that are specifically directed (or reasonably allocable) to the Product (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PV</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) prior to [ * ].  For the period of time commencing upon [ * ] until [ * ], Exelixis shall be responsible for [ * ] of PV Costs and Collaborator shall be responsible for [ * ] of PV Costs.  Thereafter, Exelixis shall be responsible for [ * ] of PV Costs and Collaborator shall be responsible for [ * ] of PV Costs; provided, however, that in no event shall Collaborator be responsible for more than one million U.S. dollars ($1,000,000) in PV Costs in any Calendar Year during such period of time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;FINANCIAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The milestone table in Section 8.3(a) of the License Agreement is hereby deleted in its entirety and replaced with the following: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:15%;"></td><td style="width:9%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:10%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:11%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Milestone Event</font></div></td><td colspan="8" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;<br>Milestone Payments</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For HCC  <br>(2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;line)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For RCC  <br>(2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">nd</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;line)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For RCC  <br>(1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;line) as a combination therapy (including, for clarity, the Takeda 9ER Trial Opt-In)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">For RCC (1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;line) as a single agent </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tier 1 Indications </font></div><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tier 2 Indications</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tier 3 Indications: Clinical Trial sponsored by Collaborator or its Affiliate</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tier 3 Indications: Investigator-Initiated Clinical Trial</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone #1: Upon [ * ] the first Phase 3 Clinical Trial for the Product in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone #2: Upon [ * ] the first MAA for the Product in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$16 million</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone #3: Upon First Commercial Sale for the Product in the relevant indication in Collaborator Territory</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;Cumulative Net Sales Milestones</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The milestone table in Section 8.4(c) of the License Agreement is hereby deleted in its entirety and replaced with the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:92.52136752136752%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:72%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cumulative Net Sales of all Products in the Collaborator Territory</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cumulative Net Sales Milestone Payments</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exceed   $[ * ]</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:29px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;padding-left:17px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #00000a;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exceed   $[ * ]</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:29px;border-left:1px solid #000000;border-right:1px solid #00000a;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;padding-left:17px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$[ * ]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;GENERAL PROVISIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;Effect of Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as expressly modified herein, all terms and conditions set forth in the License Agreement, as in effect on the Amendment Effective Date, shall remain in full force and effect.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;Entire Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The License Agreement as modified by this Amendment is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to its subject matter.  They supersede all prior and contemporaneous agreements and communications, whether written or oral, of the Parties regarding this subject matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If, for any reason, any part of this Amendment is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not, to the extent feasible, affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Amendment.  All remaining portions shall remain in full force and effect as if the original Amendment had been executed without the invalidated, unenforceable, or illegal part.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;Counterparts; Electronic or Facsimile Signatures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;{SIGNATURE PAGE FOLLOWS}</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><hr style="page-break-after:always"><div><a name="sE17A5459CC293F126223400F8B43424B"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the Parties hereto have caused this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Second</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to be executed and entered into by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;By: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Michael M. Morrissey, Ph.D.</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  President and Chief Executive Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TAKEDA PHARMACEUTICAL COMPANY LIMITED</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;By: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Tsudoi Miyoshi</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  Tsudoi Miyoshi</font></div><div style="text-align:justify;padding-left:6px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:  Head of Japan Oncology Business Unit</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">{Signature Page to the Second Amendment to the Collaboration and License Agreement}</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exel20190630exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s66335F576A375B8B99E017003A8DA0F3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exel20190630exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sED1487A7244650F58D07F85A872A833E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">July&#160;31, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exel20190630exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD71B6AE3C56855E3B6783F97FEE61200"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">June&#160;28, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">31st</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">July 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exel-20190628.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20190628" xmlns:exel="http://www.exelixis.com/20190628" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190628_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190628_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190628_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190628_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails">
        <link:definition>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInvestmentsBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDaiichiSankyoDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails">
        <link:definition>2403410 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2111100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2411402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesDetails">
        <link:definition>2408401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2105100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2405402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2305301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exelixis.com/role/Leases">
        <link:definition>2112100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails">
        <link:definition>2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsOfLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails">
        <link:definition>2412404 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2">
        <link:definition>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails">
        <link:definition>2412402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exelixis.com/role/LeasesTables">
        <link:definition>2312301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2110100 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails">
        <link:definition>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2310301 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2106100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails">
        <link:definition>2406402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2406403 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2306301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details">
        <link:definition>2402407 - Disclosure - Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails">
        <link:definition>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails">
        <link:definition>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails">
        <link:definition>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.exelixis.com/role/SubsequentEvent">
        <link:definition>2113100 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.exelixis.com/role/SubsequentEventDetails">
        <link:definition>2413401 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_ASDMember" name="ASDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AccredoHealthIncorporatedMember" name="AccredoHealthIncorporatedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AchievedMember" name="AchievedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AlamedaCaliforniaMember" name="AlamedaCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CashAndRestrictedCashMember" name="CashAndRestrictedCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ChangeInContractWithCustomerAssetCurrentRollForward" name="ChangeInContractWithCustomerAssetCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" name="ChangeinContractwithCustomerAssetNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" name="ChangeinContractwithCustomerLiabilityCurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" name="ChangeinContractwithCustomerLiabilityNoncurrentRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ChargebacksAndDiscountsForPromptPaymentMember" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementAdditionalUpfrontPayments" name="CollaborationAgreementAdditionalUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementMilestonePaymentsEarned" name="CollaborationAgreementMilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementNumberOfPrograms" name="CollaborationAgreementNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" name="CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" name="CollaborationAgreementResearchAndDevelopmentExpenseAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentObligation" name="CollaborationAgreementResearchAndDevelopmentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" name="CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" name="CollaborationAgreementWithIconicTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementsUpfrontPayments" name="CollaborationAgreementsUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementwithDaiichiSankyoMember" name="CollaborationAgreementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementAnnualReimbursementLimit" name="CollaborativeArrangementAnnualReimbursementLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetCurrentOtherAdjustments" name="ContractWithCustomerAssetCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" name="ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" name="ContractWithCustomerAssetNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" name="ContractWithCustomerLiabilityCurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" name="ContractWithCustomerLiabilityNoncurrentOtherAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" name="ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_DiplomatSpecialtyPharmacyMember" name="DiplomatSpecialtyPharmacyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareDenominatorAbstract" name="EarningsPerShareDenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareNumeratorAbstract" name="EarningsPerShareNumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinancingLeaseLiabilitiesAbstract" name="FinancingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInAccruedClinicalLiabilities" name="IncreaseDecreaseInAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInAccruedCollaborationLiability" name="IncreaseDecreaseInAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" name="IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" name="IncreaseDecreaseInLeaseLiabilityNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInRebatesAndFeesPayable" name="IncreaseDecreaseInRebatesAndFeesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" name="LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_LesseeOperatingLeaseMonthlyBasePayment" name="LesseeOperatingLeaseMonthlyBasePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_NotProbableMember" name="NotProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityLongTerm" name="OperatingAndFinanceLeasesLiabilityLongTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityTotal" name="OperatingAndFinanceLeasesLiabilityTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" name="OperatingLeaseAdditionalAreaOfRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesAbstract" name="OperatingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" name="OperatingLeaseLiabilitiesDurationOfMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" name="OperatingLeaseSurrenderedAreaOfRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCollaborationMember" name="OtherCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCustomersMember" name="OtherCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OwnershipInterestByMinorityShareholder" name="OwnershipInterestByMinorityShareholder" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ProbableMember" name="ProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductGrossMember" name="ProductGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromCabozantinibMember" name="ProductsDerivedFromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsAdvisoryFeesIncurred" name="RelatedPartyTransactionsAdvisoryFeesIncurred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ResearchandDevelopmentMember" name="ResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ResultingFromDiscoveryEffortsMember" name="ResultingFromDiscoveryEffortsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetAmortization" name="RightOfUseAssetAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SalesDiscountsAndAllowancesMember" name="SalesDiscountsAndAllowancesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusAxis" name="StatusAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusDomain" name="StatusDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_TenantLeaseImprovementsAllowance" name="TenantLeaseImprovementsAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exel-20190628_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190628.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190628.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190628.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190628.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190628.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190628.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190628.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190628.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190628.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190628.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190628.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190628.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190628.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190628.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:href="exel-20190628.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190628.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190628.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190628.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190628.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190628.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190628.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190628.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190628.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190628.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190628.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190628.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190628.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190628.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20190628.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventDetails" xlink:href="exel-20190628.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_dd2c0b6c-bd52-a4d4-2c85-63d78ccca807" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_dd2c0b6c-bd52-a4d4-2c85-63d78ccca807" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_dd2c0b6c-bd52-a4d4-2c85-63d78ccca807" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_46f34c13-26a5-ca6e-3613-e231dd1f2d6a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_46f34c13-26a5-ca6e-3613-e231dd1f2d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_6354506a-6731-cd90-1f5d-acac861303b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_6354506a-6731-cd90-1f5d-acac861303b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_c52c87c0-47e1-9a76-3765-621be37e2286" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_c52c87c0-47e1-9a76-3765-621be37e2286" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_019ffeca-8dfc-b224-ad5b-e231dcac7db8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_RightOfUseAssetAmortization_019ffeca-8dfc-b224-ad5b-e231dcac7db8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_bdb195e0-2bd9-1b65-83b4-44045e66ebea" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_bdb195e0-2bd9-1b65-83b4-44045e66ebea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_6b73ac58-d917-0794-67de-e231dcf86592" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_6b73ac58-d917-0794-67de-e231dcf86592" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_697c6cb6-353c-94c4-b506-e231dd92e4bd" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_697c6cb6-353c-94c4-b506-e231dd92e4bd" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_ae174790-5ce3-87ae-3055-e231dd71f8f8" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_ae174790-5ce3-87ae-3055-e231dd71f8f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_f239b460-f317-6566-0193-e231dcdfbfbf" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_f239b460-f317-6566-0193-e231dcdfbfbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="locator" />
    <link:calculationArc order="21" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="locator" />
    <link:calculationArc order="22" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_25a8c943-d653-1f00-b8d3-0f47ff48fcf4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_25a8c943-d653-1f00-b8d3-0f47ff48fcf4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5e0cb0dc-b25c-aaae-62f8-cb90f31a16a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_fcba1b70-9744-b5e7-d3f6-0354ac274304" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_InterestIncomeOther_fcba1b70-9744-b5e7-d3f6-0354ac274304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_28fe77ae-e122-e428-d718-aff2ad445bc8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryRawMaterials_fc662cb4-22a7-eaf1-57df-aa538af7744b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryWorkInProcess_02c38264-930d-9c2f-e0a7-6a0838599d0b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_2d346164-e0c8-236a-1b5c-2893bff95bd9" xlink:to="loc_us-gaap_InventoryFinishedGoods_4b469d73-0d86-8f9c-e98a-661ef709c068" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_EEB79B0E5C7CCBD40ACC44568A5E2655" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_EEB79B0E5C7CCBD40ACC44568A5E2655" xlink:to="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_66b601d4-fa3f-7d40-f560-84d87697ff03" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_EEB79B0E5C7CCBD40ACC44568A5E2655" xlink:to="loc_us-gaap_FinanceLeaseLiability_66b601d4-fa3f-7d40-f560-84d87697ff03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_c7d469db-1829-81a3-8e6c-82df6bd6f6bf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_66b601d4-fa3f-7d40-f560-84d87697ff03" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_c7d469db-1829-81a3-8e6c-82df6bd6f6bf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_66b601d4-fa3f-7d40-f560-84d87697ff03" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_362d72d3-5e94-ebab-8f86-75d06c8c7ee4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_864B072043DFAAA54B5644433FBE25BA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_864B072043DFAAA54B5644433FBE25BA_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_864B072043DFAAA54B5644433FBE25BA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_864B072043DFAAA54B5644433FBE25BA_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_864B072043DFAAA54B5644433FBE25BA_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_864B072043DFAAA54B5644433FBE25BA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_864B072043DFAAA54B5644433FBE25BA_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_864B072043DFAAA54B5644433FBE25BA_834dfbbf-9427-d763-5673-e231dcc3eb20" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_864B072043DFAAA54B5644433FBE25BA_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_864B072043DFAAA54B5644433FBE25BA_834dfbbf-9427-d763-5673-e231dcc3eb20" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SubsequentEventDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exel-20190628_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190628.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190628.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190628.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190628.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190628.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190628.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190628.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190628.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190628.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190628.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190628.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190628.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190628.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190628.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190628.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190628.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190628.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190628.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190628.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190628.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190628.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190628.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190628.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190628.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190628.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190628.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190628.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20190628.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventDetails" xlink:href="exel-20190628.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6F54A9C012B0C47C8C61E7121C7AADAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6F54A9C012B0C47C8C61E7121C7AADAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F3B4DD5108DD74A657BCE7121C7A2F46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F3B4DD5108DD74A657BCE7121C7A2F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_16CF23DD2EC82628A064E7121C7AD19D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_CommercialPaperMember_16CF23DD2EC82628A064E7121C7AD19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42EB87D8DF4CA36B6B652EACE3524EAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42EB87D8DF4CA36B6B652EACE3524EAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_798074010DA81C307432E23265D67338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_798074010DA81C307432E23265D67338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_632E05A28C35A56EC030E23265D676E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_632E05A28C35A56EC030E23265D676E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FBB7363EAEE3A2215FDFE232656402F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FBB7363EAEE3A2215FDFE232656402F4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_8E42D6FA34D66A6508B2305891BFC6BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_8E42D6FA34D66A6508B2305891BFC6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:to="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:to="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:to="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_454B788092BAB7305E7D306129D72B20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:to="loc_exel_CollaborationMember_454B788092BAB7305E7D306129D72B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9C8A0F764FEA21502EE53060E0AE2810" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9C8A0F764FEA21502EE53060E0AE2810" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B2FFC3097AC41E72F9FA305891C0E1D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B2FFC3097AC41E72F9FA305891C0E1D0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_38F9D198F293E91F343044A6D2DED912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_38F9D198F293E91F343044A6D2DED912" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_9A6AF2445ACF27C08FCE44A6D2DF24D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_9A6AF2445ACF27C08FCE44A6D2DF24D3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_2EA3486678CFC7B27DA644A6D2DF02FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_2EA3486678CFC7B27DA644A6D2DF02FE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_07BE2839E89B182BB4F0E23265F5E7E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_07BE2839E89B182BB4F0E23265F5E7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_13E8D213EC051EF71FB8E23265F65810" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_13E8D213EC051EF71FB8E23265F65810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_5B13F26AFC2A2DE668192EACDF87CB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:to="loc_exel_GlaxoSmithKlineMember_5B13F26AFC2A2DE668192EACDF87CB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_322C2DCCCC193422AB892EACDF8826DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_322C2DCCCC193422AB892EACDF8826DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_C85A40F264ACFA24CE152EACDF885B50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_C85A40F264ACFA24CE152EACDF885B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:to="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:to="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:to="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:to="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:to="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_959E3DB27CC6D81D2A6DE232661EEA88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_959E3DB27CC6D81D2A6DE232661EEA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E98D73ECE2BBBE697E98E232662125BC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_EarningsPerShareBasic_E98D73ECE2BBBE697E98E232662125BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8DA80868D17DC8EC43FFE232662190DE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8DA80868D17DC8EC43FFE232662190DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:to="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:to="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0406EF9B798A36C1F8CB44A6D425965B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_NetIncomeLoss_0406EF9B798A36C1F8CB44A6D425965B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E57173D1D88C30B9DD14E23264E86231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E57173D1D88C30B9DD14E23264E86231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_EAD029C3E91EB6E2216AE23264E8E9BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CommercialPaperMember_EAD029C3E91EB6E2216AE23264E8E9BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0A27B2381A216ABF13B4E23264E9D2E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0A27B2381A216ABF13B4E23264E9D2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_28DE0ABDB47F2962B83BE23264E9DB2E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_28DE0ABDB47F2962B83BE23264E9DB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_E83DD6B1F81015945541E23264E910C6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CertificatesOfDepositMember_E83DD6B1F81015945541E23264E910C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:to="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:to="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:to="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:to="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C19591BC8DC46A2153654346A972B7F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:to="loc_srt_MinimumMember_C19591BC8DC46A2153654346A972B7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BBEA315D5641A8273D124346A9726A6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:to="loc_srt_MaximumMember_BBEA315D5641A8273D124346A9726A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:to="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:to="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:to="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:to="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:to="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:to="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:to="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:to="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:to="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:to="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:to="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:to="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:to="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:to="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:to="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:to="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:to="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:to="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:to="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:to="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:to="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:to="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:to="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:to="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0F73B190E07C218D92C827372F5A365C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0F73B190E07C218D92C827372F5A365C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:to="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:to="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449228493ACF3984DDA027372F62C1DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449228493ACF3984DDA027372F62C1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:to="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:to="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:to="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8DD1CE7AFB8E49E5835C44A6D1612F19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8DD1CE7AFB8E49E5835C44A6D1612F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:to="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:to="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:to="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AC7D4C5693DC3B9AA08FE232655B1C6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AC7D4C5693DC3B9AA08FE232655B1C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_468786B9153936CADC60E232655B5BC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:to="loc_us-gaap_EmployeeStockMember_468786B9153936CADC60E232655B5BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:to="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:to="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:to="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:to="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:to="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementAdditionalUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_6D11B76E2CCF54B5469A44A6D073FDD2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_6D11B76E2CCF54B5469A44A6D073FDD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F1BB32DA91CF227AFC44A6D07465EE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F1BB32DA91CF227AFC44A6D07465EE" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exel-20190628_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:to="lab_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_label_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_documentation_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:to="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:to="lab_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_label_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_documentation_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:to="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:to="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:to="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:to="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:to="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:to="lab_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:to="lab_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881_label_en-US" xlink:label="lab_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:to="lab_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="arc" />
    <link:label id="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD_label_en-US" xlink:label="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD_documentation_en-US" xlink:label="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:to="lab_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="arc" />
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A_terseLabel_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A_label_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A_documentation_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:to="lab_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5_label_en-US" xlink:label="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5_documentation_en-US" xlink:label="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="lab_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C_label_en-US" xlink:label="lab_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:to="lab_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services revenues</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:to="lab_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="arc" />
    <link:label id="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285_terseLabel_en-US" xlink:label="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration revenues</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285_label_en-US" xlink:label="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285_documentation_en-US" xlink:label="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:to="lab_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:to="lab_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:to="lab_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:to="lab_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3_label_en-US" xlink:label="lab_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="lab_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3_terseLabel_en-US" xlink:label="lab_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3_label_en-US" xlink:label="lab_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:to="lab_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108_label_en-US" xlink:label="lab_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:to="lab_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:to="lab_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:to="lab_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:to="lab_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461_label_en-US" xlink:label="lab_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:to="lab_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:to="lab_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:to="lab_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:to="lab_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:to="lab_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7_label_en-US" xlink:label="lab_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:to="lab_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE_label_en-US" xlink:label="lab_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:to="lab_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:to="lab_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:to="lab_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963_label_en-US" xlink:label="lab_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:to="lab_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64_label_en-US" xlink:label="lab_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:to="lab_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130_label_en-US" xlink:label="lab_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:to="lab_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0_label_en-US" xlink:label="lab_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:to="lab_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:to="lab_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:to="lab_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:to="lab_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:to="lab_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:to="lab_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:to="lab_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981_label_en-US" xlink:label="lab_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:to="lab_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:to="lab_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:to="lab_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:to="lab_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains or losses on available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="arc" />
    <link:label id="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7_terseLabel_en-US" xlink:label="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7_label_en-US" xlink:label="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7_documentation_en-US" xlink:label="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:to="lab_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="arc" />
    <link:label id="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61_terseLabel_en-US" xlink:label="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61_label_en-US" xlink:label="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61_documentation_en-US" xlink:label="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="lab_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="arc" />
    <link:label id="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A_terseLabel_en-US" xlink:label="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A_label_en-US" xlink:label="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A_documentation_en-US" xlink:label="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:to="lab_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="arc" />
    <link:label id="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E_terseLabel_en-US" xlink:label="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E_label_en-US" xlink:label="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E_documentation_en-US" xlink:label="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:to="lab_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="arc" />
    <link:label id="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351_label_en-US" xlink:label="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351_documentation_en-US" xlink:label="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:to="lab_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:to="lab_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:to="lab_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:to="lab_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average cost recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue related performance targets, shares vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C.</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:to="lab_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="arc" />
    <link:label id="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5_terseLabel_en-US" xlink:label="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5_label_en-US" xlink:label="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASD [Member]</link:label>
    <link:label id="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5_documentation_en-US" xlink:label="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASD [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:to="lab_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56_label_en-US" xlink:label="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56_documentation_en-US" xlink:label="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:to="lab_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="arc" />
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:to="lab_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="arc" />
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C_terseLabel_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C_label_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C_documentation_en-US" xlink:label="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diplomat Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:to="lab_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="arc" />
    <link:label id="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B_terseLabel_en-US" xlink:label="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others, individually less than 10% of Total revenues for all periods presented</link:label>
    <link:label id="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B_label_en-US" xlink:label="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:label id="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B_documentation_en-US" xlink:label="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:to="lab_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="lab_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Years ending December 31,</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:to="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2_negatedTerseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:to="lab_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="lab_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="lab_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:to="lab_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:to="lab_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB_label_en-US" xlink:label="lab_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:to="lab_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:to="lab_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:to="lab_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1_label_en-US" xlink:label="lab_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:to="lab_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65_label_en-US" xlink:label="lab_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:to="lab_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:to="lab_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:to="lab_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1_terseLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2_label_en-US" xlink:label="lab_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:to="lab_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:to="lab_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="lab_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:to="lab_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 302,784,854 and 299,876,080 at June 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:to="lab_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:to="lab_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties accruing to GSK</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:to="lab_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:to="lab_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED_label_en-US" xlink:label="lab_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:to="lab_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:to="lab_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031_terseLabel_en-US" xlink:label="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:to="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="lab_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:to="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:to="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:to="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:to="lab_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B_periodEndLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit on reimbursement per year</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Annual Reimbursement Limit</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Annual Reimbursement Limit</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:to="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F_verboseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:to="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payments Earned</link:label>
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0_label_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Milestone Payments Earned</link:label>
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:to="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62_verboseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:to="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37_label_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:to="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:to="lab_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:to="lab_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in short-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:to="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in long-term restricted cash and investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:to="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:to="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion included in Other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:to="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:to="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:to="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:to="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E_label_en-US" xlink:label="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:to="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:to="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:to="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:to="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="lab_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:to="lab_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Aurigene Discovery Technologies Limited Collaboration Agreement</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:to="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231_label_en-US" xlink:label="lab_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:to="lab_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9_terseLabel_en-US" xlink:label="lab_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9_label_en-US" xlink:label="lab_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:to="lab_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37_label_en-US" xlink:label="lab_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:to="lab_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876_label_en-US" xlink:label="lab_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:to="lab_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="lab_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of oncology programs included in collaboration agreement</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:to="lab_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314_label_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:to="lab_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional upfront payment</link:label>
    <link:label id="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317_label_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Upfront Payments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementAdditionalUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:to="lab_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research funding commitment (up to)</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee payment, if exercised</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF_label_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:to="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3_verboseLabel_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balances Without the Adoption of Topic 606</link:label>
    <link:label id="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3_label_en-US" xlink:label="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Calculated under Revenue Guidance in Effect before Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:to="lab_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="arc" />
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5_terseLabel_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Current Portion</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5_label_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5_documentation_en-US" xlink:label="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Contract With Customer, Asset, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="lab_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:to="lab_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transfer to receivables from contract assets recognized at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Reclassified to Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:to="lab_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:to="lab_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="lab_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of a change in transaction price and recognition of revenues as services are performed</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24_label_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Asset, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:to="lab_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Current Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Current [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:to="lab_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Current, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:to="lab_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:type="arc" />
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A_terseLabel_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liabilities - Long-term Portion</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A_label_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:label id="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A_documentation_en-US" xlink:label="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="lab_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="arc" />
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2_terseLabel_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2_label_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:label id="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2_documentation_en-US" xlink:label="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:to="lab_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="arc" />
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Noncurrent, Other Adjustments</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:to="lab_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Assets and Liabilities under Topic 606</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_label_en-US" xlink:label="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_documentation_en-US" xlink:label="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:to="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_label_en-US" xlink:label="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_documentation_en-US" xlink:label="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:to="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:to="lab_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="lab_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="arc" />
    <link:label id="lab_country_US_B8F416516D51CA82C83127372F59CD66_terseLabel_en-US" xlink:label="lab_country_US_B8F416516D51CA82C83127372F59CD66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_B8F416516D51CA82C83127372F59CD66_label_en-US" xlink:label="lab_country_US_B8F416516D51CA82C83127372F59CD66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:to="lab_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206_label_en-US" xlink:label="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:to="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="arc" />
    <link:label id="lab_country_JP_A8815B663A9A8845A88527424DE16576_terseLabel_en-US" xlink:label="lab_country_JP_A8815B663A9A8845A88527424DE16576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_A8815B663A9A8845A88527424DE16576_label_en-US" xlink:label="lab_country_JP_A8815B663A9A8845A88527424DE16576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:to="lab_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F_label_en-US" xlink:label="lab_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:to="lab_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profits and losses on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Iconic Therapeutics, Inc.</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:to="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical development funding commitment accrued</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development, regulatory and first-sale milestones</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:to="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886_label_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:to="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393_label_en-US" xlink:label="lab_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:to="lab_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:to="lab_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:to="lab_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:to="lab_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="arc" />
    <link:label id="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083_terseLabel_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and restricted cash</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083_label_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083_documentation_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:to="lab_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:to="lab_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913_label_en-US" xlink:label="lab_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="lab_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232_verboseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, amortized cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, fair value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:to="lab_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at June 30, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:to="lab_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:type="arc" />
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_terseLabel_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities:</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_label_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_documentation_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:to="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financing obligation for build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:to="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_totalLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:to="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:to="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E_label_en-US" xlink:label="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:to="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:to="lab_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) matching contributions made in common stock</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and other changes in right-of-use assets</link:label>
    <link:label id="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F_label_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:to="lab_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of investments, net and other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current portion of unbilled collaboration revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:to="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due customers</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:to="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:to="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:to="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:to="lab_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on financing lease obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred to acquire Property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:to="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:to="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:to="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASU No. 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU No. 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update No's. (2014-09 and 2016-02)</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="arc" />
    <link:label id="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389_terseLabel_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alameda, California</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389_label_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389_documentation_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:to="lab_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, expansion (in square feet)</link:label>
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910_label_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Additional Area Of Real Estate Property</link:label>
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Additional Area Of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:to="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:to="lab_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, surrendered (in square feet)</link:label>
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7_label_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Surrendered Area Of Real Estate Property</link:label>
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7_documentation_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Surrendered Area Of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:to="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly base rent</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Base Payment</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:to="lab_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, not yet commenced, monthly base rent</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate contractual base rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:to="lab_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net contract liability, current portion of deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net contract liability, long-term portion of deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="arc" />
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting from Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:to="lab_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:to="lab_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation Assumptions Used to Estimate Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_label_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_documentation_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:to="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:type="arc" />
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295_terseLabel_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership interest by BlackRock (more than)</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295_label_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Interest By Minority Shareholder</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295_documentation_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minority Ownership, Ownership Interest</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:to="lab_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees for advisory services paid to BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Incurred</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Incurred</link:label>
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsAdvisoryFeesIncurred" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:to="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:to="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:to="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exel-20190628_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190628.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190628.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190628.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190628.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190628.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190628.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190628.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190628.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190628.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190628.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190628.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190628.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190628.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190628.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190628.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190628.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190628.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190628.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190628.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190628.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190628.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190628.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190628.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190628.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190628.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190628.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190628.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190628.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190628.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190628.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190628.xsd#RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190628.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190628.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190628.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190628.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190628.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190628.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvent" xlink:href="exel-20190628.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventDetails" xlink:href="exel-20190628.xsd#SubsequentEventDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A6CB651AEFBFF48ED6B7E232654F5DFA" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_A6CB651AEFBFF48ED6B7E232654F5DFA" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_101A068E2D71EAE8AA41E7121C79B515" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_101A068E2D71EAE8AA41E7121C79B515" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:to="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_037461C30A590D564FE7E7121C7A5777" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6F54A9C012B0C47C8C61E7121C7AADAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6F54A9C012B0C47C8C61E7121C7AADAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_F3B4DD5108DD74A657BCE7121C7A2F46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_F3B4DD5108DD74A657BCE7121C7A2F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_16CF23DD2EC82628A064E7121C7AD19D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7C0EB8C48528A75DD75AE7121C7AE4EA" xlink:to="loc_us-gaap_CommercialPaperMember_16CF23DD2EC82628A064E7121C7AD19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_B9E1113A6B61A5DAAE64E7121C79BD4E" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_A8F59C187532132EA413E7121C7BBA39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_323765CC8404FB405628E7121C7BF631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_C18A21B4DEB5F8EF0168E7121C7B9175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_E06D70D5CC906647B886E7121C7BBB1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_19B99A3C82F69FEE2B0EE7121C7B09B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AEAFD8D467BCD6A7FE8BE7121C7C73C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_E82BC9B70028B24E5997E7121C7BA7B8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_BCC85B335E3638D01971E7121C7CE25B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_682CED29A52A27CD4E40E23266472BBA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_682CED29A52A27CD4E40E23266472BBA" xlink:to="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:to="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_C754AC130440501153CDE23266479933" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_MoneyMarketFundsMember_B09AF16D94A2CEF23B69E2326648C0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CommercialPaperMember_E5D74BCD7BD73E1419A4E232664817B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8A976948B0519038B964E2326648CB35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_03240B05D39DA05AFFC3E232664892A7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_exel_CashAndRestrictedCashMember_9DC49517411F10899AE4E2326649D083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E4ED37BE9B3DD70BB478E2326647D8E4" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3BE96800D22B9709EEAEE23266494F72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_4CAD8497A24F11FBF55DE2326647F393" xlink:to="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_BA4B69CEB5EA217E7F87E23266492C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_56A76B2F69A64CA9ED54E232664901A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3DA39BB07A0F14769300E232664AC842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6D79F87C102DEE061BA0E232664A3FFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82B170D41C3EA25CBF9EE232664AC218" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_DEC1B0FAFFBBE848891BE232664A3232" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_9F41E434EED5CFBDBBA4E232664B902A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_80FFDEC0E09FD61D6930E23266490913" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_BC37315EB0301A06C2DEE232664B7704" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_D286799A49619DF7419344A6D25744A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_9D2C2F0ABD3E9D81AF8644A6D258D751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_AFCB923C755691CD567644A6D258DE94" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_exel_OwnershipInterestByMinorityShareholder_85D4397EED3ABEFBA5D044A6D2580295" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_98198AC6597D2D5A133244A6D25918DF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_9511BC9728548A71BD9344A6D2594844" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RelatedPartyTransactionsAdvisoryFeesIncurred" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF78F693A2A523C2750044A6D257DBB6" xlink:to="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_44333CA8E8635EB6A8F744A6D259A4E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DDAA76DD8EFA7119C15AE2326589BABA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_DDAA76DD8EFA7119C15AE2326589BABA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:to="loc_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2C696D7B64876948D548E23265894B81" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8367BEF5DFB799602569E23265BEFE3D" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02FCD52E8EA4F92915A5E2326689A714" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02FCD52E8EA4F92915A5E2326689A714" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8A9E40CC982E9B3239EC2EACE350DEA5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8A9E40CC982E9B3239EC2EACE350DEA5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4AA1538492AAB9FE1E912EACE350A8F2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40BD61198982964E69852EACE350A81D" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_69F156E1743B03FA68A42EACE3518886" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5CDBF676E9C7376D1C902EACE3506C1A" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42EB87D8DF4CA36B6B652EACE3524EAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6BF3D58821FE70760E022EACE3518871" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_42EB87D8DF4CA36B6B652EACE3524EAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62647941D31F65934891E23265D44B6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62647941D31F65934891E23265D44B6D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_C79170BC07ABF2F19940E23265D52144" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_798074010DA81C307432E23265D67338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_798074010DA81C307432E23265D67338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_0DC94F9D632C1F34C228E23265D5268F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_632E05A28C35A56EC030E23265D676E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E6BCE003F4E4BC626CBBE23265D6EA66" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_632E05A28C35A56EC030E23265D676E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28B720FBF19C7D21155CE2326562248A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28B720FBF19C7D21155CE2326562248A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5211CFCB848E20ABA28BE23265631DD8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_947A4E71253A6E0058EBE23265623A64" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FBB7363EAEE3A2215FDFE232656402F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E36ADA32BAFEE3599A2AE2326564F653" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FBB7363EAEE3A2215FDFE232656402F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3C0289A23658720482F1305891BE9618" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3C0289A23658720482F1305891BE9618" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6BA18E96EECFA2F3962C305891BE8A66" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_8E42D6FA34D66A6508B2305891BFC6BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1B64AC6C24948B748A74305891BF1075" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_8E42D6FA34D66A6508B2305891BFC6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:to="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_DF9D196648948E7B65CF30611D1BD550" xlink:to="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_454B788092BAB7305E7D306129D72B20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_494445040DCCCF11301E30611D1C00DD" xlink:to="loc_exel_CollaborationMember_454B788092BAB7305E7D306129D72B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52414E25BA0A53AFED52305891BE753D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9C8A0F764FEA21502EE53060E0AE2810" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9C8A0F764FEA21502EE53060E0AE2810" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B2FFC3097AC41E72F9FA305891C0E1D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8C884E49E762983B5F86305891C0F64F" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B2FFC3097AC41E72F9FA305891C0E1D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C83EB8A8DC5AD1D45AEA44A6D2D7975A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C83EB8A8DC5AD1D45AEA44A6D2D7975A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EDEF95CEDE33DF78A11944A6D2DDB087" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4C6884AE5535462AF1DA44A6D2DDE765" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_B88DED61DC5C1E0A1A6B44A6D2DDE2C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F53EDF80B9A2F6BFAFF644A6D2D73BAF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_38F9D198F293E91F343044A6D2DED912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_38F9D198F293E91F343044A6D2DED912" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_4C66C0FA27E102E3828B44A6D2DE55A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_9A6AF2445ACF27C08FCE44A6D2DF24D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_9A6AF2445ACF27C08FCE44A6D2DF24D3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_F74A16F67290E62442A944A6D2DF4BA4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_2EA3486678CFC7B27DA644A6D2DF02FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C9A0B9BB228C7C4B2E1444A6D2DEC27B" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_2EA3486678CFC7B27DA644A6D2DF02FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4BBFFB2E0FA1C8281F0E23265F44222" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C4BBFFB2E0FA1C8281F0E23265F44222" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_85D59930CE8DBCD6E590E23265F5BE19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_07BE2839E89B182BB4F0E23265F5E7E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5CDBB01EE7DA980F42DAE23265F52171" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_07BE2839E89B182BB4F0E23265F5E7E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_76502FA2FA1894592605E23265F4DAD5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_13E8D213EC051EF71FB8E23265F65810" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_13E8D213EC051EF71FB8E23265F65810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiability_D4211816A6F924E369B1E23265F6D139" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A9640E3B157265992B8DE23265F6E46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A8A5BC57529249B427C6E23265F5A06D" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_198D0D3A3949D8D8AAFBE23265F6CEED" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09DF36F7BA55A737C05C44A6D30B1A25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09DF36F7BA55A737C05C44A6D30B1A25" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_BBDF1D44D53ECA4AFEBD44A6D30D8D8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1F98345A9EF20FDE263544A6D30BB45F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06E435EA422379DC80F444A6D30E5E43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2820DAAA575543DECFEE2EACDF86E205" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2820DAAA575543DECFEE2EACDF86E205" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_433564C6544CFE3F606A2EACDF86E53B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_5B13F26AFC2A2DE668192EACDF87CB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2B2460863F7C0E5F3D392EACDF871A56" xlink:to="loc_exel_GlaxoSmithKlineMember_5B13F26AFC2A2DE668192EACDF87CB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A917F1E75A7EEE392D582EACDF872AAF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_322C2DCCCC193422AB892EACDF8826DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_322C2DCCCC193422AB892EACDF8826DD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B116BFE0A8731BC89F1B2EACDF874A04" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4FDE80F1E391CDD4C9432EACDF889C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B4E0455534A2D1E4CC2F2EACDF86326D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_C85A40F264ACFA24CE152EACDF885B50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_C85A40F264ACFA24CE152EACDF885B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_FCA42DA898B5EDE39A8B2EACDF882F29" xlink:to="loc_us-gaap_RoyaltyExpense_2AFAE770F7D9D13D5E3E2EACDF898844" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AF371A0C73F9077BAAA9E232655D5A98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AF371A0C73F9077BAAA9E232655D5A98" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6387A1368054D600C54744A6D320EA68" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6387A1368054D600C54744A6D320EA68" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8EB2C336FF374B6E17DC44A6D320F332" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1593DBE151CE1EE2E37844A6D3207F27" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_F593BFB6CC9A3BAFD50244A6D3262D53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8427592C3E611833D0CA44A6D320B61D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_995A0E0F2E64817B338544A6D3276849" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones_63E604B0DFEDD324158D44A6D327AE2F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_4152EA9A705230DA3DB044A6D3271FE9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D26B666F69975A57534744A6D327DDB0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_A65F09524D5C440AA9B444A6D328EF62" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_FA6C5E3CCBA1307CEC8E44A6D3284F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6265F284657435DB48DE44A6D3288DA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E7DF7F2636224F12AC6E44A6D326079A" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2C824DE77A1343E750EA44A6D328DC5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:to="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C88ED13C60B68EF49FB7F33F473BF1B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_ShortTermInvestments_C596DFF503285AC89D76F33F473BD325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_ReceivablesNetCurrent_37FA29FE86E9909D899DF33F473B3DED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_1AC82A02C3830855A540F33F473B031A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_InventoryNet_1E3812A98DC16ABF095DF33F473BB1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D5B5736EC8DFBAC40F1EF33F473C7303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3EAD5EC17FBC45A3D162F33F473A776D" xlink:to="loc_us-gaap_AssetsCurrent_1CE93F5AF4D54B0287E4F33F473C657C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_LongTermInvestments_44A817D93E252789B5F0F33F473C3E6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3ABAC8905EDB4E4B4DCBF33F473C383E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8DA2EA459C60CE6FA673F33F473CCFF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3430299849DA4B9D5E2AF33F473C90FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_AA6A8AE791C1D1FC0FD8F33F473C2556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_Goodwill_4AB959134B107B695044F33F473DD9A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6F6569EAC59169B87499F33F473D334B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39513FDEB227C11928E1F33F473A9F65" xlink:to="loc_us-gaap_Assets_2A805B45B6A36E39D242F33F473D1D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E816E4AEF3CF6A1488BCF33F473ABE38" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_AccountsPayableCurrent_313FF975C33B56574D96F33F473EC3CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_8A410EE39FF715E38E15F33F473E323E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_7EBE930AC5C8BBEC224EF33F473E145F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_9BFBFEB65CFED7A62135F33F473E5249" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_7D40041B28B87CFFD286F33F473E873E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17D0C92762284DF1958EF33F473EBC63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DB4CD2B9F33A00A2D889F33F473F903A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7120D1161BBA9AC6268DF33F473D54CF" xlink:to="loc_us-gaap_LiabilitiesCurrent_D50150E4C3184FA75C1CF33F473F13FB" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_6F3FAE3BC91E8B94DB9AF33F473F44E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_E1E4C8898205780952FFF33F473FF648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_834B8E04D09DD668F17FF33F473F8AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_Liabilities_5B01A321DA57ADDF617BF33F473FA5B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_401C9F1644CB2525C408F33F4740E4E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_PreferredStockValue_204C8DDCC2209D67350EF33F4740E04A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_CommonStockValue_5187688DAE31F1D20D8CF33F4740CEFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1572D59677DF92683455F33F47409452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_A01B183C64014A29F704F33F4740D3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77FA9328949145BB0C57F33F4740A1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4D039AC76D1416D76F0DF33F47402039" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4DFFC6E7FC9BDE85AB84F33F47413CDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0B0A69ECA4A104AE6442F33F473D8DE9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_DF9A1A7E9CCF16E5C25DF33F47415195" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_40BDF72CD47C7FB564E5E2326612B40D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9102EE91BAF6CA560C79E2326612F106" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40BDF72CD47C7FB564E5E2326612B40D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9102EE91BAF6CA560C79E2326612F106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9102EE91BAF6CA560C79E2326612F106" xlink:to="loc_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:to="loc_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E21922AEBF063BC9BF344A6D4056DAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_NetIncomeLoss_1E21922AEBF063BC9BF344A6D4056DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2F674BAFC787019538F344A6D406EE17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_ShareBasedCompensation_72398E293B232EABF14244A6D4065346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_DB26653F98CC7796396D44A6D406B84F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_exel_RightOfUseAssetAmortization_D8A5B04C08D7456DA2EF44A6D407929F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_E49B33395A4624FFA68144A6D40745F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_6243BE2610272D2ECFAB44A6D40795EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_FB76100DF408144E653244A6D408F874" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_F78EB969C7BD360191A144A6D4060AAB" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_01949473D9D07609629944A6D4083246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_FA76F5E505579EC8F09844A6D40891EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_014D4432228F3C7DFFF244A6D40988D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_6736143E078345431AED44A6D409974B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_A36B65524BECC2D383F644A6D4092A81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_0211B0A8B44DCF0F635D44A6D409AFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_D23F8F8C2794863DF85C44A6D40A7B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_51F62E8F1120C28E6FCB44A6D40A16BF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_62FB0C9E44A402C6C64944A6D40AB0F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_4855ACFD6FEE3771E37244A6D40A3B92" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_35534C2B47D0D2B95EA744A6D40A6E3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46DC51663C2CD1C15A0344A6D40B2973" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_82CEC55145C3708D859B44A6D40BEF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_198A83C9263D6B83CE4144A6D408CFFE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CA4B213444211722758544A6D40B286F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E1A1D2AC8ABC7E97310644A6D40B13F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1FBC0875505E64D4F07444A6D40C0A56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1691114D233BE6EF200544A6D40C7E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2F530F91DDA1A941F7AA44A6D40C925A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_DA36B35488CA1C892D0D44A6D40DC1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_B39FABC2CF4384B42C7144A6D40DEE63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0EE3EA4828AE2E07836F44A6D40C91D8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F3F707352E1F80DC503D44A6D40DC552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_BB7C2DBCDE00F4D73BEC44A6D40EBF19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="loc_us-gaap_ProceedsFromStockPlans_CAADD8578EB0C1D3010044A6D40E3377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7BF1E420C92ED2A6B09F44A6D40E19EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_D3570A077A0321F9CEBF44A6D40FF33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_63CFF5C6A8CDF9E1333C44A6D40EC528" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_FB0A8134BD39A73F930544A6D40F15FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_F47E9BD35C725A377F9044A6D40F1C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DAE5FC48063A2039458B44A6D40F4F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15F649397AEE00AD6E9944A6D410D687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E4863D950C5BBD93D62844A6D4059613" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_553F4FB7822202230CFE44A6D4101B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1B8207C33889F4CFB94344A6D41028E7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E54071B0A036E1F442C944A6D410A8D0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C44B27C71577D3A9449DE23265D99A10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D0EECF4790EC748338BFE23265D9C8DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C44B27C71577D3A9449DE23265D99A10" xlink:to="loc_us-gaap_NetIncomeLoss_D0EECF4790EC748338BFE23265D9C8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C44B27C71577D3A9449DE23265D99A10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C44B27C71577D3A9449DE23265D99A10" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_16F9C66D350976A4296FE232658DE5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_39191F0B6AADCDAD2A63E232658DF543" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_FF86DFE2A6B5DB2013A8E232658DB259" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A" xlink:to="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:to="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_E60AA5DDDD822B79A769E232661CE82D" xlink:to="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:to="loc_us-gaap_ProductMember_B95EB99BFA292176FD6AE232661D882E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148" xlink:to="loc_exel_CollaborationMember_11D3ADC1962720366959E232661D4031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4C0FAC29FB62E50D0B51E232661CF9ED" xlink:to="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_959E3DB27CC6D81D2A6DE232661EEA88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_959E3DB27CC6D81D2A6DE232661EEA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF" xlink:to="loc_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_E98D73ECE2BBBE697E98E232662125BC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_EarningsPerShareBasic_E98D73ECE2BBBE697E98E232662125BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8DA80868D17DC8EC43FFE232662190DE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8DA80868D17DC8EC43FFE232662190DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_48608865DEADD66D1C40E232661D1550" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7" xlink:to="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17" xlink:to="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4" xlink:to="loc_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371" xlink:to="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0406EF9B798A36C1F8CB44A6D425965B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_NetIncomeLoss_0406EF9B798A36C1F8CB44A6D425965B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentType_7D48BB9E32DB54108A4B2EA7F8ACC2E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_AmendmentFlag_8105B2E5389DF85E05BB2EA7F8AD6108" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentPeriodEndDate_6D2BB089301192D64BB62EA7F8AD9457" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentFiscalYearFocus_F7FB5A9BAEB1A2260F3E2EA7F8AD630F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2FD9ABDD04E03DED25322EA7F8AD8AE0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityRegistrantName_B43DFE0B785F2534906B2EA7F8AE7461" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityCentralIndexKey_D48851DDA07ECA45400B2EA7F8AE06E8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityCurrentReportingStatus_C192F95719B154A642CB2EA7F8AE7792" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityInteractiveDataCurrent_1FF177757DBBAC04D7322EA7F8AE1EA5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_CurrentFiscalYearEndDate_CBBB67B6EA95A4387A222EA7F8AE234A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityFilerCategory_0626B475DCE80C8B2A152EA7F8AEE7A7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_68E3D13070594E3286042EA7F8AF035E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityShellCompany_4601675873E9DB0B182E2EA7F8AF8EBE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntitySmallBusiness_6D2CDA2DC8CB30C1C28F2EA7F8AF3357" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityEmergingGrowthCompany_5AF7F0BF6A500025EC492EA7F8AFAB08" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_Security12bTitle_12062FA34FB3DD50A7152EA7F8AF2963" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_TradingSymbol_6879A44561FD8B7185022EA7F8AF0F64" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_SecurityExchangeName_D051E3999FB67A8F06122EA7F8AF3130" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityFileNumber_DDEC6223EFC77591F70A2EA7F8B0FED0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_39663822570A3171F8732EA7F8B018AC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityTaxIdentificationNumber_2E1FE7024B635B09FF862EA7F8B03FD2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityAddressAddressLine1_05D320678EF8D3AA7D6F2EA7F8B05A89" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityAddressCityOrTown_5308EB0C100A5F1B55452EA7F8B01D11" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityAddressStateOrProvince_F61264E204729CAD1D572EA7F8B10129" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_EntityAddressPostalZipCode_C47A0A06C4CE762600802EA7F8B192F0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_CityAreaCode_54376C77A3285A7D63402EA7F8B1A981" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_LocalPhoneNumber_51A6EC74EDF2FAC82DA12EA7F8B1B61A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentQuarterlyReport_5E90E6873A62E93CFA672EA7F8B1CE71" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_18084B583DAA756ED3392EA7F8A9B1A3" xlink:to="loc_dei_DocumentTransitionReport_BB9BA0E4557E2030ED4F2EA7F8B1F5A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8F6F80146FB9CBE3C627E2326585CFFC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8F6F80146FB9CBE3C627E2326585CFFC" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C527B34C4220C61030A7E23264E7B09D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C527B34C4220C61030A7E23264E7B09D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1D4364666D5F23ED7705E23264E8A7EA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_E57173D1D88C30B9DD14E23264E86231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_MoneyMarketFundsMember_E57173D1D88C30B9DD14E23264E86231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_EAD029C3E91EB6E2216AE23264E8E9BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CommercialPaperMember_EAD029C3E91EB6E2216AE23264E8E9BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0A27B2381A216ABF13B4E23264E9D2E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0A27B2381A216ABF13B4E23264E9D2E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_28DE0ABDB47F2962B83BE23264E9DB2E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_28DE0ABDB47F2962B83BE23264E9DB2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_E83DD6B1F81015945541E23264E910C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5281B7D32DFC91076F1CE23264E88164" xlink:to="loc_us-gaap_CertificatesOfDepositMember_E83DD6B1F81015945541E23264E910C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_B523949CBC6CA2DC135FE23264E9F981" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9AC45C0B210AF406A1F1E23264EA8A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_820B20CF5E779BE63A2EE23264E9E155" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2C411E0E296B2A9A5C05E23264EA011E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1F0DE7A1FDB50EFB0963E23264EA218B" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_A6C66B08B45A61A2BFCBE23264EA382F" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_A08531234534EFBC12B6E23264EB94B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_63BBD7480706E5DA17ACE23264E7E0A4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2B5C2B60A13E6D360869E23264EBAAB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_5053BD5CA491BAEF1E08E23264EBE290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9D54A75C89D5DC5F4410E23264EB7990" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_94F671BD201762C9E9B4E23264EC1357" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_98A4A8D7BB52833517CAE232667FC9E5" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_B10B413A785AD45748EDE23265A1457D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_B10B413A785AD45748EDE23265A1457D" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_E900B6D7BA7AAA5A5CBAE23265A1DAB9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0D3C0D12468EC36FAF57E2326553DCD3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0D3C0D12468EC36FAF57E2326553DCD3" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9" xlink:to="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:to="loc_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D" xlink:to="loc_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE" xlink:to="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495" xlink:to="loc_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_D54A2D4DA36A95B7EC46E23264DC0A05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_D54A2D4DA36A95B7EC46E23264DC0A05" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9434618CBCD9F5E1328AE23265DF9334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9434618CBCD9F5E1328AE23265DF9334" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9434618CBCD9F5E1328AE23265DF9334" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_FA79D19DBBC3D28FBB8844A6D0A8C0BA" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FA79D19DBBC3D28FBB8844A6D0A8C0BA" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3" xlink:to="loc_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_FA79D19DBBC3D28FBB8844A6D0A8C0BA" xlink:to="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:to="loc_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_D7D518133847CA80EBB4E23266A9BE72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D7D518133847CA80EBB4E23266A9BE72" xlink:to="loc_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D7D518133847CA80EBB4E23266A9BE72" xlink:to="loc_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D7D518133847CA80EBB4E23266A9BE72" xlink:to="loc_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_C0941009905A89764C80444BD9833614" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:to="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_100E08A543EDB04025F5444BD9874AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_D867B3FE9C92E7A50808444BD9870E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_773BBDFF115463775943444BD9870203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_F010577C4473F6B8C4C9444BD9867E2D" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B9029F0043511913B8FF444BD987B5A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_DCC7EC458D725687045C444BD9882447" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_FC7FEAE3042FA345CF15444BD9824E54" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13E5FEA67E9FFF626E1F444BD988D535" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_9FAD83E5BD3B1E4628D1444BD988E49B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_32A60BEB829F72FBE4D9444BDF98A7F8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_D74AFC26DA24D40A48DB444BD98820F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_EE3EC69923D7FE1D7029444BD97FE35B" xlink:to="loc_us-gaap_OperatingLeaseLiability_F4ADCC2576FD304FFF9C444BD988FA3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_40B73AB9A5BEB03159194346A970724B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40B73AB9A5BEB03159194346A970724B" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E7CEE06BD60F4C3CE0564346A97139DD" xlink:to="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C19591BC8DC46A2153654346A972B7F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:to="loc_srt_MinimumMember_C19591BC8DC46A2153654346A972B7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_BBEA315D5641A8273D124346A9726A6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4D344FC6EC821E1D29634346A9715934" xlink:to="loc_srt_MaximumMember_BBEA315D5641A8273D124346A9726A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C297B1F3DE9A1273F3C14346A9721575" xlink:to="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7A49F4745FADBE8A6FAD4346A9723D53" xlink:to="loc_exel_AlamedaCaliforniaMember_42FDA9E18C830AB996674346A9737389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_AC4E3F413DDC199BD42F4346A971D6BC" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_003396113534C306E33A4346A973AABD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_CC8EA59E3B21BC57E1B24346A974E309" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_A9F0D22C5846BF43A8264346A9745910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeasePayments_38F68BF735D15283B95F4346A974A5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43C79BF368FCBDCE95C34346A974774E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_E08852AD7966BF9AEE204346A974ACBF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D5F4EE1E7418E8F3BA9F4346A97543C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_22E6EAAAA9625EE173C44346A975264C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseMonthlyBasePayment_6A1291B16B2828C0DFD74346A97565E3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_1278D91C2D46434E33CE4346A976D5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DDB02A60B446C75A50474346A97356EB" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_B19C40CDF628775ABF564346A976109E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_C046E844C9AC1FB2A31BE232668C94EC" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C046E844C9AC1FB2A31BE232668C94EC" xlink:to="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C046E844C9AC1FB2A31BE232668C94EC" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_C046E844C9AC1FB2A31BE232668C94EC" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C43D0FA55FF4A321D71EE23266DC5359" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C43D0FA55FF4A321D71EE23266DC5359" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:to="loc_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93" xlink:to="loc_us-gaap_NetIncomeLoss_FADA02EB932CA1D43EE1E2326684A655" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:to="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:to="loc_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_636710B9D3B7BB1F7408E23266846818" xlink:to="loc_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9508AA59FA2C37ACAF4EE23265D09C42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9508AA59FA2C37ACAF4EE23265D09C42" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7" xlink:to="loc_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_09A7E738C2652333EBABE23265CA2D73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09A7E738C2652333EBABE23265CA2D73" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_09A7E738C2652333EBABE23265CA2D73" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E345EE14686BEB24B8D3E2326598D1EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E345EE14686BEB24B8D3E2326598D1EA" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1C64835A651E73F88FC227372F79FC57" xlink:type="locator" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1C64835A651E73F88FC227372F79FC57" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:to="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EDD5707C51E91F3401CF27372F79D046" xlink:to="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_32231E67CA0C0D524A9127372F7A1518" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C003EBCD7983A9F4CCA727372F79AE41" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_18AEA8E4A98B7611B34A27372F7A6D91" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_F1ABD209C9BF9D50613627372F79D6A5" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="loc_exel_NumberofProductsinCommercialMarket_0A917A1A336EF433788227372F7AB26C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_77BFD273E812ADDB7DD027372F7A7B06" xlink:to="loc_us-gaap_NumberOfOperatingSegments_EC0711DE20BDDAE0D80C27372F7B3044" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23E1ECADBE1269705078E23264D701E0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8DC5CC183BDACDE38E6BE232668E11F4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6626EE668C6C4678185AE23266A397D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6626EE668C6C4678185AE23266A397D9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0" xlink:to="loc_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_287457A0DA1F7307B9F3E2326582E0D8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_287457A0DA1F7307B9F3E2326582E0D8" xlink:to="loc_us-gaap_Depreciation_25BA82C5A802830E1E70E2326582D77F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2717253E3F39E2A8A45AE23264DA4537" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2717253E3F39E2A8A45AE23264DA4537" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B34BE81947967211B999E23265966FC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B34BE81947967211B999E23265966FC3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C977AD8C677E1D600DD62F16D1020226" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C977AD8C677E1D600DD62F16D1020226" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_86415915D0C9A630B5CD2F16D102BE39" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_5C4A307AC56E032EF7602F16D10387CD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_3A11FD60091AB0D73A952F16D10347C9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_10B48F89CA6AAF33C8C22F16D102E60D" xlink:to="loc_exel_AllowanceForProductRebatesMember_0D037A1FDE5362D728F82F16D103C7A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_BC3AA7A5740ACD4BEE982F16D1029F61" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_A6510DD965507F4BDBD62F16D10394D6" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_BD1265A52DB8F55D104C2F16D1044F33" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_31906329BE26DD71A8D22F16D104E271" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_F439D4BDC0A6F0E28A062F16D1049C2C" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_168F990A185FCA9E2CAE2F16D105BDD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_F67050C4C10D5B4F537C2F16D105BE35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_A1741C5F2BC3E7858EDA2F16D1043DDF" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_87E5BE6ED39BBEF903B82F16D1050286" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40B9192E399D9313EA1627372F4648DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40B9192E399D9313EA1627372F4648DE" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_76250153F4540239085227372F4628B1" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member" xlink:label="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_47838D52F8A729D0424E27372F476B7B" xlink:to="loc_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member_1B886A2FBCF6AEF5F10327372F47F7E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_24ECD58EC53226241D8527372F46A3F6" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeInContractWithCustomerAssetCurrentRollForward" xlink:label="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_9CF2A1E221017EB9F07327372F48C78C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_123C22CB477650EB731227372F4813CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetReclassifiedToReceivable" xlink:label="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable_AFFBFC0EDF72F76FD47F27372F481FFE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_exel_ContractWithCustomerAssetCurrentOtherAdjustments_CA4EA4EA1678FA57FD9927372F48CD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeInContractWithCustomerAssetCurrentRollForward_F849AED2B8534D85DE5627372F4725F5" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_FC588E1F500010C3D4F427372F48BA06" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerAssetNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_B82449B3FAB24EC1211227372F4984E4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues_F3E41C48DEF33157A4C127372F498D8C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerAssetNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments_CE5E548A3F42825429EE27372F49DD24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward_830DD83A80AC985C777127372F49A0F8" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_094CC22FEEDA60DFC03C27372F490B30" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityCurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_304DCEAF4AD3245C163E27372F4A2353" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_9989D930498AA1EBFB8D27372F4A4850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_D686E8484214FA46B4B327372F4A934B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityCurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments_43760FAD6A820F0DC6B427372F4A039E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward_60F27BE47AEFDFCA693127372F4ADD4B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_47211BE40CFAB42013AC27372F4A9F35" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward" xlink:label="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_308FA265827239BEA13127372F47597F" xlink:to="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B789CF462B872F510CA927372F4BF9E6" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue" xlink:label="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue_777B98FC322F33FE9D4927372F4BF8F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments" xlink:label="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments_A2AACECE5E316DCB574927372F4B1D56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward_EBC00B9808A3658A9BD827372F4B600A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_3BA1BEB01D582B911AEC27372F4CCD93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_40B9192E399D9313EA1627372F4648DE" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_D99FA7CF9D0C154D4EEF27372F4CCC8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_708EF7AF935927143838E23264D137CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_708EF7AF935927143838E23264D137CC" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:to="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D" xlink:to="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B" xlink:to="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:to="loc_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A" xlink:to="loc_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_61D5B228C029BDFF1E1AE23264D23451" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_626470D653B0A44B0131E23264D37CCC" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_F2D02AE000F3AE02D5622ECDB73BEC62" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_65C35F757059F5623C7C2ECDB73CBB0B" xlink:to="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:to="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:to="loc_exel_ProductGrossMember_3A0E0D0A34B4A194F5762ECDB73DE4BD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_C2CDFC35D47F5E955AE92ECDB73C9881" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_A6C6A6F185D1147B85452ECDB73D032A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D9CB097D84009348C0DC2ECDB73C4450" xlink:to="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_us-gaap_LicenseMember_6827793A3F2F25BDE5612ECDB73DEA8C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_exel_ResearchandDevelopmentMember_245030045EE37B2D9BA32ECDB73E114E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_8766DD8ADCAC84BC8A842ECDB73DC8A5" xlink:to="loc_exel_OtherCollaborationMember_68853C70FB854454D7C42ECDB73EE285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_59510A5A5B0BB2BA46182ECDB73EF2A2" xlink:to="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7EEE3A42D8125C23C4622ECDB73E2694" xlink:to="loc_exel_GlaxoSmithKlineMember_6B9438FB0E75CA3579C12ECDB73E83C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_539E7D851D892D98D1642ECDB73F899F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8795509A466DCA387C382ECDB73F851E" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_2FD10A1C22BCC6E2ABB62ECDB73F4553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_E0C6E5D4220244B5C0AD2ECDB73CE79A" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_EE43D3C3EA997E1A7BAA2ECDB73F75BC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C538A644B4CC133D6F4A2ECDB73F20A3" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_48A338C70A896D9E424F2ECDB7408902" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85A65B43C47A873B8FF427372F58BB42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85A65B43C47A873B8FF427372F58BB42" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:to="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_B0F7DFCBF36C92A8FD5427372F5840AC" xlink:to="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_country_US_B8F416516D51CA82C83127372F59CD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD" xlink:to="loc_country_JP_A8815B663A9A8845A88527424DE16576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0F73B190E07C218D92C827372F5A365C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0F73B190E07C218D92C827372F5A365C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_86BFEC955BE95CA541C327372F5EEBD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_86BFEC955BE95CA541C327372F5EEBD1" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_F11370C166A1D7CE0DBF27372F5EBB87" xlink:to="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_CaremarkL.L.C.Member_AF033847739046140F5827372F5F0ECD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_C59FE46AAE8DF643995127372F5FAC68" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_ASDMember_3C150BDC417F62E9C59727372F6075D5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_IpsenMember_A4FEE1A5E02AF23317AA27372F60BF56" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AccredoHealthIncorporatedMember" xlink:label="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_AccredoHealthIncorporatedMember_44AA12E5224C4ABB66FD27372F5F5AF7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_DiplomatSpecialtyPharmacyMember" xlink:label="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_DiplomatSpecialtyPharmacyMember_FD5D71206846BBDFC24E27372F60F91C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_E54D443230F14025010327372F5FC7AA" xlink:to="loc_exel_OtherCustomersMember_11864301C8A85F7BE5E727372F60DC0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1B2ED740E82487AD392E27372F60EF31" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_CE37008001E8ADF9F3FA27372F6043BD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_9C4129D6DEF041F1EA0727372F619EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F45CB42F272EA43E3B5C27372F61F006" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_99678A3FE92CD0313B5727372F61B696" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_D994365A24B74C88BD5127372F616A73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_47C78D988AFCEB341A8B27372F5E4767" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449228493ACF3984DDA027372F62C1DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_449228493ACF3984DDA027372F62C1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_14AA8A0549FFB869B05827372F620310" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_60F9CF40B317427858CB27372F628AAD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BDC64950BC92FD4DDBC1E232659C1357" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BDC64950BC92FD4DDBC1E232659C1357" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_4128707611A345D054DCE232659DA137" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BDC64950BC92FD4DDBC1E232659C1357" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_CCB0617712D2F5594F40E232659D602D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_BDC64950BC92FD4DDBC1E232659C1357" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_014DD7DEC217E2C4C664E232659D7389" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6C62E16C248EE6DA9ED5E232660D49A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6C62E16C248EE6DA9ED5E232660D49A5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E9B42E182F19DC8F320AE23266E7D6C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E9B42E182F19DC8F320AE23266E7D6C5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C6E57141F1321E7FFDC64479E024F033" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_3D8C82E6C874579E16F2447D37214BE7" xlink:to="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_AchievedMember_88DC9B132BC05AF2698F447DEF92279A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_ProbableMember_7F8270BF905F86DF4D5C447FF2BFB07E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_D544F4CAFB609ED04788447D3727FC61" xlink:to="loc_exel_NotProbableMember_2E4CB9505CFB48D5FBD34481F757A351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_282CEBF0692DFA82CF334479E025D09E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6C17C3EA81B00888D8F24479E025A04E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_PerformanceSharesMember_8F8D1550A62D894246384479E0260E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3852F770EB2FB24E3B6D4479E025D604" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_17A3E482586130E7482D4479E0260660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_A74B38D94CA4497C29164479E024C78E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_C0E1B0B4BC9CE94DF6AB4479E02665C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77DC674173257C9C22874479E02690E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_97E9F6EBB5298A8B28344479E02CC689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B568B2577FFF21F2A5D14479E02C1C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D0A29BB3BD7A342A008F447EE227137B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6FDD6E659DFA780E01804479E026F54D" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_C43EA40E713CC400A3B04480A3C30187" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30433BCA3980D395C07F44A6D15F35B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30433BCA3980D395C07F44A6D15F35B3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:to="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D7A44204E383F71F56D244A6D16083EC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8DD1CE7AFB8E49E5835C44A6D1612F19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_694BF589AA6927A8169744A6D1600CAD" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8DD1CE7AFB8E49E5835C44A6D1612F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17226FF897AC72A59A8544A6D160CE4E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5AA68973137B5319B2F144A6D1678847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B47C422883878CAE75E544A6D16799F3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_1411C94E1F808385DEB444A6D1688068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_358FD45D4B6119FEDF3444A6D168D418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BF7848B428F97BBF289644A6D1660BF4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3706402738F4AAB2ECF944A6D1681108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_DB1842942B3C09E2A08144A6D16806BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91CBDB5A6083E06DA7C944A6D169FC6F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_E5C0F8AFCC4C8ABA069D44A6D169A539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7493AA1DAA8277765F1144A6D16921BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_60577F629BD47874D02D44A6D1688AA7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_468162453F553C2755BE44A6D16AB68D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_08744BEE55DD11332F8944A6D16A3D68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9F98C1E3ABB1B5BA1B4444A6D16A6BB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66F348F052A9354E1A2344A6D1662588" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_12E76367386870B3730A44A6D16AC36C" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_C7DC55E9FFE7FE2A156A44A6D16ADE6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958100B309E857320B99E232662B4437" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FA42FEA5A285CD5C660AE23265B8BE29" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91990CC15220BE59051E2326573E7FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B91990CC15220BE59051E2326573E7FC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:to="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_281B830725BAC73CE41DE2326573CEBA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4" xlink:to="loc_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_B7D43D812207912E2802E23265732142" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_536F3A9F86A86B8C7709E23265740087" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5C53A39B7C7AB71FFF4FE2326559FF94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5C53A39B7C7AB71FFF4FE2326559FF94" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:to="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_02B958C37B0CF4C55F9BE232655A0147" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_AC7D4C5693DC3B9AA08FE232655B1C6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_AC7D4C5693DC3B9AA08FE232655B1C6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_468786B9153936CADC60E232655B5BC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65" xlink:to="loc_us-gaap_EmployeeStockMember_468786B9153936CADC60E232655B5BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C39FAB4CDE3639414CBFE232655ABEC4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B051C3297C780932C0F7E232655B51A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5C36E17CF43C08907CAE27372E167229" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4C60F7B2E515D3BA3B6C27372E1BC6B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F7C2008F1281462C667A44A6D0672C88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F7C2008F1281462C667A44A6D0672C88" xlink:to="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_89DA1D6AA24A988B138A44A6D06D7210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6D24BAADE2160E71770F44A6D06E2A70" xlink:to="loc_us-gaap_SubsequentEventMember_B8041F45F912E103903544A6D06EC990" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F8AA1F5E49C6DBE4490A44A6D070AEB0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_17D0242782B9E6209DB844A6D070FF28" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_3E794E62129F109313D544A6D07090EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F06A4274FF207C70BC4F44A6D0717231" xlink:to="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:to="loc_srt_MinimumMember_EA9BF2FC5791C3FA792044A6D071DB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6557B1236515439D8FE944A6D0710DD9" xlink:to="loc_srt_MaximumMember_6771CD5372316A7EF60344A6D0726876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_960C9C562A6B8464D38F44A6D06B4B98" xlink:to="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_6803ADBB37FEFC5DFE2344A6D0723AB5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_55769CACC02EA033086C44A6D0737314" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementAdditionalUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementAdditionalUpfrontPayments_D21AF1649F3B17C01D5444A6D073B317" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_909C9522181AF150151844A6D073DAAF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_5B7D7F77B6C398BD400C44A6D073D6BF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_6D11B76E2CCF54B5469A44A6D073FDD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_6D11B76E2CCF54B5469A44A6D073FDD2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190628.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F1BB32DA91CF227AFC44A6D07465EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C53A0B2C1AE229F6BA0F44A6D072FD0B" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_D2F1BB32DA91CF227AFC44A6D07465EE" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exellogo2017aa08.jpg
<TEXT>
begin 644 exellogo2017aa08.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^%(8VAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,W(#<Y
M+C$U.3<V."P@,C Q-B\P."\Q,2TQ,SHR-#HT,B @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N
M,R\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^#0H)
M"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^#0H)"0D)"3QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^=%\P-C(Q,3<\+W)D9CIL:3X-"@D)"0D\+W)D
M9CI!;'0^#0H)"0D\+V1C.G1I=&QE/@T*"0D)/'AM<#I-971A9&%T841A=&4^
M,C Q-RTP-RTQ-%0R,3HT,SHT-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X-
M"@D)"3QX;7 Z36]D:69Y1&%T93XR,#$W+3 W+3$U5# T.C0S.C0W6CPO>&UP
M.DUO9&EF>41A=&4^#0H)"0D\>&UP.D-R96%T941A=&4^,C Q-RTP-RTQ-%0R
M,3HT,SHT-"TP-SHP,#PO>&UP.D-R96%T941A=&4^#0H)"0D\>&UP.D-R96%T
M;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"D\
M+WAM<#I#<F5A=&]R5&]O;#X-"@D)"3QX;7 Z5&AU;6)N86EL<SX-"@D)"0D\
M<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D\>&UP1TEM9SIW:61T:#XR-38\+WAM<$=);6<Z=VED=&@^
M#0H)"0D)"0D\>&UP1TEM9SIH96EG:'0^,3$V/"]X;7!'26UG.FAE:6=H=#X-
M"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X-
M"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5"3$%%
M<T%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!0D%"
M3$%!04%!14$-"D%117-!04%!05%!0B\K24U716Q$43$Y455K.4=357A&04%%
M0D%!04U317AP8FTX0T5!04%B5S4P8VQ*2%%I0EE75F]G0C@T04%G04H-"D%!
M64%-44%!65=.>F-%,512;%%!04%!05-55D1)2$Y34C!)04%!04%!04%!04%!
M04%!04%!4&)704%%04%!04$P>3%)54-!9T%!04$-"D%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M4EDS0GED04%!059!04%!07H-"EI'5GI9=T%!05E104%!0G-D,U)W9$%!04%F
M04%!04%566UT=V1!04%!9U%!04%!56-L:%I79T%!06AG04%!055:,6A:5V=!
M04%I=T$-"D%!0559;&A:5V=!04%K04%!04%56D<Q=5I!04%!;%%!04%"=UI'
M,6M:04%!07-104%!0TED;E9L6D%!04$P=T%!04-'9&UL;&1W04$-"D$Y44%!
M04%K8DA6=&%104%!+V=!04%!56)75FAC=T%!0D%W04%!06MD1U9J84%!04)$
M04%!04%-8VQ24U%W04%"1'=!04%G35HQ4E,-"E%W04%"1'=!04%G35EL4E-1
M=T%!0D1W04%!9TUD1U8T9$%!04%!0D1B,T(U8VUL;F%(46=+1TUP241%-4]4
M9V=31U8S8D=6,&1#,5$-"EE73G)96$IK245.=F)80FAB;FM!04=2;&,R34%!
M04%!04%!045N3E-2,$EG4U561$YJ135.:EET36DT>$%!04%!04%!04%!04%!
M05,-"F,Q2DA1:4)*4E5-,DU4:S).:3!Y3&I%04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04$-"D%!04%!04%!
M04%!04%&:%I7:4%!04%!04%!1'I544%"04%!04%28DU71FQA24%!04%!04%!
M04%!04%!04%!04%!04)95U9O9T%!04$-"D%!04%B-DE!041J,4%!041K1FA:
M5VE!04%!04%!04)I;5%!070T54%!0FIA5T9L84E!04%!04%!04-39T%!05!H
M04%!=',Y:UI83FH-"D%!04%!04%!04):2E)536=A2%(P8T1O=DPS9#-D>35P
M6E=-=5DR9T%!04%!04%!04%!04%!0EI*4E5-9V%(4C!C1&]V3#-D,V1Y-7 -
M"EI73759,F=!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!
M04%!04%!04%!04%!04%!04%!04%!04%!6D=6>EEW04$-"D%!04%!04%U4U56
M1$E$67A/5%DR3%1)=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H
M63)59TQ30GI5:V1#04%!04%!04$-"D%!04%!04%U4U561$E$67A/5%DR3%1)
M=4U30D5:5UIH9%=X,$E&2DA1:4)J8C)X=F1826=C,T)H63)59TQ30GI5:V1#
M04%!04%!04$-"D%!04%!04%!04%!04%!04%!04%!04=2;&,R34%!04%!04%!
M04Q&2FQ:;59Y6E<U:EI30E=A5U8S85<U;DE%3G9B;5)P9$=L=F)I0G -"F)I
M0DI254TR351K,DYI,'E,:D5!04%!04%!04%!04%!04-X4UI76FQC;59U63)5
M9U9M;&QD,FQU6GE"1&(R-6MA6%)P8C(T9V%7-&<-"E-55D1.:D4U3FI9=$UI
M-'A!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!0C)A5U8S04%!
M04%!051P4#1!1D8X=4%"1% -"D9!040W8W=!0D)-3$%!3F-N9T%!04%&65=6
M;V=!04%!04%"34-664%504%!049C9C4R,6Q96$U!04%!04%!04%!44%!04%!
M04%!04$-"D%!04%!04%!04%!04%!2U!!04%!06Y.<%IY04%!04%!43%*54E'
M3C%C;EE!04%!04%!045!04%!04%504-G05!!0E%!1U%!94%#34$-"DM!071!
M1$E!3G=!-T%%04%244)+044X059!0EI!1C1!67=";T%',$%C9T(S04AW06=1
M0T=!27-!:T%#5D%*;T%N=T-K04MK07)G0WD-"D%,8T%V041"04U907EW1%%!
M3E5!,G=$9T%/54$V=T1W05!902MW14)!46-"1%%%5$%2:T)(=T5L05-S0DUG
M131!5#1"4E%&34%624(-"E=11F=!5V-"8F=&,4%8=T)G=T=,05I)0FUG1VA!
M86M"<U%'-4%C14)Y44A2061K0C112'!!9DE"*V=)1$%G=T-&04ED06E90TQW
M230-"D%K14-3=TI506PP0UIW2GA!;F]#:$%+3T%P9T-O9TMS07)90W=13$Q!
M=%5#-$%,<D%V541!04U,07A91$E1371!>F=$47=.4$$Q;T0-"EIG3GE!,S1$
M:6=/5T$V241R9T\V03AC1#!W4&=!*W=$*U%11T)"345)05%T0D1S15-!4E9"
M1TU%8U%2*T))=T5M9U-O0DQ917A!5%0-"D)/144X050K0E$P1DA!57)"5&]&
M4U%664)78T9D=U='0EI91G!G5S%"8U5&,5%8;$)F64="9UE70FEC1TYW6DE"
M;&M'86=:-T)O=T<-"FY1879"<T%',%%B:D)V54A"=V-:0GES2%!19%!",D5(
M9$%E1T(U:TAR064O0CE)2#519C1#07-)2'=G>4-%64E79VAU0TE)26QG:7$-
M"D-,-$DP9VIN0U!S2D5!:VQ#5&]*5'=L:T-8:TIJ=VUK0V)O2GIW;FQ#9G-+
M15%O;D-J,$M607!Q0V]%2VU!<75#<U5+,T%R>D-W<TP-"DEG<S5#,45,85%U
M04,U9TQS079)0RM%3"M1=U-$0V]-47=X8T1(54UJ9WEN1$U!33)1>GI$43!.
M2F<Q0416;TYD03)/1&%K3G=W,V4-"D1F9T]%=S1U1&MK3UI!-2]$<'-/=&<W
M4T1U-%!#43AL1#!%4%AG.39$-5E0<W<O4$0K=U%#4D%M145-45E20BM%2G-1
M=5)$6$5055(-"D5X17A%53A28E)'345A;U)Y4DAO16=C4TIH2D9%;5%3:$)+
M:D5S35,T>$U$17E-5%%X3FI%-$U4<$)01D4K555":%%N1D5K56%H4TP-"D9+
M,%5Z:%1W1E))5DY"5E=&6&=6;7A7.49E05=!>%EM1FMK5V)"85!&<DE7,6AB
M-D9X,%A14F1L1C1K6')H9E-&+V-91WAH04='55D-"FEH:79'3E59*VAK9T=5
M55IA>&U21V)C6C-2;T5':6]A55)P,T=P-&%X4G)S1WA18D]X=&I'-&]B<VAV
M84A!26-+:'A32$AS8V]X>DT-"DA0561(:#%(2%A!9&U2,T1(97=E1F@U04AM
M;V5L0C8K2'5K9D5X."M(,FMF;$(K+T@K;V=&4T)"24=W9VU#1$5)4$%H2$-&
M24E856@-"F]32$])9G-I2GE*5DEO26ER>4QD27=O:D]#3FU)-5%J=VE0=TI"
M.&M44U(X2DMS:S)I54I*5&=L84-76$IC8VPY>5EN2FQC;6AY83,-"DIU9VY'
M0V1*2C-O;G%Y9F-+03!O4'EH>$M+26\Q0VM'2U1G<&%Y;61+9$%Q06EO,4MM
M9W%M>7)02W=)<DYI='!+-3!R,%-W1DQ$:W,-"F)I>6E,3F-T1$,Q0DQ8671Q
M>3-H3&A9=51#-D-,<F-U-VDX:TPQ;W9K4R](3"\T=TY40G--2U%W,GI%4TU5
M;WAG:D<V369)>4MJ2FH-"DUP<WDQ1$U.33!9>F9Z3S1-+T4P2WI2;$Y*-# R
M1%543E4P,6AZ6$-.9C R3GI:>4YQ-#(V5&-K3C)!,VY$9EA/0E$T541I34]-
M9S4-"D)4;$-/6#@U=D1N-4]J639D1'%Y3W4X-TQ4=')/-F\W-D1W;E!'53AP
M1'IJ4%-).5E4,FA094$K240U9U!Q02LT1#AH4#)%+V]J+VD-"E%#3D%:14-M
M44]D0DM51G%187A"-VM)=U%N2D-T54PS47IP1&954$%204Y%4C!32U)--49%
M:U964EIP1C-K66E2;61'<3!B=U)Z5D@-"F4P9D%3059)4S!I4E-.9$I(56QJ
M4V%L2CA%;S-3;C%+>$5S35,Q3DQM:W9I5$-P36-K>39444I.4VLR5%1D>$]*
M535U5')D4$%%.4H-"E0U3E S5D%N54A&474Q14=55D)2;3%(;55J1E-F1DQ(
M57A.5%@Q3W%5+UI546Q34%9.=%9+1E8Q5F-*5T0Q6F-6<6Q7.3%D158U2E@-
M"C1&9W972#%9>3%K85=7;%IU1F](5VQ:87!L<C%7,%9B;%9V;%A$5F-H;'I7
M6%-D9&5&,TI8:'!E8D8V.5AW.6995BMZ64%69U8R0W$-"EE0>&A4,D=I6696
M:5-72V-9=D)J43)/6%DK=&M11U-56D]L;%!75U-:961M4%=A4UIU:&Y05V54
M6BML;U R:5=A3WAP43)M86%F1G$-"E-'<69A=F1R5#)U;F$O.7-6,GEV8E%H
M=%E',C5B:$IU83(W16)X-79E1R]28T-T=VAN1&=C5'!X;%A(=V-K='EP;DU"
M8S$Q>G5(454-"F1(0C!Z2%5O9%E6,31862MD<'0R*TAD5V0W3C1%6&AU94UX
M-4MN;4IE960V4FYQ;&5W4C=9,W9#9D-&.&=8>FAF548Y;U@T0F9M2BL-"G=N
M.&IF-%(O-5E"2&=+:4)#;T9R9V,R0TU)2U-G=E-$5C1/-FA",D5G251J:%5E
M1G$T64]H;DM',31C-V@U*TE"26AP:4TV2DTT;5H-"FEF-DM:27)+:7I#3&QO
M=CAJ1T]->6\P>&I::4XO-#5M:G,V4$YO*V5K06%18G!$5VM4*U)Q2DE2:VYQ
M4S0U3DYK-V%524I32VQ04U8-"E@U6$IL:E-7;C5C2VPS5U@T2FA-;4QI6DI*
M;5%M9GEA84IR5FTP2V)R-7=C;DEM8SDU,6MN9$ME44HV=6YX,F9I-2\V;T=M
M9S)+1D@-"F]B86E*<4M7;W=A:F1Q4&UP1F%K>#95-'!A;6U'<6%,<'8R;F)Q
M9F=Q1DMO>$MK,W%A;7%(2W%0<7=+<F1A=G!R1GES,$LQ17)B:74-"DQA-FAR
M>&%V:3=!07-(5W<V<D9G<V1A>5,W3$-S>FEZ<G)1;'1*>3%%-U=+=&=',F5B
M8G=T,FDS-$QH6G5.1S53<FY#=6IU-G1B<W4-"G4V93A)8GEB=E)7.6HW-$MV
M;U,K+S<Y-G8O6$%C341S=U=F0C0X2F9W='9$5TU057A&2$5Z<U9,>&-J1U)S
M8D1X,$A(=CAG.7E,>DH-"D]S;35Y:FI+=#AS,GDW8DU.8WDQ>E183G1C-#)Z
M<F)03C@K-#!$;E%U=$4X,&(W4U Y3$(P,%14>'122C%-=E94=%A2,6Q85S).
M9&,-"C$K1%E:3FIO,E=Z6CAD<#(R=G9B9TYW1C-)<F1%3C)7,VAZ96]T.' S
M-B]G3G5#.3155&AZ3TI4-'1V:EDK4'(U2%!K+T]7135G,VT-"FQU8V8U-FYO
M375I.#958G P3W!B-G58<F-/=C<W26)T164R8S=I:G5T3SE!-SAZ=U=01&PX
M6$QX+R]+33AX;GIP+U$P.4U,,5506&4-"CEM,S(K+V5+*T)N-'%0:S0K8V8V
M5B]R;BLS9CA"+WE9+U-N.75V-4PO='HO8F8O+R\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44$-"D)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX.&8-
M"DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8-"DAX.&9(>#AF2'@X
M9DAX.&9(>#AF+SA!04519T%D045!07=%4D%!25)!44U2068O14%A24%!04%(
M05%%0D%114%!04%!04%!04%!448-"D%W24=!44%(0T%K2T-W14%!9TE$05%%
M0D%114%!04%!04%!04%104-!=U%&0F=C24-1;TQ%04%#05%-1$%G44-"9V-$
M0D%)1T%N34(-"D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E0
M0E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/>DYH9%4-"EI(
M5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]013%/5#!:6%=&;&%7
M,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95@-"G W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6G%B;DHR96XU2VIP2U=M<#9I<'%Q=7-R
M839V;U)!04E#05%)1$)1544-"D)1645#04U$8E%%04%H141"0T53355%1E52
M3FA)9UIX9UI%>6]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H85-5>5=I63=,
M0T(S4%,-"DYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<# K
M4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R8D<-"C%U8C)2
M,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM$;$I75VPU:5IM<'5C
M;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V$-"D%!=T1!44%#15%-4D%$.$$Y
M531Q-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M;#D-"GHU:#!#,75H85A/<%<P1C!D=E)K;5)8<65L5DIQ2S563%!J:6%-9T0W
M,TIX-DQ.3U!&1T5J2'9!2UE!9VEO,T(V2$Q81V1I<5A7=74-"C)L,W)&>G!L
M<T=L97E65&1Z0VYP;S<O6FER,V5L4V9$-3542$U*5$U2,#4O<6-R2G!*47A2
M>5,R12M1-FYZ.7E9-6,T<G-69&ER<U8-"F1I<G-69&ER<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7%895I,=39S
M+TPR<%AD<B]V5$(-"F)3>5%K8C!:54I"<#=D8W Q16I(2$EJ;4%82S!/3TTX
M.$EY*VMY05!Z9DU5:VIY3S!K:D8U2$I:,UDQ2DHS2DI/8U548C8T04%+2$H-
M"C=R*U1T+V989FQ)<F1->G)A,T1W5S=T=6940TEW6&9S<%EG9F0R>G%/>5IY
M;&DS-D=N>G(R;7=W:'%B:B]&1WHW-TM*+TU,>G%D1'0-"D5S3E O938U9F9"
M8E)Q3U)J1$AJ-FA(:EA:0C-0>7EE=C%N:$1H:CEC=516,DPR6"M9;'AZ,G=W
M-2MF;"MT3F9*,VPT849O8TYO-34-"C-K:$TY.4U457902G4U2E!7;E0V378P
M;41W;T%D95HY-V@Y<#8S.'AM36@Y23)I3S9)-4HS;5,V.3)+=7A6,DMU>%8R
M2W5X5C)+<TH-"B].=GIB<69L<GDQ2%!P:D-/.74U,6=367%'.4YE3$]Z04U#
M2R]$5&-946=V1G8X06QA+S5H9CA!5C5K+S5&=R\X,%EA4F)V*U9R+VT-"D8O
M,65:4#A!:UA$+T%-,%DP='-O+TQ0>G@U.3%Z>FI:5V1Z9GDS5FE/8C-I8TEW
M;VI61V]72W%+9D94=FE1:TUS+TYU9GHQ;SA3-C,-"F]7<%-P<&]!4SET5E-.
M=E-B;W-G2E5N:3-1*T(K97=#;$EF>7DO3B]56CE56%-F33%Y2F\W;VAB4SE:
M55%P251S:FQ1;S1T,E!9*S,-"E))548W5&=3.$TO368X-$Y53W1'>#AS,VYO
M5V1M4VMT,&=2+U=K-DYX3$)H=UAO0T]V6'!42D%)=&U(-510-3(Q3WIB5R]-
M1V]Y>3(-"FMW-#)&;WEX<GE(95IU2W%A9&PK+W=!34)5354O3E@X>2].5VTK
M8EHY2C!Q-TYL8E=34FAU0TEZ4U!*1W-P66PQ8F](<%%9449,1'8-"BM6<B]!
M2FAF.5AM5"]K6$0O=T$P63!I,V8X<E@O34PO04MV36XO275(+VUJ1VQT-T(K
M5&UT95IT6C!/-W8Y8FYE-%9P*T9N3$EQ<%8-"E98-"M014Q58W1Q*T]!<$1'
M9GIE+TU8>E!P2&U.3DHP:34K<'=1=W!*239O:D\W>59/-6-.44%D:&E!<%HW
M*U=7<F%H<3-K:E1D43$-"D=9,T8U4#8O<7I-04,S0S1K4F1L04=Y<4)I56AL
M1T)71R]M>#5R,4QY,3571C-P<%9,>35U171O-6U!8C K4T\U64LQ45133VTK
M14D-"DQ%=GE:.#9E6CEE,3(K='17=C-U-%ER6#%),%I55VIE;V]R.$MR,D]*
M54DO.#!.5C@V84)Q160U<"MO>4IP5C,X2V]%:DEI;%5B<%4-"G%44F@X42MN
M3D@R;&QZ67!C55IE:W999&=A9E-A;4)H3T$X4U!V,TAF>BM#<BM74#5H,V5R
M,T5M:F$S2W-T,#9L<E-C<7%M44%F2$<-"G=5045G8FIB<%A*9&TV.#5$=U0U
M.4=(8C-9<V-%4FQW:6\Y4C-D>%(Y-RM44&Q7-79M=55K=4QA2C(U3F)236Y!
M5C-)6&MR1E(W6EH-"E!S:D5:6'502GAS6'12<5EW-%-)>5!E8G8W,#,Q<E9D
M1#AJ*U=L5T-.55-)1T]X=$%F:6MK3RLU-CED,F(K3UI'8DQ$5%ET=F=(0S -
M"G5N>F1O86IC,V4X:C-$.&-G=V8X<V1*=F9-4&U+-3@R87543#9,;C!#=S)A
M8VHY:V9Y>$PP2&)B=WI79&TT<%IC:'EZ-F9F*W@V1'0-"C=543 R0T]M>&)7
M3B]W0W(O=T%E4#95-B]/5'IL<EAL>E,W1DY*:T5%.3E)-G9C1E%Z2W-953!5
M34-T5S5D8S9%4$5&1"]K<#5P,2\-"E@W6%9N,64X83=A,V5%46QL4F5)65!Y
M*WE&-C!X2VAK;FXO>C%:955D2U<T:U0Q-S(T2E-Y=&$P-4UO*TIM4%I6<4LT
M9TIE139N*V$-"G9N,U4W:FM.4VMT9W@O9'=79T53:7998V9J8B]!1U)/1VU.
M<4YL*UHS;C)Y;35P<D4W:TAD2C942V99:5%.:E,R.64O3$@X,')J>E0-"D\K
M;3,Y;#9D+T1'6E1C=T%M0FQ"02M)16MO,B]I469B05%K1DMR>E@O37AV:'%0
M-E%K=#1V5&UK:TIQ3&5+84Y*;5<P-$(K2EE.0T4-"DEA3W)F1E)G,T59<3E9
M:5IM:5)M6&EZ2T-Y*T))-EE%<G-695=F.$%/468O04-J3VYF.$%-8B]Z2V9#
M149I+S5$439F3'$K<4,Y4T8-"C%&=6Y!5$)32S@K,TQ#5D0R:C9L-5HO-5HW
M3"]!24-,*VU24VER2TQ466=Y,E-1;T1U-G=H4CE*-#1Q<E1W43-%16M%-DQ,
M1$MP4U<-"DYH5E=6:%%G9SEI359F32\U;651<"]+=7-K=V=V<$8R4S%L2V0K
M4&-X368U;#=E22MN2D%S4VU&>"MC3W1Z95-6,$4X=C!I9C-%=7 -"F-V:6$R
M06]"-"MO9G-L=D0S3TY*=$0O;%HK6#AN;6I69G).-&A':3)403-,9%!69G%)
M5E!V*S!2,$AZ1TI+02MK;S0T-#0Q:FI52D<-"F=#;VEI9T%'=T%!-UI&:RM:
M+WII+W=$2FHV=B]!3D<O+U5,1FMG>$PR4#A!3'$P,$(O2D=J=%!$871-8F-C
M,FM737-453EA:75!<%H-"D@Y4SAS+SA!3%!:9CA"1B]406Q-62]4.4YF4W V
M9%!G-# T,#EQ67$K9&9Z>"\U5#)8+VU(:"]58VM%1C9Z*U1V+VMU3DDO-D]0
M.$$-"G%+;'=&47I006PU;B]W035!9CA!2T<R9B]B4FDO=T-413)%24Q%=BMC
M9E K56TQ2"]M0R\U;7!H2V@W4C5G,$\P,7I33&I48F]F=34-"C%O<C!Q56-B
M<38K-$]9*V9#37-$13E83#!7<FQP.&]Y4C5J-V9*.#185G1Q96=A,CA,:W=A
M:' X=V\V.6U1,59L<C%",DDY<S0K55H-"EEP,7EL179Q94]E4%4T8D<X2F@W
M-6]V;FI3<C-Y;4YF=5I&9VIH5VPV;E5P2W5X441V>4I(2#5J3W%W-C)%<UAI
M2&%U9G9F3CE6,E0-"FMX-FYW26EY9G X>#,O<F5-835R3W(K9&9-,%-O<#54
M=4E,0S%R.$UA13DO*TI/,SA--7I.;6YQ8W9V,D%E.#!M;'AA1%1M*V=U4C<-
M"B]W061!.3@P2%)R6%)D271T3G1H*S=T,$-L=6AD:G5Z;C-:=#@V<D)H1T]!
M:4]J-79R3E9,4&QL:VQZ:V9W2&PS+T]22"LX96@O.$$-"D=3-"\T:DAL=V-5
M=2]W0V-D+SA!95!84"M-;'8O=T%2:WA+:$IV.$%N24U82"M*=$],5BMR1WE(
M<"M(4#%8-2]H>'=H4W4O2C-Z=C4-"E P0S!U3%165BMQ6#@X=DID44M&=S!:
M54)9>7EH;5AI450P<'9I46]E<E-W*U)F3CEU56(V;'%Y.6%O>5!)=BMY52MO
M;C1:1DM-.'8-"BM6=$$X=E<X:T=J,F%7:V-P-5-K1FY::4]N2C-,36%D=#A6
M5D@X=6%&2F9F6#-S65=U*U%K37!58G5V4GE/:%ED;7!81E5X>%8R2W8-"DQ0
M.$%N25 O04I2;E1V.$%M3B\U;%!H0T,X5S!B>3ER5W13>5)A5EIY6&MK2VAP
M1FI!2E9384%M=5-1;3,O2W,O4&XO049:3&XW:"\-"EA"83 Y62]*5'E8<FUG
M439J96%T06)6-WHP:V=G66=V>&HU17-W0DY+;'1H9TM1.4]W2EE&*V,R=&%&
M6F55<')(54EX8UA6.3A.:$(-"E=J3$EV*S=Q.6A(6#9E;F,T46=V;D1*2694
M2#53-C%O5V]E54Q7,S!U3F)A4WA54EAL<E=R3$MD>DE4,T5H<3%F;S=:17!$
M3DU#6'H-"DXK8U@O:W@Y6"\V3B]W1'%&:7E166Q+-TAY1C5X=C=32SAS.4IN
M;G1:,3524W%">%IF16(T,G%*:B],1'HY239O3D9N0EDP0F)I;RL-"FML9T)J
M83 K:V9+*VQZ-E8U8S S5%HR5G W4S)J:&Q:3C$U2V]"<%AT6$ES;F<S-30O
M.$%+97DO.'<X4#9J:V=G=E=F>60O.&QX<$@-"B]2>"\Q1E,T0V]:;F=3.'HO
M=T-C9U X06Q$8E O=&]X9CAM2G-)45=*9CA!3U!N+T%#:S)O+SA!348O>DY4
M0U9$,VY)<&5(+T%*>E@-"C)M6$AM84M',E%F5S=714IE>D0Y<&HX4TEF9$90
M6#-P,GIM93$U>$]7:'I!,V91=EIF1FMJ<'E:2#!Y4'!(,VXT+VIM>'!F3"]M
M0F8-"DMS;7)H6%A2,VY25U-P05IL0E9:4W94:4,S2&PT;DU0=TUN:&-F.$%"
M9C1,=%1R34(Q27AF-5AH+T$O5%-C9FQ0<65M,DAM,DPV-F<-"C582TY"8E1N
M<$A+-490.$%G=G,O5&U2,EAK:DA,-G5U=V-(,FDP*U1*<&IW9G=M>4\X9G,U
M=F9C-G X,F50.$$O3U)(*SAE:"]W1$<-"E,T+S1J2&A#0S<O;DAF.$$S:C%Z
M+VI*8B]W1$5:35-O6B\U,3AK-E@U<S!X8D\X2FEM:$IE,75K04QX<U)1-TAQ
M<"]A6'9G=$QX3%<-"G9Y5#@W864W1S%H:C%+059):W0S06%N=DA*=V%V<W1C
M;&%+661E861R3VHS4W)E5S%X65A+;7%E;VIX4%5D,4I!4#!J0V@V,RM4+S4-
M"FUA<&9A:VYL,U=P:F1'6E=.:F1U87EC:U5S63-B.7%Q9VM%-R]/=5))4T,Y
M:W=*9&ER<U9E5V8X-4(O.&]Z<#,O36(O04UY;G=H0ED-"DXK5"]!2G4P3'DQ
M<5=O5#9V33!-9'A#:5)&56%3<D(V;C=)3T5Q2'%F+TLV=GDY+S5B<% K4D4S
M+TY/0VQT1V%0*V%F:WI73E-G,#(-"G=U,VMU-VML66M-36EG:TM73S=+0C!'
M3DIT4%!-1W9A9F]/:S-'<5@W.$QE0F$P2#)N62]:4D(S6FHP=TLK661D,6Y7
M=D]0;54S3&\-"C Q-61U27)3,51C271A2D=N>7(Q*UIY5$8V>&-F:V9:1'E3
M=&Y%5E!M4E Y24XS5VEV2U)V0E4O-W(R;T0T-SEY349P<#56-58X>38-"G0U
M3SAX0S921U8T5TU.+UI05F5A03!E3F@R645B2'-C2T@P+V\R<U='<S9:8C9L
M65-E<F$S2SAK8G5/>%9H,EI4<U)K5U0U>B]/3"\-"D%-;5!Q+SA!,&(O.5%S
M5U-$17924$I(-7)E4W1+.' V6G Q-V502&17,$E36D)$2W=$5DHV:%-$9TE4
M865F.$%+-G9Y.2\U8G!0.$$-"FM23B]Z5&I3,GE$>7HU=3!,>DQ"3E!P17I4
M4C(W0DI3>4Y(4FE+:C=11T),=WHX.&8K53EL+S5H-&8Q2$I"0EID*UA(-6XK
M5'1%.&T-"F%D<&5O,V)X6&QV-C-Q;W--:F=C-35(6#1L56HW3$1!471S;"]W
M0U8Q9FPW+W=!=#!N+TEI8B]M;D=L=$M0>C5N:FXX:F%D4$5A>'D-"C,X3&]E
M;%9A,VU)>$-L:3,O3U!N+TM486HO>D)F.'I5=VQ1.6DX,F5965!,*VA83W!3
M56%20G=T-'HK,TLR>4PO12LQ8WAD5FY'3$<-"EI(.$9Z*WIT1614;6IJ2$QR
M-41R*T\Y-'0U23AP6'9M+UA*8G$Y6FI9<$E:9%%U5'-89&IY.4Y4+TTS9G=(
M,%IZ96HP<W123S5F5#$-"DPS=F$S855.1FA%66985E)(9#4O1#=8=3AU;5=%
M=6UT<')W3#E284PP1$%"4E)(5&IX04A48D]P3T]*:G<Q-F54-3%(4$U:4$5"
M.60-"C-F;2MC9DYF;#(V.'4V-U!P.'!*5D1Z='!U;D]*:CA$9E!S9F9/4#%7
M;D]'6FEF9RMP9&YA,D]Q=VE9*TDW:C$O2&,Y<B],9GIC4$T-"D]H2THS<G%6
M;E-+-TAD='9G:R\R44<O=EA/:S=0,5AI=S,K;V,O,79!.75D;2]L<S-P+W4U
M8FHY22M(,TU,+S5Y22\S:C!0+T%)>5@-"D@O15DX,D%D25AF.#0W+S=X-C4O
M>&MT+RM)>5EL46YV-6AF;35B958Y4EA3-U,P1CEF2W%V8SAN-$I'1S-69&=3
M5TLW*S(S6$5"8E<-"C9$*V58;$,O:%5A:UI.2W5F,FMK5G!9-B]W0U1*1W!0
M+T)+36%7,'0O37(X>E!),F]E5C=R5&)346%P9#-+.%E&5TYW<U16,FQ,=7$-
M"C!+.75/+S!99TM3.#DO2T14<FDY."]A8UEG949R>G5*,U@Y;$519U8Y:7I+
M=C T4V=0<&Y)<VY9<3=&5TDO;58U2G5V3C)L5W1L8E@-"DM7<E<X+W)&-4%7
M0DA";'!T+W)9459E9&8Y0S@V>B\Q9')B+T%*1G9H=$9/+W=#:&5D6B\V=3%T
M+W=!:3-X=&%:2C5$+TIK*UAT8VD-"C%I+W8Q=7!B64XY6&AI47%V2FQ+.&U:
M:G9113=5=T5R4TXO36(X=F9-;FTV.6E#86Y$8F%88D%'0S%+=5-:0U!I:V5M
M>&)S4$%F330-"F=Q,RM84#555R]L83=M,4,Y;E,Y,45J:&)/<6Q6:5%J-&E+
M+W1.,'(T9E!%;&%E9S1%=E!0>D$O2TMZ.'I8=S%/>75266%G=T,S1E4-"C52
M>3!&07I524EA;3%D.7-)2TM6=GDT.&@K62]+33 X12MP43-E;#-!-4YB2W)H
M:VQ(4C!R='5.;3AF;WA*5DIV3R\U3C9N-6DX,%@-"G5S=S9J1$)&9&5L>&ED
M2$Q$,#15:DY33G1Y;&-15G!)=BMH961:+S9U,70O>4QF1&$P-R]!2T8U,6XO
M<3<R+R]!0TQF1S%P-EHK6"\-"D%*2'0O2T=K4U=A6$)U<FDT:SE7-&Y+.$%4
M44M&5F%T44%$>"]P9TI3>&8X=U!Y:C%(>E U:69664PK1S-J84M/4# U15ET
M5D)3=%(-"FE#:6U.+SA!479/<R]W1%8R='8K4F(T8E=K4EDO=T1/4$XS.6%J
M3CEQ.&8Q545'4EE9,C5S3S1"66=#=FIV.$%,0F$P>C<X>%!*33,-"FUJ>3EA
M-E1:>G@R;C%A-%-:5V-&;#12>'9(>$90.69%1DM$+T%#,R]!0WEJ.&]08S-5
M,3,Y8W9R;%)(>5)3:4I'1'E)04I*2DQ$<FD-"E-I;4TK9%HW-WIR-7EI.'4V
M5S%B3%1Y4E!.,5)8-E-Y3E0K5#=#*R]Z>FYT6DM7<'I$2$AL2#A%=F,Y;%%H
M;TY+8RM4-C4X:#$X:#@-"F5:+UDY43!04F)$4F1-:# V>%1H0D-/<"LP-T@W
M5'-E-5DU=3A/1T]/26I(:TAK3EAQ<#4X:'E43S4O1DDO3%A'67HU-#AJ,F9M
M;3 -"FE2<&9Q,35B:VU#-4,X.6HY<$=&5G%P*V4R65=T,%%Z9V1#3W)T=7EE
M,7!A3U).8U5:8W@K;&IV;$0X<W1F.$%,;71X86A&<6-,>&8-"EEU;T%R:C%)
M;39J-6IQ4&9-4%-D;EI-37A)4TAM-U1T3'0W1'%S2F=94W9O9'1I;5@U;2M1
M3'IZ:$)P.&1T9'@R<',R:UIJ27).>3D-"E%+0E1J+W$U=6=8;$-I=GDW.&=W
M*U0Y3W5)4')2=3=Q-V18;FPT.$9!445+<7)6=6Q4=EA%;$M*.#,K45!,=FUQ
M141526I(9'AI:TX-"C=#47-Q:G=*24E:9EIH.'%9,G)Y+U50*V-E=&%342]O
M-U9B86%/=G<O5T9K:$Y09F=*<TYO<%I9+W=$3U!F;4(U44PO049/,&AI<G4-
M"C!!:VUA;GED65(K3TYR5#%8>6(U1S!4>7!:3D)P-FPU-7%'-74U2T=346IO
M3G5I:G-O>4YP6D1I<G-69&ER<U9D:7)S5F1I<G-69&D-"G)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U931'IP<F1Z<'5K*VQP-FU85CE18C9R<#!3+V%-
M:FID+VMI+T95-V5/66US>D=%2VH-"CEC=&<W3'-V4WAY-6)N=&EH-G!(>3=V
M:GE7*U-V2T9T-6(P<U$Q170O4%(W,C4V;#,X051V>%AT.2]F2%(V55E9,2]%
M95I4,G(R;$P-"E9:3#512#!J.&17435L=7-D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U8-"F1I
M<G-69&ER<U9D:7%K,7!B4&-P8W9%:EA%4VQ9-5-!5U97*S!&2C96-S!Y2FE,
M=G%Z1U-1:5EG*VLY1EA*34A9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T98+R\R43T]/"]X;7!'26UG.FEM86=E/@T*"0D)"0D\+W)D9CIL
M:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+WAM<#I4:'5M8FYA:6QS/@T*"0D)
M/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#IB-3!A,C8X,BTU.60V+30R,&0M
M8C=F."TX93$X,&5F-60T8V,\+WAM<$U-.DEN<W1A;F-E240^#0H)"0D\>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.F(U,&$R-C@R+34Y9#8M-#(P9"UB-V8X
M+3AE,3@P968U9#1C8SPO>&UP34TZ1&]C=6UE;G1)1#X-"@D)"3QX;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T03@U
M.3!$,S$U,#A#.#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@T*"0D)/'AM
M<$U-.E)E;F1I=&EO;D-L87-S/G!R;V]F.G!D9CPO>&UP34TZ4F5N9&ET:6]N
M0VQA<W,^#0H)"0D\>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@T*"0D)"3QS=%)E9CII;G-T86YC94E$/G5U:60Z8F1C,S)B
M,S<M-&$X82TQ-30Q+6$P-V8M.#)F9C$W9F,W-#$W/"]S=%)E9CII;G-T86YC
M94E$/@T*"0D)"3QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3%F-S8Y9F(M
M838P."TT.#4Y+6%B-S<M.3(U960Q-CEC9CED/"]S=%)E9CID;V-U;65N=$E$
M/@T*"0D)"3QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HU1#(P.#DR
M-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#.#PO<W12968Z;W)I9VEN86Q$;V-U
M;65N=$E$/@T*"0D)"3QS=%)E9CIR96YD:71I;VY#;&%S<SYP<F]O9CIP9&8\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@T*"0D)/"]X;7!-33I$97)I=F5D1G)O
M;3X-"@D)"3QX;7!-33I(:7-T;W)Y/@T*"0D)"3QR9&8Z4V5Q/@T*"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z9C1B.3AA,3<M,F8W,"TT-38W+6(U8S M968U
M,C0Q-F8R969D/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H
M96X^,C Q-RTP-2TR.%0R,CHS-3HP,BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)
M"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-#
M(#(P,3<@*$UA8VEN=&]S:"D\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)
M"0D\<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)
M"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F(U,&$R-C@R+34Y9#8M
M-#(P9"UB-V8X+3AE,3@P968U9#1C8SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)
M"0D)"3QS=$5V=#IW:&5N/C(P,3<M,#<M,314,C$Z-#,Z-#0M,#<Z,# \+W-T
M179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#0R R,#$W("A-86-I;G1O<V@I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)/"]R9&8Z4V5Q/@T*"0D)/"]X;7!-
M33I(:7-T;W)Y/@T*"0D)/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R
M:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O9FEL93X-"@D)"3QP9&8Z4')O
M9'5C97(^061O8F4@4$1&(&QI8G)A<GD@,34N,# \+W!D9CI0<F]D=6-E<CX-
M"@D)/"]R9&8Z1&5S8W)I<'1I;VX^#0H)/"]R9&8Z4D1&/@T*/"]X.GAM<&UE
M=&$^#0H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_>'!A
M8VME="!E;F0])W<G/S[_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M
M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
M]&>.)F4?BP _&LJ]:%&G*K4VBFWZ+5F^%P]3$5H8>DKRDTEZMV7XGY&?\%+?
MCW)\>?VL?$$D4YDTGPW(=$T]0?E"PL1(X['?+YC9[KM]!7@%23SR74[R2,TD
MDC%G=CN9B>22>^:CK^",VS&KC\95QM;XJDG)_-[>BV7D?ZMY#D]#*<MH9;AE
M[E*,8KSLK7]6]7YL****\\]8**** "BBB@ HHHH **** /NS_@B)\>I-"^(W
MB#X=WD_^AZ] =4T]&/"7,0 D51ZO%AC[0#\?TPK\*_V/OB&WPK_:C\!ZZ)/*
MCL]:MTN&':"1Q%+_ .0W>OW4K^K/!?-Y8K)982H[NC*R_P ,M5^/-\C^#?I)
M</PP/$D,PI*RQ$$W_CA[K_\ )>5OSNPHHHK]@/YY"BBB@ HHHH **** "BBB
M@ K@OVD/VA=!_9A^$^H>*_$$O[BU'EVULKA9;^X(.R&/_:;!.?X5#,> :ZGQ
MEXRTOX>^%-0US6KR'3])TN!KFZN)3A8D49)]_8#DD@#).*_&7]NG]L?5/VP?
MBS)?_OK3PQI)>#1;!C_JHR>97'3S9, MCH JY.W)^ \0.-J608+]W9UYW4%V
M[R?DOQ>FUVOUCPE\,Z_%F9_O;QPM)IU)=^T(O^:75_96N]D^#^/GQTU[]H[X
MI:EXK\17'F7VH-A(D)\JTB'W(8P>B*#]222<DDGC:**_CC$8BKB*LJU:3E*3
M;;>[;W;/]&,'@Z.$H0PV&BHP@E&*6B26B2]$=9\#O@_JGQ\^+.A>$=&7-]K=
MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
M4444 %(6VKD\ 4M? _\ P5G_ &]_^$9L;SX5^#[P?VA=Q^7XAOH7_P"/6-A_
MQZ*1_&P(WGLOR]6;;X'$O$6%R3 2QV*>BT2ZRETBO7\%=]#ZS@O@_'<2YK3R
MO K66LI=(16\GY+HNKLEJSQO_@J-^WO_ ,- ^*Y/!/A2\W>"M%G_ -(N(F^7
M6KE3]_/>%"/D[,<OR-F/C^BBOXJS[/,5F^-GCL8[RE]R71+LE_P7JV?Z5<*\
M,8'A_+*>5Y?&T(+?K)]92?5M[_)*R205ZG^QQ^S?>?M3_'S1O"L/F1Z>6^UZ
MI.G_ "[6D9!D;ZMD(O\ M.O;->65^NW_  2D_96_X9_^ :Z]JEMY7B;QJ$O;
M@.OSVMJ 3!#['#%VZ'+@'[@KZ'P]X7>>9M"C-?NH>]/T7V?^WGIWM=]#Y'Q<
MXZ7#&05,32?[^I[E-?WFM9>D%KVO9/<^F]$T6T\,Z+9Z;I]O%:6.GP);6T$0
MPD,2*%5%'8!0 /I5NBBO[1C%17*MC_-F4I2DY2=VPHHHJB0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
MA4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;6^,G_16O
MB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KX
MF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;6^,G
M_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_
MT5KXF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =H_X;
M6^,G_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&U
MOC)_T5KXF?\ A4WW_P =KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?\ A4WW_P =
MH_X;6^,G_16OB9_X5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':
M/^&UOC)_T5KXF?\ A4WW_P =KS+YO:CYO:BR"[/?_P!G/]L'XMZY^T)X#LKW
MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
M"C_AW]\$?^B5^!?_  41?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X
M*(O\*/\ AW]\$?\ HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"
M_P#@HB_PH_X=_?!'_HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\
M"_\ @HB_PH_X=_?!'_HE?@7_ ,%$7^%'M4'LV?S]?-[4?-[5_0+_ ,._O@C_
M -$K\"_^"B+_  H_X=_?!'_HE?@7_P %$7^%'M4'LV?S]?-[4?-[5_0+_P .
M_O@C_P!$K\"_^"B+_"C_ (=_?!'_ *)7X%_\%$7^%'M4'LV?S]?-[4?-[5_0
M+_P[^^"/_1*_ O\ X*(O\*UO"?[&WPE\"WRW6D_#7P-8W2G<L\>B6_FH?]ER
MA8?@11[5![-GXC_LT_L$?%+]JW4+?_A%_#-XNDS-A]9OU-KIT2YP6\UA\^/[
ML8=O:OUO_8'_ .":OA/]B+1VOUD'B'QM?0^7>:S-%M$*'!,-NG/EQY')R6?'
M) PJ_2:J$7 X Z#THK.4VRHQ2"BBBI*"BBB@ HHHH **** .%_:@_P"3:?B)
M_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK:D9U ^;V
MH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^
M$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK
M,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE_P""Q7_*./XC
M?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F]J/F]J/F]J/F
M]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*_P#)8_"7_89L
M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
M/F]J/F]J/F]J/F]J #YO:CYO:CYO:ON?_@GU_P $;=7_ &A=)L?&7Q$FO/#?
M@^Z"SV-A" NH:O'U#G(/DPL.C$%V'("@JY3E8:5SXG\,>%-5\;:U#INBZ;J&
MK:C<'$5K96[W$TI_V40%C^ KZ(^&/_!(;X]_$V*&8>"VT"TFQB;6KR*S*9_O
M1$F8?]\5^S7P5_9W\#_LZ^'1I?@KPSI/AZUVA9#;0_OKC'0RRG,DC>[L37:5
MDZG8OV?<_)#PW_P;[?$R\B#:IXR\#Z>2,[;=KJY*].#F)!ZYP3^.:U?^(>CQ
ME_T43PS_ . 4_P#C7ZM45/M&5R(_)?6/^#?#XBP*?[/\<>"KIMN0+A;F#YO3
MY8WX]_TKA?%W_!#+X[>&T8V=KX5\0%<X%AJX0M]/M"1=??%?M%13]HPY$?@!
M\0O^"=WQO^&0D;5OAEXJ,<9(>2QM?[0C3'4EK<R*![YQ7C^H:;<:/?26MY;S
M6MU"=LD4R&.1#Z%3R*_I?KFOB-\&_"7Q?T[[+XJ\,Z#XCM]I54U*PBN=@_V=
MZDJ>^1@@TU4[D^S/YO\ YO:CYO:OV9^.'_!#GX.?$V.6?PVNL> ]0;)5K"X-
MS:%CW:&8L<>R.@KXG_:)_P"")_Q>^#*W%[X?AL_B!I$.6#Z5F.^51W:V?YB?
M]F)I#S5JHF2XM'Q]\WM1\WM5G6M$O/#>JW%AJ%I=:??6CF.>WN8FBEA<=596
M ((]",U6^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU)_X(J_
M\$^!X:TJV^,?C"Q_XF%_&?\ A&+.=.;:%N#>D'^-QD1^B$MSO4KX;_P2T_X)
M?7W[27B2R\=>-K*:S^'NFS++;VTR%7\12*<A%!_Y=P?OO_%RJ_Q,G[%6]O'9
MP1PPQI%#$H1$1=JHHX  '0"LJDNB-(QZLDHHHK$T"BBB@#XK_P""Q?[!EQ^T
MQ\,H/&WA:R:Y\:>#X&#V\2YEU6QR6:)1WDC)9T Y;+J,EE%?&_\ P2O_ ."E
MDG[(WB%O!OB]YKCX?:Q<[_-P7DT&=L RJO5HFXWH.1C<O.Y7_9RO@G_@HS_P
M1TM?CKJFH>./AC]CTGQ;=%I]0TB5A#9ZN_4R1MTAF;OGY')R2AW,VD9+9DRC
MK='3?\%!_P#@GS<_\%'=5\&^+/"/C7P_:Z38Z;)%%,R-<Q7B2.'62-XS@CJ/
MP_+WS]BG]G>Y_92_9D\,> ;S4X=8N=!%SYEW#"8HY3-=37'"DDC;YNWD\[<\
M9P/QK^%G[2?QP_X)P^-KK0[>35_#;K+ONM!UFU,EE<$'!<1OQAL?ZR(J6 'S
M$8KZV^'G_!PVJV"1^+/AJ6NE4;KC2=4Q'(?:*1"5_P"_C=?;D<96LB5)7N?I
ME7YT_M3?\$+KGXM?'?7O%'@WQ5HOAS2-=G^W?V=<6DC?99WYEV%#C87RP&!M
MW;1P!3?%'_!PWX;M[*0Z+\-M<O+C'R"]U.*V3..I*)(>#V[CTKY9_:._X*S_
M !D_:G1M!L[I/"VCZ@Q@&F>'TD2>\#<"-Y<F5\YP50JK9Y4T1C)#E)'TE^W=
M_P %++[X"? :S^#WAWQA;^+_ (CP6 TOQ)XJL%,<5H%&QU0[FS=,O#NK?(VX
M_*_RIYW_ ,$5_P!@ZZ^*/Q&M?BMXEL9(_#'AF??HJ2I@:G?(>)%SUCA/.1P9
M H!.QQ1^P;_P17\2?%#5+'Q+\5K6Z\,^&(W65-%?,6I:F!SMD'6WC/0YQ(1D
M )D/7ZP>%?"NF^!_#=CH^CV-KINE:;"MO:VMO&(XK>-1A551P !1*22LA)-N
M[-"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !63X\\"Z3\3?!FJ>']>L8=2
MT?6+=[6[MI1E9HV&"/4'N",$$ C! -:U>0_ML?M>Z'^QA\$;[Q1JGEW6I2YM
MM'TW?M?4;H@E5]0B_>=NRCNQ4$ _%W]O3]DR;]C3]HG4O"/VZ/4=-DC6_P!+
MG\Q3,UI(6""51]V12K*> &V[@ & KQKYO:N@^*WQ2USXU_$35O%7B2^DU+6M
M:N#<7,S^IX"J/X550%51PJJ .E<_\WM74CG#YO:CYO:CYO:CYO:F ?-[4?-[
M4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM3[6W:\N8X4V[Y6"+N8*N2<#). ![D
M@"F?-[4?-[4 ?NW_ ,$W_P!AO3/V+?@I##)]EO?&'B!$NM;U"+#*6QE;>)N\
M4>3@_P 3%FXR /HJOSK_ ."+W_!1#_A-=)M?@_XTOLZQI\6WPU>S/S>P*,FT
M8G_EI&H)0_Q("O!0;OT4KFE>^IM';0****DH**** "BBB@ HHHH **** "BB
MB@ HHHH **** "OS?_X.(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z
M_-1_] MZJ.Y,MC\NOF]J/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:
M@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;
MVH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#[3_P""#O\ R>Y=
M_P#8LWG_ *-MZ_9*ORS_ .#>WX4SW?Q!\?>.)(RMK8:?%H<$A'$KS2":0#W4
M019_ZZ+ZFOU,KGJ;FT-@HHHJ"@HHHH **** "BBB@#A?VH/^3:?B)_V+.I?^
MDLM?SJ?-[5_17^U!_P FT_$3_L6=2_\ 266OYU/F]JVI&=0/F]J/F]J/F]J/
MF]JU,P^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J /3?V*?\ D\CX2_\ 8Y:/
M_P"ET-?T,5_//^Q3_P GD?"7_L<M'_\ 2Z&OZ&*PJ;FM/8****S+"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *^9?^"Q7_ "CC^(W_ '#?_3G:
M5]-5\R_\%BO^4<?Q&_[AO_ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH
M^;VH^;VH /F]J/F]J/F]J/F]J #YO:NG^"O_ "6/PE_V&;/_ -'I7,?-[5T_
MP5_Y+'X2_P"PS9_^CTI ?T?4445RG0%%%% !1110 4444 %%%% !1110 444
M4 %%%% 'RK_P5<_91M_CQ\!KCQ-8I#'XD\#P2WT<C$+]IM -T\).>P7>N>ZD
M#&\FOR-K]-/^"SG[59\&^!;/X8Z/<;=2\1*+O5V1OF@LU;Y(CZ&5UR><[8R"
M"'K\RZ_D?Q@KX&IG[6$7OQBE4:V<NGS4;)OY;IW_ - OH[X7-*/"D98]_NY3
MDZ2>ZAU^3ES.*MMK=IJQ1117Y6?NP4444 %%%% !1110 4444 %%%% !1110
M 4444 ?H%_P1*_9QL]5OM;^)VH-;7%QILK:1I4(=6:VD9%::9AU5BCJB].'D
MXP0:_1JOQO\ ^":O[7K?LL_'**'5+CR_"'B@I9:J&/R6C9Q%=?\ ;,DAO]AG
MX)"U^QT<@E565@RL,@CO7]<>#^/P-;(8X?"KEG3;YUU<GJI>C6B[6MT/\_?I
M#97F>'XJEB\<^:G5BO9/HHQ23AZQ=V^_,I:<UAU%%%?JA^$A1110 4444 %%
M%% !1110 4444 %%%% !7S+_ ,%BO^4<?Q&_[AO_ *<[2OIJOF7_ (+%?\HX
M_B-_W#?_ $YVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 'S>U
M'S>U'S>U'S>U !\WM73_  5_Y+'X2_[#-G_Z/2N8^;VKI_@K_P EC\)?]AFS
M_P#1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@#)\<^!M'^)OA#4- U_3[75
MM&U:%K>[M+A-T<R'J".Q'!!'((!!! -?C[_P44_X)*^(/V7[N]\6>"8;SQ%\
M/F+2RA09+S0AG.V4#EX0.DHZ '?MP&;]F*&4.N#R#U'K51DT3*-S^9KYO:CY
MO:OU]_;=_P""*7A7XVSWGB+X;R6?@OQ-)NEET\H1I-^_7[JC-NQ]4!3C[@)+
M5^7/QU_9O\;_ +-/BQM%\;>'=0T.[R?)>5-UO=@=6BE7*2+[J3CH<'BMHR3,
MW%HXCYO:CYO:CYO:CYO:K)#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]
MJ/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]C_ &/_ -N3QS^Q
M?XR^W^&;[[1I-RX.HZ+=,6LK]?4K_!(!TD7!'?<N5/CGS>U'S>U+<#^@;]CO
M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
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M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
M]G?60Q/P]2WD9=H>WUB_CV_11/MS]0:P-2_X(D_ &^*>5H6O6>W.?)UF<[^G
M7>6Z>V.O>OK:BJYF*R/C_P#X<<_ ;_H'^)__  </_A4UC_P1#^ =I<;Y-'\0
M72XQY<NLRA?_ !W:?UKZZHHYF'*CYCT;_@CM^SOHY1CX!:[D0DA[C6K]\^Q7
MS@I_$5VWAG_@GE\#O"6W[)\+?!<GE@ &\TY+P\#'_+;?S[]<\]>:]FHI<S'9
M&/X5\ :#X$M_*T/1-(T:(C!2QLX[=2/H@'M6Q112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>exel2019063010-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exel="http://www.exelixis.com/20190628"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20190628.xsd" xlink:type="simple"/>
    <context id="FD2019Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-07-22</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-29</instant>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="I2018Q1Fiscal">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="FI2018Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-30</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:DiplomatSpecialtyPharmacyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-29</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-29</startDate>
            <endDate>2019-04-29</endDate>
        </period>
    </context>
    <context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-28</startDate>
            <endDate>2019-04-28</endDate>
        </period>
    </context>
    <context id="D2019Q2Jun01-Jun28_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-29</endDate>
        </period>
    </context>
    <context id="FI2019Q2_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-31</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-30</startDate>
            <endDate>2019-06-28</endDate>
        </period>
    </context>
    <context id="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-06-29</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-01</instant>
        </period>
    </context>
    <context id="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="FI2019Q2_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="program">
        <measure>exel:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q2YTD"
      id="Fact-0D034E00754B5551E714E231C4923916-wk-Fact-0D034E00754B5551E714E231C4923916">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q2YTD"
      id="Fact-8FD2A8238FDB5582F401E231C48CA1C0-wk-Fact-8FD2A8238FDB5582F401E231C48CA1C0">--01-03</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q2YTD"
      id="Fact-46BF84598624C055E38BE231C48FD581-wk-Fact-46BF84598624C055E38BE231C48FD581">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q2YTD"
      id="Fact-BC89D796E328D0A32C04E231C48527F8-wk-Fact-BC89D796E328D0A32C04E231C48527F8">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q2YTD"
      id="Fact-0DCFCE6100C9FBBA6FB7E231C48E01BB-wk-Fact-0DCFCE6100C9FBBA6FB7E231C48E01BB">0000939767</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-A7C65FF32F498C224398E231C45760DA-wk-Fact-A7C65FF32F498C224398E231C45760DA"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-A0D53BE6F0146D146596E231C457CDBF-wk-Fact-A0D53BE6F0146D146596E231C457CDBF"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5"
      unitRef="shares">299876080</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-E74606558B0226F4AFDDE231C4640017-wk-Fact-E74606558B0226F4AFDDE231C4640017"
      unitRef="shares">302784854</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41"
      unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-8128CED27A255CDEB63FE231C461B23E-wk-Fact-8128CED27A255CDEB63FE231C461B23E"
      unitRef="shares">302784854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-5"
      id="Fact-16F345F01953046CEB3CE231C4403A6E-wk-Fact-16F345F01953046CEB3CE231C4403A6E"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-5"
      id="Fact-87A31F1D23D0488FC515E231C4407F7C-wk-Fact-87A31F1D23D0488FC515E231C4407F7C"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="Fact-E8B0510F4D0B5AA6B9B1E231C4413E86-wk-Fact-E8B0510F4D0B5AA6B9B1E231C4413E86"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="Fact-F637FF5F0338C5167E91E231C43F594D-wk-Fact-F637FF5F0338C5167E91E231C43F594D"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="Fact-6699277FFC24D0563079E231C4963835-wk-Fact-6699277FFC24D0563079E231C4963835"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="Fact-098AC4BE22032B1988DDE231C4960EC1-wk-Fact-098AC4BE22032B1988DDE231C4960EC1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="Fact-44EED50ABC0AC834268BE231C4959404-wk-Fact-44EED50ABC0AC834268BE231C4959404"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="Fact-986BDEF24DF3E5799619E324999D2515-wk-Fact-986BDEF24DF3E5799619E324999D2515"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="Fact-D768C70B83D205279A74E231C4961806-wk-Fact-D768C70B83D205279A74E231C4961806"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="Fact-EB64BE5F80A483824186E2B93A288753-wk-Fact-EB64BE5F80A483824186E2B93A288753"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="Fact-C6C6BB38F7C3594F179DE2B93A1D1474-wk-Fact-C6C6BB38F7C3594F179DE2B93A1D1474"
      unitRef="usd">413000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="Fact-AF501F44226AD4A5FF12E231C496FD27-wk-Fact-AF501F44226AD4A5FF12E231C496FD27"
      unitRef="usd">807000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="D2018Q2Q2QTD"
      decimals="INF"
      id="Fact-4F15E06F59A17AD80B10E231C43E9C27-wk-Fact-4F15E06F59A17AD80B10E231C43E9C27"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q2QTD"
      decimals="INF"
      id="Fact-59CDABF2D6C45F5BC819E231C43E7D70-wk-Fact-59CDABF2D6C45F5BC819E231C43E7D70"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="Fact-D2233C827CA25D35882DE231C43F6CB9-wk-Fact-D2233C827CA25D35882DE231C43F6CB9"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-885864F0CD5615F96590E231C457FD01-wk-Fact-885864F0CD5615F96590E231C457FD01"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-50B4079A052058F49951E231C45B0EF0-wk-Fact-50B4079A052058F49951E231C45B0EF0"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q2"
      decimals="INF"
      id="Fact-CD11292302CC0DE24BCFE231C45704C3-wk-Fact-CD11292302CC0DE24BCFE231C45704C3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <dei:DocumentType
      contextRef="FD2019Q2YTD"
      id="d277971135e413-wk-Fact-398EB30CEBBCE2086764E26437E38B1B">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q2YTD"
      id="d277971135e428-wk-Fact-34B88F625E626678BDC6E2CB04B17691">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q2YTD"
      id="d277971135e439-wk-Fact-6CA696FB4A4013567AEDE231C46C9CE9">2019-06-28</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q2YTD"
      id="d277971135e459-wk-Fact-35E23755D6A40AFD0A6CE2CADB55EC15">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q2YTD"
      id="d277971135e469-wk-Fact-5E8EABDB74C4B186C34EE27386ACBE7A">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q2YTD"
      id="d277971135e491-wk-Fact-A9129BE9D9E7DA6506A3E26F973BEEE2">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q2YTD"
      id="d277971135e512-wk-Fact-4F88CBF82DAFBB5AB1A8E26FBD320DA6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q2YTD"
      id="d277971135e517-wk-Fact-DCECF88F926BC07F364BE27017A72D60">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q2YTD"
      id="d277971135e532-wk-Fact-A6882D5FFC0AB3A2EECDE27046A8AC9D">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q2YTD"
      id="d277971135e538-wk-Fact-41EB1EE40FC9B81EC15FE2706A7A668B">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q2YTD"
      id="d277971135e543-wk-Fact-30D4ED56CA292C28FF3FE2708C3EEFB9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q2YTD"
      id="d277971135e548-wk-Fact-38D8F2DD691797D14ABCE270A88797A1">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q2YTD"
      id="d277971135e556-wk-Fact-CB24FD6EBCF8F499B083E270E5E3F3D7">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q2YTD"
      id="d277971135e561-wk-Fact-62910D1AA01D3AEAFF29E270CA5415CA">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q2YTD"
      id="d277971135e602-wk-Fact-BEA9363D9D793DA776F0E2719D52883D">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q2YTD"
      id="d277971135e607-wk-Fact-DCD38F0964B2B3F3764BE2717F35E7CB">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q2YTD"
      id="d277971135e612-wk-Fact-85746CB4810C9EE253D6E271BF19F008">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q2YTD"
      id="d277971135e617-wk-Fact-135B08DBBBAB16770ED0E271FA2A2F0C">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q2YTD"
      id="d277971135e631-wk-Fact-765BC42F0F3AED559B97E2721F71414E">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q2YTD"
      id="d277971135e662-wk-Fact-080FFAFE526CC4609762E27254A2B04A">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q2YTD"
      id="d277971135e713-wk-Fact-1AA19B36CFA1117B9E90E272724E39D6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q2YTD"
      id="d277971135e729-wk-Fact-9F9D66854DB4A0B706A8E2728DF6BFAF">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q2YTD"
      id="d277971135e760-wk-Fact-355191110BC2963509BF273548FD2E44">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q3Jul22"
      decimals="INF"
      id="d277971135e776-wk-Fact-426FBA4DA7FE8E51AE0AE231C46B624C"
      unitRef="shares">302906238</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e551-wk-Fact-93396699141361E328C7E231C47489B6"
      unitRef="usd">369789000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e585-wk-Fact-3327E69FD30B91F4B321E231C46C66ED"
      unitRef="usd">452328000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF"
      unitRef="usd">378559000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e624-wk-Fact-8DA38EB09C159648B9D1E231C49EB65C"
      unitRef="usd">97541000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B"
      unitRef="usd">162771000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e663-wk-Fact-C24AFDB65FBBA1E39222E231C461AEEE"
      unitRef="usd">12390000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4"
      unitRef="usd">16056000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e702-wk-Fact-CACC8D14CC82B815D59EE231C44C667A"
      unitRef="usd">12352000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6"
      unitRef="usd">9838000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e741-wk-Fact-6CC1DCF54B3059CD5FA6E231C450D210"
      unitRef="usd">12847000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C"
      unitRef="usd">15017000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e780-wk-Fact-778AD48461D708D3D932E231C498360A"
      unitRef="usd">957247000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD"
      unitRef="usd">897016000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e819-wk-Fact-8C777A59195473D6E06FE231C46CA92E"
      unitRef="usd">337785000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544"
      unitRef="usd">157187000</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e859-wk-Fact-11BD26FD71BDB949C36BE231C48D8C87"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e898-wk-Fact-BDAF3FADB3E4FBED7CE7E231C46AAA2F"
      unitRef="usd">50709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e937-wk-Fact-705EF9248DFCDC918917E231C44F2EE4"
      unitRef="usd">16573000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367"
      unitRef="usd">5867000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e976-wk-Fact-46C13E9EDA3F333CED1BE231C4886BA2"
      unitRef="usd">210237000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6"
      unitRef="usd">244111000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1015-wk-Fact-42AFF11119B5CB16AD27E231C49C574C"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1054-wk-Fact-5036163CDFFA8EFF5DFDE231C463895F"
      unitRef="usd">5763000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1"
      unitRef="usd">2424000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1098-wk-Fact-6077AC819FD698C01D1EE231C4844313"
      unitRef="usd">1643098000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74"
      unitRef="usd">1422286000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1219-wk-Fact-1A820338DDC1752F2114E231C495D103"
      unitRef="usd">12274000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1"
      unitRef="usd">10901000</us-gaap:AccountsPayableCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1253-wk-Fact-49B1085ECF14489B887AE231C46D019C"
      unitRef="usd">23709000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060"
      unitRef="usd">18231000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1293-wk-Fact-2B2A8F02938D53C0B481E231C4762B81"
      unitRef="usd">24144000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A"
      unitRef="usd">32142000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1332-wk-Fact-44E2432780D7D1399FECE231C487D2AB"
      unitRef="usd">17273000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2"
      unitRef="usd">14954000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1371-wk-Fact-1E8C7DD47B52722CC48BE231C48FFBC3"
      unitRef="usd">7847000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198"
      unitRef="usd">7419000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1410-wk-Fact-D0A13340B1628806C194E231C4861769"
      unitRef="usd">321000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1449-wk-Fact-8CAE734F92DD2B2556A3E231C47692A9"
      unitRef="usd">25228000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250"
      unitRef="usd">21825000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1488-wk-Fact-0BDDD6183D8E6D0D014EE231C49F2513"
      unitRef="usd">110796000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553"
      unitRef="usd">105472000</us-gaap:LiabilitiesCurrent>
    <exel:OperatingAndFinanceLeasesLiabilityLongTerm
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1527-wk-Fact-574AC09395D318FBDAAAE231C48A7B4B"
      unitRef="usd">22543000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
    <exel:OperatingAndFinanceLeasesLiabilityLongTerm
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3"
      unitRef="usd">12178000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1566-wk-Fact-229DE50DEF12B74C475CE231C49D47E0"
      unitRef="usd">16632000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61"
      unitRef="usd">15897000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1605-wk-Fact-0A31F19CA2F4C93C4B96E231C490D5E6"
      unitRef="usd">4495000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8"
      unitRef="usd">1286000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1644-wk-Fact-D051332CC3AF195BE4EEE231C48ABEB4"
      unitRef="usd">154466000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632"
      unitRef="usd">134833000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q2"
      id="d277973521e1683-wk-Fact-BE17891463096ECA70CAE231C48EFF8E"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1764-wk-Fact-99C747DE653ECBA011D9E231C48DE0B8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1803-wk-Fact-09EE11327AB9D847DD8FE231C49A60B7"
      unitRef="usd">303000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93"
      unitRef="usd">300000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1842-wk-Fact-03FBB525858D962BBAE1E231C4771979"
      unitRef="usd">2211668000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83"
      unitRef="usd">2168217000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1881-wk-Fact-28A6EC3FFF9380B99748E231C4904BEC"
      unitRef="usd">2207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56"
      unitRef="usd">-701000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1921-wk-Fact-AB056D7FB3C3EA5574FDE231C488FA2F"
      unitRef="usd">-725546000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0"
      unitRef="usd">-880363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e1962-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E"
      unitRef="usd">1488632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766"
      unitRef="usd">1287453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277973521e2006-wk-Fact-7E5C2FF395C84D46289BE231C46C6CF7"
      unitRef="usd">1643098000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE"
      unitRef="usd">1422286000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277975668e680-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277975668e699-wk-Fact-4F7C2030B0B97CB91993E231C43E6734"
      unitRef="usd">145836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277975668e718-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277975668e738-wk-Fact-50091E677B09B1D05D0EE231C4388469"
      unitRef="usd">280108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277975668e753-wk-Fact-86F42DC59D3F418CDD1BE231C4B67703"
      unitRef="usd">46600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277975668e772-wk-Fact-D3E4E43AD79C4893D9B1E231C454E6C0"
      unitRef="usd">40272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277975668e791-wk-Fact-83181898E532FF40688FE231C4796437"
      unitRef="usd">82506000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277975668e811-wk-Fact-DCC8DAB3437F1E74BCECE231C44105D8"
      unitRef="usd">119719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e831-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e850-wk-Fact-24161066F0F7476E837BE231C4A56D73"
      unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e869-wk-Fact-31347911C2A9E3B534C9E231C4637FEC"
      unitRef="usd">455762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e889-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD"
      unitRef="usd">399827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e991-wk-Fact-FA17F23C378A02BDF47DE231C4B6597A"
      unitRef="usd">7539000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1010-wk-Fact-37B03D2EFF3598084DA3E231C4376B55"
      unitRef="usd">5997000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1029-wk-Fact-4C7AC6BD22E111D8B6B6E231C44F6DD8"
      unitRef="usd">15040000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1049-wk-Fact-E2F1FF0D48BFC4265812E231C4A7FF99"
      unitRef="usd">11636000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1069-wk-Fact-0F7FC73FE5888E182DF8E231C482BE40"
      unitRef="usd">81932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1088-wk-Fact-929A07F13F4828CCAFA4E231C4724573"
      unitRef="usd">42488000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1107-wk-Fact-642C0E3ABB8EEE7A9E3AE231C43D7BC9"
      unitRef="usd">145221000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1127-wk-Fact-84CA7C08F545565774C4E231C4A86AA0"
      unitRef="usd">80245000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1147-wk-Fact-E7C38F1AF89F04E3C26BE231C4B9711C"
      unitRef="usd">58815000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1166-wk-Fact-90740CCFCC87D9728FABE231C4323734"
      unitRef="usd">51853000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1185-wk-Fact-480334831CFEF97916BDE231C44C0FBA"
      unitRef="usd">118953000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1205-wk-Fact-D9A234E40EFCB19B623FE231C44D7CBB"
      unitRef="usd">105869000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1225-wk-Fact-AF450CEF291F922CE164E231C4912810"
      unitRef="usd">148286000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1244-wk-Fact-62D96B9EF59F2ACF6469E231C4AEF15A"
      unitRef="usd">100338000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1263-wk-Fact-C0F84FB18B188601B349E231C4B38EFB"
      unitRef="usd">279214000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1283-wk-Fact-A0B4B1420F639FA4F6E4E231C4A722DC"
      unitRef="usd">197750000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1304-wk-Fact-D284AF06FC8CE4404CADE231C4784088"
      unitRef="usd">91989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1323-wk-Fact-697279857112B21C89D8E231C4781914"
      unitRef="usd">85770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1342-wk-Fact-765DA0857B10289DFBA2E231C43BFF24"
      unitRef="usd">176548000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1362-wk-Fact-F556A5C6045B3F820347E231C4346ADC"
      unitRef="usd">202077000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1464-wk-Fact-8AF25846D0BE23E50DD9E231C49EC8DB"
      unitRef="usd">6975000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1483-wk-Fact-37AE4285E79B0D09FA37E231C4B0A4EF"
      unitRef="usd">2697000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1502-wk-Fact-47AF38BA57F3E4F7D76CE231C446D660"
      unitRef="usd">13062000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1522-wk-Fact-32026EAF2654618FBFA7E231C4AA85E6"
      unitRef="usd">4592000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1542-wk-Fact-1B9F842616813BE404F6E231C4464C24"
      unitRef="usd">803000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1561-wk-Fact-D7EFA64AE8C69619FF77E231C4A0B066"
      unitRef="usd">-72000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1581-wk-Fact-1D82234933E95547F29BE231C4B49F70"
      unitRef="usd">828000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1601-wk-Fact-A660457319FD4C6D6C70E231C4A64868"
      unitRef="usd">97000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1621-wk-Fact-C253682F306DA0C1B6D5E231C446E66B"
      unitRef="usd">7778000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1640-wk-Fact-9218DE217749DD55E252E231C4A107C9"
      unitRef="usd">2625000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1659-wk-Fact-316024DC6F3D42BF5D23E231C4A8D1A7"
      unitRef="usd">13890000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1679-wk-Fact-8D785BCEDAAF9C55A53DE231C4413AFB"
      unitRef="usd">4689000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1699-wk-Fact-81B70EDAF84EC843EE64E231C49F8D85"
      unitRef="usd">99767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1718-wk-Fact-19F42E7DD991783B7EF2E231C4B467FF"
      unitRef="usd">88395000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1737-wk-Fact-0BC5155CFF2C4B5FFE26E231C46F55AF"
      unitRef="usd">190438000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1757-wk-Fact-BF54AC4A24B420DE88B4E231C43A073B"
      unitRef="usd">206766000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1777-wk-Fact-EBD8030D420964FD023FE231C4B8333F"
      unitRef="usd">20725000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1797-wk-Fact-02379BCDEC313F7AAD11E231C47F6E60"
      unitRef="usd">901000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1817-wk-Fact-943A5A8B43BBD83CEFC9E231C4419503"
      unitRef="usd">35621000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1838-wk-Fact-5DAFBEF242A84CB7BC15E231C48FD013"
      unitRef="usd">3415000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e1864-wk-Fact-ACA33AEAAB4725288007E231C442BE5F"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e1883-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e1902-wk-Fact-B80960B704D8361B606AE231C4A09B4D"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e1922-wk-Fact-2A814F972C0BD074AFC1E231C43F3652"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d277975668e1942-wk-Fact-4B26B5AB9595C15EACD3E231C452EDCE"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q2Q2QTD"
      decimals="2"
      id="d277975668e1961-wk-Fact-F3A995FE72E51F9D3971E231C4A986C0"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d277975668e1980-wk-Fact-9F4C610798472730DF9CE231C47B1AEF"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q2DEC30-JUN29"
      decimals="2"
      id="d277975668e2000-wk-Fact-BB84C7A53A3F37741239E231C44DA175"
      unitRef="usdPerShare">0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d277975668e2020-wk-Fact-0299983057549E97DDBEE231C4A8C4BF"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q2Q2QTD"
      decimals="2"
      id="d277975668e2039-wk-Fact-D29BE3A6B68F7E6F3193E231C43E6608"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d277975668e2058-wk-Fact-E3AFB87B37B6205B4E96E231C4A21E71"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q2DEC30-JUN29"
      decimals="2"
      id="d277975668e2078-wk-Fact-43D96EC8BE7C5483B2A2E231C43B448B"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e2093-wk-Fact-4044463EA64232983585E231C4379D71"
      unitRef="shares">302188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e2112-wk-Fact-266587292C7A6833D40AE231C433B369"
      unitRef="shares">297336000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e2131-wk-Fact-57892A0C65D150C9B129E231C48EA534"
      unitRef="shares">301365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e2151-wk-Fact-29A95E9E14C8CF8203C4E231C4A9A235"
      unitRef="shares">296874000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277975668e2172-wk-Fact-939D5E643961456211DFE231C4B20A6E"
      unitRef="shares">314911000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277975668e2191-wk-Fact-9C5B62466C75220A7FA3E231C47AF2DA"
      unitRef="shares">312241000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277975668e2210-wk-Fact-461891499FE2723E9818E231C44E4D54"
      unitRef="shares">314786000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277975668e2230-wk-Fact-20D4CCDAE0A8ED18948DE231C435BB67"
      unitRef="shares">313024000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277976473e598-wk-Fact-ACA33AEAAB4725288007E231C442BE5F"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277976473e617-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277976473e636-wk-Fact-B80960B704D8361B606AE231C4A09B4D"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277976473e656-wk-Fact-2A814F972C0BD074AFC1E231C43F3652"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB"
      unitRef="usd">156000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345"
      unitRef="usd">-384000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277976473e834-wk-Fact-6B31F55CF62600F10450E231C434000D"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277976473e853-wk-Fact-6857FCD418F62C6E01F2E231C4358FCF"
      unitRef="usd">156000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277976473e872-wk-Fact-554E5ABB145FD1448009E231C437C9A8"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277976473e892-wk-Fact-D004AC02AA989303FEDCE231C436FD6D"
      unitRef="usd">-384000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277976473e918-wk-Fact-E625688885FF57CAFAA9E231C43924D6"
      unitRef="usd">80521000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277976473e937-wk-Fact-11629364F13040E1431CE231C435C482"
      unitRef="usd">87650000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277976473e956-wk-Fact-663B83BF5218ACFEAF1EE231C438DE33"
      unitRef="usd">157725000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277976473e976-wk-Fact-7264C9C7F206CFB5971BE231C43895FD"
      unitRef="usd">202967000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e791-wk-Fact-F3B983C5C1A25D1ECEEEE231C4904A07"
      unitRef="shares">301519885</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e810-wk-Fact-7AF2929F30C016B06491E231C491D0AE"
      unitRef="usd">302000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e829-wk-Fact-E7B4BCE1947B92A4B01FE231C4945906"
      unitRef="usd">2188578000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e849-wk-Fact-4E6FCCF4358D4436CEEFE231C492956D"
      unitRef="usd">728000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e868-wk-Fact-2E9D2A5307E4E92271FCE231C494395B"
      unitRef="usd">-804588000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q1"
      decimals="-3"
      id="d277983881e888-wk-Fact-C7A1EE9B14540F7650F0E231C494C375"
      unitRef="usd">1385020000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e976-wk-Fact-6BD0AE1DF3219A74E456E231C490B30B"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277983881e995-wk-Fact-ACA33AEAAB4725288007E231C442BE5F"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e1069-wk-Fact-B6E5C3B1D371BA10DB83F32770963C59"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277983881e1107-wk-Fact-6B31F55CF62600F10450E231C434000D"
      unitRef="usd">1479000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e1128-wk-Fact-D90EC0F075A821DC0754F326F205BD46"
      unitRef="shares">1264969</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e1142-wk-Fact-9D775E464783BAFF2D8DF326F3F66601"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e1161-wk-Fact-25F71F39A4DCFBCC5FFEF326F5776E10"
      unitRef="usd">8011000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277983881e1219-wk-Fact-09EDBD39DC0CD79E3A3AE231C4953780"
      unitRef="usd">8012000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e1273-wk-Fact-48A41889233A74AFFC56F327B02E4784"
      unitRef="usd">15079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277983881e1331-wk-Fact-5D9FE01A5EC4CA0D0529E231C4932444"
      unitRef="usd">15079000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e1352-wk-Fact-E7A9EDAC33C3F65F8FFBE231C466BFEE"
      unitRef="shares">302784854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e1371-wk-Fact-33C29D0FCDF8E0798424E231C46AB67C"
      unitRef="usd">303000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e1390-wk-Fact-2887D1C3E6BD2FB4DCC6E231C46C621D"
      unitRef="usd">2211668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e1410-wk-Fact-15AEEEEC559C38EEBF24E231C469DE66"
      unitRef="usd">2207000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e1429-wk-Fact-3807618F1E469F0ED00EE231C467FFBB"
      unitRef="usd">-725546000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277983881e1449-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E"
      unitRef="usd">1488632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e1851-wk-Fact-74A94E301A0FE65B0D79E231C440902D"
      unitRef="shares">296694330</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e1870-wk-Fact-8E2D32825FEA7C4EA271E231C43C8AD5"
      unitRef="usd">297000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e1889-wk-Fact-7226943225C2D520C251E231C43E7A73"
      unitRef="usd">2125166000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e1909-wk-Fact-B1904F7234B8652D19B4E231C43D69C3"
      unitRef="usd">-887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q1Fiscal_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e1929-wk-Fact-0EF77CD21878039E0CD2E231C43CC865"
      unitRef="usd">-1454576000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q1Fiscal"
      decimals="-3"
      id="d277983881e1949-wk-Fact-7F28215F6A433B128B21E231C43ED973"
      unitRef="usd">670000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e2037-wk-Fact-05C351918F4FE711EAFCE231C43CB9AC"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277983881e2056-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e2130-wk-Fact-460E22C69790E6CAE1D7E231C43DA1AC"
      unitRef="usd">156000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277983881e2168-wk-Fact-6857FCD418F62C6E01F2E231C4358FCF"
      unitRef="usd">156000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e2189-wk-Fact-CE23BD25434BF854E97EE231C43FDA11"
      unitRef="shares">1197850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e2203-wk-Fact-2206B40278B4B0F07D5EE231C43B6F99"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e2222-wk-Fact-574C37EC0FCAF3645D2CE231C43D3203"
      unitRef="usd">8268000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277983881e2280-wk-Fact-0B771E0F00CD5C9681D4E231C43D55F1"
      unitRef="usd">8269000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q2Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e2334-wk-Fact-3CD2E5C485BF942DB3DDE231C43A9D92"
      unitRef="usd">9283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277983881e2392-wk-Fact-CA21072E27374D29635BE231C43B7746"
      unitRef="usd">9283000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e2413-wk-Fact-163DA00AE5F8891A9784E231C43C27F0"
      unitRef="shares">297892180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e2432-wk-Fact-11C5E8318656A97FA1AAE231C43C5DFF"
      unitRef="usd">298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e2451-wk-Fact-BDE5D5F6AFF2D4BC5923E231C43B030B"
      unitRef="usd">2142717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e2471-wk-Fact-95D61F1C2C7777C036F3E231C43F792D"
      unitRef="usd">-731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e2491-wk-Fact-12915F52C678D491FF49E231C43BFF0A"
      unitRef="usd">-1367082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277983881e2511-wk-Fact-1B5B2840456185E2435BE231C43FFA3C"
      unitRef="usd">775202000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e2932-wk-Fact-5D510C9190F560BB9E72E231C4648933"
      unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e2951-wk-Fact-B84CF36E533822EBA362E231C46917F0"
      unitRef="usd">300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e2970-wk-Fact-C86F8C2ADBB11C369156E231C466F485"
      unitRef="usd">2168217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e2990-wk-Fact-109BF504E684107F77A3E231C467DB06"
      unitRef="usd">-701000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e3010-wk-Fact-5DEE42FA41BCED0CC284E231C46E1EAC"
      unitRef="usd">-880363000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766"
      unitRef="usd">1287453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e3118-wk-Fact-10C5D7C54928A22C3A3D44C6DCB7984B"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277983881e3137-wk-Fact-B80960B704D8361B606AE231C4A09B4D"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e3211-wk-Fact-CF8D8ED4D32F89CDDDCFE231C46B14EF"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277983881e3249-wk-Fact-554E5ABB145FD1448009E231C437C9A8"
      unitRef="usd">2908000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e3270-wk-Fact-2BEAD5113ECB62111B83E231C46A40C0"
      unitRef="shares">2908774</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e3284-wk-Fact-160D2E22BB66EF802357E231C46883F4"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e3303-wk-Fact-DEC9CD8E55AF3B353776E231C46A2C96"
      unitRef="usd">15843000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277983881e3361-wk-Fact-154C2A6989C3919E50B0E231C46BCD30"
      unitRef="usd">15846000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e3415-wk-Fact-CCF7825C73341D9E98B5E231C46752D5"
      unitRef="usd">27608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277983881e3473-wk-Fact-6C6C8F78BC3080605666E231C4690374"
      unitRef="usd">27608000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e3494-wk-Fact-E7A9EDAC33C3F65F8FFBE231C466BFEE"
      unitRef="shares">302784854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e3513-wk-Fact-33C29D0FCDF8E0798424E231C46AB67C"
      unitRef="usd">303000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e3532-wk-Fact-2887D1C3E6BD2FB4DCC6E231C46C621D"
      unitRef="usd">2211668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e3552-wk-Fact-15AEEEEC559C38EEBF24E231C469DE66"
      unitRef="usd">2207000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e3571-wk-Fact-3807618F1E469F0ED00EE231C467FFBB"
      unitRef="usd">-725546000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277983881e3591-wk-Fact-DAF95E02E72A8839DF2DE231C499BB4E"
      unitRef="usd">1488632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e3993-wk-Fact-210A650B8A0D880966E2E231C4A8619D"
      unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e4012-wk-Fact-37533C211990CB39BF7DE231C4A6ED1F"
      unitRef="usd">296000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e4031-wk-Fact-5B38E61FF36E3E8228A8E231C4A9C8F8"
      unitRef="usd">2114184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e4051-wk-Fact-4C4D341067612DEDC7B8E231C4ABC82E"
      unitRef="usd">-347000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e4071-wk-Fact-BF916A2AEA5FF32F0F9DE231C4AA75C7"
      unitRef="usd">-1829172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277983881e4091-wk-Fact-46CC1A4A94C716FA8A19E231C4A72828"
      unitRef="usd">284961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e4181-wk-Fact-BFB15673FC46D8384DB3E231C4A49EEA"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d277983881e4200-wk-Fact-EDFB2604DDAC9F1B878CE231C4A6A3A6"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e4295-wk-Fact-A32CBEA42C527B378E40E231C4A775E7"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d277983881e4314-wk-Fact-890674B2F854679BBAD5E231C4A91E1F"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e4407-wk-Fact-88862EDA205945E922C7E231C4A88787"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277983881e4426-wk-Fact-2A814F972C0BD074AFC1E231C43F3652"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e4500-wk-Fact-1E147BD21BA55C5F6712E231C4A42F5D"
      unitRef="usd">-384000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277983881e4539-wk-Fact-D004AC02AA989303FEDCE231C436FD6D"
      unitRef="usd">-384000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e4561-wk-Fact-05F608BDB96805DD2C17E231C4A03F73"
      unitRef="shares">1682754</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e4575-wk-Fact-7DAF788DCA9CDB4C85E5E231C4A28B4B"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e4594-wk-Fact-441A5C844FB4FB4CDD88E231C4A39DCE"
      unitRef="usd">9945000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277983881e4652-wk-Fact-4C121D584FCE4CBB447DE231C4A5BC89"
      unitRef="usd">9947000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q2DEC30-JUN29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e4706-wk-Fact-E91DA41BAC14AE1105ECE231C4A17146"
      unitRef="usd">18588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277983881e4764-wk-Fact-10C3D8C1CB89CD34B5B3E231C4A33B50"
      unitRef="usd">18588000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d277983881e4785-wk-Fact-163DA00AE5F8891A9784E231C43C27F0"
      unitRef="shares">297892180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d277983881e4804-wk-Fact-11C5E8318656A97FA1AAE231C43C5DFF"
      unitRef="usd">298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d277983881e4823-wk-Fact-BDE5D5F6AFF2D4BC5923E231C43B030B"
      unitRef="usd">2142717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d277983881e4843-wk-Fact-95D61F1C2C7777C036F3E231C43F792D"
      unitRef="usd">-731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d277983881e4863-wk-Fact-12915F52C678D491FF49E231C43BFF0A"
      unitRef="usd">-1367082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277983881e4883-wk-Fact-1B5B2840456185E2435BE231C43FFA3C"
      unitRef="usd">775202000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e509-wk-Fact-B80960B704D8361B606AE231C4A09B4D"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e528-wk-Fact-2A814F972C0BD074AFC1E231C43F3652"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e584-wk-Fact-7CB2C2D7F968FD8E109FE231C4A75E34"
      unitRef="usd">3998000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e603-wk-Fact-0884BEE04DD7A69BD1C6E231C4AC2FC1"
      unitRef="usd">1176000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e623-wk-Fact-18E83557C0118F31C1FEE231C4A27767"
      unitRef="usd">27608000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e642-wk-Fact-70A685DDB71C0082419AE231C4B72C05"
      unitRef="usd">18588000</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e662-wk-Fact-633D5C14BEAC3D13F2C3E231C4B57842"
      unitRef="usd">3551000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e681-wk-Fact-DCFE99E7BB6524BF2307E231C4AD4D25"
      unitRef="usd">2723000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <exel:RightOfUseAssetAmortization
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e701-wk-Fact-312AA8B0517866327ECBE231C4AA595B"
      unitRef="usd">-7071000</exel:RightOfUseAssetAmortization>
    <exel:RightOfUseAssetAmortization
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e721-wk-Fact-256B1512DB76549A5AC5E231C4B4CE11"
      unitRef="usd">0</exel:RightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e741-wk-Fact-4755F1F7F8C9D54B232E273928A2F282"
      unitRef="usd">-33067000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e760-wk-Fact-9F0A8381C46FBC8A53172739287E92DC"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e780-wk-Fact-EE3E90207A2B88C3C404E231C4B071B1"
      unitRef="usd">730000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e800-wk-Fact-08C2D4BF68CFE89482F1E231C4B62756"
      unitRef="usd">209000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e821-wk-Fact-7B1AEBAE3B879B04655DE231C4AE063F"
      unitRef="usd">2919000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e841-wk-Fact-589C80C04B7237DC32E1E231C4B530C4"
      unitRef="usd">490000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e904-wk-Fact-2347F96A2F014A45E329E231C4B95B0B"
      unitRef="usd">-65230000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e923-wk-Fact-A21E21DA02B71E975B42E231C49FCD36"
      unitRef="usd">76698000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e944-wk-Fact-4C10F54CA9E97A2A3CC4E231C4A03892"
      unitRef="usd">-3661000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e963-wk-Fact-433685ACD2EED001BD4DE231C4AD4E16"
      unitRef="usd">9271000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e984-wk-Fact-FB20047B16F6B8D9E377E231C4AEB82C"
      unitRef="usd">2514000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1004-wk-Fact-C327B73E9B2262DEBED0E231C4A441EB"
      unitRef="usd">1714000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1025-wk-Fact-FB1B3EC438F6D19CF68DE231C4A86103"
      unitRef="usd">2150000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1045-wk-Fact-33F9527823CACEC322CEE231C4A9337D"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1065-wk-Fact-057AFAEFAFC25115B2C2E231C4B767A3"
      unitRef="usd">-2170000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1084-wk-Fact-D2A5EED5808AD57190DCE231C4B1BAD9"
      unitRef="usd">1577000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1105-wk-Fact-C3579A5A99C3213D17F6E231C4B817F8"
      unitRef="usd">4789000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1125-wk-Fact-118224085444D1EBB33CE231C4B2596A"
      unitRef="usd">-3000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1145-wk-Fact-A9FA94405957D48A1F19E231C4A8C966"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1164-wk-Fact-4FEA6EC7703804ABF5B1E231C4ABFEF9"
      unitRef="usd">-1535000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1185-wk-Fact-9A3C92DC53493F7B5AFFE231C49F0920"
      unitRef="usd">-7998000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1205-wk-Fact-D2AA4937DDCA9767449FE231C49F9F4C"
      unitRef="usd">465000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <exel:IncreaseDecreaseInAccruedClinicalLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1225-wk-Fact-71F11C90ED1A1779CC4EE231C4A65302"
      unitRef="usd">5478000</exel:IncreaseDecreaseInAccruedClinicalLiabilities>
    <exel:IncreaseDecreaseInAccruedClinicalLiabilities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1244-wk-Fact-8AF2A8E6BB93F5AD10EAE231C4B0F872"
      unitRef="usd">-3048000</exel:IncreaseDecreaseInAccruedClinicalLiabilities>
    <exel:IncreaseDecreaseInRebatesAndFeesPayable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1265-wk-Fact-1F1D910A00725FB46008E231C4A197DC"
      unitRef="usd">2319000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
    <exel:IncreaseDecreaseInRebatesAndFeesPayable
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1284-wk-Fact-61A345BCDDD8CB42042DE231C49ED7F6"
      unitRef="usd">3578000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
    <exel:IncreaseDecreaseInAccruedCollaborationLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1305-wk-Fact-8D1ABCFB8EBF3D104CA1E231C4A20BE4"
      unitRef="usd">428000</exel:IncreaseDecreaseInAccruedCollaborationLiability>
    <exel:IncreaseDecreaseInAccruedCollaborationLiability
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1324-wk-Fact-4C8E1ADD2324A10F58A3E231C49F2B79"
      unitRef="usd">-1261000</exel:IncreaseDecreaseInAccruedCollaborationLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1345-wk-Fact-4D593EBB8FE20E68B3A2E231C4B8A5D6"
      unitRef="usd">4656000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1364-wk-Fact-5DA16EF022D28807C8C9E231C4B6E555"
      unitRef="usd">5910000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <exel:IncreaseDecreaseInLeaseLiabilityNoncurrent
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1384-wk-Fact-FE18FAA570CC197A664EE231C4B71787"
      unitRef="usd">6777000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
    <exel:IncreaseDecreaseInLeaseLiabilityNoncurrent
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1403-wk-Fact-76205CE7C254997E5ED0E231C4B825AA"
      unitRef="usd">-181000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1424-wk-Fact-0D1D54862DB310C19576E231C4AC01A8"
      unitRef="usd">7709000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1443-wk-Fact-A1D48FE024D39C19DCEDE231C4AEFC11"
      unitRef="usd">6463000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1463-wk-Fact-8495DF829ACDDAA26C69E231C4AAD93D"
      unitRef="usd">293321000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1482-wk-Fact-C58F6C6BBB6C3D442ABEE231C4A41FB8"
      unitRef="usd">146273000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1543-wk-Fact-8F128C773B6FF38A19D5E231C4A739D4"
      unitRef="usd">3516000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1563-wk-Fact-C5621A5ED3C4FB863C11E231C4A1DBA0"
      unitRef="usd">15182000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1584-wk-Fact-F11D5AFA7614BB5E6918E231C4B392BE"
      unitRef="usd">518268000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1604-wk-Fact-2C90A2CCA735CAF37266E231C4AD35C8"
      unitRef="usd">227012000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1625-wk-Fact-BE16FB26E0D3B83751A9E231C4B26EFC"
      unitRef="usd">258791000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1644-wk-Fact-33CECCA5F64577A6E988E231C4AB756E"
      unitRef="usd">139948000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1664-wk-Fact-26FEC1F4E6C811796563E231C4A057B3"
      unitRef="usd">11677000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1683-wk-Fact-183153D80E16F90BF15FE231C4AC0BEB"
      unitRef="usd">10237000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1703-wk-Fact-345DD6A6BA03BB2627C5E231C4A77E28"
      unitRef="usd">730000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1722-wk-Fact-3277AE841AF036448EC9E231C4AFE810"
      unitRef="usd">209000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1743-wk-Fact-B2CECABF4D79470EA1CBE231C4B307D8"
      unitRef="usd">-250586000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1763-wk-Fact-AA0296B6682D8D6F73D0E231C4B34474"
      unitRef="usd">-91800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1825-wk-Fact-2E9940DC23BA261FD0D5E231C4AADC02"
      unitRef="usd">10590000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1844-wk-Fact-1F8E83D096279AF005E4E231C4A55F60"
      unitRef="usd">6550000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1864-wk-Fact-B70E49139DBAE3F99A32E231C4B91DBD"
      unitRef="usd">4145000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1883-wk-Fact-A98897774B377CE096A5E231C4B0F9C9"
      unitRef="usd">3650000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1903-wk-Fact-52DC709C0B33084F4FB7E231C4A0C1F0"
      unitRef="usd">2434000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1923-wk-Fact-190156C5E3A104511259E231C4A6D4D5"
      unitRef="usd">2976000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1944-wk-Fact-4ADD9FB58639B5D82F70E231C4B896F6"
      unitRef="usd">22000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e1964-wk-Fact-361CD9EA5DDB448A819CE231C4AC63D1"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e1984-wk-Fact-4435E0F4144D07B6A59DE231C4B4BD38"
      unitRef="usd">12279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e2003-wk-Fact-2CCB477483FCA3AF4468E231C4A3040D"
      unitRef="usd">7224000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e2023-wk-Fact-99A3DB597B425E5ED165E231C4AF4586"
      unitRef="usd">55014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e2042-wk-Fact-C130F013C33EE62CE406E231C4AA5013"
      unitRef="usd">61697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277978785e2062-wk-Fact-0EE8CC5629FA14CBB5A7E231C4A3D199"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277978785e2081-wk-Fact-1FA1A8CFE095CE90F68DE231C4A3FC97"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277978785e2106-wk-Fact-89C66780BE1D0B94DA83E231C4B3ADCA"
      unitRef="usd">370889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277978785e2125-wk-Fact-38A5D9EB56083282C921E231C4B09545"
      unitRef="usd">250011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA"
      unitRef="usd">11338000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627"
      unitRef="usd">17180000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277978785e2338-wk-Fact-ED7C76A22F1DEDCCB875E231C45332F5"
      unitRef="usd">1350000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277978785e2357-wk-Fact-87F2A4D6A6AC4D447F8EE231C451FC9F"
      unitRef="usd">13972000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-BD485E72C303EBFB8DFCE231C4C7BCA9-0-wk-Fact-B40D02783970E25BD79EE231C45A37FF">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (Exelixis, we, our or us) is&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;Two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019, March 30, 2018, June 29, 2018 and March 29, 2019, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2019, March 31, 2019, June 30, 2018 and March 31, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating results for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&#160;22, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we adopted ASU &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the individual unit of account approach for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;releasing income tax effects from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we also adopted ASU 2017-08&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2017-08). ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;shortens the amortization period for certain callable debt securities held at a premium. Specifically, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;requires the premium to be amortized to the earliest call date. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The financial impact from the adoption of ASU 2017-08 was nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Accounting Standards Codification (ASC) Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d277984132e432-wk-Fact-ECC7FDC9114379A2D148E231C45B48D2"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember"
      decimals="INF"
      id="d277984132e436-wk-Fact-8417ECBA9F86C21A77F0E6F5CA906316"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember"
      decimals="INF"
      id="d277984132e440-wk-Fact-CA475057AEBCA9E4BA3BE6F70010800B"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F4F925D23E2A17F79DEBE231C4C8053B-0-wk-Fact-BC05B6DD23644205AAA4E231C45C34EA">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-873E457FF91028A0E2C3E231C4C7AF2B-0-wk-Fact-4956EE39E184EEACC1CFE231C45BE26C">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="FD2019Q2YTD"
      id="TextSelection-8B1C180CF24CD9C4794AE231C4C89168-0-wk-Fact-D7F5DF70644324E18313E231C45D1600">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019, March 30, 2018, June 29, 2018 and March 29, 2019, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2019, March 31, 2019, June 30, 2018 and March 31, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6EE5D812E9B97499764AE231C4C8E324-0-wk-Fact-4A95CCD08A617F441B92E231C45C7534">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;All of our long-lived assets are located in the U.S.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d277984132e534-wk-Fact-BEF847B642D471CAC1FDE231C45D00EA"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q2YTD"
      id="TextSelection-90B334C10DDE114C6B4CE231C4C7D639-0-wk-Fact-51E295E63D67DA50FFC1E231C45A15F8">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D6CB69FBB2301D8599CDE231C4C83760-0-wk-Fact-112FCD2BF5A661C9CB43E231C46C5EC8">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we adopted ASU &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the individual unit of account approach for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;releasing income tax effects from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we also adopted ASU 2017-08&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2017-08). ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;shortens the amortization period for certain callable debt securities held at a premium. Specifically, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;requires the premium to be amortized to the earliest call date. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The financial impact from the adoption of ASU 2017-08 was nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Accounting Standards Codification (ASC) Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2018-15 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Condensed Consolidated Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9575069913D0C501269CE231C4C8A4D1-0-wk-Fact-1BAA8938F148571831EAE231C4A378DF">REVENUES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;464,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(46,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;280,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;36,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,908&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;189,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;364,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;280,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56,595&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,622&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;171,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;150,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;287,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(57,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(22,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(87,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(947&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$36.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$61.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$32.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$103.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-87901CC17B3BDBAD5ACFE231C4C96D35-0-wk-Fact-58DB03B1076D4AB68486E231C4A13D37">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;172,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;464,168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(46,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(26,810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(51,974&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;280,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;36,393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,908&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;60,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,898&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,559&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,877&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;82,506&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;189,015&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;141,121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;364,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;270,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;373,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;280,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,475&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;69,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56,595&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;32,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Diplomat Specialty Pharmacy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,557&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38,622&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;171,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105,129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;196,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;150,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;378,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;287,072&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,679&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;240,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;455,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;399,827&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d277989623e683-wk-Fact-BB3F3684AF445C5F1510E231C4462578"
      unitRef="usd">240418000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d277989623e702-wk-Fact-F032A66A1A622A210A7BE231C4470696"
      unitRef="usd">172646000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d277989623e721-wk-Fact-16CE19CBAD55007F003EE231C44139D0"
      unitRef="usd">464168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d277989623e741-wk-Fact-9BAB84E51F02E6074CB6E231C444B91A"
      unitRef="usd">332082000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d277989623e756-wk-Fact-C927A66B1B3FA056B953E231C444FF50"
      unitRef="usd">46743000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d277989623e776-wk-Fact-4F03AA2DEC862BD9A48DE231C443D924"
      unitRef="usd">26810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d277989623e796-wk-Fact-331CA3BC969912104F00E231C44447B7"
      unitRef="usd">90912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d277989623e817-wk-Fact-6A1D3F2650F969822848E231C446ED16"
      unitRef="usd">51974000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e838-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e857-wk-Fact-4F7C2030B0B97CB91993E231C43E6734"
      unitRef="usd">145836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e876-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e896-wk-Fact-50091E677B09B1D05D0EE231C4388469"
      unitRef="usd">280108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d277989623e1000-wk-Fact-C0861B81A0D95FFEB585E231C444DF96"
      unitRef="usd">36393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d277989623e1019-wk-Fact-94378C10C74323D9A7B1E231C4437FD3"
      unitRef="usd">31908000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d277989623e1038-wk-Fact-1D5276EFE4EAC3CFDF8BE231C445D875"
      unitRef="usd">60902000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d277989623e1058-wk-Fact-5E0693FFD4B16123A31AE231C4400623"
      unitRef="usd">100938000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d277989623e1080-wk-Fact-3D0A5BFEE7001E6DC7FCE231C441DA46"
      unitRef="usd">10898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d277989623e1099-wk-Fact-A22C595D4A3B113A65F0E231C4413F95"
      unitRef="usd">6805000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d277989623e1118-wk-Fact-8AD478EC4CAD0F8759DBE231C440BF52"
      unitRef="usd">22826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d277989623e1138-wk-Fact-3AD02ECA678E73C02F5FE231C445DD1F"
      unitRef="usd">16904000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d277989623e1160-wk-Fact-A9EF62295D1B68B89B08E231C446B80A"
      unitRef="usd">-691000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d277989623e1180-wk-Fact-E41DDF6616AD80EB393AE231C4436F57"
      unitRef="usd">1559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d277989623e1199-wk-Fact-E63EBAE27FCD89818DA8E231C4477BD2"
      unitRef="usd">-1222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d277989623e1220-wk-Fact-3F98F5A86B7FAB66F9CDE231C44470A8"
      unitRef="usd">1877000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277989623e1240-wk-Fact-86F42DC59D3F418CDD1BE231C4B67703"
      unitRef="usd">46600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277989623e1259-wk-Fact-D3E4E43AD79C4893D9B1E231C454E6C0"
      unitRef="usd">40272000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277989623e1278-wk-Fact-83181898E532FF40688FE231C4796437"
      unitRef="usd">82506000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d277989623e1298-wk-Fact-DCC8DAB3437F1E74BCECE231C44105D8"
      unitRef="usd">119719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277989623e1324-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277989623e1343-wk-Fact-24161066F0F7476E837BE231C4A56D73"
      unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e1362-wk-Fact-31347911C2A9E3B534C9E231C4637FEC"
      unitRef="usd">455762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277989623e1382-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD"
      unitRef="usd">399827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="2"
      id="d277989623e1412-wk-Fact-86FEAADED3B607A95BA5E231C4A32505"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d277989623e1648-wk-Fact-B015F4CE2F307092586EE231C4747F2D"
      unitRef="usd">189015000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d277989623e1667-wk-Fact-D4FBD20DE1AC5A1CFF19E231C47620B2"
      unitRef="usd">141121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d277989623e1686-wk-Fact-1B6366209B2C01DCC623E231C4763237"
      unitRef="usd">364905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d277989623e1706-wk-Fact-302F767BA3EE0E87E009E231C4734C31"
      unitRef="usd">270055000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d277989623e1721-wk-Fact-21813CEBD623B02C465AE231C4777593"
      unitRef="usd">4660000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d277989623e1740-wk-Fact-2B355D0DF4302A93C00EE231C4712EB8"
      unitRef="usd">4715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d277989623e1759-wk-Fact-3B62F2C54CD57A8B23F1E231C47331DD"
      unitRef="usd">8351000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d277989623e1779-wk-Fact-310AE8EEEE98CC333C43E231C472F841"
      unitRef="usd">10053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e1804-wk-Fact-CC33CCD8C49DC7CFFC59E231C4B2C835"
      unitRef="usd">193675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e1823-wk-Fact-4F7C2030B0B97CB91993E231C43E6734"
      unitRef="usd">145836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e1842-wk-Fact-192B690D7F24E8BEECF0E231C43C8E5C"
      unitRef="usd">373256000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d277989623e1862-wk-Fact-50091E677B09B1D05D0EE231C4388469"
      unitRef="usd">280108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d277989623e2125-wk-Fact-D117BFD29DC8FEBEB879E231C47CD6EE"
      unitRef="usd">37237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2139-wk-Fact-950748D06EFFA9D02EEDE231C4776BF4"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d277989623e2159-wk-Fact-83FB7BE9C60D718B59F4E231C47B0D85"
      unitRef="usd">26421000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2174-wk-Fact-5D9449DC22E163947DC3E231C4757748"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d277989623e2190-wk-Fact-D72BC4062AB6DE954683E231C478EA18"
      unitRef="usd">31284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2209-wk-Fact-D14CD3D79403C74E2040E231C47D9978"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d277989623e2224-wk-Fact-B27D77DDA808A2C38A96E231C477B844"
      unitRef="usd">23321000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2244-wk-Fact-4669F98DEAEE39EC1E18E231C47CDD5C"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d277989623e2260-wk-Fact-1D7A7EEB1259365EA3CDE231C47964CB"
      unitRef="usd">23366000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2279-wk-Fact-4718AD87A433F69D056CE231C4823C85"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d277989623e2294-wk-Fact-DC0BC572957FFF6EBC41E231C47A6025"
      unitRef="usd">17028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2314-wk-Fact-4B6E8B659D0E7BA065C8E231C4771417"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d277989623e2330-wk-Fact-DED6C70B4A79CB4BE06FE231C47BF31B"
      unitRef="usd">22249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2349-wk-Fact-22D247C94FE42C759C6FE231C48503B6"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d277989623e2364-wk-Fact-1D76F2D7DF400F188A86E231C4767EE0"
      unitRef="usd">34043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2384-wk-Fact-CE1C370B5732E2806ABCE231C481F331"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember"
      decimals="-3"
      id="d277989623e2400-wk-Fact-44104B4E05ED3389D7B5E231C47AE5D8"
      unitRef="usd">18688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2419-wk-Fact-A1F29EFD36EC0900C03FE231C474E6FA"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember"
      decimals="-3"
      id="d277989623e2434-wk-Fact-2766E417FC8AAA012FA5E231C47E6A20"
      unitRef="usd">19714000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2454-wk-Fact-09A50D3785726B6AB2EDE231C48120E5"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember"
      decimals="-3"
      id="d277989623e2470-wk-Fact-8F453D113FED12620742E231C47B651E"
      unitRef="usd">15318000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2489-wk-Fact-58B4719F465FC543C6E8E231C480ED82"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember"
      decimals="-3"
      id="d277989623e2504-wk-Fact-280A0EE092476EDB5D0FE231C47658F8"
      unitRef="usd">18475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2524-wk-Fact-DCE2C7EF5C7CAD48B8E1E231C4759153"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d277989623e2540-wk-Fact-0F49709A38697D37BB33E231C47D01CA"
      unitRef="usd">92133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2559-wk-Fact-339D4D02C8D05C13C205E231C4788F17"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d277989623e2574-wk-Fact-B5994DBE78E624A04922E231C47D8DF3"
      unitRef="usd">47106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2593-wk-Fact-F367C8F43B50B69CF86FE231C47F1620"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277989623e2614-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d277989623e2628-wk-Fact-61AD1F294A5A300FC94FE3359C6ED5BA"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277989623e2648-wk-Fact-24161066F0F7476E837BE231C4A56D73"
      unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d277989623e2663-wk-Fact-54284BF458040B9B70E1E3359C8437B0"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d277989623e2921-wk-Fact-88F21E3E26F19F9A03E9E231C482308E"
      unitRef="usd">69935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2935-wk-Fact-396ACE837010D244A9CCE231C477DC97"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d277989623e2955-wk-Fact-0B4DA2569BF5210C4F6EE231C48482B6"
      unitRef="usd">52809000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e2970-wk-Fact-16ADD12153867EF466EDE231C480D978"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d277989623e2986-wk-Fact-47CF20DA221E94151B0CE231C4811F6E"
      unitRef="usd">56595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3005-wk-Fact-21A8F8CB7D1ED11BFDF4E231C47D8D0E"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d277989623e3020-wk-Fact-73750D21313D8A7FD72DE231C47E1B1D"
      unitRef="usd">44652000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3040-wk-Fact-7A0EA1AD7D19CB77B72DE231C482A58B"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d277989623e3056-wk-Fact-039F2A64EC2C10612C6CE231C4847D28"
      unitRef="usd">45268000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3075-wk-Fact-28FCD53CCD5881363054E231C47F37D7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d277989623e3090-wk-Fact-4112E0B10DF0FDB2BB22E231C4856DB1"
      unitRef="usd">32763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3110-wk-Fact-B18612EEC7F5324D225AE231C47AA8D4"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d277989623e3126-wk-Fact-2C5D2D4F854AF945163BE231C4804E81"
      unitRef="usd">44117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3145-wk-Fact-BFB5366D6278041F83E5E231C484A8B7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d277989623e3160-wk-Fact-A9D184F4942C848B8D59E231C479C7E0"
      unitRef="usd">87852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3180-wk-Fact-9A5C6371E6031468D11AE231C47AF7B4"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember"
      decimals="-3"
      id="d277989623e3196-wk-Fact-F54BFDC980D5BF0F1055E231C47C590F"
      unitRef="usd">41183000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3215-wk-Fact-FCB02BEB9D68E26C893BE231C47CAC5E"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember"
      decimals="-3"
      id="d277989623e3230-wk-Fact-5F75F6508ACEC9A3399CE231C47931D5"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_AccredoHealthIncorporatedMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3250-wk-Fact-50841154615FBBE75C6AE231C47E2BDF"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember"
      decimals="-3"
      id="d277989623e3266-wk-Fact-2B4C7C20340050B93346E231C4798A49"
      unitRef="usd">27557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3285-wk-Fact-01BB6F26F2020D33DEF2E231C482FB29"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember"
      decimals="-3"
      id="d277989623e3300-wk-Fact-5640CFB40461EEA8B339E231C4842C7C"
      unitRef="usd">38622000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_DiplomatSpecialtyPharmacyMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3320-wk-Fact-CB524CBE94EEF1992562E231C47FFA4B"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d277989623e3336-wk-Fact-6792640A1121EED4CF6CE231C47CD6E3"
      unitRef="usd">171107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3355-wk-Fact-EA1E56DF5BBA5A0D535EE231C47B288F"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d277989623e3370-wk-Fact-69436EAADF65C283F15FE231C4818E80"
      unitRef="usd">105129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d277989623e3390-wk-Fact-1CD676CA77FA5D8D65DCE231C48074A3"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e3411-wk-Fact-31347911C2A9E3B534C9E231C4637FEC"
      unitRef="usd">455762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d277989623e3425-wk-Fact-D04FAB80235563ABDE76E231C479ECD0"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277989623e3445-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD"
      unitRef="usd">399827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q2DEC30-JUN29_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d277989623e3460-wk-Fact-E13E55FFC4A7F834CD5FE231C47C072F"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d277989623e3673-wk-Fact-35F36E66CF0D32964AE2E231C4846A29"
      unitRef="usd">196347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d277989623e3692-wk-Fact-703C6EC79C6E8A83DE7BE231C4865EE1"
      unitRef="usd">150079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d277989623e3711-wk-Fact-CED8F937ADCF8805DB5DE231C481A282"
      unitRef="usd">378473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d277989623e3731-wk-Fact-D820511486075A722FD7E231C47F8E4F"
      unitRef="usd">287072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d277989623e3746-wk-Fact-A3B43BC5D2B03835563BE231C4805E25"
      unitRef="usd">22249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d277989623e3765-wk-Fact-22DA57CC6DFB841D0AE9E231C481E7F0"
      unitRef="usd">34043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d277989623e3784-wk-Fact-B069417F60DE284B3364E231C4833196"
      unitRef="usd">44117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d277989623e3804-wk-Fact-307FB6D66985F828E47EE231C481AA4D"
      unitRef="usd">87852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d277989623e3824-wk-Fact-6552DFDFD9CC8C3E32F4E231C485B1DD"
      unitRef="usd">21679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d277989623e3843-wk-Fact-406160131F10E4357CE6E231C4817931"
      unitRef="usd">1986000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d277989623e3862-wk-Fact-4A720B4BFE2FBAE8B398E231C47F5AAA"
      unitRef="usd">33172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d277989623e3882-wk-Fact-399D1E1AF393F1A4A28FE231C480FBE2"
      unitRef="usd">24903000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d277989623e3907-wk-Fact-B3CC8807AB404D342EB0E231C47AC8D0"
      unitRef="usd">240275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d277989623e3926-wk-Fact-24161066F0F7476E837BE231C4A56D73"
      unitRef="usd">186108000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e3945-wk-Fact-31347911C2A9E3B534C9E231C4637FEC"
      unitRef="usd">455762000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d277989623e3965-wk-Fact-6C840F4B53D29F5C45D6E231C4AD3BFD"
      unitRef="usd">399827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F25F426A0670F25170EBE231C4C9B329-0-wk-Fact-BA702A9DBF4CA0B3E02CE231C4A24CD6">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;58,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;24,681&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;91,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(57,367&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(7,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(22,160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(87,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,319&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d277989623e4117-wk-Fact-7AEBC825E95DE0655563E231C4641AA9"
      unitRef="usd">2322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d277989623e4136-wk-Fact-7FE8E294C8389EF1FAA2E231C46150C2"
      unitRef="usd">3038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d277989623e4155-wk-Fact-A329B4C24CD91985412DE231C467768F"
      unitRef="usd">11916000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277989623e4175-wk-Fact-3D191EA67C7879CDB0A7E231C4674CB8"
      unitRef="usd">17276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d277989623e4272-wk-Fact-C6236B350E4BA3840495E231C45F44F5"
      unitRef="usd">58862000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d277989623e4291-wk-Fact-216EAF89268918E89908E231C46562A0"
      unitRef="usd">7695000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d277989623e4310-wk-Fact-AD3AB550ED5E4EAAE525E231C460BE25"
      unitRef="usd">24681000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4330-wk-Fact-4356F5FEBBF9C9D62903E231C465CE1E"
      unitRef="usd">91238000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d277989623e4350-wk-Fact-E236EE14B67B3004949FE231C462C330"
      unitRef="usd">-102000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d277989623e4370-wk-Fact-02A785D5C81A58E373D5E231C46005B1"
      unitRef="usd">-106000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d277989623e4390-wk-Fact-20F1CC2CAD58ABA4AB24E231C46172E2"
      unitRef="usd">-118000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4411-wk-Fact-9E3ADE1FEBD38EE39E0FE231C463391D"
      unitRef="usd">-326000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d277989623e4432-wk-Fact-6DAD4C2DFFED0186D3E3E231C467732E"
      unitRef="usd">57367000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d277989623e4452-wk-Fact-B6B6CEE2C931AFB616C9E231C46835EF"
      unitRef="usd">7673000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q2YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d277989623e4472-wk-Fact-55F2223A29057A73D095E231C46429FC"
      unitRef="usd">22160000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4493-wk-Fact-BE6984B99817636EA971E231C462AD6C"
      unitRef="usd">87200000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d277989623e4519-wk-Fact-645EFC9DE5926A7491DFE231C463BFEE"
      unitRef="usd">3715000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d277989623e4538-wk-Fact-03718AF21872E6FBBC41E231C466B169"
      unitRef="usd">2954000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d277989623e4557-wk-Fact-7A07293D9F0CBCA010BEE231C4667562"
      unitRef="usd">14319000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277989623e4577-wk-Fact-D00B7B72D5D7D9F866CAE231C4684168"
      unitRef="usd">20988000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-54DB65108F633F2840FCE231C4C85AF2-0-wk-Fact-BC9447AF098DDE737A7DE231C4A4C365">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-24944439722AF98D3256E231C4C97ACC-0-wk-Fact-7136E5A2ADAD7328B431E231C4A34EA6">Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets: Unbilled Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Liabilities: Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Current Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Long-term Portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of a change in transaction price and recognition of revenues as services are performed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Transfer to receivables from contract assets recognized at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(947&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other adjustments &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d277989623e4810-wk-Fact-F4E012750659216D6F36E231C497E1D9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d277989623e4829-wk-Fact-F69BB2C8117D0C44D7A7E231C49C1BDA"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d277989623e4848-wk-Fact-D1F954611E49C807BFD9E231C499D22D"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member"
      decimals="-3"
      id="d277989623e4868-wk-Fact-DE122CBD38CBDDC50F9CE231C49AF7DC"
      unitRef="usd">15897000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4883-wk-Fact-D80E58F5941A852445B7E231C497D782"
      unitRef="usd">3097000</exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
    <exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4902-wk-Fact-98DD90A3C9943EEA3E98E231C4972966"
      unitRef="usd">1450000</exel:ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues>
    <us-gaap:ContractWithCustomerAssetReclassifiedToReceivable
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e4961-wk-Fact-B432973169983474B162E231C49BCBB2"
      unitRef="usd">947000</us-gaap:ContractWithCustomerAssetReclassifiedToReceivable>
    <exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5078-wk-Fact-113AA4F492D17A9BD3CEE231C49B605F"
      unitRef="usd">715000</exel:ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
    <exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5098-wk-Fact-F966E403D8DE77B7D974E231C498996E"
      unitRef="usd">5788000</exel:ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5156-wk-Fact-738329FF6306B4AA75E3E231C49991C1"
      unitRef="usd">1847000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <exel:ContractWithCustomerAssetCurrentOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5199-wk-Fact-196CC2331B3327BFC3A3E231C499DBF5"
      unitRef="usd">-2150000</exel:ContractWithCustomerAssetCurrentOtherAdjustments>
    <exel:ContractWithCustomerAssetNoncurrentOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5219-wk-Fact-42AE4BCF00D5FF14AD57E231C497A44F"
      unitRef="usd">-1450000</exel:ContractWithCustomerAssetNoncurrentOtherAdjustments>
    <exel:ContractWithCustomerLiabilityCurrentOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5239-wk-Fact-1CAB3171D614D1F02C12E231C49AA3AC"
      unitRef="usd">1453000</exel:ContractWithCustomerLiabilityCurrentOtherAdjustments>
    <exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d277989623e5259-wk-Fact-8AEB2BDA355F24762417E231C49AA849"
      unitRef="usd">-5053000</exel:ContractWithCustomerLiabilityNoncurrentOtherAdjustments>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277989623e5285-wk-Fact-2B10E90F4701572B56C0E231C4986D46"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277989623e5304-wk-Fact-0D95C6D7BFF19828D276E231C497F81E"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277989623e5323-wk-Fact-D0A13340B1628806C194E231C4861769"
      unitRef="usd">321000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277989623e5343-wk-Fact-229DE50DEF12B74C475CE231C49D47E0"
      unitRef="usd">16632000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2QTD"
      decimals="-5"
      id="d277989623e5378-wk-Fact-BCB3C5834D3F231A5689E231C4A4F8F4"
      unitRef="usd">36100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d277989623e5382-wk-Fact-6143F9A7CE9B262EA2AD274349A40E7B"
      unitRef="usd">61400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="D2018Q2Q2QTD"
      decimals="-5"
      id="d277989623e5386-wk-Fact-F9E5793A3C1A0A5F0B26274373A40E8D"
      unitRef="usd">32200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-5"
      id="d277989623e5391-wk-Fact-D9F8F70BAB01637BE558E231C4A5815F"
      unitRef="usd">103800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8A7D7923DC64D32DCD0BE231C4C9A18E-0-wk-Fact-099FEDDC5B5629787C94E231C4B6DACD">COLLABORATION AGREEMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Daiichi Sankyo &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for a description of each of our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 2. Revenues&#x201d; for information on collaboration revenues recognized during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cabozantinib&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;Commercial &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$47.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Ipsen was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was included in the Current portion of deferred revenue and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;RCC&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, first-line RCC and second-line HCC by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$102.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, including an increase from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (MHLW)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#x2019;s total potential commercial milestones by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$89.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$19.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Takeda was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&#160;November&#160;2015, the U.S. Food and Drug Administration approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Daiichi Sankyo&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019, Daiichi Sankyo had its first commercial sale of MINNEBRO&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the launch,&#160;we&#160;received a&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;milestone payment from Daiichi Sankyo in June 2019. We are &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;0.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Ligand on net sales of MINNEBRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Iconic Therapeutics, Inc. (Iconic) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2019, we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#x2019;s lead oncology &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;antibody-drug conjugate&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; program, in exchange for an upfront payment to Iconic of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and a commitment for preclinical development funding. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we accrued &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$5.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the preclinical development funding commitment. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in the accompanying Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If we exercise the option, we&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; would be required make an option exercise fee payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$190.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential development, regulatory and first-sale milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$262.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties accruing to GSK were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d277991397e643-wk-Fact-1A88CC7AF6DC5D95A713E231C454F9EE"
      unitRef="usd">22249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d277991397e662-wk-Fact-BB674E2970767E389705E231C4532148"
      unitRef="usd">34043000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d277991397e681-wk-Fact-531F2C0C9B39C594BF46E231C453E443"
      unitRef="usd">44117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d277991397e701-wk-Fact-831EF5E3B803D1C77E26E231C45369F7"
      unitRef="usd">87852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d277991397e718-wk-Fact-C3F7BE21593F56206F90E231C4B3C8BE"
      unitRef="usd">47500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d277991397e726-wk-Fact-F08A770DB2DCE20F3C7BE231C4B74419"
      unitRef="usd">8400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d277991397e730-wk-Fact-5E1972C2611F9D180302E231C4B2010A"
      unitRef="usd">300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d277991397e735-wk-Fact-F4BDA5807FE65B0096A4E231C4B102EC"
      unitRef="usd">8100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <exel:CollaborativeArrangementAnnualReimbursementLimit
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e755-wk-Fact-66B92E6DBD76F3E215552EACD154F287"
      unitRef="usd">1000000.0</exel:CollaborativeArrangementAnnualReimbursementLimit>
    <exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e763-wk-Fact-3480C8E053911811DA21E231C4B60265"
      unitRef="usd">12000000.0</exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e767-wk-Fact-A50BD5E00653121AC409E231C4B169A1"
      unitRef="usd">102000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborationAgreementMilestonePaymentsEarned
      contextRef="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e771-wk-Fact-8465742988CC5467ECC1E231C4B7FE78"
      unitRef="usd">10000000.0</exel:CollaborationAgreementMilestonePaymentsEarned>
    <exel:CollaborationAgreementMilestonePaymentsEarned
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e776-wk-Fact-22645B6969C954591600E231C4B30668"
      unitRef="usd">16000000.0</exel:CollaborationAgreementMilestonePaymentsEarned>
    <exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e784-wk-Fact-690B40F989C1693EEEE5E231C4B5DF97"
      unitRef="usd">6000000.0</exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e788-wk-Fact-9B86E2CF72E10958E41BE231C4B434E4"
      unitRef="usd">89000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d277991397e999-wk-Fact-C747874DFD98BAF6A788E231C456A3EA"
      unitRef="usd">1565000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d277991397e1018-wk-Fact-9F85AF43A7B48A80A1F7E231C4565ABD"
      unitRef="usd">1986000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d277991397e1037-wk-Fact-333CEAEE5D6DD21D5C12E231C4567E89"
      unitRef="usd">13058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d277991397e1057-wk-Fact-DA34AB0F74679B5F5B82E231C4554C7A"
      unitRef="usd">4903000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e1074-wk-Fact-8CC11815B0CC1248E6A6E231C4B889E1"
      unitRef="usd">19200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d277991397e1088-wk-Fact-081E08A4CCD8A362F8AD2EADFA692F0D"
      unitRef="usd">8500000</us-gaap:ContractWithCustomerLiability>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1310-wk-Fact-0AA25D72FCEBA4F029AEE231C49C7BAE"
      unitRef="usd">1349000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1329-wk-Fact-3421BE323DF468DB2471E231C49B893C"
      unitRef="usd">2696000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1348-wk-Fact-9722E09BE0045C3AA74EE231C499F58F"
      unitRef="usd">2404000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1368-wk-Fact-95DA52DFA503C4041901E231C49A1A72"
      unitRef="usd">4069000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1388-wk-Fact-0EC7431636F1C783BDC127525A3C6CAD"
      unitRef="usd">1323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1407-wk-Fact-F6380618914F424831FFE231C49C883C"
      unitRef="usd">1546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1426-wk-Fact-31D5EA177B1D875E2811E231C4990094"
      unitRef="usd">2813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d277991397e1446-wk-Fact-6E0187E31047D2B20829E231C4993FBD"
      unitRef="usd">2895000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q2Jun01-Jun28_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-5"
      id="d277991397e1473-wk-Fact-056DBCEDFB043F06B1F42ED8F7E3386B"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="3"
      id="d277991397e1479-wk-Fact-33613171D04D5FDF62E42ED0294C8E06"
      unitRef="number">0.005</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d277991397e1688-wk-Fact-5E6B182861EA889A8ED92752ABC08CA1"
      unitRef="usd">20114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d277991397e1707-wk-Fact-D7EEA4DE798749BB26E32752AE335343"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d277991397e1726-wk-Fact-D234831B908731F8F704F32EE1593E85"
      unitRef="usd">20114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d277991397e1746-wk-Fact-D7A9C06F4456442392E9F32EE1467880"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d277991397e1766-wk-Fact-2E37B4D04AFCA13ED98B2EE65BA296FC"
      unitRef="usd">7500000</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d277991397e1774-wk-Fact-32FCFF1BECA85D57FD752F01089D104B"
      unitRef="usd">5100000</exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d277991397e1794-wk-Fact-05D8B79CBA0FACD00FD72EF6ECD503ED"
      unitRef="usd">20000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d277991397e1798-wk-Fact-B430E7C65785AF5809AA2EEF061A6350"
      unitRef="usd">190600000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d277991397e1802-wk-Fact-6A04EE4804E34312E8532EEF05FBB83C"
      unitRef="usd">262500000</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q2YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="2"
      id="d277991397e1812-wk-Fact-86FEAADED3B607A95BA5E231C4A32505"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1517E0343D8A60C7F082E231C4CA82E2-0-wk-Fact-F1FF0D1C7692038E9401E231C4B2D0F8">Such royalties accruing to GSK were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44,117&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,349&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,404&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,069&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,813&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,986&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,903&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d277991397e2019-wk-Fact-B4A17CF6C987F1A48370F330AE9B3DF0"
      unitRef="usd">7833000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2018Q2Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d277991397e2038-wk-Fact-EAAF1E1E7E8723681973F330AE92AEA8"
      unitRef="usd">5628000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d277991397e2057-wk-Fact-5EF1252E9B5EFAA86DCDF330AE8C040B"
      unitRef="usd">15115000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2018Q2DEC30-JUN29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d277991397e2077-wk-Fact-AC87DC1216A36DE9A52BF330AE88281C"
      unitRef="usd">10753000</us-gaap:RoyaltyExpense>
    <exel:CashCashEquivalentsAndInvestmentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FCA54E4024E12BF80D48E231C4CB74DE-0-wk-Fact-97C6C6A253AB5B407FD2E231C44A9641">CASH AND INVESTMENTS &lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;369,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;248,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;370,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;250,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;559,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,132,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,157,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,161,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nominal&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;809,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;674,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;326,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the most recent date for which they reported ownership data, their beneficial ownership was more than &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, the fair value of cash and investments managed by BlackRock was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$421.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$298.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; invested in the BlackRock Liquidity Money Market Fund. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We incurred &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in fees for BlackRock advisory services performed during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-7FC8C77291367FD67D87E231C4CA3CD1-0-wk-Fact-4AFBBA5E49FEACC14FBBE231C448A228">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;369,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;248,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;370,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;250,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-878B317CB1A4EB1FB79CE231C4CBA20A-0-wk-Fact-B6B2428D86F15F0D3CAEE231C4321A61">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;369,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;248,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;370,889&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;250,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e531-wk-Fact-93396699141361E328C7E231C47489B6"
      unitRef="usd">369789000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277995911e569-wk-Fact-5DD0B6131A23A5F2B474E341854249EC"
      unitRef="usd">248407000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277995911e589-wk-Fact-973E360317E74E5D2298E231C45FDF7E"
      unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e604-wk-Fact-134AE5685C003C0F4FF6E231C45DB785"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277995911e642-wk-Fact-CCE739A2751E0ECED40FE231C459C584"
      unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277995911e662-wk-Fact-4398D6AD1407D04A5F12E231C45B3F68"
      unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e682-wk-Fact-11BD26FD71BDB949C36BE231C48D8C87"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277995911e720-wk-Fact-9D7CCCFDD5B3200F0DC244AD5DF418FE"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277995911e740-wk-Fact-4D15D742437BC8EC8AD3E231C45E08E7"
      unitRef="usd">4646000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e765-wk-Fact-89C66780BE1D0B94DA83E231C4B3ADCA"
      unitRef="usd">370889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e784-wk-Fact-0EE8CC5629FA14CBB5A7E231C4A3D199"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q2"
      decimals="-3"
      id="d277995911e803-wk-Fact-38A5D9EB56083282C921E231C4B09545"
      unitRef="usd">250011000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d277995911e823-wk-Fact-1FA1A8CFE095CE90F68DE231C4A3FC97"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-784F93B75A16EA0B775DE231C4CBB85D-0-wk-Fact-4FFA9BDE71685CCCD9A8E231C44AAFE0">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;559,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,132,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,157,987&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,161,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e1148-wk-Fact-D9C48B4924B1AB2A673AE231C43425FD"
      unitRef="usd">54457000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e1167-wk-Fact-117EB7B9223FF451F795E231C4383031"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e1186-wk-Fact-C029A7C99051712220B3E231C449E1C2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e1206-wk-Fact-CB5837AB8FA4DEA7CAA3E231C437CF31"
      unitRef="usd">54457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e1221-wk-Fact-BC57072FAFA2435D0CCBE231C43428C4"
      unitRef="usd">406238000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e1240-wk-Fact-7814E4131E367D9075C8E231C44BC811"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e1259-wk-Fact-8F25ECD991D6964A3188E231C4364A19"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e1279-wk-Fact-B880C2E9A91F61A58ACCE231C439A09B"
      unitRef="usd">406238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e1299-wk-Fact-1CF9E933DA299C13C0EDE231C44A8918"
      unitRef="usd">559906000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e1318-wk-Fact-8367B973C8B498498FFCE231C4492861"
      unitRef="usd">2885000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e1337-wk-Fact-C101F2957AFA878715D5E231C44BA26D"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e1358-wk-Fact-2462EE6DAC9FDB22C840E231C43978AE"
      unitRef="usd">562750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e1378-wk-Fact-1DC82FC977FA62BD7120E231C4334EF7"
      unitRef="usd">112083000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e1397-wk-Fact-D05967463B615A72CFB2E231C437EDCA"
      unitRef="usd">171000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e1416-wk-Fact-0068C33615B4F9822BCCE231C4326E66"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e1436-wk-Fact-6C950D42F5E63AD96E98E231C433F57A"
      unitRef="usd">112254000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1456-wk-Fact-8941229AFE9612451712E231C4362E36"
      unitRef="usd">1132684000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1475-wk-Fact-57637833082E132907BBE231C44BC47C"
      unitRef="usd">3056000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1494-wk-Fact-034CE73C8E56523A879BE231C44906D9"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1515-wk-Fact-2B58AC1634D39FDE8E9AE231C43AA299"
      unitRef="usd">1135699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e1535-wk-Fact-1CFF43F3E0DC9F878971E231C4334670"
      unitRef="usd">2311000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e1554-wk-Fact-0544650E1157D8A006B4E231C437B6D9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e1573-wk-Fact-E163BEF72D26798C4022E231C43573FE"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e1593-wk-Fact-B533B0E51A1C394B0EABE231C433660A"
      unitRef="usd">2311000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e1613-wk-Fact-F056DF24C38295109F88E231C44A2486"
      unitRef="usd">22992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e1632-wk-Fact-EA21576A79C2E6A6C865E231C44BE8B5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e1651-wk-Fact-EFCC8696160B851472A2E231C4388BC0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e1671-wk-Fact-AFF7DEC4A3C4CCBFE3D5E231C435E70E"
      unitRef="usd">22992000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1696-wk-Fact-FD7F0A41BD3898645A9BE231C4358271"
      unitRef="usd">1157987000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1715-wk-Fact-57637833082E132907BBE231C44BC47C"
      unitRef="usd">3056000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1734-wk-Fact-034CE73C8E56523A879BE231C44906D9"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e1755-wk-Fact-236D729C994B50E7FBCEE231C4378046"
      unitRef="usd">1161002000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e2061-wk-Fact-303D69D2AA3E42F6C863E231C47EE562"
      unitRef="usd">47744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e2080-wk-Fact-9AB781898E05A8C67098E231C47D28F0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e2099-wk-Fact-C32488F7ABCC16B71B21E231C483A006"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d277995911e2119-wk-Fact-CD3B5C3B10BA188150DAE231C485ACDA"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e2134-wk-Fact-65D4E216FBD137762BF1E231C485DCD6"
      unitRef="usd">381134000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e2153-wk-Fact-02BB322DB4B7506DAC94E231C47ECE14"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e2172-wk-Fact-A69AD4B080703095A9EEE231C487D744"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e2193-wk-Fact-BA10D4EE06E8C658B6DFE231C4889D91"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e2213-wk-Fact-2E24144B1A6CD69043FAE231C487819B"
      unitRef="usd">344741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e2232-wk-Fact-76D3A6AEE4F503860490E231C4792325"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e2251-wk-Fact-4A3726D9E0C11E05D26FE231C47B1957"
      unitRef="usd">857000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e2272-wk-Fact-F7192DB4AC761A1CB8E6E231C488B95B"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e2292-wk-Fact-ED2F58A55ABEFC184A52E231C4874329"
      unitRef="usd">55224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e2311-wk-Fact-28555D06026BA406D01BE231C4875721"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e2330-wk-Fact-7D1C803429E17928F360E231C47B7505"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e2351-wk-Fact-97A7063282AE06C0D536E231C4788A7D"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2371-wk-Fact-0A142BA40894D3EA395AE231C4873701"
      unitRef="usd">828843000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2390-wk-Fact-11D96E0E938933BE1687E231C47CBE09"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2409-wk-Fact-D73F9845EC969D187C27E231C4879DFF"
      unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2430-wk-Fact-A087C9E3ACF4CC180813E231C43A8A0A"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e2450-wk-Fact-43436FB2AB0D50C049ADE231C487F780"
      unitRef="usd">6883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e2469-wk-Fact-96E230AD2FAD569AF610E231C4860645"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e2488-wk-Fact-0E322AEC2F0FB758FCB0E231C47C69FD"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d277995911e2508-wk-Fact-EABB322C4275D74B56ECE231C47EFC3D"
      unitRef="usd">6883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e2528-wk-Fact-64077D42E3729B6DAA77E231C47A3BB5"
      unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e2547-wk-Fact-AB56FA9DE74770B35C4AE231C487153A"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e2566-wk-Fact-1EE6E64752E6B3FCA7CDE231C478F6BF"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d277995911e2586-wk-Fact-A0BE34E589B28309345FE231C4893076"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2611-wk-Fact-6D780552FB3ED54E4646E231C48980E9"
      unitRef="usd">852322000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2630-wk-Fact-11D96E0E938933BE1687E231C47CBE09"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2649-wk-Fact-D73F9845EC969D187C27E231C4879DFF"
      unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e2670-wk-Fact-F503D333C4C07251B853E231C48937E4"
      unitRef="usd">851621000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-87C7FAE300BC4F31E0D6E231C4CA4311-0-wk-Fact-FD9F95260D6295BB3E8EE231C4490918">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3120-wk-Fact-70F856DD8883CD40F468E231C4B00959"
      unitRef="usd">33571000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3139-wk-Fact-AC971774632C0847BC35E231C4AEDEA8"
      unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3159-wk-Fact-1E6B7227F49810D850E4E231C4AF712A"
      unitRef="usd">23738000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3179-wk-Fact-9E44E7509A4657D25283E231C4B1CF12"
      unitRef="usd">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3199-wk-Fact-35ACA5A1FEAB69C0EB61E231C4AEAFF8"
      unitRef="usd">57309000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3219-wk-Fact-A6B43A08E7B4B3ADFB69E231C4B122F3"
      unitRef="usd">41000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3240-wk-Fact-9E21DE6EF4972E3288E4E231C4AEBB41"
      unitRef="usd">33571000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3259-wk-Fact-FCD479864035C31E9593E231C4AB0E2E"
      unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3279-wk-Fact-80ED2C3B74D25182C0FEE231C4B18B1D"
      unitRef="usd">23738000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3299-wk-Fact-040C5601A192E764B088E231C4ABDEEB"
      unitRef="usd">27000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3319-wk-Fact-1A3376D0B6F1C7664BCAE231C4AD98E6"
      unitRef="usd">57309000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e3339-wk-Fact-4C749623FD9FBC647DF4E231C4AA8A42"
      unitRef="usd">41000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3760-wk-Fact-1C36707CBAB6B7341400E231C45BDA06"
      unitRef="usd">236162000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3779-wk-Fact-357AA8B17D7D0A4AE7F2E231C45E9B55"
      unitRef="usd">606000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3799-wk-Fact-E15BA8442F5CC8A1FF4DE231C46122A0"
      unitRef="usd">39627000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3819-wk-Fact-A0AA51A6087BEA1A8DEAE231C45B3C00"
      unitRef="usd">251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3839-wk-Fact-008C49C27E9D0165C03DE231C4586909"
      unitRef="usd">275789000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d277995911e3859-wk-Fact-A1F0579208619D06A5F0E231C4603793"
      unitRef="usd">857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3875-wk-Fact-11AECDDC32AA5183FB5BE231C4592870"
      unitRef="usd">28105000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3894-wk-Fact-7D88FC31388F881F47C2E231C45EAE8E"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3914-wk-Fact-944B1D459B1EA77B439AE231C45F578D"
      unitRef="usd">9182000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3934-wk-Fact-B07EB165477344568DBAE231C461C787"
      unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3954-wk-Fact-DEF897441BF4E9524549E231C45F4B1E"
      unitRef="usd">37287000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d277995911e3973-wk-Fact-D1492182DD70D20655EAE231C4616404"
      unitRef="usd">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e3995-wk-Fact-1119EC40AEE1CB2F941BE231C45EE594"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e4014-wk-Fact-9288ABA2934B4189F0A6E231C4623448"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e4034-wk-Fact-3753CFA08E3A57373195E231C45A2DA7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e4054-wk-Fact-7C56793421933A30992FE231C45BD33C"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e4073-wk-Fact-69C6154371085BCA9209E231C46022ED"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d277995911e4092-wk-Fact-352F1F1CF33446172BB9E231C46017D4"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4119-wk-Fact-6B4BCEEE64C87FE8511EE231C45C0425"
      unitRef="usd">271358000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4138-wk-Fact-7662B94A9B953BF09306E231C45C4AA2"
      unitRef="usd">623000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4158-wk-Fact-FC72BE3DD418B26CABB9E231C4608EAC"
      unitRef="usd">48809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4178-wk-Fact-F12299F25EC6A899BAF0E231C45DE73A"
      unitRef="usd">260000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4198-wk-Fact-8C5983C2FB3FEFC61EC0E231C45A5E0B"
      unitRef="usd">320167000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4218-wk-Fact-BC0EC3A0880C83C68A85E231C45E8142"
      unitRef="usd">883000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2019Q2"
      decimals="INF"
      id="d277995911e4233-wk-Fact-EC9018E6CCF8FD50CD71E231C44A6631"
      unitRef="investment">42</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2018Q4"
      decimals="INF"
      id="d277995911e4237-wk-Fact-F6D45A2F96EBDA8E9F82E231C448BA3F"
      unitRef="investment">199</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="D2018Q2DEC30-JUN29"
      decimals="INF"
      id="d277995911e4262-wk-Fact-5BBB5694A53AC024DEA4E231C44083CB"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-263BC9010CCC49BF8283E231C4CBC43E-0-wk-Fact-25AED417852870F3B9C7E231C4491FB1">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;809,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;674,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;326,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e4376-wk-Fact-10813411E74ED0F287CAE231C43A19D9"
      unitRef="usd">809607000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4395-wk-Fact-60EB8B5F3BAB46E80BCCE231C43A7002"
      unitRef="usd">674455000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e4410-wk-Fact-62992509DAA73C163405E231C43A5DAF"
      unitRef="usd">326092000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4429-wk-Fact-4B178FE4AD65DDD05FB8E231C43A2F6D"
      unitRef="usd">153687000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277995911e4454-wk-Fact-2B58AC1634D39FDE8E9AE231C43AA299"
      unitRef="usd">1135699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277995911e4473-wk-Fact-A087C9E3ACF4CC180813E231C43A8A0A"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:OwnershipInterestByMinorityShareholder
      contextRef="FI2018Q4"
      decimals="2"
      id="d277995911e4493-wk-Fact-9DF9C91D30B7C106CD20E231C44B5AB0"
      unitRef="number">0.10</exel:OwnershipInterestByMinorityShareholder>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner
      contextRef="FI2019Q2"
      decimals="-5"
      id="d277995911e4507-wk-Fact-5E8C015B16191AD8C961E231C449C5DC"
      unitRef="usd">421000000.0</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner
      contextRef="FI2018Q4"
      decimals="-5"
      id="d277995911e4512-wk-Fact-074F17778E76307D4C4CE231C433645A"
      unitRef="usd">298500000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund
      contextRef="FI2019Q2"
      decimals="-5"
      id="d277995911e4516-wk-Fact-FBE59881D9D2FE3C13EFE231C432A315"
      unitRef="usd">300000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund
      contextRef="FI2018Q4"
      decimals="-5"
      id="d277995911e4520-wk-Fact-19FDE63016ADA876D6F6E231C43202C6"
      unitRef="usd">3000000.0</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
    <exel:RelatedPartyTransactionsAdvisoryFeesIncurred
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d277995911e4526-wk-Fact-D6AB157C99EF319A76C6E231C44AB857"
      unitRef="usd">100000</exel:RelatedPartyTransactionsAdvisoryFeesIncurred>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F3CEDD974D983EEA914EE231C4CBFFE3-0-wk-Fact-DCA448A7C0E9A6CC876FE231C44A3280">INVENTORY&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, also a portion of our work in process.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-91AC9DCA57B9F9F42A19E231C4CB31D4-0-wk-Fact-283F75870D397E2A296EE231C4911BAB">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,482&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,352&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,683&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277996608e487-wk-Fact-8C75851FE71B04E79B44E231C457E34B"
      unitRef="usd">2482000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277996608e506-wk-Fact-12C7BD771E93FE7FEEF8E231C4558E4E"
      unitRef="usd">1922000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277996608e521-wk-Fact-F6A970B84DDDBEF7EBC9E231C4585014"
      unitRef="usd">8571000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277996608e540-wk-Fact-C17ABAB904592C6D5A0BE231C456CF81"
      unitRef="usd">6170000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277996608e560-wk-Fact-E0892DCE1551B21EE894E231C4576EE4"
      unitRef="usd">6630000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277996608e579-wk-Fact-F134151AF8A962C27B3EE231C4580321"
      unitRef="usd">3836000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277996608e604-wk-Fact-1EE216D5D4B7E09BF2F5E231C4559BF1"
      unitRef="usd">17683000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277996608e623-wk-Fact-CA0443CA65E6511AEAFAE231C459773C"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d277996608e725-wk-Fact-3CB44351BF4417904778E231C457387A"
      unitRef="usd">12352000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d277996608e744-wk-Fact-76F1F14D8B50B16A126BE231C4581E2B"
      unitRef="usd">9838000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q2_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d277996608e759-wk-Fact-3FD6035FFD8040631C67E231C459D143"
      unitRef="usd">5331000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d277996608e778-wk-Fact-A3E09F95634407DB126EE231C4565BD9"
      unitRef="usd">2090000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277996608e803-wk-Fact-1EE216D5D4B7E09BF2F5E231C4559BF1"
      unitRef="usd">17683000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277996608e822-wk-Fact-CA0443CA65E6511AEAFAE231C459773C"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d277996608e836-wk-Fact-3D61EC933CE5AE9C5490E231C4457048"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-5"
      id="d277996608e840-wk-Fact-6DC60CC23CC71642E48DE231C43D676C"
      unitRef="usd">500000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-F5E9C66F555B02F08025E231C4CBAA0D-0-wk-Fact-A3F84486C4E0626739E3E231C4901542">PROPERTY AND EQUIPMENT &lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$4.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-D5CC73BD109BA90A6BD3E231C4CC3296-0-wk-Fact-8F4C7734F431444E9B68E231C48F921E">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,050&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(21,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d277997082e474-wk-Fact-A1E0E0D4CAF85E8DF750E231C448EFDD"
      unitRef="usd">33691000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d277997082e493-wk-Fact-36821607730EB879C09CE231C489E0E1"
      unitRef="usd">33941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d277997082e508-wk-Fact-FEA7491BA66443BC63F5E231C48AF712"
      unitRef="usd">16050000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d277997082e527-wk-Fact-4E67A768BE1578D4D43DE231C448A49C"
      unitRef="usd">15022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d277997082e547-wk-Fact-0A91621C19999EEC99A4E231C4490F37"
      unitRef="usd">13053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d277997082e566-wk-Fact-1BD6006712553038A4EAE231C48961A4"
      unitRef="usd">12709000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d277997082e586-wk-Fact-DBCCD29FD159E8A56F1BE231C44BFB96"
      unitRef="usd">7291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d277997082e605-wk-Fact-E2ED95E3F654C2328C26E231C47407CF"
      unitRef="usd">5668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d277997082e625-wk-Fact-3DEB8B5EDA5D6CE3824AE231C47464B6"
      unitRef="usd">1931000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d277997082e644-wk-Fact-7E706F6BBD5E87A29654E231C48A8250"
      unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277997082e664-wk-Fact-183A98C0C7686EC49038E231C4760EA3"
      unitRef="usd">72016000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277997082e683-wk-Fact-212486D8A46E379A8997E231C44C1495"
      unitRef="usd">68206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277997082e703-wk-Fact-19354D91B2B4A3CB10F1E231C448F30B"
      unitRef="usd">21307000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277997082e723-wk-Fact-2A4AA32A6F3DD1397D5FE231C44DF290"
      unitRef="usd">17309000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q2"
      decimals="-3"
      id="d277997082e749-wk-Fact-BDAF3FADB3E4FBED7CE7E231C46AAA2F"
      unitRef="usd">50709000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d277997082e783-wk-Fact-88772D325A59ABEAF1ACE231C49035CC"
      unitRef="usd">4000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-5"
      id="d277997082e787-wk-Fact-8FDC3C0404006B1A6524E231C4937A0C"
      unitRef="usd">1200000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1BE84FCCCC841B6CF871E231C4CC3269-0-wk-Fact-3095418B05EB840A8469E231C445D25B">STOCK-BASED COMPENSATION&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;14,044,367&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;801,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,147,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(88,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(29,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,210,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;258,157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,670,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;237,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$42.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;2.4 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for RSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;272,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(366,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(180,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,583,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During 2018, in connection with our long-term incentive compensation program, we awarded &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;693,131&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;target&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; is probable. During the quarter ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we had achieved one of the two &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;product revenue related &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;targets&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;114,843&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the PSUs and determined that it was probable that we would achieve the second of the two &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;product revenue related &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;targets&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;172,272&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; additional PSUs. We expect those PSUs to vest over various dates through May 2021 and have recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in compensation expense related to those PSUs during the three months ended June 30, 2019; the remaining unrecognized compensation expense for those PSUs was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of June 30, 2019. The total unrecognized compensation expense for the remaining PSUs for which we have not yet determined that attainment of the performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;target&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; is probable was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$70.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2.6 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4F3139F794243CCAC862E231C4CCE61F-0-wk-Fact-EB6B80A617E6EA5DE947E231C444C976">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,608&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18,588&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d278000074e612-wk-Fact-87D20BE314E4D7AC7EA3E231C49DAE18"
      unitRef="usd">5138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d278000074e631-wk-Fact-9A000BE88A0D3FF54528E231C49B2130"
      unitRef="usd">2900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d278000074e650-wk-Fact-5CAC4178B10A55D2C586E231C49BEA15"
      unitRef="usd">9444000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d278000074e670-wk-Fact-4EE68556CE126ADD2D14E231C49A5D9D"
      unitRef="usd">5933000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d278000074e685-wk-Fact-89D624E0DD999605952EE231C49D79BE"
      unitRef="usd">9941000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d278000074e704-wk-Fact-1CBACE4A593E724B8C26E231C49DFDC1"
      unitRef="usd">6383000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d278000074e723-wk-Fact-4E03CE475BBA3DF993BCE231C49BE87F"
      unitRef="usd">18164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2DEC30-JUN29_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d278000074e743-wk-Fact-50C8A51BCC6FEE27139FE231C49B6550"
      unitRef="usd">12655000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278000074e768-wk-Fact-2BB3A5468F52B4A910AAE231C49C4408"
      unitRef="usd">15079000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278000074e787-wk-Fact-D93FCF4A7237CCEB7E67E231C49CB3D9"
      unitRef="usd">9283000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278000074e806-wk-Fact-772C7871B0C1807FE366E231C49A4744"
      unitRef="usd">27608000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278000074e826-wk-Fact-93947E35FBD2B63D0E1AE231C49CFED7"
      unitRef="usd">18588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q2"
      decimals="INF"
      id="d278000074e851-wk-Fact-A46B7427B3BD1C007F56E231C4452CB3"
      unitRef="shares">14044367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-B6F7A0885F8AB877F193E231C4CC5901-0-wk-Fact-2CC81F6D3A65D742AAAEE231C4474D13">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1066-wk-Fact-E20B5D4FE30CCE2E6AAAE231C4A2694D"
      unitRef="usdPerShare">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1085-wk-Fact-21620E5FE5F797F8A689E231C4AE297D"
      unitRef="usdPerShare">9.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1104-wk-Fact-286E264F9CFF542D35F5E231C4AE24C5"
      unitRef="usdPerShare">8.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1124-wk-Fact-8A88322AB5116561D61AE231C4AF4C65"
      unitRef="usdPerShare">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1144-wk-Fact-7D58E44BD9C48ED68702E231C4A174B6"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1163-wk-Fact-41A512D3C257FCF6F41FE231C4AF67DE"
      unitRef="usdPerShare">6.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1182-wk-Fact-F7A698FE3AAD9ECAA314E231C4AE8C6C"
      unitRef="usdPerShare">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1202-wk-Fact-F03E2009AEC694F83CBCE231C4A92845"
      unitRef="usdPerShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-C1B073AF8BC55492FC21E231C4CC0252-0-wk-Fact-52C5C7BCB80F6E6E130BE231C447140F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d278000074e1440-wk-Fact-6B611F7AAB3C67E67100E231C44E925E"
      unitRef="number">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d278000074e1455-wk-Fact-F354622E0F0E3C724631E231C4528FCE"
      unitRef="number">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d278000074e1470-wk-Fact-A86441104AC3A91E3ECDE231C47014CF"
      unitRef="number">0.0190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d278000074e1485-wk-Fact-D78521D257C4739929B2E231C44E100B"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1502-wk-Fact-19D17CA665687EFD3E98E231C44F1228"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1517-wk-Fact-AAA2513F46AE2D5DD314E231C44ED449"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1532-wk-Fact-AB630C28EE875B2B11A1E231C451C5B0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1547-wk-Fact-425542F444F8E7789D31E231C46D60F9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1564-wk-Fact-0F349268BF2CD4AE9D88E231C451C8CE"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1579-wk-Fact-0E2B706D13C8E4DEEB33E231C44EDE9A"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1594-wk-Fact-25CA6BC5612170F33038E231C454DFE3"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d278000074e1609-wk-Fact-EA6237C37F16FCAFBB62E231C44D0164"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d278000074e1626-wk-Fact-70F0B21289091F1FEF6DE231C44FEF91">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d278000074e1640-wk-Fact-1A411A9550315C3AEB13E231C44E08AA">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d278000074e1654-wk-Fact-13F509AAF389AB75533EE231C44F7EC4">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d278000074e1668-wk-Fact-4AA5A3D152F85FA9F7A4E231C46E5A3F">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d278000074e1746-wk-Fact-42301D3DED169A716BDDE231C44F23FC"
      unitRef="number">0.0230</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d278000074e1761-wk-Fact-5D921E51AA3E811084D7E231C451C9A6"
      unitRef="number">0.0180</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d278000074e1776-wk-Fact-FE707F219CAAC80815C3E231C44FAB59"
      unitRef="number">0.0241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d278000074e1791-wk-Fact-4A054F419F32C3CF7811E231C46BE4E9"
      unitRef="number">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1808-wk-Fact-C4693B72090D48503B46E231C45028B1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1823-wk-Fact-51641F4EC5958B351720E231C4724C8E"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1838-wk-Fact-0CF6BCD9E83905578DE3E231C4556A00"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1853-wk-Fact-13E09F8A97B243DAE36EE231C46EB5B3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1870-wk-Fact-D24F4EEC4B42BB04BE71E231C4717563"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1885-wk-Fact-096F4831D1F6BEAA37C8E231C46D2505"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1900-wk-Fact-9F41665F7DDECBCF8250E231C44E47EC"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d278000074e1915-wk-Fact-0B2CEEC6D5F3319A5DB4E231C458C139"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d278000074e1933-wk-Fact-BAF310754A23D8245117E231C456111F">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q2Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d278000074e1947-wk-Fact-8ADC82790CB3305F50E5E231C44CF094">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d278000074e1961-wk-Fact-E5D7E98C33DFE0260CABE231C46F0327">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d278000074e1975-wk-Fact-51623801595F537A3C19E231C4730901">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-45F6716A24E1F5F207B4E231C4CC535C-0-wk-Fact-D6CF94EA11E5B7170BDFE231C44CA963">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;801,166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,147,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(88,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(29,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21,210,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.5 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;258,157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,670,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;237,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d278000074e2143-wk-Fact-E39939E363B7326D35CEE231C49888E5"
      unitRef="shares">22674062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d278000074e2162-wk-Fact-059CD1191330DE3F63ADE231C498839C"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d278000074e2208-wk-Fact-F04C4525EF6E7B9D2C5EE231C4907D5F"
      unitRef="shares">801166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278000074e2227-wk-Fact-AA60E2718BCD1EE482CEE231C454ED2D"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d278000074e2273-wk-Fact-76749F4BB7FFE8ECD0BFE231C498DE70"
      unitRef="shares">2147426</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278000074e2293-wk-Fact-85696090A4541A58E07AE231C44C5169"
      unitRef="usdPerShare">4.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d278000074e2339-wk-Fact-898289C8B5A5455AB72CE231C453C5D8"
      unitRef="shares">88105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278000074e2359-wk-Fact-A0E5CA8BE0BAC376D373E231C493B30B"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2019Q2YTD"
      decimals="INF"
      id="d278000074e2405-wk-Fact-C1DD69BB09A33C37129CE231C450A3C0"
      unitRef="shares">29278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278000074e2425-wk-Fact-655702E1C8932A5AAE0FE231C4969369"
      unitRef="usdPerShare">22.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q2"
      decimals="INF"
      id="d278000074e2471-wk-Fact-2B79E8CC5AAA03C7EB0FE231C45565BD"
      unitRef="shares">21210419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q2"
      decimals="2"
      id="d278000074e2490-wk-Fact-9BA9979C1814B08F0F65E231C494B0D6"
      unitRef="usdPerShare">9.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q2YTD"
      id="d278000074e2504-wk-Fact-EE6358B80706502DE8ABE231C4942984">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278000074e2520-wk-Fact-87149AA680CBAE73D554E231C453AF8C"
      unitRef="usd">258157000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q2"
      decimals="INF"
      id="d278000074e2535-wk-Fact-80E48F3002FC5D28CB61E231C452D23F"
      unitRef="shares">15670941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q2"
      decimals="2"
      id="d278000074e2554-wk-Fact-5058D0319128ADCF6443E231C451B00C"
      unitRef="usdPerShare">6.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q2YTD"
      id="d278000074e2568-wk-Fact-8897C6A797E38A368BA6E231C455FDC9">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278000074e2584-wk-Fact-F5A5044B60C2634948E4E231C450D766"
      unitRef="usd">237737000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d278000074e2609-wk-Fact-A5818D7C749F644090E8E231C4438DB9"
      unitRef="usd">42600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d278000074e2613-wk-Fact-AE54A404DEAE7E7F7141E231C447F3E4">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-8B91FF3D83F1F965913BE231C4CC2A52-0-wk-Fact-B473D284144F7326BB8CE231C4414FDB">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for RSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;272,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;21.72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(366,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(180,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at June 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,583,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.7 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d278000074e2766-wk-Fact-B02F64CF7515DB342607E231C489BDDC"
      unitRef="shares">4857334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d278000074e2785-wk-Fact-3DA1A1FE47DE059028B6E231C48C7AAB"
      unitRef="usdPerShare">18.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d278000074e2831-wk-Fact-7BD077FEB57179677EB9E231C488C0C9"
      unitRef="shares">272660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d278000074e2850-wk-Fact-6EB2331E512B0344BB3DE231C48B4C68"
      unitRef="usdPerShare">21.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d278000074e2896-wk-Fact-0938AFB8A46508D204DCE231C48A1758"
      unitRef="shares">366489</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d278000074e2916-wk-Fact-BFC9D6DAE129076BABA5E231C489BA24"
      unitRef="usdPerShare">10.68</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d278000074e2962-wk-Fact-D79952FC2B351E5AB1C4E231C48B366F"
      unitRef="shares">180351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d278000074e2982-wk-Fact-55507C4FC752829EE531E231C488308A"
      unitRef="usdPerShare">18.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d278000074e3028-wk-Fact-8131A9C7B986BCFA2FD4E231C48B9551"
      unitRef="shares">4583154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d278000074e3047-wk-Fact-8A9F319968F9F0ACF398E231C48AFEDC"
      unitRef="usdPerShare">19.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d278000074e3061-wk-Fact-7F7441EDB50B869C8980E231C48AA4DA">P1Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d278000074e3077-wk-Fact-8813CD00F10855094F02E231C48BEE4E"
      unitRef="usd">97942000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d278000074e3096-wk-Fact-3C3D016B5B2916C2B060E231C443BADB"
      unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d278000074e3119-wk-Fact-12D9AC29F74A9354A01A2ECA679FA044"
      unitRef="shares">114843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d278000074e3131-wk-Fact-E2B129D1FE42629C57DC2ECC20615850"
      unitRef="shares">172272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q2QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d278000074e3135-wk-Fact-E8D2B4B85BE89EAC9071E231C443926F"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d278000074e3140-wk-Fact-67E92021BB320E0D9012E36C5DE05DD2"
      unitRef="usd">2700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q2_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d278000074e3148-wk-Fact-57AE0412ACC337BA16F0F34C97BB1FAE"
      unitRef="usd">7500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d278000074e3159-wk-Fact-27D864CFE60733EAB13AE231C4476C54"
      unitRef="usd">70300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d278000074e3163-wk-Fact-ED22E795FCBF3186D847E231C446FC8E">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-0F43422F7B238C52D72BE231C4CCBDC6-0-wk-Fact-E08BD04138491CCB2DEDE231C471BFA9">INCOME TAXES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our effective income tax rate was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;18.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, as compared &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;relating to our pre-tax income &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The effective tax rate for the&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt; differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2QTD"
      decimals="3"
      id="d277997145e404-wk-Fact-77CA44FB88D23B47FF7AE231C47233B0"
      unitRef="number">0.208</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q2YTD"
      decimals="3"
      id="d277997145e408-wk-Fact-53921B965D454C3D8491E231C475396E"
      unitRef="number">0.187</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D2018Q2Q2QTD"
      decimals="3"
      id="d277997145e422-wk-Fact-49E55CCA1AC79D6EB074E231C47280C5"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D2018Q2DEC30-JUN29"
      decimals="3"
      id="d277997145e427-wk-Fact-291EE21BBF87F95BA839E231C476A5BB"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-3F8F969F9FFE07B4B466E231C4CDA3F6-0-wk-Fact-BE2B2832CC5A947581CEE231C4B052F4">NET INCOME PER SHARE&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;203,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;296,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;313,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-9DD104F1C5667DC189DFE231C4CD34DB-0-wk-Fact-A9A90091A8B2E752A615E231C4B467EA">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;87,494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;154,817&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;203,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;302,188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;296,874&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,905&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;313,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278001369e693-wk-Fact-ACA33AEAAB4725288007E231C442BE5F"
      unitRef="usd">79042000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278001369e712-wk-Fact-5E1A832A75A8B0BA94A9E231C44635F4"
      unitRef="usd">87494000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278001369e731-wk-Fact-B80960B704D8361B606AE231C4A09B4D"
      unitRef="usd">154817000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278001369e751-wk-Fact-2A814F972C0BD074AFC1E231C43F3652"
      unitRef="usd">203351000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278001369e848-wk-Fact-4044463EA64232983585E231C4379D71"
      unitRef="shares">302188000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278001369e867-wk-Fact-266587292C7A6833D40AE231C433B369"
      unitRef="shares">297336000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278001369e886-wk-Fact-57892A0C65D150C9B129E231C48EA534"
      unitRef="shares">301365000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278001369e906-wk-Fact-29A95E9E14C8CF8203C4E231C4A9A235"
      unitRef="shares">296874000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278001369e926-wk-Fact-B5324BE960F58B8B7342E231C49DB0E1"
      unitRef="shares">12723000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278001369e945-wk-Fact-80117E5448CE95D0775AE231C4AAD3A1"
      unitRef="shares">14905000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278001369e964-wk-Fact-2DC97B0D90E6106E362DE231C4B97B22"
      unitRef="shares">13421000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278001369e984-wk-Fact-CD79A30A1804918C0230E231C45896E2"
      unitRef="shares">16150000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278001369e1004-wk-Fact-939D5E643961456211DFE231C4B20A6E"
      unitRef="shares">314911000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278001369e1023-wk-Fact-9C5B62466C75220A7FA3E231C47AF2DA"
      unitRef="shares">312241000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278001369e1042-wk-Fact-461891499FE2723E9818E231C44E4D54"
      unitRef="shares">314786000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278001369e1062-wk-Fact-20D4CCDAE0A8ED18948DE231C435BB67"
      unitRef="shares">313024000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d278001369e1169-wk-Fact-4B26B5AB9595C15EACD3E231C452EDCE"
      unitRef="usdPerShare">0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q2Q2QTD"
      decimals="2"
      id="d278001369e1188-wk-Fact-F3A995FE72E51F9D3971E231C4A986C0"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278001369e1207-wk-Fact-9F4C610798472730DF9CE231C47B1AEF"
      unitRef="usdPerShare">0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q2DEC30-JUN29"
      decimals="2"
      id="d278001369e1227-wk-Fact-BB84C7A53A3F37741239E231C44DA175"
      unitRef="usdPerShare">0.68</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2QTD"
      decimals="2"
      id="d278001369e1247-wk-Fact-0299983057549E97DDBEE231C4A8C4BF"
      unitRef="usdPerShare">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q2Q2QTD"
      decimals="2"
      id="d278001369e1266-wk-Fact-D29BE3A6B68F7E6F3193E231C43E6608"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q2YTD"
      decimals="2"
      id="d278001369e1285-wk-Fact-E3AFB87B37B6205B4E96E231C4A21E71"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q2DEC30-JUN29"
      decimals="2"
      id="d278001369e1305-wk-Fact-43D96EC8BE7C5483B2A2E231C43B448B"
      unitRef="usdPerShare">0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-E92E60A82323CE137D28E231C4CDBE01-0-wk-Fact-95341AD2CEB6E8FEA5E1E231C49E5652">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d278001369e1488-wk-Fact-6BD1930805CF21AE3E4EE231C49FF758"
      unitRef="shares">5935000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2018Q2Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d278001369e1502-wk-Fact-CDAAE68C6F68356DE648E231C4B59544"
      unitRef="shares">5163000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q2YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d278001369e1516-wk-Fact-8B3AC51D933ED92BCD98E231C4A1F15D"
      unitRef="shares">5625000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2018Q2DEC30-JUN29_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d278001369e1530-wk-Fact-86159D2B7C15B05B40B0E231C49EA032"
      unitRef="shares">2606000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-FB343AB1A1429F391025E231C4CDAFE1-0-wk-Fact-F648FB816879BF255B60E231C433A6FF">FAIR VALUE MEASUREMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,081,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,104,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,158,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 11. Leases&#x201d; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-AA979453EFC3A55C4D5FE231C4CDE588-0-wk-Fact-7E72811EA780245AC2F4E231C49ED8D0">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;406,238&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;562,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;112,254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,081,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,135,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;54,457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,104,234&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,158,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e562-wk-Fact-F3E6B2671A09164C511CE231C48CB878"
      unitRef="usd">54457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e581-wk-Fact-E2B513E7CD39754084C6E231C4932D23"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e600-wk-Fact-7E6A8A2C18384EBAC909E231C4923BA5"
      unitRef="usd">54457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e616-wk-Fact-AD38B22DED4E87185DFEE231C48FF556"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e635-wk-Fact-CE49CA60F80FC86FCA2DE231C48E73BA"
      unitRef="usd">406238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e654-wk-Fact-5A3D8478A4A7589839B2E231C48E0FD1"
      unitRef="usd">406238000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e675-wk-Fact-4CBB7F015392519EB256E231C494731C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e694-wk-Fact-400FD381B9FC3986508CE231C4954722"
      unitRef="usd">562750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e713-wk-Fact-3911F2513ABA80A369F8E231C49289B8"
      unitRef="usd">562750000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e734-wk-Fact-46E31914309FD524C21FE231C48D6E51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e753-wk-Fact-E0540A5D72BFAF06211DE231C48C5068"
      unitRef="usd">112254000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e772-wk-Fact-B3CF3328E63852ACBC60E231C493316E"
      unitRef="usd">112254000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e793-wk-Fact-EA2CA2A643016AE1468EE231C48F8916"
      unitRef="usd">54457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e812-wk-Fact-9270E7C9885AF8FA6BA0E231C49668ED"
      unitRef="usd">1081242000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e831-wk-Fact-B9B6F1ACECA61AA97799E231C48DE323"
      unitRef="usd">1135699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e852-wk-Fact-702B26A9FEF55BF03899E231C499C6BC"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e871-wk-Fact-3648EC8F6F4C77FD09FEE231C48FB869"
      unitRef="usd">22992000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e890-wk-Fact-C3C80941E463CCB997F1E231C4951BB1"
      unitRef="usd">22992000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e916-wk-Fact-0BDAE211E0B951EE8E4CE231C4933D73"
      unitRef="usd">54457000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e935-wk-Fact-13246CE59A7C072CD560E231C48B7BF3"
      unitRef="usd">1104234000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e954-wk-Fact-652C0DEC91ED1E6908FBE231C495BF5A"
      unitRef="usd">1158691000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e1118-wk-Fact-D2201E726634895F1F6CE231C4B61A03"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e1137-wk-Fact-85A9C8BA3D5E5B373824E231C48DB126"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d278002751e1156-wk-Fact-F0372C860B57F3578F9CE231C4B94C60"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e1172-wk-Fact-ADFB4B5DF888A2B6F803E231C4513C37"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e1191-wk-Fact-3B39D55A911530F52220E231C4B71AB4"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d278002751e1210-wk-Fact-BDF3DDFE05B323F65D46E231C48BFE65"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e1231-wk-Fact-488FB4AFC4D268F9DC33E231C444215C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e1250-wk-Fact-A8A932B6280EFAEF27D3E231C44BDE76"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d278002751e1269-wk-Fact-95A2F4063E549A8560B5E231C44334C5"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e1290-wk-Fact-F271472F4B06B09828B9E231C45A843E"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e1309-wk-Fact-45FEF055A91D7194A21AE231C471A2A5"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d278002751e1328-wk-Fact-BDBA4EB85B5073516577E231C496E994"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1349-wk-Fact-19FA1C4997BFFB353C7FE231C4702A01"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1368-wk-Fact-AD49B31D5A577701748AE231C48E7B2E"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1387-wk-Fact-B1367375A7F792003619E231C4475631"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e1408-wk-Fact-8F4B96C81172BD400EC6E231C4ABA716"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e1427-wk-Fact-4BE5AD9CF55A71E04C7FE231C459EFF9"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d278002751e1446-wk-Fact-F4A7BA2F3212257B97E1E231C48F5588"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1472-wk-Fact-568AE4C3D259478E717BE231C451240A"
      unitRef="usd">47744000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1491-wk-Fact-7ACBCAA185E7F1DE802FE231C49D9FDF"
      unitRef="usd">796994000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d278002751e1510-wk-Fact-6E68585F85EDC72E006AE231C4791CB1"
      unitRef="usd">844738000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-6FA2D55E6724AF408B0EE231C4CEA31D-0-wk-Fact-02B9439DB7B16D3D1107E231C439D1F1">LEASES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;169,606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. The Lease&#x2019;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term; none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it probable that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The April 2019 amendment to the Lease (the Lease Amendment) provides, among other things, for the (i) expansion of the Premises by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;37,544&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2,703&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for tenant improvements to the 1601 Expansion Space. We surrendered the 1751 Space in April 2019, and as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have taken possession of a portion of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for that portion of the Lease. We expect to take possession of the remaining portion of the 1601 Expansion Space in September 2019, and therefore we have not yet recorded a right-of-use asset or lease liability for that portion of the Lease as of June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The monthly base rent for the Premises, other than the 1601 Expansion Space, is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$224,505&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through January 31, 2020, increasing throughout the remainder of the term to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$283,933&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at the end of the term. The monthly base rent for the 1601 Expansion Space, which is expected to start on December 1, 2019, will be &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$71,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through November 30, 2020, increasing throughout the remainder of the term to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$90,481&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at the end of the term. In addition, we are required to pay the landlord for certain operating expenses and taxes they incur related to the Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8.6 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-2DA18FF8E15723D1E763E231C4CD3E7C-0-wk-Fact-DB109E31502A8719C23FE231C4391487">LEASES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;169,606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. The Lease&#x2019;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term; none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it probable that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The April 2019 amendment to the Lease (the Lease Amendment) provides, among other things, for the (i) expansion of the Premises by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;37,544&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2,703&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for tenant improvements to the 1601 Expansion Space. We surrendered the 1751 Space in April 2019, and as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have taken possession of a portion of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for that portion of the Lease. We expect to take possession of the remaining portion of the 1601 Expansion Space in September 2019, and therefore we have not yet recorded a right-of-use asset or lease liability for that portion of the Lease as of June 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The monthly base rent for the Premises, other than the 1601 Expansion Space, is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$224,505&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through January 31, 2020, increasing throughout the remainder of the term to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$283,933&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at the end of the term. The monthly base rent for the 1601 Expansion Space, which is expected to start on December 1, 2019, will be &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$71,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; through November 30, 2020, increasing throughout the remainder of the term to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$90,481&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; at the end of the term. In addition, we are required to pay the landlord for certain operating expenses and taxes they incur related to the Premises.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8.6 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="FI2019Q2_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e397-wk-Fact-5DC9AEEA9A07C4490FFEE231C43453D1"
      unitRef="sqft">169606</us-gaap:AreaOfRealEstateProperty>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="-5"
      id="d278004142e401-wk-Fact-CDD30ADAB00D6A2A35F3E231C43DC9FD"
      unitRef="usd">8200000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <exel:OperatingLeaseAdditionalAreaOfRealEstateProperty
      contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e415-wk-Fact-CD8A364924FC92895541E231C4436675"
      unitRef="sqft">37544</exel:OperatingLeaseAdditionalAreaOfRealEstateProperty>
    <exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty
      contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e419-wk-Fact-DC46296FF8736FF224EAE231C43AFF0E"
      unitRef="sqft">2703</exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="I2019Q2Apr01_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="-5"
      id="d278004142e423-wk-Fact-32DABE0B5AE4A9110508E231C43F8046"
      unitRef="usd">1700000</exel:TenantLeaseImprovementsAllowance>
    <exel:LesseeOperatingLeaseMonthlyBasePayment
      contextRef="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e434-wk-Fact-F1A2EC823973921105DCE231C43AFEE5"
      unitRef="usd">224505</exel:LesseeOperatingLeaseMonthlyBasePayment>
    <exel:LesseeOperatingLeaseMonthlyBasePayment
      contextRef="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e438-wk-Fact-319A6AB07CA48BF0D218E231C435C211"
      unitRef="usd">283933</exel:LesseeOperatingLeaseMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="D2019Q2_srt_RangeAxis_srt_MinimumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e442-wk-Fact-C57AD3FC534E6C2E4F18E231C44246D2"
      unitRef="usd">71334</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="D2019Q2_srt_RangeAxis_srt_MaximumMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d278004142e446-wk-Fact-5CDD74222ADDB9D5B2C6E231C43DEFE4"
      unitRef="usd">90481</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-4D9D8AFBB2744FBC0502E231C4CD5D75-0-wk-Fact-643D6FADE16C2EBA59D1E231C436438A">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;June&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,487&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,289&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e567-wk-Fact-8224D61949D6C093189EE231C4739210"
      unitRef="usd">2696000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e586-wk-Fact-6B40B4C634B2DF75D298E231C4583195"
      unitRef="usd">2738000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e601-wk-Fact-BFCA4D9AC30573B19F1CE231C47EA833"
      unitRef="usd">22487000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e620-wk-Fact-D4EFE4CAEAE1F1CD3EC2E231C4806798"
      unitRef="usd">12099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e640-wk-Fact-3B9936765580E95A3C4EE231C4543D9C"
      unitRef="usd">25183000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e659-wk-Fact-F4634EC9C4F4DFB39799E231C47B0C61"
      unitRef="usd">14837000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e720-wk-Fact-86E97F7E5773094FFF3DE231C4446B9B"
      unitRef="usd">50000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e739-wk-Fact-234CD7B4F7FE0E272AD1E231C448991F"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e759-wk-Fact-B28933A27669ACB51C33E231C452FCFA"
      unitRef="usd">56000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e778-wk-Fact-894A80FBAE97721D5267E231C455B960"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e798-wk-Fact-FF63F61130332B0E6D6EE231C4734EE3"
      unitRef="usd">106000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e817-wk-Fact-B5F22FC6AF13405D3806E231C454D86F"
      unitRef="usd">128000</us-gaap:FinanceLeaseLiability>
    <exel:OperatingAndFinanceLeasesLiabilityTotal
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e842-wk-Fact-0ECB644B5B059D968842E231C4520305"
      unitRef="usd">25289000</exel:OperatingAndFinanceLeasesLiabilityTotal>
    <exel:OperatingAndFinanceLeasesLiabilityTotal
      contextRef="FI2018Q4"
      decimals="-3"
      id="d278004142e861-wk-Fact-872FBD6EA210CE59D532E231C4598EA5"
      unitRef="usd">14965000</exel:OperatingAndFinanceLeasesLiabilityTotal>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-BE7FF3DA9D3DC9F9E6DFE231C4CEAEF3-0-wk-Fact-1A92C6E440337F6EF74CE231C43CFB77">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,483&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,480&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,976&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278004142e1078-wk-Fact-567B44C971ABC830AABEE231C47B2E8A"
      unitRef="usd">660000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278004142e1097-wk-Fact-2C4DD00353384F238C48E231C47012BA"
      unitRef="usd">952000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278004142e1116-wk-Fact-FDB927D866413F60D73AE231C47D593D"
      unitRef="usd">1100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278004142e1136-wk-Fact-DC18A9B7B0449B54130CE231C46F0823"
      unitRef="usd">1973000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278004142e1151-wk-Fact-5B3CEE4541B38AE433B8E231C4581EBC"
      unitRef="usd">131000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278004142e1170-wk-Fact-66255C91EC10D94EAE7FE231C473BD93"
      unitRef="usd">531000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278004142e1189-wk-Fact-55224565E4BAEEB7A509E231C4768740"
      unitRef="usd">380000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278004142e1209-wk-Fact-87A670B4F0925F95E8D5E231C4713DCC"
      unitRef="usd">1003000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2QTD"
      decimals="-3"
      id="d278004142e1234-wk-Fact-92C2C37998870E7F19DEE231C4733A1B"
      unitRef="usd">791000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="D2018Q2Q2QTD"
      decimals="-3"
      id="d278004142e1253-wk-Fact-267E1FB2A155B0D3424AE231C47825F8"
      unitRef="usd">1483000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q2YTD"
      decimals="-3"
      id="d278004142e1272-wk-Fact-9E168965F1AC620DF24AE231C4737CBB"
      unitRef="usd">1480000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="D2018Q2DEC30-JUN29"
      decimals="-3"
      id="d278004142e1292-wk-Fact-59B1F001036D64AA0C8DE231C46DE477"
      unitRef="usd">2976000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q2YTD"
      decimals="-5"
      id="d278004142e1313-wk-Fact-9529A278CDD82CA6A446E231C4437185"
      unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-93953BA1E7086323F5D4E231C4CD3CC2-0-wk-Fact-F56B0446EA3F9F5A2D89E231C435CBB8">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;June&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1352-wk-Fact-74791CBFC0499BE8EC2AE231C4326D00"
      unitRef="usd">1415000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1388-wk-Fact-1F9AE19632072FFE1872E231C4B40E6D"
      unitRef="usd">3339000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1408-wk-Fact-07E5A0EBC5275224AA9AE231C4A0E44D"
      unitRef="usd">3436000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1428-wk-Fact-76041EC4CF66477E6B82E231C49F6B7C"
      unitRef="usd">3548000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1448-wk-Fact-36609FDF53F89EA5EA63E231C49D740D"
      unitRef="usd">3646000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1468-wk-Fact-C6F25F63D2F00D719FC3E231C49D1F74"
      unitRef="usd">16066000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1488-wk-Fact-31A27982A2B01E94E742E231C49E443F"
      unitRef="usd">31450000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1529-wk-Fact-7E5125DA9E0AB4F09D48E231C4319ED7"
      unitRef="usd">5106000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1552-wk-Fact-4D904521D749D717216D305631F4893E"
      unitRef="usd">1161000</exel:TenantLeaseImprovementsAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q2"
      decimals="-3"
      id="d278004142e1579-wk-Fact-3B9936765580E95A3C4EE231C4543D9C"
      unitRef="usd">25183000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q2"
      decimals="4"
      id="d278004142e1603-wk-Fact-B572FA54367D3AD5AE22E231C43AE24D"
      unitRef="number">0.0420</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q2"
      id="d278004142e1611-wk-Fact-6CC22C432B61839E419AE231C442A991">P8Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2019Q2YTD"
      id="TextSelection-1ADA7858E5636F57D68BE231C4CE350A-0-wk-Fact-1266D559C77DA1C606F5E231C4563B5B">SUBSEQUENT EVENT&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aurigene Discovery Technologies Limited (Aurigene) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In July 2019, we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;entered into&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; an exclusive option and license agreement with Aurigene, a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;biotechnology company based in India focused on oncology and inflammatory disorders, to in-license up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; oncology programs from Aurigene. Under the terms of the agreement, we will make an upfront payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for exclusive options to license three preexisting programs. In addition, Exelixis and Aurigene will initiate three Aurigene-led drug discovery programs on mutually agreed upon targets for additional upfront payments of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program. We will also contribute research funding of up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$32.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Aurigene for discovery and preclinical development work on all &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; programs. For each option we decide to exercise, we would be required to pay an exercise fee of either &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, depending on the program, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Aurigene would then become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$148.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential development and regulatory milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$280.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential commercial milestone payments, as well as royalties on potential sales. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d278002834e404-wk-Fact-A5C3740BDDB4DC6B14ED3EAA69C37E50"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e408-wk-Fact-775E3BB39A4A218312362F02F596608B"
      unitRef="usd">10000000.0</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementAdditionalUpfrontPayments
      contextRef="D2019Q3Jul01-Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e412-wk-Fact-C752F71E98C9996E6DEE2F070171C856"
      unitRef="usd">2500000</exel:CollaborationAgreementAdditionalUpfrontPayments>
    <exel:CollaborationAgreementResearchAndDevelopmentObligation
      contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e416-wk-Fact-67FE91A6EA92DC30BDC4306661CB6F2A"
      unitRef="usd">32600000</exel:CollaborationAgreementResearchAndDevelopmentObligation>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d278002834e421-wk-Fact-A5C3740BDDB4DC6B14ED3EAA69C37E50"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e425-wk-Fact-1F5A8D84A579981FA0BA305A2496E7DA"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e429-wk-Fact-C704C75B17339A71D88E2F02D4B988EC"
      unitRef="usd">12000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e435-wk-Fact-2584906A73751124AD302F0B98E0969C"
      unitRef="usd">148800000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d278002834e439-wk-Fact-9D7D9C9C309C284C06802F0BFCB64756"
      unitRef="usd">280000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1"
          xlink:label="d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl" xlink:label="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1073-wk-Fact-010A69A647F0DBD42909E231C47EA8D1"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE"
          xlink:label="d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e2025-wk-Fact-0AFFCF366CF9A97AC089E231C46E3CFE"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5"
          xlink:label="Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5-wk-Fact-0BB2AFDEF26E1DEF7F9DE231C4647EC5"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA"
          xlink:label="d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl" xlink:label="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant inventive payment and an amendment to our existing lease for office and research space. Amounts for the </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277978785e2299-wk-Fact-0C5976F0150763707B9FE231C452CBDA"
          xlink:to="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6"
          xlink:label="d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e995-wk-Fact-13425D9340224551ECFCE231C498E8B6"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2"
          xlink:label="d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1351-wk-Fact-1719127839ACD57000F0E231C46FABD2"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C"
          xlink:label="d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e760-wk-Fact-244A005BD4CFB6120535E231C462EB9C"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2"
          xlink:label="Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-2748D130DA3A562479ADE231C4664DF2-wk-Fact-2748D130DA3A562479ADE231C4664DF2"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367"
          xlink:label="d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e956-wk-Fact-3912968998CA5F0B9A52E231C4913367"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250"
          xlink:label="d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1468-wk-Fact-3948B03B26605765E41BE231C47A2250"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61"
          xlink:label="d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1585-wk-Fact-3CFC10D9D39D16C58A95E231C46E0E61"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4"
          xlink:label="d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e682-wk-Fact-44EB177408B7A2AEC253E231C46B5EE4"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC"
          xlink:label="Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-4A2BB0FCEF311A989318E231C45A48DC-wk-Fact-4A2BB0FCEF311A989318E231C45A48DC"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3"
          xlink:label="d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1546-wk-Fact-4B14B75529EDDD97266CE231C45C81A3"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93"
          xlink:label="d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1822-wk-Fact-4B6590CED4877797BD4CE231C4669D93"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD"
          xlink:label="d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e799-wk-Fact-54A14BF3C54DDDF842BCE231C497BFDD"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0"
          xlink:label="d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1941-wk-Fact-5D64F077F7EA65E5CF0CE231C472C4C0"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41"
          xlink:label="Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-5EB7E1D09C92DCD7A4B0E231C468AE41-wk-Fact-5EB7E1D09C92DCD7A4B0E231C468AE41"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:label="d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:label="d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1981-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277983881e3030-wk-Fact-657996ED63D820DE7575E231C4639766"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83"
          xlink:label="d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1861-wk-Fact-669BBE1A99110EE6B685E231C48DDD83"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060"
          xlink:label="d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1272-wk-Fact-66A42C3EDF86E50EB9ECE231C4517060"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:label="d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:label="d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e917-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277997082e768-wk-Fact-6A780DF99FE847F32BEFE231C4751D57"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198"
          xlink:label="d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1390-wk-Fact-6B261BEAB7BAA1B509CCE231C45F0198"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627"
          xlink:label="d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277978785e2318-wk-Fact-6BF29E82AF0EB56CAE1BE231C4527627"
          xlink:to="TextSelection-DA3878707B9173306803E231C4C71BFB-0-wk-Footnote-DA3878707B9173306803E231C4C71BFB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632"
          xlink:label="d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1663-wk-Fact-6CFF257C83A33DA2BB13E231C49EE632"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B"
          xlink:label="d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e643-wk-Fact-6DBC3BBAEC3C64729796E231C44DF28B"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938"
          xlink:label="d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl" xlink:label="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277976473e755-wk-Fact-70EDEC32D325D10AD30AE231C435F938"
          xlink:to="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9"
          xlink:label="d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1034-wk-Fact-7B792C0EF80E3575A1D2E231C48E7FB9"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6"
          xlink:label="d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e721-wk-Fact-7F460126B3D69504C71AE231C49B2BD6"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553"
          xlink:label="d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1507-wk-Fact-83EEE4FCF6CC49F1453AE231C4601553"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB"
          xlink:label="d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277976473e774-wk-Fact-8610E47D742FDC5A6755E231C436C5AB"
          xlink:to="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF"
          xlink:label="d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e604-wk-Fact-8966055C7F1130779895E231C46912BF"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345"
          xlink:label="d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277976473e813-wk-Fact-89EAE397DF709EBD60A9E231C4371345"
          xlink:to="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:label="d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:label="d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e878-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277995911e701-wk-Fact-A004B6A973E2F497A836E231C475C85E"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A"
          xlink:label="d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1312-wk-Fact-A04B1AC666DA81477678E231C46B5A8A"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7"
          xlink:label="d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1702-wk-Fact-A30651EF3D341993CA20E231C49CD1D7"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76"
          xlink:label="Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-A6064A9954C0B62FFCF5E231C463AD76-wk-Fact-A6064A9954C0B62FFCF5E231C463AD76"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1"
          xlink:label="d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277995911e623-wk-Fact-AB2CB2DE7C02596E6A1AE231C45A1EA1"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C"
          xlink:label="Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-AD4F2977471467430FC5E231C45B609C-wk-Fact-AD4F2977471467430FC5E231C45B609C"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0"
          xlink:label="d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277976473e793-wk-Fact-B468944FC325E2A3B6ECE231C438D3D0"
          xlink:to="TextSelection-C0EDF80A13745A704F23E231C4C7DEDC-0-wk-Footnote-C0EDF80A13745A704F23E231C4C7DEDC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:label="d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:label="d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e570-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277995911e550-wk-Fact-CAE246300A27452F68D6E231C4716937"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56"
          xlink:label="d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1900-wk-Fact-D0A5EEB0F22EAFC24C0EE231C4707B56"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74"
          xlink:label="d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1117-wk-Fact-D1C168C484A9451FDFEBE231C44ECD74"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE"
          xlink:label="Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-D23BE8DCEAE8D3A29A18E231C45DABCE-wk-Fact-D23BE8DCEAE8D3A29A18E231C45DABCE"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8"
          xlink:label="d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1624-wk-Fact-DBBB56712AA41AB1AE40E231C45C84A8"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6"
          xlink:label="d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1429-wk-Fact-DDB8D47E7C3E597FFEDCE231C4690EA6"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E"
          xlink:label="d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1783-wk-Fact-E34742614BE1A6BA1C10E231C47ED84E"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1"
          xlink:label="d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e1238-wk-Fact-F28000FCF04EE5F6D648E231C466E1C1"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544"
          xlink:label="d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d277973521e838-wk-Fact-F985F40F06B12D02BC70E231C46E3544"
          xlink:to="TextSelection-C0ADB22279E75801680DE231C4C7135D-0-wk-Footnote-C0ADB22279E75801680DE231C4C7135D_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6911060064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jul. 22, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 28,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,906,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6913591904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 369,789<span></span>
</td>
<td colspan="2" class="nump">$ 314,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">452,328<span></span>
</td>
<td colspan="2" class="nump">378,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">97,541<span></span>
</td>
<td colspan="2" class="nump">162,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">12,390<span></span>
</td>
<td colspan="2" class="nump">16,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">12,352<span></span>
</td>
<td colspan="2" class="nump">9,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,847<span></span>
</td>
<td colspan="2" class="nump">15,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">957,247<span></span>
</td>
<td colspan="2" class="nump">897,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">337,785<span></span>
</td>
<td colspan="2" class="nump">157,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td colspan="2" class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50,709<span></span>
</td>
<td colspan="2" class="nump">50,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">16,573<span></span>
</td>
<td colspan="2" class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">210,237<span></span>
</td>
<td colspan="2" class="nump">244,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td colspan="2" class="nump">63,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">5,763<span></span>
</td>
<td colspan="2" class="nump">2,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,643,098<span></span>
</td>
<td colspan="2" class="nump">1,422,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,274<span></span>
</td>
<td colspan="2" class="nump">10,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">23,709<span></span>
</td>
<td colspan="2" class="nump">18,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">24,144<span></span>
</td>
<td colspan="2" class="nump">32,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">17,273<span></span>
</td>
<td colspan="2" class="nump">14,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">7,847<span></span>
</td>
<td colspan="2" class="nump">7,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">321<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">25,228<span></span>
</td>
<td colspan="2" class="nump">21,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">110,796<span></span>
</td>
<td colspan="2" class="nump">105,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">22,543<span></span>
</td>
<td colspan="2" class="nump">12,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">16,632<span></span>
</td>
<td colspan="2" class="nump">15,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,495<span></span>
</td>
<td colspan="2" class="nump">1,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">154,466<span></span>
</td>
<td colspan="2" class="nump">134,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 302,784,854 and 299,876,080 at June 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">303<span></span>
</td>
<td colspan="2" class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,211,668<span></span>
</td>
<td colspan="2" class="nump">2,168,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">2,207<span></span>
</td>
<td colspan="2" class="num">(701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(725,546)<span></span>
</td>
<td colspan="2" class="num">(880,363)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,488,632<span></span>
</td>
<td colspan="2" class="nump">1,287,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,643,098<span></span>
</td>
<td colspan="2" class="nump">$ 1,422,286<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Long Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6911065632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td colspan="2" class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td colspan="2" class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">302,784,854<span></span>
</td>
<td colspan="2" class="nump">299,876,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">302,784,854<span></span>
</td>
<td colspan="2" class="nump">299,876,080<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6913708016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">7,539<span></span>
</td>
<td class="nump">5,997<span></span>
</td>
<td class="nump">15,040<span></span>
</td>
<td class="nump">11,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">81,932<span></span>
</td>
<td class="nump">42,488<span></span>
</td>
<td class="nump">145,221<span></span>
</td>
<td class="nump">80,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">58,815<span></span>
</td>
<td class="nump">51,853<span></span>
</td>
<td class="nump">118,953<span></span>
</td>
<td class="nump">105,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">148,286<span></span>
</td>
<td class="nump">100,338<span></span>
</td>
<td class="nump">279,214<span></span>
</td>
<td class="nump">197,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">91,989<span></span>
</td>
<td class="nump">85,770<span></span>
</td>
<td class="nump">176,548<span></span>
</td>
<td class="nump">202,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">6,975<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">13,062<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">803<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net:</a></td>
<td class="nump">7,778<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
<td class="nump">13,890<span></span>
</td>
<td class="nump">4,689<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">99,767<span></span>
</td>
<td class="nump">88,395<span></span>
</td>
<td class="nump">190,438<span></span>
</td>
<td class="nump">206,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(20,725)<span></span>
</td>
<td class="num">(901)<span></span>
</td>
<td class="num">(35,621)<span></span>
</td>
<td class="num">(3,415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income per share, basic (in shares)</a></td>
<td class="nump">302,188<span></span>
</td>
<td class="nump">297,336<span></span>
</td>
<td class="nump">301,365<span></span>
</td>
<td class="nump">296,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income per share, diluted (in shares)</a></td>
<td class="nump">314,911<span></span>
</td>
<td class="nump">312,241<span></span>
</td>
<td class="nump">314,786<span></span>
</td>
<td class="nump">313,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 193,675<span></span>
</td>
<td class="nump">$ 145,836<span></span>
</td>
<td class="nump">$ 373,256<span></span>
</td>
<td class="nump">$ 280,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 46,600<span></span>
</td>
<td class="nump">$ 40,272<span></span>
</td>
<td class="nump">$ 82,506<span></span>
</td>
<td class="nump">$ 119,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6652057952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,479<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80,521<span></span>
</td>
<td class="nump">$ 87,650<span></span>
</td>
<td class="nump">$ 157,725<span></span>
</td>
<td class="nump">$ 202,967<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646642016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gains or losses on available-for-sale securities, tax impact</a></td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6917899280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No's. (2014-09 and 2016-02) | ASU No. 2014-09</a></td>
<td class="nump">$ 258,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Adoption of Accounting Standards Update No's. (2014-09 and 2016-02) | ASU No. 2016-02</a></td>
<td class="nump">234<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 29, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 29, 2017</a></td>
<td class="nump">284,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 2,114,184<span></span>
</td>
<td class="num">$ (347)<span></span>
</td>
<td class="num">(1,829,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">203,351<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(384)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,682,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">9,947<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">18,588<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 29, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">297,892,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 29, 2018</a></td>
<td class="nump">775,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">2,142,717<span></span>
</td>
<td class="num">(731)<span></span>
</td>
<td class="num">(1,367,082)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">296,694,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 30, 2018</a></td>
<td class="nump">670,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">2,125,166<span></span>
</td>
<td class="num">(887)<span></span>
</td>
<td class="num">(1,454,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">87,494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,197,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">8,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 29, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">297,892,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 29, 2018</a></td>
<td class="nump">$ 775,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">2,142,717<span></span>
</td>
<td class="num">(731)<span></span>
</td>
<td class="num">(1,367,082)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 28, 2018</a></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,168,217<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">154,817<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,908<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,908,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">15,846<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">15,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 27,608<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 28, 2019</a></td>
<td class="nump">302,784,854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302,784,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 28, 2019</a></td>
<td class="nump">$ 1,488,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">2,211,668<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="num">(725,546)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 29, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">301,519,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 29, 2019</a></td>
<td class="nump">1,385,020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">2,188,578<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="num">(804,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">79,042<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,264,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">8,012<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 15,079<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 28, 2019</a></td>
<td class="nump">302,784,854<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302,784,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 28, 2019</a></td>
<td class="nump">$ 1,488,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">$ 2,211,668<span></span>
</td>
<td class="nump">$ 2,207<span></span>
</td>
<td class="num">$ (725,546)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6917420384">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 154,817<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,608<span></span>
</td>
<td class="nump">18,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash', window );">401(k) matching contributions made in common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetAmortization', window );">Amortization and other changes in right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,067<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(730)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Accretion of investments, net and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,919)<span></span>
</td>
<td class="num">(490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">65,230<span></span>
</td>
<td class="num">(76,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,661<span></span>
</td>
<td class="num">(9,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,514)<span></span>
</td>
<td class="num">(1,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Current portion of unbilled collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,170<span></span>
</td>
<td class="num">(1,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,789)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="num">(1,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,998)<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,478<span></span>
</td>
<td class="num">(3,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInRebatesAndFeesPayable', window );">Rebates and fees due customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,319<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedCollaborationLiability', window );">Accrued collaboration liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">428<span></span>
</td>
<td class="num">(1,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Current and long-term deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">5,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,777<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,709<span></span>
</td>
<td class="nump">6,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">293,321<span></span>
</td>
<td class="nump">146,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,516)<span></span>
</td>
<td class="num">(15,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(518,268)<span></span>
</td>
<td class="num">(227,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">258,791<span></span>
</td>
<td class="nump">139,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,677<span></span>
</td>
<td class="nump">10,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">730<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(250,586)<span></span>
</td>
<td class="num">(91,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">6,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,434)<span></span>
</td>
<td class="num">(2,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on financing lease obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,279<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,014<span></span>
</td>
<td class="nump">61,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">370,889<span></span>
</td>
<td class="nump">250,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,338<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred to acquire Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 13,972<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant inventive payment and an amendment to our existing lease for office and research space. Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInRebatesAndFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Rebates And Fees Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInRebatesAndFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6650750544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>four</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>Two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019, March 30, 2018, June 29, 2018 and March 29, 2019, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2019, March 31, 2019, June 30, 2018 and March 31, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Accounting Standards Codification (ASC) Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Condensed Consolidated Financial Statements. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905077072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>464,168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46,743</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(26,810</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90,912</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51,974</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>280,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>60,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,877</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82,506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>189,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>141,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>270,055</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,053</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>280,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>92,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56,595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,622</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>171,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>196,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>150,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>378,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>287,072</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>91,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(326</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(57,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,673</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(22,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(87,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,788</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,150</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,053</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$36.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$61.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$32.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$103.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627910704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cabozantinib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">Commercial </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$47.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, of which </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in the Current portion of deferred revenue and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, first-line RCC and second-line HCC by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$102.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including an increase from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (MHLW)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#8217;s total potential commercial milestones by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$89.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$19.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo is responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the launch,&#160;we&#160;received a&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;milestone payment from Daiichi Sankyo in June 2019. We are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>0.5%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">antibody-drug conjugate</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$5.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the preclinical development funding commitment. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in the accompanying Condensed Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we exercise the option, we</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would be required make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$190.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$262.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties accruing to GSK were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6904972208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS <div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>369,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>248,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>370,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>250,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>559,906</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,885</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,132,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,157,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,161,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,571</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>42</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>199</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>809,607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>674,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>326,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the most recent date for which they reported ownership data, their beneficial ownership was more than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>10%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and investments managed by BlackRock was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$421.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$298.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> invested in the BlackRock Liquidity Money Market Fund. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in fees for BlackRock advisory services performed during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635220608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,630</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, also a portion of our work in process.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905050176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT <div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,016</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$4.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span>, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6791072304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,941</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>14,044,367</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.66</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674,062</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>801,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,147,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(88,105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(29,278</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,210,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.5 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>258,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,670,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>237,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$42.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>2.4 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>272,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(366,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(180,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,583,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.7 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2018, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>693,131</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (PSUs). The PSUs were designed to drive the performance of our management team toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable. During the quarter ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had achieved one of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>114,843</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the PSUs and determined that it was probable that we would achieve the second of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>172,272</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional PSUs. We expect those PSUs to vest over various dates through May 2021 and have recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those PSUs during the three months ended June 30, 2019; the remaining unrecognized compensation expense for those PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of June 30, 2019. The total unrecognized compensation expense for the remaining PSUs for which we have not yet determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$70.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including the PSUs described above. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2.6 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627352656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20.8%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>18.7%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.0%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.7%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span> differed from the U.S. federal statutory rate of&#160;21%&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905077072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>203,351</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>296,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>313,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.65</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627843872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,081,242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,104,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,158,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Leases&#8221; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6623925296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>169,606</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term; none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it probable that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Lease Amendment) provides, among other things, for the (i) expansion of the Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>37,544</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2,703</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. We surrendered the 1751 Space in April 2019, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have taken possession of a portion of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for that portion of the Lease. We expect to take possession of the remaining portion of the 1601 Expansion Space in September 2019, and therefore we have not yet recorded a right-of-use asset or lease liability for that portion of the Lease as of June 30, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The monthly base rent for the Premises, other than the 1601 Expansion Space, is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$224,505</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through January 31, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$283,933</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. The monthly base rent for the 1601 Expansion Space, which is expected to start on December 1, 2019, will be </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$71,334</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through November 30, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$90,481</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. In addition, we are required to pay the landlord for certain operating expenses and taxes they incur related to the Premises.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>660</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,976</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,066</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,450</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4.20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8.6 years</span></span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>169,606</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet. We have made certain tenant improvements to the space leased on the Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have two five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the 8</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term; none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it probable that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Lease Amendment) provides, among other things, for the (i) expansion of the Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>37,544</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2,703</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. We surrendered the 1751 Space in April 2019, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have taken possession of a portion of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for that portion of the Lease. We expect to take possession of the remaining portion of the 1601 Expansion Space in September 2019, and therefore we have not yet recorded a right-of-use asset or lease liability for that portion of the Lease as of June 30, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The monthly base rent for the Premises, other than the 1601 Expansion Space, is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$224,505</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through January 31, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$283,933</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. The monthly base rent for the 1601 Expansion Space, which is expected to start on December 1, 2019, will be </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$71,334</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> through November 30, 2020, increasing throughout the remainder of the term to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$90,481</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at the end of the term. In addition, we are required to pay the landlord for certain operating expenses and taxes they incur related to the Premises.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>660</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,976</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,066</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,450</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4.20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8.6 years</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6623792768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENT<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an exclusive option and license agreement with Aurigene, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">biotechnology company based in India focused on oncology and inflammatory disorders, to in-license up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> oncology programs from Aurigene. Under the terms of the agreement, we will make an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license three preexisting programs. In addition, Exelixis and Aurigene will initiate three Aurigene-led drug discovery programs on mutually agreed upon targets for additional upfront payments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program. We will also contribute research funding of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$32.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Aurigene for discovery and preclinical development work on all </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs. For each option we decide to exercise, we would be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would assume responsibilities for all subsequent clinical development, commercialization and global manufacturing of that program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$148.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$280.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6626696208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended June 28, 2019, March 30, 2018, June 29, 2018 and March 29, 2019, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended June 30, 2019, March 31, 2019, June 30, 2018 and March 31, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div>All of our long-lived assets are located in the U.S.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (the FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in Accounting Standards Codification (ASC) Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2018, the FASB issued ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2018-15 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also requires us to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-15 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-15 on our Condensed Consolidated Financial Statements. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div>We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized.<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6631939728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>464,168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46,743</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(26,810</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90,912</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(51,974</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>280,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>60,902</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,898</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,826</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,559</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,877</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,600</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82,506</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,719</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were partially offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>189,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>141,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364,905</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>270,055</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,053</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>373,256</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>280,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,321</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,028</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,688</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,714</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,475</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>92,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,106</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52,809</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56,595</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accredo Health, Incorporated</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diplomat Specialty Pharmacy</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,622</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>171,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105,129</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>196,347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>150,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>378,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>287,072</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,679</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>240,275</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,108</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>399,827</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58,862</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24,681</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>91,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(102</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(118</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(326</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(57,367</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,673</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(22,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(87,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,319</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract Assets and Liabilities under Topic 606</a></td>
<td class="text">Changes in our contract assets and liabilities under Topic 606 were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets: Unbilled Collaboration Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Liabilities: Deferred Revenue</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Current Portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Long-term Portion</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of a change in transaction price and recognition of revenues as services are performed</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Transfer to receivables from contract assets recognized at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(947</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,788</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenue recognized that was included in the contract liability balance at the beginning of the period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other adjustments </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,150</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,450</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,453</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,053</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>321</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,632</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes reclassification of deferred revenue from long-term to current and adjustments made due to netting of contract assets and liabilities by collaboration agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6647719440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text">Such royalties accruing to GSK were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,833</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,628</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,115</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,043</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,349</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,069</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,813</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,986</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,058</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,903</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6823457168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>369,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>248,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>370,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>250,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>369,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>248,407</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>370,889</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>250,011</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>559,906</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,885</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,132,684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,056</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,157,987</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,056</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,161,002</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,571</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>809,607</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>674,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>326,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905064272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,482</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,630</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,352</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6625440976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,691</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,050</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,931</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,016</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6623176128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,933</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,941</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,164</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18,588</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.00</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Used to Estimate Grant-Date Fair Value</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.66</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.5 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674,062</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>801,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,147,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(88,105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(29,278</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,210,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.5 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>258,157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,670,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>237,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">six months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:49%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>272,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21.72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(366,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10.68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(180,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.03</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,583,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.7 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6647098320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87,494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>154,817</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>203,351</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>302,188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,336</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>296,874</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,723</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,905</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,421</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,241</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,786</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>313,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.68</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.65</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):<span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:48%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,163</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6904971920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>562,750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112,254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,081,242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,135,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54,457</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,104,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,158,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6635284512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 28, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock', window );">Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">June&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,696</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,289</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>660</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,976</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,339</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,548</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,066</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,450</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,183</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space we have taken possession of as of </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">June&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Financing Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6822354512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2019 </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6913787952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,249<span></span>
</td>
<td class="nump">34,043<span></span>
</td>
<td class="nump">$ 44,117<span></span>
</td>
<td class="nump">87,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">193,675<span></span>
</td>
<td class="nump">145,836<span></span>
</td>
<td class="nump">$ 373,256<span></span>
</td>
<td class="nump">280,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">240,418<span></span>
</td>
<td class="nump">172,646<span></span>
</td>
<td class="nump">464,168<span></span>
</td>
<td class="nump">332,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,743<span></span>
</td>
<td class="nump">26,810<span></span>
</td>
<td class="nump">90,912<span></span>
</td>
<td class="nump">51,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">82,506<span></span>
</td>
<td class="nump">119,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">36,393<span></span>
</td>
<td class="nump">31,908<span></span>
</td>
<td class="nump">60,902<span></span>
</td>
<td class="nump">100,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember', window );">Research and development services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">10,898<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
<td class="nump">22,826<span></span>
</td>
<td class="nump">16,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember', window );">Other collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">$ (691)<span></span>
</td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="num">$ (1,222)<span></span>
</td>
<td class="nump">$ 1,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_OtherCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6802426944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">193,675<span></span>
</td>
<td class="nump">145,836<span></span>
</td>
<td class="nump">373,256<span></span>
</td>
<td class="nump">280,108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">189,015<span></span>
</td>
<td class="nump">141,121<span></span>
</td>
<td class="nump">364,905<span></span>
</td>
<td class="nump">270,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 4,660<span></span>
</td>
<td class="nump">$ 4,715<span></span>
</td>
<td class="nump">$ 8,351<span></span>
</td>
<td class="nump">$ 10,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6918225952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 37,237<span></span>
</td>
<td class="nump">$ 26,421<span></span>
</td>
<td class="nump">$ 69,935<span></span>
</td>
<td class="nump">$ 52,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C. | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 31,284<span></span>
</td>
<td class="nump">$ 23,321<span></span>
</td>
<td class="nump">$ 56,595<span></span>
</td>
<td class="nump">$ 44,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_ASDMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 23,366<span></span>
</td>
<td class="nump">$ 17,028<span></span>
</td>
<td class="nump">$ 45,268<span></span>
</td>
<td class="nump">$ 32,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_ASDMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,249<span></span>
</td>
<td class="nump">$ 34,043<span></span>
</td>
<td class="nump">$ 44,117<span></span>
</td>
<td class="nump">$ 87,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 18,688<span></span>
</td>
<td class="nump">$ 19,714<span></span>
</td>
<td class="nump">$ 41,183<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 15,318<span></span>
</td>
<td class="nump">$ 18,475<span></span>
</td>
<td class="nump">$ 27,557<span></span>
</td>
<td class="nump">$ 38,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember', window );">Diplomat Specialty Pharmacy | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 92,133<span></span>
</td>
<td class="nump">$ 47,106<span></span>
</td>
<td class="nump">$ 171,107<span></span>
</td>
<td class="nump">$ 105,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_ASDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_ASDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6817543808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">196,347<span></span>
</td>
<td class="nump">150,079<span></span>
</td>
<td class="nump">378,473<span></span>
</td>
<td class="nump">287,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">22,249<span></span>
</td>
<td class="nump">34,043<span></span>
</td>
<td class="nump">44,117<span></span>
</td>
<td class="nump">87,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 21,679<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">$ 33,172<span></span>
</td>
<td class="nump">$ 24,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6650603424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">$ 17,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">91,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(87,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2019</a></td>
<td class="nump">20,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">2,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">58,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(57,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2019</a></td>
<td class="nump">3,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(7,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2019</a></td>
<td class="nump">2,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">11,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">24,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(22,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June 30, 2019</a></td>
<td class="nump">$ 14,319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6821247168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable', window );">Transfer to receivables from contract assets recognized at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues', window );">Increases as a result of a change in transaction price and recognition of revenues as services are performed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,847)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue', window );">Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,053)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36,100<span></span>
</td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="nump">61,400<span></span>
</td>
<td class="nump">$ 103,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member', window );">Balances Without the Adoption of Topic 606</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward', window );"><strong>Contract Assets - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward', window );"><strong>Contract Assets - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward', window );"><strong>Contract Liabilities - Current Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward', window );"><strong>Contract Liabilities - Long-term Portion</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeInContractWithCustomerAssetCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Asset, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeInContractWithCustomerAssetCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerAssetNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Asset, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerAssetNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityCurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Current [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityCurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability, Noncurrent [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerAssetNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerAssetNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityCurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Current, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityCurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Noncurrent, Other Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetReclassifiedToReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetReclassifiedToReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6794336640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 22,249<span></span>
</td>
<td class="nump">$ 34,043<span></span>
</td>
<td class="nump">$ 44,117<span></span>
</td>
<td class="nump">$ 87,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6624975728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Ipsen Collaboration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Net contract liability, current portion of deferred revenue</a></td>
<td class="nump">$ 321<span></span>
</td>
<td colspan="2" class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Net contract liability, long-term portion of deferred revenue</a></td>
<td class="nump">16,632<span></span>
</td>
<td colspan="2" class="nump">$ 15,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">47,500<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="nump">8,400<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Net contract liability, current portion of deferred revenue</a></td>
<td class="nump">300<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Net contract liability, long-term portion of deferred revenue</a></td>
<td class="nump">$ 8,100<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6721673872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,565<span></span>
</td>
<td class="nump">$ 1,986<span></span>
</td>
<td class="nump">$ 13,058<span></span>
</td>
<td class="nump">$ 4,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6801688688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda Collaboration (Details) - Collaborative Arrangement with Takeda - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 29, 2019</div></th>
<th class="th"><div>Apr. 28, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAnnualReimbursementLimit', window );">Limit on reimbursement per year</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones', window );">Increase in maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">102.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementMilestonePaymentsEarned', window );">Milestone Payments Earned</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Increase in maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementMilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementMilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAnnualReimbursementLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Annual Reimbursement Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAnnualReimbursementLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6822293952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits and losses on U.S. commercialization</a></td>
<td class="nump">1,349<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">2,404<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,323<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="nump">$ 2,813<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6798419520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Daiichi Sankyo (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,600<span></span>
</td>
<td class="nump">40,272<span></span>
</td>
<td class="nump">82,506<span></span>
</td>
<td class="nump">119,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,114<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,114<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905054304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 240,275<span></span>
</td>
<td class="nump">$ 186,108<span></span>
</td>
<td class="nump">$ 455,762<span></span>
</td>
<td class="nump">$ 399,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,114<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,114<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6905055408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details) - Collaboration Agreement with Iconic Therapeutics, Inc. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued', window );">Preclinical development funding commitment accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development, regulatory and first-sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Expense Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6624789824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties accruing to GSK</a></td>
<td class="nump">$ 7,833<span></span>
</td>
<td class="nump">$ 5,628<span></span>
</td>
<td class="nump">$ 15,115<span></span>
</td>
<td class="nump">$ 10,753<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6823568192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 369,789<span></span>
</td>
<td class="nump">$ 314,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 248,407<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in short-term restricted cash and investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in long-term restricted cash and investments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 370,889<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 250,011<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6916845488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,132,684<span></span>
</td>
<td class="nump">$ 828,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">370,889<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">$ 250,011<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,135,699<span></span>
</td>
<td class="nump">828,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total cash and investments, amortized cost</a></td>
<td class="nump">1,157,987<span></span>
</td>
<td class="nump">852,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Total cash and investments, fair value</a></td>
<td class="nump">1,161,002<span></span>
</td>
<td class="nump">851,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">406,238<span></span>
</td>
<td class="nump">381,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">406,238<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">559,906<span></span>
</td>
<td class="nump">344,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">562,750<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">112,083<span></span>
</td>
<td class="nump">55,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">112,254<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Amortized Cost</a></td>
<td class="nump">22,992<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 22,992<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6911395632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 33,571<span></span>
</td>
<td class="nump">$ 271,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">23,738<span></span>
</td>
<td class="nump">48,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">57,309<span></span>
</td>
<td class="nump">320,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">33,571<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">23,738<span></span>
</td>
<td class="nump">39,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">57,309<span></span>
</td>
<td class="nump">275,789<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6806080160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jun. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain (loss) on sales of investments available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OwnershipInterestByMinorityShareholder', window );">Beneficial ownership interest by BlackRock (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner', window );">Fair value of cash and investments managed by BlackRock</a></td>
<td class="nump">421,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund', window );">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsAdvisoryFeesIncurred', window );">Fees for advisory services paid to BlackRock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OwnershipInterestByMinorityShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Ownership, Ownership Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OwnershipInterestByMinorityShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsAdvisoryFeesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Advisory Fees Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsAdvisoryFeesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6627529728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 809,607<span></span>
</td>
<td class="nump">$ 674,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">326,092<span></span>
</td>
<td class="nump">153,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 1,135,699<span></span>
</td>
<td class="nump">$ 828,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6817262288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">8,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">6,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">17,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on inventory</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">12,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 5,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6804207824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72,016<span></span>
</td>
<td class="nump">$ 68,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(21,307)<span></span>
</td>
<td class="num">(17,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">50,709<span></span>
</td>
<td class="nump">50,897<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,691<span></span>
</td>
<td class="nump">33,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">16,050<span></span>
</td>
<td class="nump">15,022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,053<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,291<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,931<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646487216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6801518544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 15,079<span></span>
</td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 27,608<span></span>
</td>
<td class="nump">$ 18,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,138<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">9,444<span></span>
</td>
<td class="nump">5,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 9,941<span></span>
</td>
<td class="nump">$ 6,383<span></span>
</td>
<td class="nump">$ 18,164<span></span>
</td>
<td class="nump">$ 12,655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6911296576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">14,044,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,044,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 15,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 27,608<span></span>
</td>
<td class="nump">$ 18,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">42,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 70,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="nump">4,583,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,583,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,857,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_AchievedMember', window );">Achieved [Member] | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="nump">114,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_ProbableMember', window );">Probable [Member] | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="nump">172,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_StatusAxis=exel_NotProbableMember', window );">Not Probable [Member] | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6821223376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.67<span></span>
</td>
<td class="nump">$ 9.82<span></span>
</td>
<td class="nump">$ 8.83<span></span>
</td>
<td class="nump">$ 10.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 6.84<span></span>
</td>
<td class="nump">$ 4.80<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6800037472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.41%<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6810592080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">22,674,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">801,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(2,147,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(88,105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(29,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">21,210,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">15,670,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">15.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">22.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">9.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period | $</a></td>
<td class="nump">$ 258,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period | $</a></td>
<td class="nump">$ 237,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6800807088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity (Details) - RSUs<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4,857,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">272,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(366,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(180,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4,583,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">21.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">10.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">18.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">RSUs outstanding at end of period | $</a></td>
<td class="nump">$ 97,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6623523520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">20.80%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6794844272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 79,042<span></span>
</td>
<td class="nump">$ 87,494<span></span>
</td>
<td class="nump">$ 154,817<span></span>
</td>
<td class="nump">$ 203,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</a></td>
<td class="nump">302,188<span></span>
</td>
<td class="nump">297,336<span></span>
</td>
<td class="nump">301,365<span></span>
</td>
<td class="nump">296,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">12,723<span></span>
</td>
<td class="nump">14,905<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
<td class="nump">16,150<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)</a></td>
<td class="nump">314,911<span></span>
</td>
<td class="nump">312,241<span></span>
</td>
<td class="nump">314,786<span></span>
</td>
<td class="nump">313,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6625377984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">5,935<span></span>
</td>
<td class="nump">5,163<span></span>
</td>
<td class="nump">5,625<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6913411600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 1,135,699<span></span>
</td>
<td class="nump">$ 828,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,135,699<span></span>
</td>
<td class="nump">828,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">1,158,691<span></span>
</td>
<td class="nump">844,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,081,242<span></span>
</td>
<td class="nump">780,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">1,104,234<span></span>
</td>
<td class="nump">796,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">54,457<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">406,238<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">406,238<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">406,238<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">562,750<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">562,750<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">562,750<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">112,254<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">112,254<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">112,254<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">22,992<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">22,992<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">$ 22,992<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6651980752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 28, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Aggregate contractual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Tenant improvement reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty', window );">Operating lease, expansion (in square feet) | ft&#178;</a></td>
<td class="nump">37,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty', window );">Operating lease, surrendered (in square feet) | ft&#178;</a></td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseMonthlyBasePayment', window );">Monthly base rent</a></td>
<td class="nump">224,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Operating lease, not yet commenced, monthly base rent</a></td>
<td class="nump">71,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseMonthlyBasePayment', window );">Monthly base rent</a></td>
<td class="nump">283,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Operating lease, not yet commenced, monthly base rent</a></td>
<td class="nump">$ 90,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Additional Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAdditionalAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Surrendered Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646638176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Classification of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 2,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">22,487<span></span>
</td>
<td class="nump">12,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">25,183<span></span>
</td>
<td class="nump">14,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_FinancingLeaseLiabilitiesAbstract', window );"><strong>Financing lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing obligation for build-to-suit lease</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityTotal', window );">Total lease liabilities</a></td>
<td class="nump">$ 25,289<span></span>
</td>
<td class="nump">$ 14,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_FinancingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_FinancingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6646559808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">$ 2,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6798929952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2019</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract', window );"><strong>Years ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">3,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">3,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">3,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">3,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">16,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">31,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(5,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement reimbursements</a></td>
<td class="num">(1,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 25,183<span></span>
</td>
<td class="nump">$ 14,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities, Duration Of Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6904956656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - Subsequent Event - Collaboration Agreement with Aurigene Discovery Technologies Limited Collaboration Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>program</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPrograms', window );">Number of oncology programs included in collaboration agreement | program</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementAdditionalUpfrontPayments', window );">Additional upfront payment</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentObligation', window );">Research funding commitment (up to)</a></td>
<td class="nump">32.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">148.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">280.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementAdditionalUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementAdditionalUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPJXW]F#_L?%54+;PZR[D%U!+ P04    " "8@?].F5R<(Q &  "<)P
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ME '###AEP# #21D(S$!2!@(SD)2!X*M_N/QA!I(R$)B!I P$9B I X$92,I
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MT/580%J3I4"@/>>2X=!;*0V5Q_D#:305R/DS<:N/O!;RO0 *1B)]/QV@FY!
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MI^_U_NQQ?]%6N^%<=7$XW+WX'U!+ P04    " "8@?].-]=W/(0%   +'
M&    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(V986_J-A2&_PKB.Y?XV([C
MBB*U0=,F;5)UIVV?T^(6=(&P)"UW_WY.2+EPSNMI7UJ2O+9?G]B/CYW%J6Z^
MM9L0NLGW_>[0WD\W77>\F\_;ETW85^V7^A@.\<EKW>RK+EXV;_/VV(1J/13:
M[^:49?E\7VT/T^5BN/?4+!?U>[?;'L)3,VG?]_NJ^><Q[.K3_51-/V]\W;YM
MNO[&?+DX5F_A]]#]<7QJXM7\4LMZNP^'=EL?)DUXO9\^J+N5\7V!0?'G-IS:
MJ]^3OBO/=?VMO_AE?3_->D=A%UZZOHHJ_OL(9=CM^IJBC[_'2J>7-ON"U[\_
M:_]IZ'SLS'/5AK+>_;5==YO[:3&=K,-K];[KOM:GG\/8(3N=C+W_-7R$793W
M3F(;+_6N'?Y.7M[;KMZ/M40K^^K[^?_V,/P_C?5_%L,%:"Q _[> '@OH2X%H
M]K\*F+& ^5' #-$Z=V6(S:KJJN6BJ4^3YOQZCU4_BM2=B=%_Z6\.P1Z>Q?"T
M\>['4N5F,?_H*QHUY5E#UYJ+8AYKOS1!J(F21'&Z;6 E%2KSN D->Z&'"O1-
M+RRNP, *S%"!N:Z - O#69,/FL-98TVA'.N,E%&FM4V$S$([%O0GQQ7DL()<
M]B=G1LNSQEX9U=X7K#=2I)1+6''0BI-6+ ^M$ZV0RS/N1:I488L"FRF@F0+$
MA353%C(N]NKUG;U($;FK$7-CQ4,K'ECQS(H7K<Q<YK@7J<JP$95A!F32BLLX
M!#(9%IWQ0;4"LI29!) 4,*.X&04"HS/N!:@H!18%X?6@"-@A;H= 0UYY[@?(
MC$^%!Y-. =2YQ+A3F'5*PB[G$W+47%O-+<D(2]G,Y;E/S$F%::>L-"36("N'
M7Y[SF0!4,T\NP5Z%V:DD/*\6D]&.Y.*,K#+<#Y#%T6P2?C! %2"H$_&1<)R1
MLN*%25EJ_&& *DG0JY5I] +@*("R JJ9LLXE[&"(*DE1&1I 4>,*,3NE+#&O
M"&.4)$8=7W-)XI'G&2N@B8'1B7R&,$9)8M3QU840164* &0FE5T1IBA)BCJ^
M[)*DHS5<M0*JF<Y, CB$(4H:S"@^Q4?1[:L23 <J;5W*#@8R@>S3\4E%$K6&
M1'0 CQ7EJ70=XY@DCI4<R)*T<5#DW(]46:\2Q"&,8Y(X+L2[DIS-'?>\ JJ9
M*E+!P3 F!&,QE"5EG<O$T)&JW.0IYF <$TAHY3P'//9:$U\]@4Z9G%+I!6$D
MDY<92I%XY1J35(.$M. YH :8C-LL/@213%E54,(1QJD&66G!TT ->-JWQ'<8
M*R0D<IE*F<)4U2 W+7@FIR4PR1;.\Y</="KN!U-DU8F-."!KP1=D+9FIXO:4
M3U<DRT@G$@2-V:H!6P4^M,2FW$T 47(SH3%9-2!KP4&O00Y+-K-<N$)"'Z=:
M:JYAO.H<3-=4C#$3-6!BP9FHP>X]LUY$&4#1VE27,!0U@")/]THM86>4L=P.
M. S(DW8P$#78Z?-^EQHDJ60TWU! F4\=R!B,5P/PRGE0&L!-X@=W0)2(C<%<
M-8"KGG/52%RJB$N^G@*9(TKLM0Q&J@%(]>(@$&2J-A.;/R#+5>X3<\M@H!H
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M#7BS:?ZUM0%0RN8.5ZC%!S8["NH0S?=HNW'-1B?8;GI!;'[&Q1]02P,$%
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MR\;^UX@.O)3DQH]0ZS_88BBH73@>_-E,8S89#OOY!['E&Q?_ %!+ P04
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M_&"+H:#VX?@%SW8:L\GPII]_$%N^<?$74$L#!!0    ( )B!_TZ;;^%&MP$
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M!UL,!;4+QSM_-M.838;#?OY!;/G&Q5]02P,$%     @ F('_3OKO6*JU 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL=5-A;]P@#/TKB!]0
M[DBZ5:<D4J]3M4F;=.JT[3.7. DJQ!F02_?O!R27IEWV!;#Q>WXV)AO1/-L6
MP)$7K3J;T]:Y_L"8+5O0PMY@#YV_J=%HX;QI&F9[ Z**(*T8W^T^,"UD1XLL
M^DZFR'!P2G9P,L0.6@OSYP@*QYSNZ=7Q))O6!0<KLEXT\!W<C_YDO,46EDIJ
MZ*S$CABH<WJ_/QS3$!\#?DH8[>I,0B5GQ.=@?*ERN@N"0$'I H/PVP4>0*E
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M:A>.'_W93&,V&0[[^0>QY1L7?P%02P,$%     @ F('_3D$G!56W 0  T@,
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M73C>^[.9QFPR'/;S#V++-R[^ 5!+ P04    " "8@?].]3O!1\,!   W!
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M-&GB.64@+N<OZE]C[;Z6,[-PJ\4#KUR;XSU&%=2L%^Y.#]]@JF>'T53\#[B
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M?CO#'2@5B+R,UXF3SBD#<'G^8+^/M?M:3L+"':H_LG1-1F\H*:$2O7)/./R
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MN;GN^EBWL*KN>S0=?A397U!+ P04    " "8@?]./&%LZ,T!  "<!   &0
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MH_XFE5(:L*5$-[;AVCX5<\"A-&Y[:_=J')@Q,+*;W@(R/TC9/U!+ P04
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MC<Q]V9T>= ]U<>Y/1H+;\<SR/U!+ P04    " "8@?].)T)W!;P"  #""0
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M80S\!+F7(+_?7@C\YP6XP^ .=&5=E@/H.NS#Q1 BZ!XN8QQ.XAPX?&L/#J4
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MIV02R?G=M(W==';WY 0TLO5U3A.8>J]M(J59]AJXTA _&6I6B.:B\*2#BPW
M;"S!"-=,/)H*XJ>:B4^SK&]G&1BEZ'C1+@$=C!?%$P1H@J!+$ P2!%H_>DW4
M::I>XZ<Q7B5$JX1(E5"KTFO"JRIW:3!2)4*K1$B52*L2F56 A#Y>)D;+Q$B9
M6%NCL3%DOF8D-HR,F$A0$PDR\0F>($43I!83GQH>23 V5L3'-[1O,2E*-)B5
M&Y5&T$$LYD6)\&%79FY)AD90>#P00.9F9%<3?%L3^GE?%H@HU!&D-#:=P?E
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M>BRZKMA-%&_[CH^&OQW+OU!+ P04    " "8@?].6D^7#T8"  #S!@  &0
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MT+ @<!)J&LLYZ_IPMQ"TZ:\8--QSV3]02P,$%     @ F('_3NN2Q80K @
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M2-*]_0!3U\$D]?[$@,\YW'MP+G=ZH>R5'PD1WEM5UGSF'X5H)D' MT=28?Y
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MF&9P9$R",N\]J1,MU 74+R@<I9XF:L[;-MPN)&NZ&P;UUUSV%U!+ P04
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MONL#8Q*4=>]!'5*I_B7CAL)!ZN5"K7D_4?N-9.WPLT#C'RO_"U!+ P04
M" "8@?].:;4S@I<"  #0"   &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6R-EM%NVR 4AE_%\@,48V/L1$FD)FFT29M4==IV31.26+6-!R3IWGZ J><
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MF*1JY<F=ZHFC^KP8)C7=2STLU)CWAVP_D:RSWP]@^(A9_ -02P,$%     @
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M.0TGI\'DO/LL-7<=Z\2;&A<)0]A) ITDP(E7X\N$W>3.=[L"&K<JV$D*G:3
MB?2<I'RZ0NHD\S/.=:X A0JLC(%^#/#C%?K2 #\ZS4SJ^>$ZHTE2P$\&_63
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M#<6^-W;_3;[(0L,[)KK&2A5-_]=;'9I6E6,63:7,7H=K7O77XYC_+0P'T!A
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MH7:OJR1/%]%5*^HQ18>!(PP8$)'2/IB /A,%=,3AO8&-BP#Q[!ZS=3$I]K-
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M'B)\FQCQ-W;2:>W6C#K*S)Y621XOHI--U&/N.PP98<@E8CU%T'R 1(; P(*
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M[6MFWF77+78#+=J^$XZ&=GSU#U!+ P04    " "8@?].6\R=U]P!  !A!
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MX8:N9S3U55B?$#RD*!S1UR!H*'!XEA$TS(&^CSG-.,1!,!02/*D(&D/]):%
M/>'PJ8=\HG,:"5Q#0.J'GC>@ !A6  PH !I( (85 -^@ !A6  PI@)Y#;"H
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M?X\76XR,@T7\+/E53L:>D?(DQ+.9?-FO?&0RXA7?*4-1Z,^%Y[RJ#)/.X_=
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M&R<5/R@SC/6XZSN6?J)$.W1CP=@2KO\"4$L#!!0    ( )B!_TXHQ:(C$P(
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M:@+4Y8 N^"L6WX8]DR.PN)S:#O>\I;W'\+GRWX6;71BH *WXWN*1K_J>2N5
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M8DWU+-<;3KKAFD+C79G_ 5!+ P04    " "8@?].[T?TM6,"    "   &0
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MM1O<T[G--\X[&KO)/GL7<R#,XJZ848M=HQH-XF@\B:==PSJ=SX%X*E]^\-[
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M"12CPTNNB\\=OU!$ \5*Z$^7+=B+%Q@M6U46'(9WY$6CP!_!*T=>.(G\9)3
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M.C?),*6H\F&*?TV&X83F[YYN:Y+\E'NJF:[R@E$YJHJ4ND&-BN"_VD*\\*Y
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M^-P<3T=(RNW>Y+^=TZ>X8=JT;-&V64DC42&#J7U&HIDW0_WT$'5,7KM_/"C
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M%)0KQK=F>\'9Y*VII"T_C.%4XG]]S>L[>5?K#')K_O^(/,J'D$A6??W=1:M
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ME45,!8Z7ABA<PX$290:W"%0"*GIS6-[E=C-[0+BM2WC4.SZ_OKP\^4:FYJ[
M.K0PAS$[9J=416?JCTB/&%,YL'TJ"4V)QA,_1NTP)9,*$&D"C)R/<^>2DEF;
M0PNF<!N3"1(./CG\H:&Q[0_]1=;$.!4U,7[<9*MZ\ I%B^8%RBO^7H".$9^
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M>_L_-?I_W^Q?=?J7-XB(<0'LH[**A(/F?\O$*7H3TG6N*G=+]4I5TR4!:KV
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M:'Q]*R=1^5Q7JD5S76!]!YPTRX:YO:WROVVQU?-/[2 FZ\<=J4"GL,V(;FG
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M$1$<[%N<DII=VH+#_XGX)U!+ P04    " "8@?].K[E-%2L%  "*+0  #P
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M<Q+R&:PCXS2/[7=!3,PZ";%U$,SKM>UT2)AU$F+KH-'LO$(I9J%TH,DMC_G
MGV T4\Q"*7GMY"CFO=YRB(E9*!TJU3EAEUQ*B(E9*"6OGV!M$PX]4K2 0EY!
M.?ZF%YU)L12S4$I>0T':9O=-QRR44E=1^O+;X'<?RD+"[CW%+)126Z@?<[\&
M,3$+I=06ZL?<IT00$[-02FVA?LP;;D)SW< B)&:AC-I"6#2[M5+,0AFQA<#L
MRZ5P7%:=;#+#S),1F^?8],L;)\3$S),-4GXYM$B(B9DG&Z@.$Q*-JM(0$RW>
M$YL'P0SQA)B8>;*AYMQ.V%^B4W7.,/-DQ.9!,,,D%\3$S),1FP?!#+L@)F:>
MC+J:<QSS?O8G3'ISS#PYL7E@1;.W5\\QX>3$PNF=!CYIX]FX3G>98_+)B>5S
M!/-..W^>A-E9CLDG)Y;/T?GJW6.'F)A\<F+YO,U7OX_21'_#Q,R3$YOGP+C_
M>G'6WNJBXM;*!4QT<_3#,6+S'###&Z-5^[3U@K6;V=4+Q,3,DQ.;YX#YG;O&
M[&8Q/>:M'RKY@V&BFV/FR:G-\Z\"?7^SQ*23M](9M0?;\[-2+*02Y8V_NO7;
M"UX5=X:%G]V'2VD6/DA8-%5UX;?=JF^:A^WM-?:?09__ U!+ P04    " "8
M@?].4?TPDT0"  "$*0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MQ=K!;MI $,;Q5T%^@"P[NS,D5<BIEUS3OH %"T8!V_)NE>3MZW*I*R7^>D"?
M+R $FOF??EAK/[ZD<UU.79N;4Y]7[Y=SF[=54TK_S;F\:]*ESG==G]KQFT,W
M7.HR?AR.KJ]WK_4Q.5FOS0W3&=73XW3FZGF_K8;GO:]6/^OAF,JV<N]G]]8-
MK[E)J61W??-WXX+Q)Q]]^I_UW>%PVJ7OW>[7);7EDXJ_"RKW>9#,!PD]*,P'
M!7I0G ^*]""=#U)ZD,T'&3UH,Q^TH0?=SP?=TX,>YH,>Z$%^#61<\Y,0UGRM
M/>#:\[WV &S/%]L#LCW?; _0]GRU/6#;\]WV &[/E]L#NCW?;@_P]GR]!>@M
M?+T%Z"T+7&NCBVV^W@+T%K[> O06OMX"]!:^W@+T%K[> O06OMX"]!:^W@+T
M%K[> >@=^'H'H'?@ZQV WF&!LQ)T6,+7.P"] U_O /0.?+T#T#OP]0Y [\#7
M.P"] U_O /0.?+TCT#OR]8Y [\C7.P*](U_O"/2."YQUH\-NOMX1Z!WY>D>@
M=^3K'8'>D:]W!'I'OMX1Z!WY>BO06_EZ*]!;^7HKT%OY>BO06_EZ*]!;%[A7
MB6Y6\O56H+?R]5:@M_+U5J"W\O56H+?R]3:@M_'U-J"W\?4VH+?Q]3:@M_'U
M-J"W\?4VH+<M\*P)>MB$K[<!O8VOMP&]C:^W ;V-K_=FHG=NZB'M?Y3AU![S
MK4O^&?YES03N7#[.Z?89UZE?[I\H7<8MR5U?;_YW<9WZ)\)-*_+3;U!+ P04
M    " "8@?].!0U48P$"  "S*   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-
MVLM.XS 4!N!7J;)%C>LK%U$VP'8&:7@!DYPV49/8L@V4MQ\G7"10D8IHI7_3
M-#G..7]2ZUOU\O[%4YQM^VZ(RZ))R5\P%JN&>AM+YVG(E94+O4WY-*R9M]7&
MKHF)Q<*PR@V)AC1/8X_BZO*&5O:Q2[/KU^MCZV5AO>_:RJ;6#>QIJ+\TG;\U
M+ -UTYK8M#Z>Y 7%[':;N\1\;5GD:BS8'A.^WCB>Y_O^/E$(;4T_BN96J[:B
MVE6/?;ZEC#Z0K6-#E/JNC(T-5/]+H1W6;WGO;$A_;)\;LVW'/BTHCY<CO72T
M.\!4.>3DE+<%[1HU%5X_^:\&ON^&R@6:^Y"K(;4['B]'NLO5R,:%AWQ$&K=.
M3?5>PW/KX_VPSRYLIN^[7OA',;+I\+NW?K@< B2'!,FA0')HD!P&),<I2(XS
MD!SG(#GX B4(BJ@<A52.8BI'096CJ,I16.4HKG(46#F*K )%5H$BJT"15:#(
M*E!D%2BR"A19!8JL D56@2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56B
MR*I09%4HLBH4616*K I%5H4BJT*15:'(JE!D52BR:A19-8JL&D56C2*K1I%5
MH\BJ4635*+)J%%DUBJP&15:#(JM!D=6@R&I09#4HLAH460V*K 9%5G-$6:=C
MV=MV^"[)@W.;]_EL^J_BU7]02P$"% ,4    " "8@?].'R// \     3 @
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M2P$"% ,4    " "8@?].E%#.K:L"  "'"0  &               @ %#$@
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ F('_3O!1*Z";
M!   &!4  !@              ( !)!4  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( )B!_TZD*0<.M (  &@)   8              "
M ?49  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "8@?].
M4%Z(@2$"  !4!@  &               @ '?'   >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ F('_3D)2O>2^!0  Z!T  !@
M     ( !-A\  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M )B!_TXWUW<\A 4   L<   8              "  2HE  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " "8@?].4N%V++(!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " "8@?].D:7W@K4!  #2 P  &0
M    @ %_-   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M )B!_TZ(_05=M@$  -(#   9              "  6LV  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ F('_3IMOX4:W 0  T@,  !D
M             ( !6#@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " "8@?].^N]8JK4!  #2 P  &0              @ %&.@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )B!_TY!)P55MP$
M -(#   9              "  3(\  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ F('_3O4[P4?# 0  -P0  !D              ( !
M(#X  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "8@?].
M<%L@(;<!  #2 P  &0              @ $:0   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( )B!_TZ,!_YM!0(  #0&   9
M      "  0A"  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ F('_3CQA;.C- 0  G 0  !D              ( !1$0  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "8@?].E15'N[0!  #2 P
M&0              @ %(1@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( )B!_T[5#*:!Y@$  &8%   9              "  3-(  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ F('_3IKA_7NW
M 0  T@,  !D              ( !4$H  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " "8@?].WZZ)(+<!  #2 P  &0
M@ $^3   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )B!
M_TZ3-V(Z[@$  &8%   9              "  2Q.  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ F('_3KO#O:#" 0  -P0  !D
M         ( !45   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " "8@?].RH"[&;(!  #2 P  &0              @ %*4@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )B!_TXFQ$]!T0$  )P$
M   9              "  3-4  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ F('_3H[Q%8$# @  !08  !D              ( !.U8
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "8@?].."X%
ML-T#  "J$0  &0              @ %U6   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( )B!_TXG0G<%O (  ,()   9
M  "  8E<  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MF('_3B>^#2;!!   .QH  !D              ( !?%\  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " "8@?].$622DKT"  # "0  &0
M            @ %T9   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( )B!_TZ4D]/]0P,  #\.   9              "  6AG  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ F('_3HOG3$RS P
MCQ$  !D              ( !XFH  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " "8@?].5$MU=$T"  #V!@  &0              @ ',
M;@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( )B!_T['
MIJ)@C0(  (((   9              "  5!Q  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ F('_3EI/EP]& @  \P8  !D
M     ( !%'0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )B!_TZ_XLTQ%@(  ,$%   9              "
M ?Z   !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ F('_
M3H,R%5$[ @  O08  !D              ( !2X,  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " "8@?].:;4S@I<"  #0"   &0
M        @ &]A0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( )B!_TZ*1HX;E 0  )08   9              "  8N(  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ F('_3NRH@D-W P  7A
M !D              ( !5HT  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " "8@?].R9J!RI@"  ";"0  &0              @ $$D0
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( )B!_T[1</ S
M[@$  /4$   9              "  =.3  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ F('_3C:<=]>D @  #PD  !D
M ( !^)4  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "8
M@?].)TOS-_0"  ":"P  &0              @ '3F   >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( )B!_TY;S)W7W $  &$$   9
M          "  ?Z;  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#
M%     @ F('_3HRF"%=\ @  30@  !D              ( !$9X  'AL+W=O
M<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " "8@?]./G3*^I,#  !T
M$   &0              @ '$H   >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM
M;%!+ 0(4 Q0    ( )B!_TX[LKF93@(  "@'   9              "  8ZD
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ F('_3E@!
MJA?/ @  ) P  !D              ( !$Z<  'AL+W=O<FMS:&5E=',O<VAE
M970U."YX;6Q02P$"% ,4    " "8@?].]B3*5PH#  "U"P  &0
M    @ $9J@  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M )B!_TZFZLGMHP(  "H)   9              "  5JM  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ F('_3L>Z]S(# @  CP4  !D
M             ( !-+   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " "8@?].3.!I]-L"   >"@  &0              @ %NL@  >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( )B!_TXHQ:(C$P(
M -0%   9              "  8"U  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ F('_3LC)7J3Q!   ?QX  !D              ( !
MRK<  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "8@?].
M&(^HT\("  #T"@  &0              @ 'RO   >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( )B!_TZ:5V<F1 (  %0'   9
M      "  >N_  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ F('_3A<4S^13 @  -P<  !D              ( !9L(  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "8@?].[T?TM6,"    "
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "8@?].K[E-%2L%  "*+0  #P
M            @ &V.@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ F('_
M3E'],)-$ @  A"D  !H              ( !#D ! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ F('_3@4-5&,! @  LR@  !,
M         ( !BD(! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X 3@!4
)%0  O$0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>304</ContextCount>
  <ElementCount>378</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details</Role>
      <ShortName>Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Ipsen Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Takeda Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails</Role>
      <ShortName>Collaboration Agreements - Daiichi Sankyo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403410 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Balance Sheet Classification of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="exel2019063010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SubsequentEvent</ParentRole>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel2019063010-q.htm">exel2019063010-q.htm</File>
    <File>exel-20190628.xsd</File>
    <File>exel-20190628_cal.xml</File>
    <File>exel-20190628_def.xml</File>
    <File>exel-20190628_lab.xml</File>
    <File>exel-20190628_pre.xml</File>
    <File>exel20190630exhibit102.htm</File>
    <File>exel20190630exhibit103.htm</File>
    <File>exel20190630exhibit311.htm</File>
    <File>exel20190630exhibit312.htm</File>
    <File>exel20190630exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exellogo2017aa08.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel2019063010-q.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 304,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20190628_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20190628_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel2019063010-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20190628_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20190628_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20190628.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 510,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 29,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 34
   },
   "keyCustom": 54,
   "keyStandard": 324,
   "memberCustom": 35,
   "memberStandard": 36,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20190628",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashAndInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Property and Equipment",
     "role": "http://www.exelixis.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Income Taxes",
     "role": "http://www.exelixis.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Leases",
     "role": "http://www.exelixis.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Subsequent Event",
     "role": "http://www.exelixis.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Leases (Tables)",
     "role": "http://www.exelixis.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:NumberofProductsinCommercialMarket",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:NumberofProductsinCommercialMarket",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_srt_ProductOrServiceAxis_exel_CabometyxMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)",
     "role": "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details",
     "shortName": "Revenues - Changes in Contract Assets and Liabilities under Topic 606 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exel:ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
     "shortName": "Collaboration Agreements - Ipsen Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborativeArrangementAnnualReimbursementLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
     "shortName": "Collaboration Agreements - Takeda Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborativeArrangementAnnualReimbursementLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember",
      "decimals": "-3",
      "lang": null,
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
     "shortName": "Collaboration Agreements - Daiichi Sankyo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember",
      "decimals": "3",
      "lang": null,
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
     "shortName": "Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403410 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unitRef": "investment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails",
     "shortName": "Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
     "shortName": "Stock-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.exelixis.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails",
     "shortName": "Leases - Balance Sheet Classification of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FI2019Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementNumberOfPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - Subsequent Event (Details)",
     "role": "http://www.exelixis.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2019Q3Jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementNumberOfPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "program",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "I2017Q4Dec29_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019063010-q.htm",
      "contextRef": "FD2019Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_ASDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ASD [Member]",
        "label": "ASD [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "ASDMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accredo Health, Incorporated [Member]",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved [Member]"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AlamedaCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alameda, California [Member]",
        "label": "Alameda, California [Member]",
        "terseLabel": "Alameda, California"
       }
      }
     },
     "localname": "AlamedaCaliforniaMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CaremarkL.L.C.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caremark L.L.C. [Member]",
        "label": "Caremark L.L.C. [Member]",
        "terseLabel": "Caremark L.L.C."
       }
      }
     },
     "localname": "CaremarkL.L.C.Member",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashAndRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Restricted Cash [Member]",
        "label": "Cash And Restricted Cash [Member]",
        "terseLabel": "Cash and restricted cash"
       }
      }
     },
     "localname": "CashAndRestrictedCashMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsAndInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Investments [Text Block]",
        "label": "Cash, Cash Equivalents, and Investments [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsTextBlock",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "terseLabel": "Total cash and investments, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Total cash and investments, amortized cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChangeInContractWithCustomerAssetCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change In Contract With Customer, Asset, Current [Roll Forward]",
        "label": "Change In Contract With Customer, Asset, Current [Roll Forward]",
        "terseLabel": "Contract Assets - Current Portion"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetCurrentRollForward",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ChangeinContractwithCustomerAssetNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract with Customer, Asset, Noncurrent [Roll Forward]",
        "label": "Change in Contract with Customer, Asset, Noncurrent [Roll Forward]",
        "terseLabel": "Contract Assets - Long-term Portion"
       }
      }
     },
     "localname": "ChangeinContractwithCustomerAssetNoncurrentRollForward",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ChangeinContractwithCustomerLiabilityCurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability, Current [Roll Forward]",
        "label": "Change in Contract with Customer, Liability, Current [Roll Forward]",
        "terseLabel": "Contract Liabilities - Current Portion"
       }
      }
     },
     "localname": "ChangeinContractwithCustomerLiabilityCurrentRollForward",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ChangeinContractwithCustomerLiabilityNoncurrentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability, Noncurrent [Roll Forward]",
        "label": "Change in Contract with Customer, Liability, Noncurrent [Roll Forward]",
        "terseLabel": "Contract Liabilities - Long-term Portion"
       }
      }
     },
     "localname": "ChangeinContractwithCustomerLiabilityNoncurrentRollForward",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementAdditionalUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Upfront Payments",
        "label": "Collaboration Agreement, Additional Upfront Payments",
        "terseLabel": "Additional upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementMilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Milestone Payments Earned",
        "label": "Collaboration Agreement, Milestone Payments Earned",
        "terseLabel": "Milestone Payments Earned"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Programs",
        "label": "Collaboration Agreement, Number Of Programs",
        "terseLabel": "Number of oncology programs included in collaboration agreement"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPrograms",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "label": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "terseLabel": "Option exercise fee payment, if exercised"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Expense Accrued",
        "label": "Collaboration Agreement, Research And Development Expense Accrued",
        "terseLabel": "Preclinical development funding commitment accrued"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentExpenseAccrued",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Obligation",
        "label": "Collaboration Agreement, Research And Development Obligation",
        "terseLabel": "Research funding commitment (up to)"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentObligation",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "label": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement with Aurigene Discovery Technologies Limited Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementWithIconicTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "label": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "terseLabel": "Collaboration Agreement with Iconic Therapeutics, Inc."
       }
      }
     },
     "localname": "CollaborationAgreementWithIconicTherapeuticsInc.Member",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreements, Upfront Payments",
        "label": "Collaboration Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "label": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaboration Agreement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborationAgreementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "verboseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAnnualReimbursementLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Annual Reimbursement Limit",
        "label": "Collaborative Arrangement, Annual Reimbursement Limit",
        "verboseLabel": "Limit on reimbursement per year"
       }
      }
     },
     "localname": "CollaborativeArrangementAnnualReimbursementLimit",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits and losses on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "terseLabel": "Maximum amount eligible for development, regulatory and first-sale milestones",
        "verboseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues",
        "label": "Contract With Customer, Asset, Current, Increases From Change In Transaction Price And Recognition Of Revenues",
        "terseLabel": "Increases as a result of a change in transaction price and recognition of revenues as services are performed"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerAssetCurrentOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset, Current, Other Adjustments",
        "label": "Contract With Customer, Asset, Current, Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCurrentOtherAdjustments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues",
        "label": "Contract With Customer, Asset, Noncurrent, Increases From Change In Transaction Price And Recognition Of Revenues",
        "terseLabel": "Increases as a result of a change in transaction price and recognition of revenues as services are performed"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNoncurrentIncreasesFromChangeInTransactionPriceAndRecognitionOfRevenues",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerAssetNoncurrentOtherAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Asset, Noncurrent, Other Adjustments",
        "label": "Contract With Customer, Asset, Noncurrent, Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNoncurrentOtherAdjustments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerLiabilityCurrentOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Liability, Current, Other Adjustments",
        "label": "Contract With Customer, Liability, Current, Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrentOtherAdjustments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractWithCustomerLiabilityNoncurrentOtherAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract With Customer, Liability, Noncurrent, Other Adjustments",
        "label": "Contract With Customer, Liability, Noncurrent, Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrentOtherAdjustments",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue",
        "label": "Contract with Customer, Liability, Current, Deferral Of Milestones Earned, Excluding Recognized Revenue",
        "terseLabel": "Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityCurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue",
        "label": "Contract with Customer, Liability, Noncurrent, Deferral Of Milestones Earned, Excluding Recognized Revenue",
        "terseLabel": "Increases as a result of the deferral of milestones achieved in period, excluding amounts recognized as revenue"
       }
      }
     },
     "localname": "ContractwithCustomerLiabilityNoncurrentDeferralOfMilestonesEarnedExcludingRecognizedRevenue",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_DiplomatSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diplomat Specialty Pharmacy [Member]",
        "label": "Diplomat Specialty Pharmacy [Member]",
        "terseLabel": "Diplomat Specialty Pharmacy"
       }
      }
     },
     "localname": "DiplomatSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Denominator [Abstract]",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Numerator [Abstract]",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_FinancingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Lease Liabilities [Abstract]",
        "label": "Financing Lease Liabilities [Abstract]",
        "terseLabel": "Financing lease liabilities:"
       }
      }
     },
     "localname": "FinancingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IncreaseDecreaseInAccruedClinicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in accrued clinical liabilities",
        "label": "Increase (Decrease) In Accrued Clinical Liabilities",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalLiabilities",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInAccruedCollaborationLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Collaboration Liability",
        "label": "Increase (Decrease) In Accrued Collaboration Liability",
        "terseLabel": "Accrued collaboration liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCollaborationLiability",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones",
        "label": "Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones",
        "verboseLabel": "Increase in maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleforDevelopmentandRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Liability, Noncurrent",
        "label": "Increase (Decrease) In Lease Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilityNoncurrent",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Increase (Decrease) In Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "verboseLabel": "Increase in maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInRebatesAndFeesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Rebates And Fees Payable",
        "label": "Increase (Decrease) In Rebates And Fees Payable",
        "terseLabel": "Rebates and fees due customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInRebatesAndFeesPayable",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating And Financing Lease Liabilities [Table Text Block]",
        "label": "Lessee, Operating And Financing Lease Liabilities [Table Text Block]",
        "terseLabel": "Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "terseLabel": "Tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Monthly Base Payment",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Operating lease, not yet commenced, monthly base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable [Member]"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingAndFinanceLeasesLiabilityLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Leases, Liability - Long Term",
        "label": "Operating And Finance Leases, Liability - Long Term",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeasesLiabilityLongTerm",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingAndFinanceLeasesLiabilityTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Leases, Liability - Total",
        "label": "Operating And Finance Leases, Liability - Total",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeasesLiabilityTotal",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingLeaseAdditionalAreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Additional Area Of Real Estate Property",
        "label": "Operating Lease, Additional Area Of Real Estate Property",
        "terseLabel": "Operating lease, expansion (in square feet)"
       }
      }
     },
     "localname": "OperatingLeaseAdditionalAreaOfRealEstateProperty",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities, Duration Of Maturity [Abstract]",
        "label": "Operating Lease Liabilities, Duration Of Maturity [Abstract]",
        "terseLabel": "Years ending December 31,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesDurationOfMaturityAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Surrendered Area Of Real Estate Property",
        "label": "Operating Lease, Surrendered Area Of Real Estate Property",
        "terseLabel": "Operating lease, surrendered (in square feet)"
       }
      }
     },
     "localname": "OperatingLeaseSurrenderedAreaOfRealEstateProperty",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Collaboration [Member]",
        "label": "Other Collaboration [Member]",
        "terseLabel": "Other collaboration revenues"
       }
      }
     },
     "localname": "OtherCollaborationMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Customers [Member]",
        "label": "Other Customers [Member]",
        "terseLabel": "Others, individually less than 10% of Total revenues for all periods presented"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in Other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OwnershipInterestByMinorityShareholder": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minority Ownership, Ownership Interest",
        "label": "Ownership Interest By Minority Shareholder",
        "terseLabel": "Beneficial ownership interest by BlackRock (more than)"
       }
      }
     },
     "localname": "OwnershipInterestByMinorityShareholder",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable [Member]"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products Derived from Cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_RelatedPartyTransactionsAdvisoryFeesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Advisory Fees Incurred",
        "label": "Related Party Transactions, Advisory Fees Incurred",
        "terseLabel": "Fees for advisory services paid to BlackRock"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAdvisoryFeesIncurred",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Cash And Investments Managed By Minority Owner",
        "label": "Related Party Transactions, Cash And Investments Managed By Minority Owner",
        "terseLabel": "Fair value of cash and investments managed by BlackRock"
       }
      }
     },
     "localname": "RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund",
        "label": "Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund",
        "terseLabel": "Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund"
       }
      }
     },
     "localname": "RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ResearchandDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development [Member]",
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development services revenues"
       }
      }
     },
     "localname": "ResearchandDevelopmentMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-of-Use Asset, Amortization",
        "label": "Right-Of-Use Asset, Amortization",
        "terseLabel": "Amortization and other changes in right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetAmortization",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_SalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Discounts And Allowances [Member]",
        "label": "Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "SalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value",
        "periodEndLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "negatedTerseLabel": "Tenant improvement reimbursements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20190628",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "invest_InvestmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Line Items]",
        "terseLabel": "Investment [Line Items]"
       }
      }
     },
     "localname": "InvestmentLineItems",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "invest_InvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Table]",
        "terseLabel": "Investment [Table]"
       }
      }
     },
     "localname": "InvestmentTable",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r121",
      "r178",
      "r183",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r119",
      "r178",
      "r181",
      "r307",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r120",
      "r178",
      "r182",
      "r309",
      "r314",
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "verboseLabel": "ASU No. 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU No. 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r162"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r50",
      "r53",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r190",
      "r192",
      "r224",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r192",
      "r218",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of lease property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r285",
      "r298"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r125",
      "r145"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r129",
      "r131",
      "r295"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r129",
      "r130",
      "r294"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r122",
      "r126",
      "r145"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total investments available-for-sale",
        "verboseLabel": "Total investments available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r194",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Calculated under guidance for revenue recognition in effect prior to change to new guidance for revenue from contract with customer when using transition method for cumulative effect in period including initial date of application.",
        "label": "Calculated under Revenue Guidance in Effect before Topic 606 [Member]",
        "verboseLabel": "Balances Without the Adoption of Topic 606"
       }
      }
     },
     "localname": "CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred to acquire Property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r27",
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r81",
      "r85"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r263"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r166",
      "r291",
      "r304"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 302,784,854 and 299,876,080 at June 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r110",
      "r111",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r110",
      "r111",
      "r261",
      "r262",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r110",
      "r111",
      "r261",
      "r262",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r110",
      "r111",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r110",
      "r111",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r242",
      "r247",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contract balances and changes in contract balances.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Contract Assets and Liabilities under Topic 606"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r170",
      "r172",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r170",
      "r172",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, Net, Noncurrent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional.",
        "label": "Contract with Customer, Asset, Reclassified to Receivable",
        "negatedLabel": "Transfer to receivables from contract assets recognized at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerAssetReclassifiedToReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r170",
      "r171",
      "r179"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Net contract liability",
        "totalLabel": "Net contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r170",
      "r171",
      "r179"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "netLabel": "Net contract liability, current portion of deferred revenue",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r170",
      "r171",
      "r179"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "netLabel": "Net contract liability, long-term portion of deferred revenue",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue recognized that was included in the contract liability balance at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Adoption of Accounting Standards Update No's. (2014-09 and 2016-02)"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r136",
      "r150",
      "r153"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "In an Unrealized Loss Position 12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r136",
      "r150"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r136",
      "r150",
      "r153"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "In an Unrealized Loss Position Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r136",
      "r150"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Gain (loss) on sales of investments available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r133",
      "r146",
      "r153"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r134",
      "r147"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r132",
      "r149",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r135",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r116"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r94",
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r293",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r94",
      "r97",
      "r98",
      "r99",
      "r100",
      "r103",
      "r293",
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r90",
      "r228",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average cost recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r254",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r254",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r254",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r266",
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "exel_OperatingAndFinanceLeasesLiabilityTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Financing obligation for build-to-suit lease"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion included in Other current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r149",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r237",
      "r246",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedLabel": "Gain on other equity investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r117",
      "r231"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Current portion of unbilled collaboration revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Current and long-term deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other current and long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r42",
      "r155"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-downs on inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Aggregate contractual base rent",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r286",
      "r301"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r57",
      "r60",
      "r80",
      "r102",
      "r292",
      "r305"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r269",
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "exel_OperatingAndFinanceLeasesLiabilityTotal",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r267",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r273",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r272",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r92",
      "r115",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r55",
      "r58",
      "r240",
      "r241",
      "r243"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r47",
      "r51",
      "r52",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Reclassification adjustments to net income resulting from realized gains or losses on sale of securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r45",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized gains or losses on available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Accretion of investments, net and other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment charges on available-for-sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r71",
      "r123"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash",
        "terseLabel": "401(k) matching contributions made in common stock"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r69",
      "r123"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from other equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r69",
      "r123"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r221"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r163",
      "r303"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r21",
      "r302",
      "r313"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedTerseLabel": "Principal payments on financing lease obligation"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r227",
      "r317"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r10",
      "r85"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash included in short-term restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r85",
      "r315"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash and investments",
        "verboseLabel": "Restricted cash included in long-term restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r169",
      "r300"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesChangesInContractAssetsAndLiabilitiesUnderTopic606Details",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalties accruing to GSK"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r192",
      "r217",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r192",
      "r217",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r22",
      "r23",
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r85",
      "r284",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r194",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r196",
      "r207",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Valuation Assumptions Used to Estimate Grant-Date Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64",
      "r154"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs awarded (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding at end of period (in shares)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in shares)",
        "terseLabel": "Product revenue related performance targets, shares vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs outstanding at end of period (in dollars per share)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "verboseLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r198",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of period (in shares)",
        "periodStartLabel": "Options outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r191",
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r212",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r287",
      "r288",
      "r290",
      "r297"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r168",
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r168",
      "r169",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r169",
      "r193",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r238",
      "r239",
      "r245"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r187",
      "r289",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r108",
      "r112",
      "r113",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at June 30, 2019",
        "periodStartLabel": "Balance at December 31, 2018"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r270",
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing net income per share, diluted (in shares)",
        "totalLabel": "Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net income per share, basic (in shares)",
        "verboseLabel": "Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r318": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r319": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r321": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r322": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r323": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0000939767-19-000157-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-19-000157-xbrl.zip
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MK_^Y]^'D4\<28F+V1;ZLWMI%^#G5>C6F[A&A4]&R=WHL7X\!@V%S3##VYGH
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M#Y/JRS=:X?UCK,LJR_HZ*_]W<?GO;8['^Z_^W$[/XB= ^'U*T6^\/S4J((7
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M3\\]@CO<A._BW):3\><]??!NPA#3KBG+,? T(]#RIEC]H.Q_.\EFA,90#BM
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ME*#L-J6+P)3I?)DN\^V.(C69+&^7L^+"M/BQ^I*OXECV"%GGWXJ<0-I(S0%
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M, @MU);2(0M/GIMBTQ&F TA'OBDQG.Q^K69O^RBL)4(H(, :8SR$&$!7TF0
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M:P"%SG/H=5FXW3/Z^D.BF^KD?8 [E&!MB^%^.XV_3&?3Q?U>VWI/O\@2!*&
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M3FZNI@LG7/."Y;W=]X]DJ^L(T=X3=+8>^2OCML\4FD<O_ WSE?WI.=U\[&N
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M?4[OIA,&V*FS>\N9ORFHCF?J[FXVG:P#?U8KUJQCA:9?$W=UE4P6G[-XGE<
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M&U((QXA]G[+;6N_:/51D''64"(4]00)1@J2K/(O26C2B#(XQ2EA+.'M1P*J
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M!2#G6)ZD1P-X9.PXRR50U TMZKG8Z=?I93*_''();/MV!(SF-.Q:@ ;8(?;
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MR&XCZ-P9#3V70IIX"$-"?=_U&42=49K$_JS:S18GAY A4RH#J3HQAYT933M
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M&8!$+=E1YL^<[!RGY*SL]&1Q*K+3UXU7LF.$%ZD3B,V7]UG@;C,I39(D").
MXAAAZ$<A]G:F/!]*O0/9RX!EN>FFY\,="_7-87WZWM:909A3TQ@MTHR<\SS!
MQ0EQZ4W=^,+2WX7"8%=2C6/8<I5O4F[AMM@\S4#@!0D,$4EI!-(H\;"+.BLT
MQ-(G3'2^/4S44F-R.E"JL8HB6[(ABCVBM"(328[,Q2//_#\;AN@Q-;Y(]$+_
M*NCHPX)"9J6XOR_65U4Q_^WJ+N/=YG);E56V%I<!9T%$?>+Z( 0HAM3WH@#
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M'5:O^S7*&0T?J+6GH>M#.5N,,J+LZ#^^X9K(,5W?;8KM[1WC\:: 5^[QD9#
M 'L,^0GP1-%#"-P6'TVI*U6I='A40\T*F4"ZGQBJ!K!S(Y:@XD\LS1$&FLWL
M=#%LBXT^<S3-+B:.UF%'>%S/(N7TIY$W&\O C&*N0WQ;DXM!OS7G&=/,FYER
M]K^;^<Q%&*8>"5 4XR@&?-;KS(,T0+.JJ+*5B1E%P:C2A+'#)ZU!U^*?\#7$
M;EGH9*]$R.14H4*WB9G $M/&A7Y*@KS_G;;>:M#^+<BICEM*:JG-F_1>H;A:
M(0;ZY8VHC'&?X_5"5/;=Y'?YNN22W/[I+@L4N['+0!)@3%*"B8<#OT$1$8:@
M[.K>M%E[8W6'M-G*.X#H-!A'2YXJ<GAN-\92:TQC"%OS[N6NB54690=TO=%X
MQ.POZTV>K9;_E2_^K5B)TIX_9<OUAZ(L+]<'R=[-LN1_1>HUXZ=\LRP6U]G7
MF1NP. T"XB,0AP&&7MRE?B-"$57*LHZ!S_(B>P_=N>6@RSKMRI'G_%?K(_&3
M4QY,_57VU5G>/_ .H196C=+.<N(^]296FP":G?NCRO^= /_]Q9E0[JI>LQ]T
MD-9S1[C>_GNG==EI?'8:IR]$L9]A)Q0+[79FTAFSETQC8AJ5@6(Z8];,!"=
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M*?)"P%(6='8 I$"EQ('ZUY643;>F0?$J2=4S1_4V:9JY*:-\]<U)C9R(4DE
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M B477L-QI[@&JZ/(L\'/P.NQLTR=6YJ9H7@:8F3*F9<+-I,<]5Z[S1* <4J
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M]DD".I0NHR;R!!;168^;?AXP5AJC=7MD(R;2K,;R%:>F+O9BZL(& IXQFMI
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M:8B6(5\*&QU05:2.GUTARW*^*LKM)K_.OU8)=_ZW&:1QB+R0(1;'4!3WAEY
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MM/[Z0PIQ;W,6(L_S?<]EV TQQ1ZW%G4&(XZCKP))FAE)@QIT!E1(EDU]';)
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M\2ZG$(M^:!Z++39/.PELC5$OB(!X;0=C-TDBX(HU>6,,49K*AZ#Z)FPOBG?
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ML>U512 YYZ3EJZN[K%P^9/M=OJJX!/VU39%Q'%-&0X^2@'C,11X*<8T$4,H
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M:L:4PL+#I_E.B9WEN^JW;"E&75]L/XN7O^3O-EY6^=%1V\A+((:4$9^/&D4
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MH>\%B1=0ER0HA"X.".T&QPPF*I5P0T-.JZ@'[/4+W:%W!'RMN\U-.4(NKYS
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MZO6T=3S6!PNK2(L[K#.X1ER)205!->.1>:JI(=O>D%*3#)KO95BD,(W<" :
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M?QR,<WX7YCFM?6-O.+3BI%,[$Z=]*N81+Z8FX>E>QSGX9(((]6E_?YV5"Y(
MGR?W*"0D"+PHBA+7[W R#'SU,]+'QZBB>MKGIG=7JQ='XO7R >G.+_FVN4ZU
M^LMD,4W6O:.',PL^G44D.W,:R]YM"&O@CQ.]%!^"GRYPJ=IO+V9I>6*L</4K
M_\5==;YMKB.IZ]X+/ME#)(P"%C#H QR"E'1(B4=2I4[:*?!9GDK5D+()8Y"6
MS\:)0K;=-5T<:BP39P@WMK6+1.\K%KW@'HO1:,C#\'/$HT$,&(Y(P[TA'9-V
MQ>J/\ZK:9VNZ+WD$;(9L2E#U#UM(['M6KG(.=Q%%OH\3Y+,X"#W*(C>@/1 "
M>!*MU!MK 8#UAM<>RH"X8H%WR; Q$>&31X7.GJ/ ,')$4&;^E.#;<^-,]-RB
M@4_EVC:78\T0TJ*\R;KC;1LC%G%(J L("R#&2<CG,9@D'5+71ZIR/0%"ZWK>
M@IIRGJ#EN7'F"=9<-GE$.+)LLIA@WCD69PE#'H691)4I&3 \2QCNC;'B$OO^
MD)?-O3T]4D+\("'0C1"@/@I"B(*@0QJDF(T;EW00CC#/X*"FC$I:?ALG*EES
MV.11Z<BR]QJ57G".Q:@TY%'X.:+2( 8,1Z7AWIAN^3\F48HCR$ 0!X"Y&$=1
MV.%,H0]5KS0>'Z'ZXK_R-<>O+/T_NL]8*F3-4KJF70*6=>_/(5L#[+>^!*SF
MB?$2Z;H )78RM#@Q]F!$PBB,718F+ 0A2EN<U$4X'',!6!V=Y>7?(T!Z$C47
M)XZ54]OTW^25?V'7^^Q+>N88J]FT[D/P<P2E ?8;SZ2'>6*"//KOF;BC-%NC
M;UFYO,VZ]9++,E]EHA_XINT'!E$0>[X/((H1B#WFDGY"0%VB=GK[#.%;#FL=
M3*?%V2]M.C5243)H='&R?EMCS\'H#;E3/ (SZ=A]Z[&:ZEZ3\;T[SIS/]*/V
M<\1?FP39FS7:\>7,(OC"Q6&",80$Q&&<(G''6=?U0.,@99-NCQF$?(Z;9M;\
MN5F6E?A6,U&=;O_,L*=B5D'<Z*/P/B+W3QFNIX_1TD_2OU5@EF=EFFBLZ#5C
M(;A2ZOD^:4$<1# 0^4(00^P'+/12V%L0!_Z"_]%U86S^/")R%>T]-E)K0Y#U
M^#JFRPW%V)GZVGR<K?0W$[VO:&O.HT,B[@3/U3N)NE,PHQIY)_/>:-&WWQPB
M9P0C4>#','8!I-"E'H)]'1[ZE!@M7X\+?9P5V;E$8,-N'RD(3^?Q">/P"]NW
M?K90K.17F]'8S@/VDP1D2^28CLDV?3A:6'YAB\-),SR7!CX(4I_"P(<N"Z-^
M6QY-7.:./#,V#=_Z]/CQ3KC)P[-Q]X\4H*?T^X0A^L7]=#];D%;TK<TP;>LQ
M^TD"M35Z3(=JNWX<<0[];.?'23,BGP*0>@&,"20A<WV(N[5P%OO4'WD6;1:\
M]7GT86O@Y&':N.-'FT=/Y_-)9](O;##\V<*THF_MSJ;M/&8_29BV1H_Y&;5-
M/\ZMUXO&( 8X30DA((XQ)@23#GWD S+A7LA!N.>T0U(A<O]WJ\XH3\4[T=2Q
M69FH54?-:Q-LPCP]34M)@E+@TRBAOD<C+PQ1A]X- )YH:^8@S%-OV)RZ)]:8
M[\?IB9W"[=/UQ#[:Y_F^IC-F_#C.ME C3]+/$6B-LV)O"ZE!K[T5:+/O7-IJ
M7-<GH%__./R*4H[P.;M?YF*_A+AL7>Q'VR\W5UEYWVU/6X" !"1-18:0IJD?
M>BCN)UYAFB0R@7?N-HR]Q;0'[!PA=@1DN0 \=S[?",ASA_\^ O3I32NO/V(R
M6T_?U].V+E9[,5X-Z=_BJ7MD\4_W]#W)&H7CZES0#4%<9X(3N_*%S/"]/%S3
M9HKOAJ7B?4F&1LGFE$'8M$%@D;IA1&//\V)&P]@G*2:=)2G L<XNJYE98+V=
M3*80KE&_F1F-*K6<F4'_N=/&"6H\X_KWK7K/3)^V&=5^YLK02W6@N6(=-9*_
M7M%ZS1)OD0813D&4T"@F,?0I0+1K;D\1B>BXD=R&!=8C^:F%F7$CN)4'8)P(
M/K7GY[HR\[-$< W_6HS@-I^VGR."6V7(< 2W[\VQVB?0>IV+?RPW-*]6FZ(2
M?>]]_0![!(:8 =]CC##F,IS0#G., [--X5:16EZA0;>W97VIC'/.W9YOJWSE
M_&VYV8]\Z.= ;X[3!C&>(Z<+L0<;G2,CW^VAG2==9K'/P<RC,J/X.#T7AGL:
M3'IH@J;K7JUKL5XD/O+"$*+(]USL(S<-&>AC=!A$$YV$K8C2<JRS5$>>QJ'C
MA+QQ?#F3FK!L!C3+2/>JI\9IF]=\.GZ."&> !WNM\8,\,T$]]C%>;Q&2"/I1
M%+O 1Q3Y;HBC=ILR=!- O,G*KJI _SVKJ\KN'+V(:M./,ZF53A_9K+AJG+*G
M[O,QH]@V,1'VBIC#?",;W3YGW[+M/DLYN5UU]._Y[H[LJUUQGY57V?<=YIS_
ML:!! # C/+B2-"#833!N&N"#)$RBR%69AAD;U/*LZC/[&_OTE7U1BS#F*)6+
M%Y.PJ:;^+41'O,/]$I;S)T?I=#"=WP50IT8Z<B5.EL 3FFS<!_-06/-F%9:?
M7<7<?K?<U;)\<?-EQX>Y*S:<T8K]<Y_O?O05,Q(EOL<2&!$/D#CV@]1S?1^%
MU >NSXATP<+(8!93M Z?2*V/$?Y/I\$X7:E<AKE3&9-1YN?Q:AJVZ6D>8X$Q
MY9>R&4TD4L66?UFA[WFU@!@F 02!3Q(&<4P#E.)V3"_$GEHY>-!(MG=Z-^_<
M 11__3@LR?T]ALA45#;K/*HIFC*%=M7K)79D5&L0JS-3JV&VO*92!AB25:<G
M0]%"])8LHCCQ"?88]1CS?#<@*8FZL5RB=E*?W@@CJY'S>X-+48XTV9.3(?O$
M#9.?MSFSHC\OTG)"=X;1. ^]&6A#8?+!4M,7/LI]L:V3KM^R^D[KR$T8]J ?
MTL!%<8J\A 7].%!-6]0_W;*N-(":Z8::E&@0)2<C=CE2DY!C>IS?&S@CR\<S
M.DY(ASYU\Y"- ?@+4P^1FEP<>GTNE_GZ?$N6#_ENN6G'Q&X2I;Z?Q'R*Y@*7
MBE.1VS$!1B14D8YA(]GN]3ST]@ET'_*MT^)3$Y6!=,H)S'A,JHG-ZR1.)#TG
MB3HA0V8(GH<D&;*EL/$(*DK5:K6_WV_XE&U]L;O+2I%/E=E=MJWR;]GY=E7<
M9]WX/N5#8T@#EGB4)7&$O&Y\$*102;:,C6I;P@Y G1JI\PBJTV!U?OE85)7B
MF7X&F9=4N$E(5U2["W+NH-VNS*_WN[JQ9%=PW2OKB=HT<B?+VBGI,\[\3&30
MO%U/)=$2<_(K\3L^J\S6;%F*O4I5.QCS0413X"; (Q'R,8.XJ[&#- !21[4-
M'&)$X:/93;[*=ZH+[GK,R2ZO6R=-=3&] >1TB":2JY>).;E(/HC)>0C14".>
M+8 ;X$1^LOA?^VHG"N;B1IU/V9_\U2OVVQT?^+(LMOR?J^:<_[I^CCP^9?7\
M(.1C SYUY7/7M,4 >1:HI#QF1[8^F>S!.C=%Z7"XS@&O\QBPUJJ<84?(3CNG
M\H'J--0@_9;FI0I,GIRGVO#(/'32DFW/YK'V&)15U2O^VQ<W:%W4+9RM@%,_
M(("Q(( P12R "05Q-U1$0D]%/+4&L*R1 I/H$^I0::X'ZG$GIW?6:5.3-77&
MK&C72ZR<D*A!),Y#B8:94!A\J)3K9:V4?1'[G9;ENOKZL.;3).Y9WTW:L4./
MPM1%P,-QXJ5A0F/0348A]&.BMH?(S)@J+Y'6=B#TY:OSJ?BK(U!]<!/E:I@)
M7J4K82,3JIAL'1*K'J#3(.S8G:X:]C9SIRMA!IF?AY09MNEY!<PX8R;$+G1!
M.S:*8AI@D":409[%17Y"6#]VY,6*"P,&1K0]%3T(7?C!!>:$3H'3X4)GATZC
M0B?8G:'0]<QI"ITZ\_,7.@V;%(1.ES&-_JYZ)^#Q?G8^9 H3X*:IEV(< DQ#
M -LA?88BV%XIR5&7.SF5&S2<RMOX%)GTBXF7_,M55E]>5M40%5<WAS$JIVZC
MT:@F:L?M86?-WNG')W],UBKVC"6YKC%]<N>A6V9,>;V7;"@_\GMPGF[Z.=^N
M-GLQXF51UGN:CU;.KXI/G!ZQ?Z_8;)IS.3(.<[>(HRB.6 P]2B/DH01AOY-0
MW_==JJYG(P$;4_G&WHUB@L 3;_/('IK'>S^VT<\VPDS N73&TZSNY]\R=G.3
MK787-T_J]/EVE3^( P^:*\,/Y;6%EU#*/"^%+HM9[-$$)IVX!20(E/I7+<*P
MOA[95HQ%]?C$-.93\3^KOSJ_=&4;_M-N9J.:45GTF&2^-0]G*69C/6BG02T<
M]FSULD7N\'2WP7Z\*#!ROJ;-\JELSK[KYJ'Y8QCZ-!,<BUM9;7^M4TXTJ7[*
M.+ZKY?<7(U#3:+EP?0:"E!(/Q)2Z,,!QVJV<!*[OIFJK%[;16%_7:/I^5X_Z
M?O.V[W=SLN_7BCX,Y/.$2(SEJ7DHQ6C6%M.\#QISR_.JVF=KNB^%;#43J'IJ
M^_+ID(O(I8@ E'@8D#3$&/BHVSP5H"1D:J<^F!_?<@8HT-9%,IXJK)J:3U5O
M"=QO^:/K9,U&8ZX4W&M",T3JU_S" __$.VZ.\\ _L-(OLEEQFEPN.+6_U)+
M!I;3X#W4Y%X\U_!P+-R9L[SASX63%N5-EN_VY115 36.WRH!6/+8/!3=JH4O
M3>ZMLCE0N>L#"E\! E(WQ#XA$:1Q$,1NA!*_!1(RF"JMV%H8_IWHMA&M'N2F
M05(]EH<&*74-\KT*]0F&U77:A+MF+=-&#)13:7-<:FSRN"I>V>?[\C&UGX4>
M5?DN^Y*5W_)5UECP.5L5M]OZ4]ICUD/*IP*!&Z5QR'P/IBCH9@5ABK'22;"3
M@[4< .JGHE63U1%Z[>TB$[E4L@=H:IP6VX<NSXE$<.#SZS(385ML7"%%M7..
M;)ALDXH59YSJ2)K+<S"/*#0?.E[?/3,'/QEIH2)IS #S8P@#/Z24!8%+NB%1
MC-*VY8!MUP8:J-X:3+V-H,-EI7WJW33]R/(ZC_?;C"DJ33]J_(S<]!/ D&&(
MO, GF'(ZHR#MSL4+?8"AZALX$JSQWM7_;O@9XI]YO/-C&VVGX4>-<UD=^9A5
M599]%'DPS:I5F=<KT%<"R0(1GT]M>2I *?&2!/.14A_Z(4HBCX:8J$P>AXQC
M>=[70#MS:G!GSA$\Y_<:H.(^V4&4RDW>QF)3;=XU@$@K:GJ"I1,2:8+;>>B>
M$4L*\T^>G$)EW_F+@#;+^VR]),M-SF?IVWS9[O?@GTQ1PCQQ%;R+<)*$8=0.
M!2,82YUW,F@ VVV$#:PSYP!,3H2&L79:?48C3+'<\YRKMW>'&21M7:SV8E[>
M%(HG)^\1'+LD/E%M86*MQ6X(XEJ)3QG]@@0;X6A:[35C0F'PF3&1#W[,M]GY
M+KNO%I1B%Z#0Q;X?DBA @>OWHP8\01V>$\J/-6%>*$ Z-4HCR:$"OT,21#O4
MFDL295@=,5/LZ5+.%M6)GG/&J&&-5-:HRY+TZFJ9+2]N/F?+#:O$[3.79?&0
ME;L?"\X,3$+/@P'T"71#!B'JAD,(4Z554=U!;&>0')=H9=G42UP/+:JF]/S/
M_;+,G)LLVZD>3JS-J.2BY!AD*F:7+8\"E-.@<CI8(R\2OD+.J<6]H7S.0Y:&
MF_%T,<T,+U)3V$;[+OCG+\6^CUH$/^;+ZWR3[WY<9=OE=G=^S]_/;_6R].<L
MO[_>\[>]7NE;$!(S%(@[L8"'21 Q#X,6#Y]KN_+S7*LH+$M9 \_)#_B<\A%
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MJS/F6$Q@OT9RY02Z@7Y^VZ2PNQ$#<%6QCS3U/L[Z5*Y 6K DIT_Y)EWS.,X
M;HJ'=T=X  \&--%,_$*DMJR<,(;Y>X(9QF( #Z5I8U32V [#VHU \KK[2#=
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MR7[ZUS_ZOV%_\(70O_[Q/U!+ P04    " "8@?].32UF]/:(   8&P< %0
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ME1+Z6N.^2;*G_W$6:<;+.@UE6&,!)51$,"<<E$!35*'A#$\)?GW;@1'IE.P
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M,UZA8/LS9"K91-K9XP"I>4IRU/+[-%/'^?M]H(ZO?C.#B"0B;$>%XF2#AX>
MIR0[&2 ]$SF1Z/=IAO5;NDPF'$&6>86)94PQ"H2NQJ@W3)]9/HO.]'[\9;)F
M"CAR6IO/%H^FM/#;\^DL?)1]F)67R]'B8O:IF-V/1\6>17-?T<QZ::%DC(@
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MIGH/W(FV;H*W 80Y08B1RD"OD<)PU_Z3"2.)JV0[ZZT4^R+)+URO/-E1MMF
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MW&*?.UH0&%@KL!) &2FHX9R7FT:I@*]436[\CN$X=MD="V<,]N^1CIHF\'&
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MXJ;Y[#:#Y_B*3UX+*2AM/ $:0TX0%U0875(J5*/+>%,*XS6'88M2Z#7Q>;N
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M\I<"!,9J2$7*LO&&<A"Y6/!3(CVUPOKC\@F'E65?NK$/W[Q,7Z'?1R!?;8
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MSAGG@-/2EKP6NM'I_=EAELDYJ&,4X:6HRQ-;=[(Z4.??#)*HN%W&BA,(-%'
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M<H:HTG)(B563?B6C3,8>$=8[E53_^-XW*?H8_US-K^)/6ZK^6,XW3:!=8]S
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MR[YH=]MW-9%^0?^Z<$]ZX^!6OS&,WEEJT$,]<'\47)_T(L44/QADI\ %F'@
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M2J'G^,YL:E)XPF9&""MM#*9P24(.)41<8&DY+N4J3/)!@6/?LEUD2%A%0L[
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M-9++7'^?#G31HDD:OIO_8TT!Z2$K19@->ZJ+INV/)TCKN&RH_T@6K<6(9]^
M1,YFFW?;W%KQDJ_Z,H5!,"K&<1L-AZ-P/N3+.,OBVW=P<M=+XU$T[/T)Y/_Y
M?H5#2'UA1;F6?B[>4/[5C$IH29B<96N?J!:)^?M+I,O?MV\X^Y^^_-Q;%?@'
M]#Y\0N8RN&<Z_C"CH#+[XWB<EW>*!KFQG_DS4#D/(2DMUF(I/!L#Q[/UN1P@
M&&=$F4^"N8>%#>V3WCC0Y=N&8?3.C0?Y;2&Z[IB"^:S>UA=M>OVB'OZ_+MR3
M]Q"<_I(['LL1O%]P=HW!.63>YIIDS8H^RM40JT0N]-]6%?= Y71404*@J+5?
M_8C^NU8Y2O'?.ZC&&0(;0NPJ/S?:1[ 9AE82!:/>K^-H$ _#WL_G-8]NPQPJ
MG5PGMA ^4WXV0XQQ8;L.\Y!CZZ5GSB2LPMPOTR!1XQ[=?PDG<9+5PZ]WI<4Q
M^_$D4E-.PX$B:SRZ#$:C.+N,[T[>_\^?)"?L^\<#])7Y]5!I;N'69J4)JI7F
M__Q)Q0W?E__\Y5?KRX7WY<._>E^\SY^^7/0^__KE_%?KXT7OXE-/N9X7RK_L
M0=S[]*4'Z7?#/_<^^;V+OWB]DE>Z\$@MYT(W0XE)4_KO(7U6>4 >*"PB*O7=
MTTFHS'6<]+*;L/?'7"Q[LWJ,O5!]<K@PY,_YQ _KK_AV$ZG86*O.4,GNMR28
MG&R#'5ZFX)AC,<E\FU@$J#;&+6]>M<21CB>K8/<YGY4W*]3\.-"]&^H[#E3'
MFV%P?Q\&23@^>?_7Z3CL(='OZ6>V8>_YM.L])W18$28B'@C3Z1ZD*4[V%*L9
MRVXL^]XM.UVJF+R^%*?494K'6+X++%URP;%<FU+/@;32FTX4,B*=P6O$M!-C
MVC>;]HLOUL?SL]R -VK;JZ+7YQKW5]+(%734%Q)'J:X_W?,CI?D^YE5NWZU8
M^FU 8:6R$)[P+-NU.7&4TRN8@XGG(8X%LQS;XU89*%Y>.5I_=?;1#:'G+G/.
M2X^?8H P77"N&CB-$G('T_P 7> ! !^DV(\J\8<!>&;B#VXU?[-O[)S:>_&,
MT[H,:*_X]KJ7)H,?3W0IYU%\'2N4\"  XLV_)]<GO6"4U345;RV$@.E@HO X
M9*'-WZJ7KZNYEZ/-HQ-NM9!X^92;+.W2U[7_;$^ZTN.NQ2A@%O80\R7'MJ>T
MX+KN^Q)>1VFF_(3LHVK9H/^\?WH?SOYY=M[OG7UTWNR8A&M/WOKQ+IYX!C]G
MSW[GW2FFY"37:WO)@M2](.VEDW"@;Z(8]J)Q+\K2WN FCW?_W'0B\ZDJW@0X
MSPEP**B/<,IM!QOA/,E#>8P^HZ4C,\07PK%]O<SNVS;5^\.$UF>VBQ%P]=:F
MA_KL;#R(DTEQO4A^)Z033\=9<N^H0&R'^"?5CTZ2^*O^@$ZSN.$H^!;H^Q4.
M) 1J$T=+>U$=SU%,]25BM@.XCQFQE7>NW 2+(U>7Q7G(T8O@[JRXMF>0<W6K
MJP[(*4:48TF;-%.OQ+4&S% .@UZ<].+L)DQZ_YXF43J,\LU#VBY%9<CDW9+K
M8!S])_^YRAQUD$1G;[Z\.7_3\VXGH_A>T6A5XHJ0M''3K.E!*NWP]L3C8W"'
M2R?GF%!:E/J^ RP;6\CS'%?CCC!+6(YTUW%G#8=)F*;%7Q_4'&!#X7&%&H&"
MPMY?@D09Y9X=W/<^!\GOWX+[ED;/>^/7<B&/0,^&GD> [TA;0)WA\S6_F,4M
MQH1=RR]'_?-3<A%_&^^/6\5=ROU78<]C"%DJ@8.!2SQ7%V!"$CE(^#[."2D<
M['EY]9$:0N9:\U/R6?D 2D-N"HV>24W':B\=2RO+PA4^<ETFH6IV(=$''!0=
M+2'4SQ:LI>/G6/E2H_\OFFSVP)Y+14DH0!W3%XV-];M=F%ZZ2\"Q$?%=YMG*
M9_.)E#806#/=HQ[VL3YOO62Z5CQ6$@;[93.CX"69_.>=X%*NH(DD!"ZT+ !=
M;'F6KZO!*<HY%B60.BM9Z ^Q<J$^W\3C9K/0%=,1F)_JZUY:BI/G^$4-.(&%
MPNIKCW@TU2/I_2>:]/027K\7C(>]+!R%$\VGWNPFOG)/%1H&1=>57,___$D@
MR+]/>Y-$=8XFP:@7WH6#:19]U5DAY6*&Z9^?1J('V]/6-L+O83G]7(T\B;(H
M3(LIADDX[$VF23K5>:TL[IW/3B7,%L0@^N[RSYH>>D.'-<C>O=P*18?35Y*]
M88A)0>#L3_R\9!;>OEPAZY-9"-:WD>-(=.5O'X:#(H1^-U4BE6AATB<[HFQV
MLB,,!C>]P2A(TP.(J/=,DR3(5>;Y_:VR$=\]5']'2)&/Q1)!+B3AW>!&7[O<
MB\>];S>1^LU2U3XI<Z5(<H#T>F*RD97*!=F>)3'#KG2YQ*[%]<6+R@F#TJ5(
M"+R2]"@LVSU$ESEF-SAA>L."XLUY%@]^[_W7&P"@SE?T_AZ,IJ'>K-C+[UIN
M(%%\9(PK9XE=+'P@&;&1K2(-/LL20^YCZG%G)?M1:).9,MFR@&EXLB-/2FLQ
M@G+"')L("!SI>8AB7<M$%YF&T@= 5(')*U39YK7EM<47K0'GZRX7RG/\&*3#
MX(\"<#\'R>]AUOOPP7G!DR"PZKS-GGWML_%0YY_#WN5];W 3JJDKA_!W91+"
M/(VO7>IEF/&N]QW\\\SIO@G2WE4T4GYY,!JI+GKGGW;7_YA&VEE7/OIE6'10
M;U[UU['._\^VIA5>>\GCGW-3>_*Z.=^:-E2MRI;KKI,D'(2Y98>HEV]33GO?
MJ?<I]O;2J;)CZ4VLE[CG&[JSFR![,(W>MV!UJ'J<LX>+B?QY%HI]ATJSO522
MHCI=_EO-13^4]U=/ZJ$4+]/;(=-\)/E(@S3K2= ;!O?IG]^L;^2;_;E#Z,]*
M2USJ9QL(7=C"LB'CNH)T;G5\"UG(!\YZILR9)HD:WVR3IM9E69!-T\8VH_TK
M3/<6\*]N@]SVOG^HR6D!2:M>HS3*]XUL[_\8/VXTVS?I+K:]/B4\;[W.Z&GL
M*-C<1EFFT)87%$CBL39VH_M>J S??>],FR(EU3I;X099,-NB^4"9+-]1S@1\
MF:J>!%"M*KZ$U]-9+8'>^>G%OI7&;#P+-1 VA'%<JLC-J.T0A68?6YY+J;0E
M5QA'T.>00%TP9'UCPH*0FHX%Y W&#<;WB_$H[06]49 HLQT,!@KC*OQ4*-&P
M2+0IK?QM3\G/:65#>JN4@_I*,K=52H!OU63N^]IS4*]3EE9GK:Y[UTG\+;N9
M-[]1CD28CVT87D7C_%!"JC6#SH\B\'W="/-F^/V\V]8.]>.;=]3>0]&Y9JSS
MGM$XUV'S5.;E*9K]L_",RN[0&Y/8;,.^/+;]X!';D*[<D.7<L)T/\?HV_+A7
MMB4YVOBQF4>&F6P99@(!?-_R/8KT30VZY@Y#VK)2?6TO(#7'-Q)'J83K.+G?
M)<K,G\ZUR*!X6@><'ZHU47?W_3W21++O6S+76'WJ:A1_>W<3#96*VV&FT5@9
MR*A"PE=]B?;P<@]XM):"/9MU(=UMF_J^Q/BAIW<48MQA^_*QRE-M"8N-.!NM
M_,A]%;.P93;C1>PR^[&(2MI'AU<Z%<]+-::@94%I8^;XEBYY;4M/ZERK^B_Q
ML'0K#HCDE+:GJ0J)T@TIUDX<B#<FIA%P>M5I@I8PN06 +!6CEKY"'1.4N#:Q
M@*TWK L-2.'ZS%9QW3H@Y]3]*2>N,Z.M >9!&TLS/S._G0S'P:W-7VW(=>MM
MP94I^NBJ:@4N7W=3D<LXSI?-INDL3ZXF,*MXEBVJ^,S7P/3:F/[6Z%Y__%ND
M/JT^VQN'WW02/@F_1FD>"8V#\4 K>!4?Z4.PNG.:!>-AD SU?N3X:S2LWKW;
M@_B[H&H+@$YU]]1_GK4(!)EXXG++*^QX?L)J2WH3CD9S8>A]IUB<KWG,COKG
MJZ+Y8D*O8AVA?J'R7V'ZQ'5+SD"IBA2%4GG*P':09)@":?N(8TJ$LK&>KC&_
MYB_KR3S;*C_> UF/:W=;SMP@>2^Z\+AU&?1P%ARM?*&N">+]=3JZGY$/H7G!
MPN>_M:]AE(2];_J/!NM#S@3/SU?ME4Y\"*O2]8E$UR2PB&MQWQ,>A98WOR6>
MV0R1JBT_^1[2?$=;OELT_33-<MVL&+T*L[,<95B1#J&3WG0<S7Z=YD^=*-4R
MB%1(FZJ.'Y5WG2K_(,S7Z<IU(\?3VV&<%5U/WF. ^A*P/L)B#J_Y+!\ZRL\A
M8V\VQKF>JS@3,YCMI$WSC7WQD@)OU@\-K5Q[<),LUSZOP]/+) Q^/PVN5/#S
M+AA]"^Y3O;!VDSRXDF+[%0[F2HK_O/"5%'O>Y/JP:M%C5>Z+#W2M*O"GC[V\
M</VLY'EKQWWVT?7^:38_M&'SP_9S7'##+@:QH0VV9:N"B;M?;GY=J\=6H;P^
M*^=A2RJ[A*X6'@C9W86HT>,+IX*X+@"N!81M6]1G0/A80@)\2_\)?=&T_?BL
MS%[OK'?:\\\^6A^=,^N#LM3:\%D7Y7N6@EH&O1I3]K#0<):%M\5NPS>[('9?
MLVU,X);RY0MF4Z0B)>':U+:Y#3P+2,=5_\10>NB9%/07.:^\?,MMC>/ZVB>\
MUNX]>CGRXMW!U'6#M\[PAW[IWK3%LQE.A5+3U.+4(3:5#I,0<PJ)BQ&W$ ;L
MF7A2P9]BB\XFJW_E]C_?9&,'(P6SL'=^$X;'!;#M]#8 ZQ; L/0\#SN^ZV!J
M.UQX/H9"(H\*X'  ]@.PI?72*1A=U/0V/"J8;:4Z,3#K$LP8(]PGB$C+Y]02
M2%H.];CE0-?V?=O;DQU;A9E>Y4K"&]5/GW8\/M!MYX$!7:= ![CG4HPLSX<N
MI=2Q+=^S;:5Y?=^BW'U*O;F=09<O@=W$HV&8I,6Z4,_[8QIE]\<$O>V<H 9Z
M78(>IJXG"?(@))*ZD@KA28\23!U7>@18+V+O@O2FYRLN'E4$MYWRW$"M2U!S
MA(-<R%Q(716JNY9TH".)]"62/@+LN2G'CW$6IGKO7 WFCCTEN9W\\OCR^ZBK
M^7W";>929B.L'!=*E!]#&;"9 ZC$C'/Y3 K^'(R#ZQQ#BSU$;I0.IK/K W5I
M!VL<C.[3*#=P2^AI;,ZVT.H^7\)T.IK9P$^3<%:/\:@PN9U+Z G^YJ&#$G<5
ME+Z+B<^X90G+HK9@PE?_XLH%$L@7'.-G4O 7O7L\4L9-ITTTOM0O1O.?-3Q'
M<3K5&P&MRWB:S0OX?8G2WX\)<]N9@)_@>!XZYDA7,>=(&_J619@K":7<$1 )
M@!S!B:"^( TD-+,D'J4YWCXG\2 <:H@=$Z"V4W@SH(YN:X\-'!M3;+F,4 !\
MVV%24 JXAY'G8'\_6WOTWIY/%W_QOASYOIY>9[?T:(-&"",NYY@Z4@'0D=3Q
MF8 8 P:>)U<G[S^$U\J!SU5<7B?RJ'3<=MKJ(QS'@Z)B=YS552P1:ML,N8Y%
M$*&.)VQ&B10.<#@4&$GZ3!)JG[NG3RS%R5'!:#M9CPM&O<[FGY2+PQQD(Y<0
MER(/2\"DS]4?S"(.@,]UNW\=EZX].@]&L]-ML_7*\CEI[97_FN;GIPK+=51X
MV\X%!HX*;YU-+5&E2JE#/28<BPJ*I.=:/H/,!H)+YI-G$L\-KX(\5?OK1)<.
M#\=1G)1P=DR8VD[I(\-49U-'R,:N:_O*OV<>]:"T 84"0,5D]3_Q["VG/T?C
M4-FNJU"9K%)V]IBPM)W"1X8EVE4L^3["#N((>1ZF/I>V8C9S;&Q[#I.8/M<?
M_)07@3D;SXHM1/'XF%"TG;;'A:)9<H)U%4J>YQ+'=[FKCX8BX I@$XJ5RO0=
MVP'^<_?1>'<WT65T7'MCMI-T,X*.;0D#6T!YN\*%V).4^-("S(+<1;Z4BGKD
M>;M+*I8PSL]^^FA=_/K%.]^T8E%3O*ZN*LHZZ59)NU/]I^(-*RRNJH+1I+93
M4A<G[^9U $[>HP<*;_CD$CV/.'UN2O3\9Z\E>A[H@L=5:'E%\9LUZO?,J[NL
MX?CAS;OC.+]T]Y&E!Y84+(3T$4?85X2T(5+G$GN0A.X5ZY^;M\*NT?D11YL?
M1V=3=:INH,ZGCZ[W\=QS>^I?YY\^G+G6A?K!MCXH0'B]\[]XWL5YB\?_733N
M93?Q5#TT3/OZYNQPDLW*SN4I>'T9<_'3K:Z ^O"J\79-9CH.IL,H"X<[C/))
MZGI](J5/;%4Q1U-0*W<W-A;4XG1#T:S'U=/:Y;%]?JRE]?OE,X F&[1AFX[,
M;(_"6EI2JRW$_>MT7-RRB$&_EWNJY=JPQU64S4C3,Z7)#0?A[:6R_!CF-8;%
M_WW2=26WBMNC\/O+8/#[=:*<A^%I,<#!( ROK@XN1UGA<5CGYVO^W>YB^)($
M:L5AR".8N.'^HQ7$H>D!%?7-[A[O!6D:9NF[9TK H3/:N!3=F6O35OW%#KD_
M"\ZZC(/.=@ST/\(_IM'78+2>6MN;L-?2\B6)\%_[,. ;)KWS6N%S)K?M/@I,
M$0PIA<M;V#"6C$D)"<0,>A@)A\_NH^!$2'MQ+>(T/;T.@LD[+4+6>*C_\I;R
M8V5.D"3ZCJ&_!Z-I^.#VE]F]%.4K*:;IL'P?Q2E>7$>!-U]'P62?"[GM*HHF
M.-N42-:JIF*9Q3B31N-T7^/PY<52CN4APC  %N*$(I\)EQ4:!S*)>5,:1_Q"
MFM XD/0YIYW6.$\,8 ["Y3F_B9/L- N3VUXT_AJF6<52XIKSB_;@_+80E((N
M;WO#B'M,^BX&MH0^L3&"Q;54#F.>^Q"4.5DO%%7/ED3=F]576J*O'),&,=A:
MX]X!&WYD*&* +% DE"L-*'6X#R$&JHN0M$"1A,CVGXBBABP9%WU*F_2=VV^P
MNA2\7R3!4%^--PB5#W0Y"M-^;QQFS\1@H\%$"\&)2N!T+2P\&T@'4LF(L*5;
MF#CIV8PZ#\'Y94GICV%69$+W9N,D[U,".^UF'G-@:P!9 )+@!2"9:SO8MBW/
MP0XC'$DNBT"0N#X2]E,!V8RYA RIP*_;B.QRX#<[;U4RE\9;U?AC2_PYB%B^
MJTR?KT (/2P10H6W"BW/\Q[B+Z?HRUI%J (_";K@LIK KW-0$FAYJS?Q;,@Y
M <+F%E(6#5$\O]6;>AYY%I2:LF=]0%D7H'24T9_.$(RS.+DW4=]69'* 2JL-
MCB-<2-2?R!:0NE1ZA9/I,,:MA\A<T%E!<J]FC:).NY8FV#,XY&BYSX#[A &(
MF(U=)BD@#E<^YBS[8B/;7=MGL 6'S=A$V1>XR66%]L&PRQ'>YR2<!-&P%]Y-
M]&4:LU)J<1[V#5;V+3X7I7O8/=]"L)(E6)GC0-?Q*;$QH-)QJ6\5F1D*7 3!
M0[ 6G/!FC+#&P]R_M7+BOT"(* AO$L1;V-U:DWI4EO,X,,F6VV80(18 U-9E
M0&P&$:!XOK:(/%NN+5\\#9,-Q9JT#^!18++A6!2S0S"\%W$6C!JVL4UZPH6T
MY$>,'R\JKX=RL40YY\)RB2 ,NAP(%[L2%SE9*3 #:^'JR]A827D?-6MDZ_C]
M--Z]MNDUT>RQ8UC*!88IL2"Q?>Q0XKJN+PBRG0+#W/;=M;UT+V.3A>3**#>9
M #XP#'?XF-Z'6(_.['%=QZ6 2UP*AW-N40DE)1R[S /,G^]QM21:6^_45'VI
M+:X8\SX736XS;ZVM/":3V!$08;$ D2\%]0GP ;,A<H$R;1P4(/(P)6LKG8\#
M45-A)^]#T:2;VGYCU9FB$V4KEBA12:*!OA-Y,#^RVIQEZ_BJBZ!+DP>A[2+F
MNUS];4LB'<SL&5J%*QRQ=M;JRX+P^KC5QW@\V'?VM@]!D_M[VK<"8T)' TG!
MEP;4 H#8S%(M'O)51&@)/#_^2!U!U[S0'2#9D!7M/"0[' E^3N*)FLI];C)U
M@8>)MIA-[!GJ"!+E$HFV:_G8MUP;>\2W/9<[7E'Z@%F6A=9.:\UI^WD4C#-K
M//3FY-WG5B$*^AQTXM"6B0N[!B8)^7++@,4%<'TI?4\0[F-D>_[<K$&7KGF:
M.X*I&=.FP"2DB0\/-#[\I 0FR-3W>Z,P2,->/HK3^.ITJGYHWRID"_&*EWCE
M@'J^1"H.]!W7D5 H,!?[8GU4M6-]3OP/FO9?]!0^7?V:AOGBQ?["0]:G''?:
M&37QH0&FI&Q9B4-"))F04E_>Z -;6G2^ P!BS-8,Z:[ ;,B2]@5[D?T [;>P
MAV=(W? J3/2UQ%EP5QA.$R$NL,B76"3,T?='>:Z%?8RQX[EPGCX5S+;00RS.
M"7LV'L2WX45P-UO:WV=\B"#H(]P)G]8$B)W#DEQ6F(*8(.I*3 !"A%+H.?Y\
M5XSPQ'JAR9VPU(Q10X3T(6SRR'_[K5>'XL.?XGCX+1J-C*^Y"9,0P"4H";)\
M7XD\E#9U;,@L%Q51H'0H)VN;RN<DWILY8[C/!.FT8VD"/@-""/"R,!6WN40.
M\'P!/$PYM:!;1'S"X[XM=P!A,W;P"$#8X>AN5OAFM-A,8\Y [@!+NH0E!9A!
MAAW7]RWA^3YU?;=8'L1"TK7EP=+YJA?8.$/[G#6:&&WK"2L3%1X?"OFR2!6
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M(,VZ?XGUL&ZR;/+N[=MOW[Z]N;M,1F_BY/JM<CKP6Q7QA&_G?4]Z=[>C=Z-
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MD0:1'4>D6"+2 C:Q(4' 9UCZ%O&9-U\IY0BY:ZLLCS.2#4>?DO<Y;;0B>>N
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M0#974ON270Y!A3?07P)^!?QZ#K\:[>1H"I7 2'%GEX%82:)JDXQA:A:Z@/P
MO]I.C> =(EL= !@ + !8 + # ##9Z.,7"R 9B#D@B< ,Q@PP5;<ZD3%)UE#
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ML,?P^01R;B-[08 .1:VF4J^]Y3NKZ!QR4"* 60"S9\ ,SRMO(61(8D8,Q("
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M+..DU&N=T6Z%S'!2J&_]8G94XP(?\]NK?-S(X?1QW:*9QGEZ9F9YG.#')=0
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M72,#Z ;0/2+078:Y8HZYFBN8IC*&A!)@.*/ @!IS->8+<VPVB;FMS)G @G8
M:K77VGXIF&^:-;;Y4<!K=\!MM>)C$[SK<P+1.BB^L\;, 8C/E1,3 WT%^@KT
M%>@KT%>@KT!?>TA?*]E.S0Z'+'8I(S Q&$&I.$D)975278S!@K_*JJ_ST2//
M-L_?JN?I1UYZV0&DS?20P(6!"]OB0DEG7*BTPEBE2L6$(XJ$ ("77$A0G-*%
MF7NK<6%@H"//0C]_=ISM6_N7]T3IVKWVMCM%O;LJ( *I!E(-I!I(-9!J(-65
M]7$(V#P++F8IU3B&">8P5A DL<#61.8<2(8UE=L:6[_#&7"P0[C<1H@RH$)
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M#@D'\5P;@E#35& H&&46!(V"2M4X2!.SD#._B6Z2&T#,]2?WM)D-%% RH&1
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M'GM31*G%YMZ#O"*Q:]E5;T5,+-#2"K14AM\CK_T>IUTY(QBK@(]']RNFVFZ
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MJOG2+F;' ODD*YSVV768/AW8RSF!89>MWZM W"]$-+*B8OQFW$;FVJE6A%-
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M<GC" 9.L=3RQ<"(,G.P+4"!''4:8!Q0/*!Y0V@(4!.M401;%4$8V<XT"P!,
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M:A 1+"%(1U1JG! H(JUA>3(2,LY!^YE?FP<:M@,<A'48:(5G]V #G_Y Q./
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MHF_T:S09NVD;W@9=,X/_-L9:?]B_7@OF9@;L"O>'LW0N:%_,>E]EUN0TGUP
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MV(B+A"P6(:/&SHAYJ "C4147X9# E4:4VXB+G)VY(;VU<7XY%N_'>>;3* H
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M!!8R3F"B5-G5@$$*HI4RG%TCY?PK!AOGG9 +C\XZ=,:?BT8&+6MGKCVBJ0[
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M63 4&75^FY:ZV3\:M]]6!IO/GC^X VTZ_ZNZ\1:1VH+Z?'_F4>*S@01>0P)
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MLN.1PR/'&Y!C#:_6Z2.+K)O AS&3@H12"L@99K&2'%:'ITJS]I&E!1 0O(-
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M./LVMD^T>^UX,NK-NM-@W!]G=M$N V4FW0[*W+AP%NS'Q=/L!=>SW/R<&W?
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M(%?NL_55YG8U+5D]J24*7%R;K=AJ?D6'Y@;6',VT!)KQJ#]LCJ;DHC*;^=A
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M!S:D!AL6&TN#QQ@"PC4*$1!(5F"#D^W111YT#,A@CFR377>_H9X#Y.LY+=(
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M@!?F3PQ?OQ':+;B8OR:66"1IK>R#[Z49MU7)U%5.]1LU7HT:O69KY!NSNQH
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M&;S&#&B-0(%EEZ>*(6TY1!5F8.+2%?+=';OCOWVI!$.-![\LQ:(U[( 0]8#
M)]V^*X;<(V:LQPQ9.Q<64,DX85@S2!5')M6H2K!S#S24ZD)D8.M PK?7VB""
M2 21HP 1 NLL70"8,!A[!-$DE0(AO3S70\PQUL4(1>L@LM6S_8@A$4..$$-P
MC2',2 HL02EU#"LKF9-57A!.*5]KB&PIX+$+IP71[;49.02L>%T. 6:'$!#Y
M.IGU1W<8VE?YHF+TLP #RAIM;@E$2*K42081*8H,JR1!Y/!+#8IG1C+:4.<>
MQ*C'1)L*W=D]_)2VZF-1,E[WDJ:<82YPZ 'CO-1*P+5>9N$3;G;H^K?1<[4'
M:$S%B5K7R>-\(ALMCC$Q+J3B.,HHPDIP6:F=!,SN,@$^'L3'@_A3U-=UZDIA
MO4LB'=+4(</$8IE:)YRLN+I42'MMUR]MR02E/2;E,6R&IT@NO.SKE=_M%!D+
M39Y66DR;B>DIP2EVP!J9"BXDA\N3<,;!MMML/R?"E/V1C?[SX&^WF.**V^W2
MW;G04:=@H:N[\M%K/FU8UY001H&#D'(K% !,D^H\6[=H7;=QGKT-!(@5IE']
M3TW]>=U_WGE#7;N4(XL8E\(0@*K L;\L79LVN\N3Z*C^4?VC^F^N_K)6?TTQ
MUL!1J*#!DO@_544BA1D#RT/DH'J;&?VA)4[1$<<.I^>CR72>9QV"@9/S _;:
M-W7+X8 PC@L_DEDV3287?OVO)]/A(RTS6TL].1)P8+ &AQ109E-$#!9(4@AD
M*I;MXA$1*X?*^P@*+.ML&HO^\<(NEKP]/$ ]*=$.<TXZ:R&<E"%P(BJ/4>T.
M*.3= Z:X-,@QQ8Q@R])9)S3M4C1@2ZJ_S[34J/91[7>F]K3FDG6I\9HNF9\]
M+2@D'*DJ"B"$-BOA_R[DHT>UCVH?U?[E:L]KM5=IRJTS1&%#C-&IPQ51!J:.
M ]=%[S\:_)U.&* '$2)8))F?5WD#C6SSC9<6^Z4=3.9^;]P(.;8>,7K.-+VF
MA<;:V5@K1P>&I[+.PD\M3X$B4%LLI&"$JBI3$5.!.&P/3_UG74KAI[PG19M=
M.%XO19VUI8[Y;"7B8\3'1_"1PUA $3$O8E[$O./!O+7E*QS'\I6=R,51%;Y$
MM(QH>81HN18L::-X"#/+D312$DV!XZDVKLI&%H"P'7K0V_27&>P!L+WPXD'8
MCD7@\:^S,/_+]XM_&X\S&HZSMY=9 6$0@9_N2_1]BL_PNC&$\X(V\RYZ+"\9
MCCWL+5ZW+/6K VY]2*LW;=QB[7B;SS .@CJZ<TL(%D!1K$URGHU&Y:?_YPUX
M4[SV8SNO7C\P2U^'5]DT^9#=))\G5_V5O>6JGW\?CA>/UY_/)M4;BZVJ>.=F
M.)A=^JO]_)2B[:5VU+^>9N^J/_YV7U;?+./8RS,?R-X\'N9>W(/(G_[V9D7+
MROL_\1%XW=?BS5YSL[UF*^[KP!+2+IU8K@"/W  IPW?+;:A\UL5GX6<J1"K>
MN5F U+?):+#0=[^+!CIMOUN&G3/S3V"S\^+4;S&G&/82OU.+KJ6\[DN(\!YD
MZ 5G>YV5JN7YR:,;^2&,(AS^G'C:1U2 UXE.$5TZ:.&O0V,'/8QPF/&:M(2H
MQ%&)HQ)W9!@A./]8ZXZHQ2_4XJ-R7T)F9%*D1D8VG^++[Y^D?GVWJ8QM=Z)*
M$2ZB:&MR/#MU '/$)T]1-*)H1-&(HG&8HK&_23CF1O6_>MOK-KGJY[]GL^1B
M_FBO^M9-\Z[G'AQD!@$"K*YIP@!;)BU2"CN"TE#!C!<9!-PYRM 6F/#%/\FS
MRY8*R?NU$+PTR%U[#7YYCY/(HG\ P!IQY6!P18 EKDBEN8!""@>H$H9Q4+7;
MX1:)M+42Z76YZ_L!FVU61T>@B4!SZD CY1)H#$9$B)0K;0QDFD.-2BIF@0,]
MZZ[RQ2/01*")0'-D0 -A V@LUM1@#8%64 A(@2T;-0BJC&VS@6#TD%K%D[:/
MA0XB9F,F5U=9'@0GN>Y?9WED>7U:TQLE:(Q:XA!DJ;80<\Z03BN3@EICM]$=
M\"4:7Z_LI["PK2D\%J&U2ZNM0CM711%C]%'7$:0U:2M 6F.$K"::4\"L,I)4
M\4_C(.EBG*(U (AL[E'WCTSWU]6:(\AK^E;%I+)$ P$XP$!2)5U9/BFX]<9O
M%V,'V]K]=\+?OJH5'7-M8QWZB>+&6MAH=H%0$'@/P0'FA&%4:&;3$C:$M!+N
M*1*P7;\ '[5M<,S9&V:27X<LVBSY-GDT=>/$6K BU&C<@!PBD! -%?/>O00$
MIU5DCPLH]=[]_7+]M%^^^C[MZ3<A/=XJ44UG3?Q3VI&/15$;[18XLU@QY1Q)
M*<"" 2)!Z:Q+?]W.VBUT27NA %%SH^9VT=5&C98)1&&.F)4.& @=H!:QTF;F
M&DK*N^EJ;U=U!6V3 _@H?>NH]IU3^[5:WPBPI1S*$%M7AK/0,U$+QRI/64NZ
MUK+>FJ>\?8L:L'AV?JAGY[^=?3E+OOHM93K/;XN6!]\#:(R#("73Z\EXZO>7
M05+4R%[GPT=+E5MKIG+LT34D&SW5+$JI4)0J[5(#!5$45=XXP>BE!+!M>^._
M?:D$0XT'ORS%HC7LH+2'4*N'\*^5K<[Z C'@'B'# T+M7"!!*;6  <2T(H!9
M '4%&92CM0'Y?<0%MHTCN^S&%"$D0D@'(61M@ +CNF")6V@$P 1)![E$(L6L
MBBV&S*#68HMM!BBVCB&T"R!RE(&-"$ G $!K\:<1()5<<< P$D@YP RP%)>A
M$BZ$XG9/H9)=N#M@>TTR#L%6>5WN 6:'$$E9=(X</LE1M8>PZ0L89+H!%(TN
MM$!!@H*;(R2QV"DLZ3); 7/P4F?GF?&1-HX[D.@)TFH>T:N6<=^^QRGM\">A
MG++V(B"TDCG@)!828^T@$[S<Q8UVH+7N5<^(1+226["%*$+4UJBM^W3Z":AK
M>BW'J12$.B.9M%!P@WBUETJ;ICMT^MO88$6;F^NKW.Z=Z'A,-HBJ_IR-F33"
M>PIXY98.*Y,28Z   I8\9U@)!5JNWF_)6O:&_M'OOZ?(V1QZZQ5I!?FRW5YR
M[M^+-3A/ZS.M]9E@@EFJD=+ 4F  D<I6.W?*Q0J_V$;-#U\90PM=%__SX&^W
M%CYCO78W_>Y%QSH%"UW=S8]>\UEML\L0%@?*HE19RJ1*&2P/Z@0#C'2J"& ;
M"!"+]J/ZGYKZ"U&'OQU&2#F#4I!J3D5J='5.;YA,UYZ3[?*</JI_5/^H_ANK
M/P6U^CM5\/48@CBUG&C*G*GX>E*#;7L=ST.GH:+1D!U.ST>3Z3S/.@0#)^<'
M[+4=[9;# 6$<%WXDLVR:3"[\^E]/IL-'.I&VEEQS+." :G!@!'!N"7*8(ZF9
M58I7IV\*:[WB&NPC*+"L06HL^L<+NUCR]JJ"68]*ML.TFLY:""=E")R(RA->
MQ_6]!9 J:1TGG .-J2'+;!A(\=JX_EXH =I5_:UZ!%'MH]IW1>T9J_-LG&..
M$4Z18QJG1G%CJVS9E.E='MQ'M8]J']5^BVHO6.,47SM,'!52(X&!Q(16S'L2
M \ZZZ/U'@[_3"0/T($($BSSZ\RIOH)%0O_'28K^T@\G<[XT;(<?6(T;/F:;7
M="99.QMKY>BP\)0U"J>9Y0)0BE*-G:7$$48J?A8I@)/MX:G_K#N%"!3U,-I>
M@?1+9*BSEM0QGZQ$=(SH^!@ZXEC,$1$O(EY$O&-!O+4%,8S$@IC="$9DL(AP
M&>&RVW"Y%BUY;2 &%G*+,3;$ (XHU(+B93B2.[)#]WF+SC+L,;0]AHZ#,!V+
MF.-?9V'VJ_<WDK0';K.8W@_S*_^5\SOC' W'V=O+K$!&B,!/]Q7E/J4J#)IS
M?W+N8!*H+AB./9C.WA'AWVA3F<IE6X:*@X<S+2*7([_QARRG<3*[S)) _U&D
M/#W-$)+<9'F65!/6WF.-)U?#<7_4_@\G Z^6X^_%&-O_]=EEGF7%;$Z'?R17
M_N++:9+YI1QL821M_V0A=QY= O^RQY$@])F_S]_GXVRQ(V/02SQZR2V,)4S9
MCL83\+?]$9S=!8T[F'%W [!A"O^)_OUU)2'^GHE^;U>Y:Z)_"F=4?E3+T["O
MX=*O_BYZ-#G__4VQ.X:77[)15NP+;[W+P%/E, #:D!1#!VP94C:*!-+.QO9I
M92HI8OX*)*G6V(FR_1Z10$*QV-.&XWDV4+,7WP>^23*_PUV'G2*?9V^.#5._
M>FRY\.N2_ @+LV"I#DZ6W_*K)6R@[1J '8[]#]S_9G)=+O\"?_M3;R>,O!$^
M3?X\#/@]F?NG'4S_\BZY*Y8;S#.X.\WG!<7V ]/8N,63JQ!>-Y]A' R=T=VE
M!0M#L]C=D_-L-"H__3]OP)OBM1_;>?7Z@:7[.KSR<_PANTD^3Z[Z*[[)53__
M/APO'J\_GTVJ-Q:N3O'.S7 PN_17^_DIC2._V*/^]31[5_VQ(GQOEH>@=<(
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MLDI+Z2A\[70N'J]@K0]M)H)#?*=I;G]%D^X(U3VI>X#N/C4J]$T%B#B(="J
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MQ*UMZ1+76JP!=QHR2CC'A% FK%;5X;[A@A_2&=76E3KNZ!$,#@P,UF(!K;'
MNE1(3@C4*7&2(D*)K'9TO]>_T+S?RGG)ME4<\QX2;<8 X\8==;6]C9OC6EDA
MD<@;F=9R8!%@E+KEQLT((-T+WF\]CM9F#.T@]^?3K,V[NLKR(';)=?_Z,1ZB
M9T/%NBK05F>NB_: ;$;MH72& .4<-!JETEL&5;C/4?E"B-EYR5HE%Y^"6+2&
M,KP'Y/;XLE\@<)VU+(XYI2+BR#-M%0*:H4(DA-(*24PT@4*F0)4DR@QA0L0A
MG1ML"U<Z@2D':?5$/(IXM,ZN(: 1\\2<8I,J(!Q6E&..H:2E7:.055N.>78%
M?_XWRR>#_O0R")A $/VM"P 4C9H((AT&D4:PE!O*N#=H$)08*PRD1.F2SP-C
M<T@')Q%3(J9$3-D3IC1BNDP:!BG!' )!M5$2 5DE9"/D7IA2L:6"E1A6B6@1
MT6)O816)&L0X*(4I-"G&A##(D=9+N(#<=O (* 9/NA8\>67AACB$HZ''N@W$
M=J];FY$#*I5;A[2PP>3 --'&.<>($3QU@D+H2F?/ (*V3$'V,.BV4AT,>YB*
MV.#Z!))E(N*=/.*M-2XA%G5\BS&D)5%22XIU"B0&K((\HM0+&UQOY<RN#;Y$
MA&/OZY@2')$S(N=&MB*M@3,UWA%WV%H"A4;,J(97+IS:\L' UI"2B)X K1+)
M1%,Q EX$O&X"WGI3D3<0#R(D98JH,TP)*;6J>&2H=1RK#AR%MN$L,Q!-Q6@J
M1N2,R+F1J2AKX!2&2H$-2C5.76H8=*8"3D4=T-L[[VVC5 Z!'F2M\F5%BS#B
M6L2U;N+:6HL0P1K8M,<Q@Q40 A@/<$PH4678.@')"X.'&YQ,M\$)*&*(</,C
MYK_.PH)6[V\DC@_ L%^>\X7;T%^L3V/ H^$X>WNY:(4($?CI_OR!>U,,PX3>
MGZ4[$ :J"X9CC[VS=R2<AK<YCW>[.[[Y^:N'["RY"?]4 V_OQY]GMB!<IZDY
M([UR.69,*E)+@;$<+K2;*,8P;$.[/\Q#:LC'B^KU0_HM_XD:^CT<_\BFLY!R
MTE3S]Q_2I9Z#IP-<:_EZVIOS@D9R?TO):]>=V5#TD$KFM%7"R524C&Y$:(73
M72WE7:C>="FA7!NH;'$MZZ>=^K_]TOJ!5/.0C/Q$)-?ER)/^-)E<;&'A_SX?
M9PO[#8->$E3C8&369N=%%ECY^+!X?-'^?7I)GDVO,R\,/[+1[5EBO0R/OR>S
MRVU@ZNPRS[)BPJ;#/Y*K(EZ59'ZW&&QA7=K^R4=:!1^LC#TRGNV(F=^ED\%P
MC^#.ZOQ0JK6F3!)%L3( $>L4*<$=>*M\);SPT2M#'D[AOV97@68[OWU_==T?
MY@': J _#?YW4=T6H(ZL=P/ V[__]@')QTWQQX'=S\QY /<;;]].L_&;G\>3
MW0'[S".&%YJ!%\K;9!+FYNW,3\[;634[R7 Y/<GY93__GGEX'R>3>9[TJ\EY
MZT?S=NJ'EDR7,W>6Z/[4[PWSZ_+J_YGW\UF6C^[\8I[]&&8WO4*@,O_IE;=C
M!QZO^K,"M.[M,?[6A7TXGLR2_FR6#[_-9^'R27*>9X.A_[GA]/=>XM]=7'>=
M^\G/_<3X/6DZ.1\&-RJY&<XNPTC&821^*QL&3FN_MR6!<GWYV/ZAPP-,SR^S
MP7SDW_"K58XL[&YA0,TM,:AT>*\:1*&$BW'XQ[KQ6^+5Q#_0:/B[Q^7P_K@8
M1'&!'_O-<#1*+B>C,/1LFMWY:3^W23^Y]HLY&81;SX97_KGF%Q?#\V&8PL7G
M816],W9;/=SYQ(_H6W\ZG!:3ZZ7V?#0?/#VWP_&]<366LY[XAX3D[*ZKLA!>
M;Q+YASZ_:P?9A4G[[Z\K=1[OZS&;D5^OX<4P&^C;<%(2M&#>'_VZ6();ZQ?J
M:Y"[K_YG]6AR_ON; B+"RR_9*"M4YBUB6 <;'AACB-3>YA-X 0Q&&X+=V[IM
M-:+*V7#:0P-/=XJU-+S$$ E3[6W]S&ON=7 L\WGVY@@]K^3":V3RHS^:9T&"
M[HCVJI9_NRT6M5R62C5N%S+2#R([&DUNILF?AT$')G/_*(/I7][=%9(-YA#<
MG<+S@I;^@2EJW.+)&0ZOF\\P#N \NKML8!&>+#S\Y#P;C<I/"S0/K_W8SJO7
M#RS+5Z^VT^1#=I-\GESU5X*9'J>^#\>+Q^O/9Y/JC46$I'CG9CB87?JK_?R4
MH1"_D*/^]31[5_VQ(EAOEGGOR^H3\>;QK/C%+3C]Z6]O5D(]Y>V?^ B\[FO;
MO%E'6S;(#518KFCPXK/P,Y7D%N_<+(3YF]]6'C,/GU6NA#<L5]KRU*YH?U<F
M]ZXO443TF@[%:1VN1&G:4)J>#B&<.#_>PC(<?R],V'&6W&;]//%V\2B;/M*H
MIG5]BVW#NGZXMRZJ@#FK60&!@)A Z#AQ%J3>+3 E\2A64-J5KHKWXP1U!"'$
M$WY=^H[_\L[G</QQG/W;2VCJ;>[_#B;WVK#_JX_U@.PQ$#MW=P,#NY3/$"'N
M)"&N07S*@--"TQ1KI0ES FAC*HCC *RD+[0.<2T5-W'2([1-5N0#@[B.NKBM
MFG7]"V^4UY;=[-(OS_?+Y&+X8_'.IMT(M^%T=%#]":QCG@Q)B2B05BF.#628
M %JI/[5JY5#\N>JOPE)Y[?^Z6*/4+U$ @NGVC1V,6 _(-AL2K1.+SIHU1V"]
M1-V]I[NH9FH@&G*1.J(LH]9:0%,M*MU%*5LY6MFF[K:SBT.*>ZS5GB2=U=V6
MXS.8'<).7K#4K#E6ZDQ6]G&Z.6OK#D[(#R(-CE.DJ5"% 62Q3*T33BY#/<H;
M22\#T_K5UNP<V(.8]MCZ]+^=2$<WG:(8]XF(&1&S3<1L,+@J(+B1#BN3$F.@
M"+'R"C&% BNET!L@9DO5+:'[_/K4]Q/&R]V4K]1)8<]+_WE=OA38:KK4ZT]P
M/V=%'5?RJ9_/;I.ON;_A0@[O1:^.*[ELL5/ID=>'SY/SWWN+U^_'YV?)GY?O
M_J67])/OH\FWT. LG_P8#D*XKYF'YB\8_!A.)_EMD6L9$CV3J_ZX_SU;)"I.
M1O-B*D,&_/4DGU69CMLJ1MA=1G_(U;P*V9QY%I(3DH$7HB+I\^9R>'X9/KZM
MQSRY&6?Y]')X'2[K%U\>YLFW;)R%=%$_N_4%RZ34(AMU7ZG<1-;[BK2I-!):
M##0W$#!C45DI3C15&E3[2O9'-GKWL1K(^S)_5]_^.O0:.9S=?KGLYUG(IGT&
M4]!XOF#GK7<5M-Q4WJ*G[?!5JHR?ME> 4^;U3N:SZ<QK0(B*GT^NKB;A][T&
MG25+92KU8AJRAKU4A%FODH+[T\M"?9J.>+CFPN]"D[-$Q<J=;E3N++3^;D[N
M@XNW6.I!R,BMUS]H]K;T^;_6*30%=>$==<( 2#5D4$)EA9&LJJ&4AEIS1Z'+
M[;'8'9N;H_'C5N-!(SW\U\6@:X4OL.#%_C9=*CI;4S,)SU95/?'3Z)5F?)CE
MD^N7$=8E-H"3%'+.A>,, VZ)(=5),6:$JFTOX]-.P'.7$4EQMGI,O/5E[)7[
M]+ JP-CCDM;Y3:EV5 H!K;0H==AX!ZYL[(.1PI"VNJ2+"S)_X:_>$K[]M9__
MGLU2[QIM367!V2J=P;$K+*K/=F&(8WI5A4Q9)3BS+&75Z@)DV-Y6MQU-QGN!
MXV$YSF2X* VK]]M_#/]G/AR$ IAB!I+%%"1A#LZV(!#_"O5AY_,\WRN8H!I,
M+%,:4FZD="F&4G%F6$65H 7ESQ(W5;IW:99-WY?#>_-X[5@+$+':3V,70I1<
M^ $6_ELM0$O7UO_(C^&Y__PZR\.S^Q4>;+.$.Q9NOV0L9ZL1K15"EI__KWZA
M*U/)O4XX!K73@&*+)="(6D2PL,9R0T.%4O\E(9_C"H9]^/C5)=3#XZMK1<<S
MKS%V.#T?3:;S_.E:T!0;9ZWDQ$J!G5,2$E?5@J;>_FG4@EJC"!&*&^"D8L;X
M[3.MP PC 1:8Y-<\&ZC9B^^S4DKZ_L-_NP]?/W[^]TJ =/.*VB]E\?+'B^5\
MF8"KX]GZZEGOKQGIYX)R+5.9$J2@K$:"H27-ZEF!4TX%!U[(N4,*258.VN\4
M6NF5ZME[>O.:]8*;+0,ZNAK>Y0J'>9D."T,E%(N',$)1C1LVD5B/6T]QK,>-
M];C+)>]*D5^LH(SUN+$>]R"D*=;C/G'^_[E_$UA!_(?>*8_5:;$Z;<U9,&-
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MW?^>O?V69_W?WQ;-8=_U1S?]VZE_AK]>YN54/7?\Z!Y_62%+CP]6+,;:?_%
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M$=5/6BMK[[-"$?OEZT?S_[S5ZHNSB?GXZR?WX8OZ^O[CA[4<L6LTX#E/LLE
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M(-J4?AY.?W][$2*JPV"H9=-9XNVD;-\)0OO+KB&D/B=EFD&8<J4T-BQT?X,
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M+A_CNW@BR&<>>\%)8QMIT.53.'UP^EB+0D^+:,*#<\C-GV!)%@*HSG_$8*W
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M:&L*@S*9C(AZT)J.(6T:/WDXZ !8I:,R$(E2 ;;</!H2\0G;%MW":M[B<AW
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MXM;%]TDQ3DNP/2)BV%/&FD1@P8\ MAG2'\#1\[]Y.=]RN OJP/LU]:%YW+Q
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M0GUD(46R6WDOCF%*KA9*MJ*'MAY8OLY82%9][ZF:W('L*4GJTI[JO]ET2L7
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MN;F)R6*1LU4,%K@I07^/]W\'K'J&90!&^$LRG4\2$GL@XD<BE.$KDJLR6-"
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M>8;>2H8^&H9'9P_1\)ZAMX.AGVXKZOGA)K:[527<.TO57DUMEYH:'!V'P^'
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M.VQ%B[Y_LB0NJIFO."PXBU=+\]3L ^:U9IWG@Q>PE&:^0GAL3ZG'27CT($"
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M6!6^AG(US1MZ!&@IX-T*=I*.X3$DACN#<TCJMP0*R.=Q4S<@E<!"3XND0KF
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MUT!OE,BA7PU>X5\_@F7&IM#[]V'POE8S_FEP8:(W_VK@,PJ<*G!CYD59HV(
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M'I\FXSV.MN7SDY]8!R(!YQ7QY0\FA'JQ0H-N5Q7(!UMWV;(:K%E!1L8&^C=
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MQXP[+5_CVA2FQ'L_>$\!!^T&V\O@U9#,!1$I5\DKI//'G:"C$K8?S1<UPCJ
M<J:2G4=L^$1']LGVA&+2^[4^+;SL]WG25'6YV"4)T^/)X[GH'DPXIDD)O,-)
M="#@G'NHI5,"YR2HN:*U!\U<HIJ(.:)*<E"!9&,);5Y>O/[PR]LO__>_%"+
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M)BDN$U[N:$-$*C>.U@KGU%'7"%DFX#VF8J%CM!.+B/9L\X(I8$<.LK$LM*C
M="1 +0*?,;_J!LS%SX$3!ME-,BT!FXIZ1J*QTG, L10D0KRU7%]K[[9<_NTY
M\_W@+7"\6+YZ/V8'^HLLP*3@KE=#VXZ&ENM#3A;0T8JUL57O_-$AV;!W161-
M\PV)O&TI^ILEZ.I#*CK<LL.I_K/O3_7[C/V.3T%Z<!"T[7/TF-6],:!$H?F!
M'US6'JRHYM-%!4Z\3)FH4[94P,7,:@S6E 30ITJ![2-4)_$I4:(T8-QN]P#F
MSEV8H-VM]X$"_H8(DT'8;-D[*X0PW>T(%*  >?;$O>%,Q$3JM1.<8-\-UVZ=
MJAX*,+"/OQ !"$0E_Y F;MRA_64,OMQ /.@X.&&H0J>Z)'HI^'I@YIF$6EE$
MB40:E^S#UHEK&Y$-0G.<-OC45I?$9R:.)??+T<2;^.AF+HR"O*%A$&[PT+B2
M+]NL4S/8ILHR(?H_/3MX1C_#IV+]L]$WEG&.'$9R>,LE_2_I#([VG^HZ^%3,
MHOQ5L,PU-:BI.M'/OTZ3>OKR%%D2=5B=X!_E'W^DC[8^?H7Q([A:85U8U2WZ
MOO/^%IL36Z^5C\E?/GG54>&\J=5;N,UFZ<JJ34JBI9K]4) Q)<C<_5LG1L>Q
MYK3B7#XA<VJP%6I[ZSL:NN8_$E5ZXO3$>0MQB@_6CK:VT6MI\HN.@>.#L7:+
MHL-,O=W$%&N-%(%)8?\\&JM#R5S4P2.U/$E[DEY_;,HD]$PO,1@G(&8MIC!9
MA!2=0M1MBDV H>')SY/?PW=@HW)-;E#3+ YRGO-O*%<8.=B>E!TGIT3*(:AP
MC3'NNY&Z3@#1$ZPGV.\S 6S:UBKQ+!JIS-;:5#<XNK;QT85M$,7./YH2"$^L
MGEB_CUC-# Q+JRO);JK*:(X3$3S5>:I[N$XGBM,QQ"JHHZ\JE_IR'2&S%4AM
M+*@>:NW4(6 Z*0?BR"*<?^I,_S*9>C? ER+Z?\2-QEQJ0:Y3.VV(+X5?>ZKW
M5/^=L0'!:6H3,%.VE.2&MAZKKTY-!V;=,JV@:N98@>GIT]/GPW?0*?7HJ[WC
MV5 371V9SD;8%6BJ;9VL#SI>3B:$BK2MT.5,ROJ!!VA0DV<"SP3K8@*%@QNE
M(!L+ZC(<ZM-PBRU6"B]XZ)G4*DLY*,&G:U;8OXT<MRM/;"I?4XT71E,JJ;77
M--95RIIBNK&1NQEO22O2A#6V&ENEBKF:1%+@XTQ!U+G+'UKROKU% '>NV= >
M8R'E6%+6YR!+HHVOXFD.SY^8*6W2FUGKZ7[H<!IHY,+@M=LF"QF?A:VK'.+3
MME$,OZ=Y!=M=-8H9^;:C$@:CM.CX+GA&\%MSWI@[HA[+5)"O' ??5E:DR!3I
M.!40,OH</!<X!%;V&U>C8RC O4@J:*"*\9#J\=(8/*\RTQ6(^) ([S('0R #
M1HMY.2:HL!_\XC3?NDA?E9/5(DG;",; A&I=@>3@ 36W07,1=0CN7SFAANM*
M1256;-!$4-L>5-7@[M%O00292;<TJ\T9E8@-:V0(41=P7V$C&4C\+:H)O[)T
M"!9 @_*-D8LZ?7VPY-:8PIP:EPLMK)!Q:*0E'@851XO@<N,Q5 :,'6-.RT'1
MPX$C&4+70@I$"3>1O&*;&PO#LFX?HC =X;IK?WOEZW0Q";\VJM*L1PYPN[84
MF[N32NG/NM1*\II+5?7P;L1C4U+3GR-!F:.A>I52R3%65#R#76F.;##=X@:E
MXSKBB8VDK&#5999BM;(&I7:IA[[+);KX3NX@N$%*]8@F+"?&MG?>)U7,N-4^
M_"<T.O+*85+0/F1<MUAZ%=]W?L5%VT3G4<58@Q@[B:-$87>(815L$TGK1F+1
M)EM"?1C$%>82=(.;8]O#83&NL,'SF(.3T##_:%Y$(F3*KU*0?E$IU?]P*F]
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M,)LR=UQ57OA(.9B5C(AAVE@Y$AV9R#@/0=7]#EH N%Q)NI /2,MT"5\V];3
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ME\>'ZX"?N(C2)X1C*U0[5[[ @1\+H_'QS]J1BR,&\Y^!)4W5D0CK@P&!3'"
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M4*L$H%N\ILC*X(>SIV^F#HA00@[#HG9M0%"I8$)*GA(FQ)S2T%=+ !^GD%B
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MY9-%G> +<1?CXH!>=Q-'/3 0]\6 0E:R)KJ%@FYMW'0W&,3]]K0 RHWQ>+N
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M0JX!6(-(?L(: SF7K+2YD#7J1*OM<!#OST^#*&X KM?7@"A+78'1.GS4W,S
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MWL\74$:/M*CVK@;W!79.L2.RUTG:5\\(=5Q@K;&UA>90Q^A4TZ[NY='!;78
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M65;5*G%'+%A.8A?Y4+D<0=Y*17FT =W9)ZZ"G9,B=5_<!I%8>B?D$7.V,N?
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M;(FBW.;] Z0VO0*8Y>RUJ0=I_:#MD\KUP3?+!"' RB8,.VNPQF!==3[\OVE
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MT@$YL0?M<3F&;;XW1_I3^VRZH;$3V#13R&Q,/1]6#]S\TO@\S:M^]$KW&02
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M=+OB@>S"&Y([=,5Z0F62-6P2P$7)S8S7 MM%:+IHKG]&:)FHL[ 2W K0M.@
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M>[[?$W_&__D/Z]G\N+][(#D8%W_Z,Z<03_DM8$2^SJY$ZXEM"2D?*@:S?ZA
M8U&GQ2>!A-P[_"^',]>UB$P#BNFR0OU$>@YS$$M3(X -U2],<DS$8,]:1W*2
MZ8BW=<U,LC99K:GI?- ;0^YEDSDJ AHU99EPM(XO['-'FR9=":@V'*>H+TSM
MQTSK!&5)HE@1HMYJ9.$VL2K,+NPPL 5>:C[[TZ-F]_3DV>G^R?[9TZ=GA_OG
M!T>[SXY>/K?_>7;\]'1W[]DC[1C>0=A'7>G?,9"@0JLE)%6+86@5!S,#O@Y<
M9_NYTD#LOS7+9'\G^;6LS47> !?7+'DOI;7G=I_M[?]>M\O,DE\;E)2W -QK
M9@V=@^%_MSG^^ L00! 2R60,W-])Y.')L\/#T\/S9R].CP]?'.X?G9\=OWRV
M]^QD]\7SHV<OGT:)')7(@QVK3><9YD=^75FU\-Z40+SI)3%*EY6N_9.#L[.3
ME[O/=I^='Y[O'9WL'NZ]V-VS@F7_[\7N;I2N4>EZNI/\#*PG[[.YL>KM+&^F
M106EJ5&J0*I>OMP_.-U_OK]_?GYP^/+YT8D5K&>G)P<GYZ?/C@X.XRTZ+E6'
M.\D;+!EY56)E$WP@RI.5I_/SLZ>G+\^>GYV<'!_N[YZ]V#UY>GA@==3+TY/3
MW9?[OZ\\V<E.']O? =+C#TVW7&;U^ML5LF=0[4+>P[W)5F_9."\V7 +UBAM7
M58^!YQF(\R[Y^I\5_+@NLM$;K=W$"\"/@>%E75O)+VH<$/Z&0AU[NW9])E5M
M_>3'B.VQ:LP/\L- F'R\Q'X$5O]/C_8.'FV.C] [7OR7"J:$?]K;_*>#:_YV
MW9\>R-?T:M?5%6W&OI.57EB')%\VFL_!WNI3TE1%/DOD< 9BO=]7+\-XF_X5
MB19'SJ[-67M9/;J#;CFZ1]7"*F6C1ODCS.&7#JH/QF-]MQ:0KR$ $$N:%]75
M#XM\9O7C9]PM>6G-B7PDPCCF8'_V7.-AN/8P6 <4XDZKH1GW$*7*W7?/HU1]
MF?7F8LX0Y9RLDW>0+H.Z[<])3VR/0$4U=4>!>ID79O:'OK'_8N4?DA2;LE+7
MYAJC=%PO'?;C#U.Q1''Y0F627&=!1ZF)4K/)4G[RA[Z%CE?8DOCI#SV)!VY,
MQM/[93H?"C/.LO8A2LVMJME^<]FX_RS-P<[> ]S=WWQ3AY/)@OU6QP^;%2$_
MHO?JY<LP$67H:G6--(NV7?WPY,G5U=6._=C.177YY+B>+O)+TSPQLXNL?@)D
M3$^.#HZ>/WO^Q#YP;^_H8&__<&]W]W#_^>'1DYGY=+"WLVB7]RI=QTOJIX:R
MH'= JPH5=:>PY$@6@75"8>0#JHH^F2+_E#<I_,GG#;,HH=NC=O9V'_\MZIUM
MVU7[W\<'N_L'AW%KMVUKHYVPC9OZ9&_WR?[NWF[<VJV;W\-Q8/8?X.Y&!V;,
M@=F_=P>FYZN@/R,@8]&Y^<-(;W1NXJY&YR9N;;0A'M"F1N=F:^?W<)R;@P>X
MN]&Y$>=F?__IT?[>BR>S@\/G1\\/ODZ2)OHX6R'$OZUF>A%=G.W;U.CB;.W6
MQOS-%F[JX9/]0W!QHO>Z??/;5A<'5-'3![B?O\?\;H:B^YW]G%WZ<>\I_'QP
M],18S\'JLZ=[]B_\\'MP> 8NSBG!MMN?WGE4J^,+9BX$/AGU^S?(#AO]FNV\
M4J,GLR7;&'V7+=K,Z*ULQ3;N[3[90P<E&GS;-[]M=E#B)1(=E%L[*'>O.ALX
M*&\<.CTD7GXF).2?&<7Y'X]/S0I O3_8+<Y62+K(/@F!.L-W\K*MHL.RE;=J
M=%BV8ANCP[)%FQDKR+9B&Z/#LL7SVV:'Y=D#W,]8)B;>R1&4C.T?/G$IDZEW
M)RJ[OJ:\?Q<EEHG],84X>B=Q&Z-W\K V,Z93MF(;K6=R ,Y)GQ3\06_FELQO
M6YV381WJ\P>XN]%5V>2J[&?D.EC/H2;'X;<!(3M9%]E5$]V0[;PK8[?* ]C4
MZ*)L[=;&=,H6;FIT7[9W?@_%?7D:(RD/TGW9LT[+B^<H!7M'3_6O'N_"_\$O
M=]I/[;T*V_N5F>;6>4E.J^422*[;:OI1IU6BL[*-.N;]X[WTB]@F[G\H69.P
M?QZUWK:)V<'!P>.C9P?1?=J^K8U6RC9NZI/GUGO:C7!FVS<_])Z>(-FY^[U<
M_#_]]Z1^<BM#(!S_1I9W6),]F._P"<$ZCM&V?TWY?M:7;/SOHI:GK[(+\WA2
MF^SCXVQN1_M#5EQEZ\:.X<FBYJ6Z[?SW>YSVV'RR>;(O>C[(K2>*7V2?XS^:
MY\_L_A\]/SG??W9\>')T^N+@V=G![HO]L^.3HZ/SP[TO74X:W@<0'^QNMW^P
M<VA&O(.;A&KCHO'!V>V=K=U1,1I*B7K%C3*FQ\"458'H[M)1Q=.23$U1\%__
M]&CW$?[;SGHJ_QY9R@_6I6J27\Q5\JY:9H.#O<R@RX:&EW5M);\@/8&_8;;Y
M7;L^3!YF9;G(5HWY07X8"-<C%QYQ5,E[!X\V1T_H'2^N(;O?_*>#:_YVW9\>
MR-?T:O_&'-TW<<W=WK[X5ECBF./Q#\V.>!VQZ4,B<8^'X7X.0W)FFFF=K^!/
MW\1*_ZY2Y>Z[YU&JODBJPL+YR3IYX&RN44W=4:" S7OVA[ZQ_V+E'UK=OR@3
M&:7C>NFP'W^8BB6*RQ<JD^0Z"SI*392:39;RDS_T+72\6IEREG_Z0T_B@1N3
M\?1^F<ZW4TS.= G*PY&:;:UU _B+F#A^D.5MNCMG]VA78,Z.=I_N[O'#]W;O
M XCYPR*O9PH[8(;-.,>K.B^2O32!=Z9)6R6O3=:8Y/BB-D9][N=LG>SCIYZG
MR<2T5\:4R7$#9Z'.FV1O]S!-7K\^Q4X?:>N)73U;I*!B'\]6;.-N[-S9GLV,
M1L-V[./3)X>Q.V<[Y[?5'LO^__L =_3WW,C?!*G9>2#/#G:=!W(?2,OO[<#*
MH0L"K@5X%<X#:1<F>=^M5L5ZX(:\-).ZRVKKBQSA%YZED)4%IT-\DA!3 /_T
M:M78/[Q=9/4R2]X?OX\N29Q?G%^<7YQ?G%^<7YS?']4"_\=#\S<.HK_Q4/R-
M@]_8WSB%[I&)5'J"U_ ZMV(\D@GY:U:B!W*PZ](A-WH@'[*/9I:Q"S)%VIBL
M &P!.[NU?=,R;U598'1+XOSB_.+\XOSB_.+\'NS\_JB&^D-R2P;(+GLQ([L-
M95PC/LG!WGU487D(,:9B>5OGY31?67? ^@U3ZQE<&N:]KY.W7=UTF?4\D%!R
MNLC*"^N/3-OD75>8)MD[R![O/?TN^Y[PE>WODKW#&?TJ.A-Q?G%^<7YQ?G%^
M<7YQ?MMA7C]PUR(BLV^K:W&_1/8#U^)E7F;V1_M3="WBU1'G%^<7YQ?G%^<7
MY_<-&V+1M?C-7(O]G;W_\Q\O]O</HV!OJ8>Q?^_)B^:F[ 5X#K=U0?9>)+_N
MO-\YW4G>FRGZ+WL'A[O1TXCSB_.+\XOSB_.+\XOSVPYK^R%[&@!E].J7]U&H
MOX4VCGL4Z9-WKY-79=-:$]\D9]6T@X:)A[G+#G3]:!-&]C;L^(>%27+9\!EO
MN/W!-$E9M4FV6IFLMI_ YII7H%>LIPK>X5G69@DBUT[,-.L:^YBV25" VNRB
M2;+:)&8Y,7:K9@D 3;MG@!M,'Y3W[3QP3?K^]"\/\XQM[[E"^?Z0?:K*:KE.
MSC^UIFP@'/)^NC#+[(&KUCB_.+\XOSB_.+\XOSB_[;)G'WI4Y/3X=13JAV'+
MVR=-NX+*-%_GY<<) &Y'RS[.+\XOSB_.+\XOSB_.;WNLVX=NV9^=OXQ"_3 L
M^S,SS\L\&O9Q?G%^<7YQ?G%^<7YQ?MMJW#YTP_[U\4D4ZH=AV+_.)J9HHE$?
MYQ?G%^<7YQ?G%^<7Y[>-ANU#-^K?OCN/0OTPC/JWM6FL4,5"G#B_.+\XOSB_
M.+\XOSB_K35O-YKV3]IL4ACW>_RO&B4TWCY>&)S#WO[N?_5GNMM;C#V8Z,T&
MGGI#L+:[\NV\M!M._]9#**MZF17A&W=I:7$>R=04!?_U3X]V'^&_[<2G\N^1
MQ?R0+TV3_&*NDG?5,AM(V54^:Q?V1SOW257/3/UX"GR!J\;\(#\,)OS(N4RN
M(WS_T6:'BE[Q[+]^?#001OK3T5/_MV_"(?OJ=OMGL7UNPX3?5K5#5FL7>9,P
M>ENRR"ZA7]Z42;7,6V"AS!K[;SON)%\N,ZLX %@- ->NJJX *DHK=,N5:7/H
MN2_6"1!/SKLBR>?)JIL4^=3^;I8WTZ)JS.R;;:/_Z@O^!:"'VS#M#R!;TP N
M/)M.D8TTMVH01>]_NJRV<F7EY)U96;E,[(=>6LV;[.T^_I\TR0GG80;4J+-D
MGA>,UH!8#>_/3U$8^4-M!0*9E].J7@&PH?WH9)W49FYJ _ 1>6D_ 42H]C$@
MTE;Z>QRJ"(-(CS;3SE[J,$Q *[<?W3LZ.$CA/&3 \VIF:5(-/AH@G--WGNKO
M)-]=+8S]3ITLLQF<M'E5&WA.-F_YQ4#^ZL[EM8OSO5V=NC;-RA#BA?T23.["
ME*:VI]2O ZQ[88?591=P7LLVL[?<#$ SFFZZX-7823[SUO[IOR?UDY%;?&AK
M/+K=+3]VI?,3;KRWOZ84/^LSK>%_%[4W*B[,XTEMLH^/<1M_R(JK;-W ';JH
M>:FR))_]Z5%S<+R[^^+YB[.]@_.CPZ<OCXYWGQWO/3_;?WETM+][]O0(OI,%
M:WS;A=O?';&%-J_2"UJD[+-7"+_(^)__T3Q_9BW<H^<GY_O/C@]/CDY?'#P[
M.]A]L7]V?')T='ZX]Z7[0,/[@%:6%>M3^P<[AV8$I_,F:;RK3?G["R#]$9XC
M%BG^YHKF-*F*V8]]-->R*HT=POM7?_[E^,.O[\Y[.%CW;7)?NSA/7WSEXZGA
M74&!UN9?75XCDS8;.+=0T?3%B[QI:WC4PJKL66?5+B('S4@9UZ2"Z99I[.SM
M'ZQF!5BAB5EDQ1QN&W@0WB+\ 5#VIH.+!Y^7=>VBJNU<O#%TGU;&T-_\4L6+
MYL-OX$RI5SY>5O\FL^7KNUC/]W:>[K\X?+['_SWX#(=KF=47>4G3MOM9R2_(
MXMH=<\B>WNB0[;_8[)%]V9\.GWV.'[?MD97MF9_R\G_[N7Y-[^'13^=WTHED
M-/SC_/6K?[QZGR9WUZ^/?GIU#P/ZY?3+_-[?4&)91^]_GB'SQSR=<:YQKG>9
MZ\T'=VD'5!BQ)WA*>ZM/25,5^2P1>^V/%^=_]--?K0U+*W.PER; _?"-2L.V
M2?O7O7=/UC]\P3RW4<"?-$]HWX?_/;V3+7"$C__+NU?O/[QY^Y?S=_=AG="X
M_KJ3O+^'H9W_\LL=1_5"#>KV_[V+BOTC2MA9UIIO1*ELN]+\)N9W?WD<UK<8
M.ADHV]L+\8L[R#!\=Q!]?/33Z:+.&SLN2&R .C)E:>IOW>F)TA[G]RW-[RN'
M5AQMVO^73PV6).<0J,7\Z>DB-W-:#$>?1O\4#K5XF./\MFY^@ZMY[P]PE%4Z
M,&_MIZ?V<=^=06[IV.66;J1&A-\?3Z=55[90",$?_W[3*7_P%0#[(Q4 _]=_
M/YE4L_5/__=_/UFTR^*G_Q]02P,$%     @ F('_3L\>]..!&P  ;*0  !H
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M(?"_\R;_F;B'=^U6I]>\[#XO%W#!1#Y]:-^UFUVG,N=GL5*CS9HH842%3D8
M=JZ($@YJW0*EX'V#B]9MK#F,A"!OP*-4P(7H1RF/9JQQ3 [)H4,P@#X#_ IF
M/7<?KL,:J^O;1.Y*"%>,^R*"F\T Q5L:I5NZ8I*H>^K[=,\;AV@LWK=7NN_&
M34)ZTJ&Z"WRG<"A X2-GY6I?XE^5P.VP21K%*8>18"6G(PF&#2>DL08-FP
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M[/>*2K/UO"*["JSL472]+J2\R@***M/"6(32GH(G0(JH%L5D0J4IT*A$E6Y
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M3,Y+ JN+24%8!"(O3626(\>HT9[')I"+07KX:0OC3J D7P4*A":" (RE$RO
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M%WW5Y68'U2]SEJ_0_#BLGR8 $F",%/7!(WZU4];Q++5=KI8\[MTB8Q\O+ZS
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M-N+=XZ,W!WMG^^WS]O'NWIN#B\9A<W]WM]TZ.CS<;]:/\94JO(KEW'M\.64
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M0*=JBW6 [=\,FA/P^+>.YNGN,,D!O@!;I5ZT9QA@;#'SU>#.4#BP;&(S/Z!
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M-+SS"JE$QJ2M1F,ZG=:GS;I4X\9PT,"MMAM"2LWJ@0DJ1^_;V'7T_ET[8C2
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M#+)H*7A@+X8Z&VD><*HX*L!S\K9DE.!.F49"M>#6EGUMJ,+U$P2"VZ!=E%+
MB)\)B@P#:EDA[H@95N0T7\Y.\&G$<"*0 *QGP0\&_<^ PN@A%)X=-DN(>'[
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M@%#%K)W!;GPB&-J#,'#N1' =(04NBR%3,5MQ''#M"ZDSH,,<5E(X@Z=*^BR
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MK:5W_JI)WPSND#[$X<#[?(*A"K5:?P0(A=7Y/E>YJ+&EELFTD^:!ME>'MWV
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MHABNN?OF@[?KDA6"QYF7&&VNC7(+3RXVRC4-1$3,)F&#\Q;7>-Y/V(4WJ+;
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M;$C,TCX'??@8ZO8!':NX0T5%1'Z_L^)2+SV.@&4#J9;MF3!CAUZ94YN6R4S
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MS5">]E&5/967*04D]SJ4@)I/F@>ZWCRK+R?+ 5[I&/3^TV+P>2$)@O$%MCT
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M_T/RD-1TGD((AV'%[<XDS"F%*(O"D:ASI/A2%7.NNG&1Y+WBIY1S=2R+9B-
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MT0^9T)L2+"2YNNV =% 8LM$K4L[HG8X;9WW5-SK2S^LH)4,XA"<'CUP4[CR
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M? 7GE6(<)DY2K7S20AC5;G;Z0J-DV?MOK)O6NMTRZWIG1UM^',ERDAZ_?3=
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M[@2!Z,[T'^!" [6[X)?[J*(3#B(]ZWE'W'8W:D6K] & =%CZ9=LHR\M' W(
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MW2KBCWP4"7VXR4[?.[J=BEU?1K9Q(_*9E@[E>E="1/785!T>@3XLD59O[F&
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M\6]F]061H"DAUZ\*%G@Y8Z1CWO0+ %\P'S!^_+>^ ":]/;L7\XT?>0BSQ,<
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MT:( *=E8/)XQ/&I>G'2(@(^85US+A7@2Q:TE5FES<9Z3^5_PJHN(I>QG-]E
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M/0YQ*BOB7D03LKULJ<,K>&&^#.;9@4HDHSX4E^<(93WI,@ZON0I-&] E16[
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M;^D^NK][@@$Q>VJ&D![@69H@R^<1I3YP^?/[RZ]:SNST0=O9ESG)E^]"T,
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M8:5.)-;$2?%E*R?WE*$RG%5@ 9U:U\;VN_0JL.8+')?RM5I=AN?N]R+ZVWY
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MVD!H;#DQB<\?7\#\&'AB9-9)6<LTS+!BORS<Q1JQ[>K^Y,$-
M      #XI[,UB?\'4$L! A0#%     @ F('_3H> A]3R%0  G?P  !$
M         ( !     &5X96PM,C Q.3 V,C@N>'-D4$L! A0#%     @ F('_
M3OZNV:2*)   H8L! !4              ( !(18  &5X96PM,C Q.3 V,CA?
M8V%L+GAM;%!+ 0(4 Q0    ( )B!_TY9'[);@E,  -TQ!  5
M  "  =XZ  !E>&5L+3(P,3DP-C(X7V1E9BYX;6Q02P$"% ,4    " "8@?].
M)IY!*-36   =GPL %0              @ &3C@  97AE;"TR,#$Y,#8R.%]L
M86(N>&UL4$L! A0#%     @ F('_3DTM9O3VB   &!L' !4
M ( !FF4! &5X96PM,C Q.3 V,CA?<')E+GAM;%!+ 0(4 Q0    ( )B!_T[&
M+<?W2:," (EK(P 4              "  </N 0!E>&5L,C Q.3 V,S Q,"UQ
M+FAT;5!+ 0(4 Q0    ( )B!_T[/'O3C@1L  &RD   :              "
M 3Z2! !E>&5L,C Q.3 V,S!E>&AI8FET,3 R+FAT;5!+ 0(4 Q0    ( )B!
M_TX\XC0EWA   +:4   :              "  ?>M! !E>&5L,C Q.3 V,S!E
M>&AI8FET,3 S+FAT;5!+ 0(4 Q0    ( )B!_T[^# ^>20@  +,B   :
M          "  0V_! !E>&5L,C Q.3 V,S!E>&AI8FET,S$Q+FAT;5!+ 0(4
M Q0    ( )B!_TY(#[@Y4P@  .TB   :              "  8['! !E>&5L
M,C Q.3 V,S!E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( )B!_T[#-G,&Z 4
M /@B   :              "  1G0! !E>&5L,C Q.3 V,S!E>&AI8FET,S(Q
M+FAT;5!+ 0(4 Q0    ( )B!_TYAT2J161$! ,+& 0 4              "
M 3G6! !E>&5L;&]G;S(P,3=A83 X+FIP9U!+!08     #  , #<#  #$YP4
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
